[
  {
    "spl_product_data_elements": [
      "Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE FERRIC OXIDE RED TITANIUM DIOXIDE SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE GELATIN SUNITINIB MALATE SUNITINIB yellow to orange yellow STN;12;5 Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE TITANIUM DIOXIDE FERRIC OXIDE RED FERROSOFERRIC OXIDE FERRIC OXIDE YELLOW SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE GELATIN SUNITINIB MALATE SUNITINIB yellow to orange-yellow STN;25 Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE TITANIUM DIOXIDE FERRIC OXIDE YELLOW SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE FERROSOFERRIC OXIDE GELATIN SUNITINIB MALATE SUNITINIB yellow to orange-yellow STN;37;5 Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE FERRIC OXIDE RED POTASSIUM HYDROXIDE TITANIUM DIOXIDE FERROSOFERRIC OXIDE SHELLAC PROPYLENE GLYCOL FERRIC OXIDE YELLOW GELATIN SUNITINIB MALATE SUNITINIB yellow to orange-yellow STN;50"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions ( 5.1) ]."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET : The recommended dosage is 37.5 mg orally once daily. ( 2.3 ) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. For recurring Grade 3 permanently discontinue. Grade 4 Permanently discontinue. Cardiovascular events [see Warnings and Precautions ( 5.2 )] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) Withhold until resolution to Grade 0 to 1 or baseline. Resume at reduced dose. Clinically manifested congestive heart failure (CHF) Permanently discontinue. Hypertension [see Warnings and Precautions ( 5.4 )] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Grade 4 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions ( 5.5 )] Grade 3 or 4 Withhold until resolution to Grade 0 to 1 or baseline. Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions ( 5.7 )] Any Grade Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions ( 5.8 )] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions ( 5.9 )] Any Grade Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] Any Grade Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] Any Grade The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions ( 5.14 )] Any Grade The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions ( 7.1 )] : GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions ( 7.1 )] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><caption> Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions</caption><tbody><tr><td><content styleCode=\"bold\"> Indications</content></td><td align=\"center\"><content styleCode=\"bold\"> GIST</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\"> RCC </content></td><td align=\"center\"><content styleCode=\"bold\"> pNET</content></td></tr><tr><td/><td/><td align=\"center\"><content styleCode=\"bold\"> Advanced RCC</content></td><td align=\"center\"><content styleCode=\"bold\"> Adjuvant RCC</content></td><td/></tr><tr><td> First dose reduction</td><td align=\"center\"> 37.5 mg once daily</td><td align=\"center\"> 37.5 mg once daily</td><td align=\"center\"> 37.5 mg once daily</td><td align=\"center\"> 25 mg once daily</td></tr><tr><td> Second dose reduction</td><td align=\"center\"> 25 mg once daily</td><td align=\"center\"> 25 mg once daily</td><td align=\"center\"> NA</td><td align=\"center\"> NA</td></tr></tbody></table>",
      "<table width=\"1000px\" cellspacing=\"0\" cellpadding=\"5\"><col width=\"114.3pt\"/><col width=\"114.3pt\"/><col width=\"114.3pt\"/><tbody><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Severity</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Dosage Modifications for Sunitinib Malate Capsules</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Hepatotoxicity <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_adcd7799-f2c5-4708-963e-7af21e95b4ed\">5.1</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Grade 3</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item><item><content styleCode=\"xmChange\">For recurring Grade 3 permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Grade 4</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Cardiovascular events <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_e28ea320-c7d4-4290-b82d-b37625f4861e\">5.2</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Clinically manifested congestive heart failure (CHF)</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Hypertension <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_8b54ae79-2b4a-4eca-a38b-c48f77974d9e\">5.4</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Grade 3</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Grade 4</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Hemorrhagic events <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_9e057e6e-d9e9-4ce3-a0fa-df7074545b8c\">5.5</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Grade 3 or 4</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Thrombotic microangiopathy <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_69b88b83-66d6-43fe-b7fb-5ba05af6a6d9\">5.7</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Any Grade</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_467fcc32-240a-4366-9c44-0a4177c41cff\">5.8</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_af3a4849-07cd-47ff-9078-da48eaff362b\">5.9</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Any Grade</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_65feff95-8f29-45e4-8b52-21fca7397c30\">5.10</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Any Grade</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Osteonecrosis of the jaw <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_a43314d2-d140-45b9-ab5f-b9462ff61c38\">5.13</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Any Grade</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Impaired wound healing <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_42c613d0-91d5-4619-bc04-0febeb1be906\">5.14</linkHtml>)] </content></paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Any Grade</paragraph></td><td styleCode=\"Botrule Lrule Rrule Toprule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS 12.5 mg sunitinib malate capsules: yellow to orange-yellow granules filled in hard gelatin capsule with orange opaque cap and orange opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c12.5 mg\u201d on the body with white ink. 25 mg sunitinib malate capsules: yellow to orange-yellow granules filled in hard gelatin capsule with caramel opaque cap and orange opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c25 mg\u201d on the body with white ink. 37.5 mg sunitinib malate capsules: yellow to orange-yellow granules filled in hard gelatin capsule with yellow opaque cap and yellow opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c37.5 mg\u201d on the body with black ink. 50 mg sunitinib malate capsules: yellow to orange-yellow granules filled in hard gelatin capsule with caramel opaque cap and caramel opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c50 mg\u201d on the body with white ink. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib. ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline and resume sunitinib malate at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. ( 2.4 , 5.1 ) Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) QT Interval Prolongation and Torsade de Pointes : Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib malate for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients who develop Grade 4 hypertension. ( 5.4 ) Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ) Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) Thrombotic microangiopathy (TMA) : TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate for TMA. ( 5.7 ) Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate for these events. ( 5.9 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate until resolution. ( 5.10 ) Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib malate for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 ) Impaired Wound Healing : Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. ( 5.14 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u226550% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate. Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration ( 2.5 ), Drug Interactions ( 7.2 )] . 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3 to 5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib malate. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life\u2011threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra\u2011abdominal malignancies treated with sunitinib malate. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate as monotherapy and administered in combination with bevacizumab. Sunitinib malate is not approved for use in combination with bevacizumab. Discontinue sunitinib malate in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n = 577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n = 83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate and periodically during sunitinib malate therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate for development of ONJ until complete resolution. The safety of resumption of sunitinib malate after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate [see Adverse Reactions ( 6.2 )] . Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 times and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for 4 weeks following the final dose [see Use in Specific Populations ( 8.1 , 8.3 )] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Cardiovascular Events [see Warnings and Precautions ( 5.2 )] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions ( 5.3 )] Hypertension [see Warnings and Precautions ( 5.4 )] Hemorrhagic Events [see Warnings and Precautions ( 5.5 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.6 )] Thrombotic Microangiopathy [see Warnings and Precautions ( 5.7 )] Proteinuria [see Warnings and Precautions ( 5.8 )] Dermatologic Toxicities [see Warnings and Precautions ( 5.9 )] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions ( 5.10 )] Thyroid Dysfunction [see Warnings and Precautions ( 5.11 )] Hypoglycemia [see Warnings and Precautions ( 5.12 )] Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.13 )] Impaired Wound Healing [see Warnings and Precautions ( 5.14 )] The most common adverse reactions (\u226525%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novugen Pharma (USA) LLC at 1-888-966-8843 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7,527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u226525%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n = 202) or placebo (n = 102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate (mean: 3.0; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u226510% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reaction GIST Sunitinib Malate (N = 202) Placebo (N = 102) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia a 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST = gastrointestinal stromal tumor; N = number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u226510% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib Malate (N = 202) Placebo (N = 102) All Grades* % Grade 3 to 4* ,a % All Grades* % Grade 3 to 4* ,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; GIST = gastrointestinal stromal tumor; LVEF = left ventricular ejection fraction; N = number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis , the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate [see Clinical Studies ( 14.1 )] . For 241 patients randomized to the sunitinib malate arm, including 139 who received sunitinib malate in both the double-blind and open-label phases, the median duration of sunitinib malate treatment was 6 cycles (mean: 8.5; range: 1 to 44). For the 255 patients who ultimately received open-label sunitinib malate treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1 to 37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n = 375) or interferon alfa 9 million International Units (MIU) (n = 360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u226510% of Patients with RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib Malate (N = 375) Interferon Alfa (N = 360) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 <1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 <1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain c 30 5 12 1 Constipation 23 1 14 <1 Dry mouth 13 0 7 <1 Oral pain 14 <1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 <1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 <1 Weight decreased 16 <1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 <1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e 47 <1 15 0 Headache 23 1 19 0 Dizziness 11 <1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension 34 13 4 <1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 <1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 <1 0 0 Dry skin 23 <1 7 0 Hair color changes 20 0 <1 0 Alopecia 14 0 9 0 Erythema 12 <1 1 0 Pruritus 12 <1 7 <1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 <1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 <1 2 0 Upper respiratory tract infection 11 <1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 <1 10 0 Depression g 11 0 14 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma. a Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u226510% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib Malate (N = 375) Interferon Alfa (N = 360) All Grades* % Grade 3 to 4* ,a % All Grades* % Grade 3 to 4* ,b % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 <1 51 <1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 <1 Potassium increased 16 3 17 4 Calcium increased 13 <1 10 1 Potassium decreased 13 1 2 <1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; RCC = renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). Long-Term Safety in RCC The long-term safety of sunitinib malate in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5,739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n = 306) or placebo (n = 304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u226510% of Patients with RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib Malate (N = 306) Placebo (N = 304) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a 61 6 15 0 Diarrhea 57 4 22 <1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain b 25 2 9 <1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema c 18 <1 <1 0 Pyrexia 12 <1 6 0 Dermatology Hand-foot syndrome 50 16 10 <1 Rash d 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension e 39 8 14 1 Edema/Peripheral edema 10 <1 7 0 Neurology Altered taste f 38 <1 6 0 Headache 19 <1 12 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage/Bleeding Bleeding events, all sites g 24 <1 5 <1 Metabolism/Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Pain in extremity 15 <1 7 0 Arthralgia 11 <1 10 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. Grade 4 adverse reactions in patients on sunitinib malate included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%). Grade 3 to 4 laboratory abnormalities that occurred in \u22652% of patients receiving sunitinib malate include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate 37.5 mg once daily (n = 83) or placebo (n = 82). The median number of days on treatment was 139 days (range: 13 days to 532 days) for patients on sunitinib malate and 113 days (range: 1 day to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u226510% of Patients with pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib Malate (N = 83) Placebo (N = 82) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes b 48 6 18 0 Nausea 45 1 29 1 Abdominal pain c 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events d 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N = number of patients; pNET = pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u226510% of Patients with pNET Who Received Sunitinib Malate in Study 6 Laboratory Abnormality pNET Sunitinib Malate Placebo All Grades* % Grade 3 to 4* ,a % All Grades* % Grade 3 to 4* ,b % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; pNET = pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3 to 4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on sunitinib malate. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia * . Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema. Infections and infestations: serious infection (with or without neutropenia) * . The infections most commonly observed with sunitinib malate include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression * ; myopathy and/or rhabdomyolysis with or without acute renal failure * . Renal and urinary disorders: renal impairment and/or failure * . Respiratory disorders: pulmonary embolism * , pleural effusion * . Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de\u2011challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections * , and rupture * ; arterial thromboembolic events * . The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. * including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 3. Adverse Reactions Reported in &#x2265;10% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1</caption><col width=\"171.35pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N = 202)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N = 102)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4 %</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4 %</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>94</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>97</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>51</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Anorexia <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Skin discoloration</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Altered taste</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Myalgia/limb pain</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: GIST = gastrointestinal stromal tumor; N = number of patients.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Includes decreased appetite. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 4. Laboratory Abnormalities Reported in &#x2265;10% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1</caption><col width=\"187.8pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N = 202)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N = 102)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4* <sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4* <sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Any <content styleCode=\"bold\">Laboratory Abnormality</content></content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>22</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> AST/ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Decreased LVEF</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; GIST = gastrointestinal stromal tumor; LVEF = left ventricular ejection fraction; N = number of patients.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 5. Adverse Reactions Reported in &#x2265;10% of Patients with RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3</caption><col width=\"183.95pt\"/><col width=\"91.7pt\"/><col width=\"91.7pt\"/><col width=\"91.7pt\"/><col width=\"91.7pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N = 375)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa (N = 360)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4 <sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4 <sup>b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>55</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dry mouth</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Oral pain</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Flatulence</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> GERD/reflux esophagitis</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Glossodynia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hemorrhoids</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>62</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Fever</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Chills</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Chest Pain</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Influenza like illness</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Anorexia <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Altered taste <sup>e</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Bleeding, all sites</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4 <sup>f</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Edema peripheral</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Ejection fraction decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Skin discoloration/yellow skin</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Alopecia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Erythema</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Pruritus</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Pain in extremity/limb discomfort</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Back pain</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Respiratory</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Cough</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dyspnea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Oropharyngeal pain</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Upper respiratory tract infection</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hypothyroidism</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Depression <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (&lt;1%), dyspnea (&lt;1%), asthenia (&lt;1%), fatigue (&lt;1%), limb pain (&lt;1%), and rash (&lt;1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (&lt;1%), and depression (&lt;1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Includes flank pain. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup>Includes decreased appetite. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>e</sup>Includes ageusia, hypogeusia, and dysgeusia. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>f</sup>Includes 1 patient with Grade 5 gastric hemorrhage. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>g</sup>Includes depressed mood. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 6. Laboratory Abnormalities Reported in &#x2265;10% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3</caption><col width=\"187.8pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N = 375)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa (N = 360)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4* <sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4* <sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Creatine kinase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Uric acid increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Calcium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; RCC = renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (&lt;1%), creatine kinase (&lt;1%), creatinine (&lt;1%), glucose increased (&lt;1%), calcium decreased (&lt;1%), phosphorous (&lt;1%), potassium increased (&lt;1%), and sodium decreased (&lt;1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (&lt;1%), calcium increased (&lt;1%), glucose decreased (&lt;1%), potassium increased (&lt;1%), and hemoglobin (&lt;1%). </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 7. Adverse Reactions Reported in &#x2265;10% of Patients with RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC</caption><col width=\"187.45pt\"/><col width=\"90.7pt\"/><col width=\"90.7pt\"/><col width=\"90.7pt\"/><col width=\"90.7pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adjuvant Treatment of RCC</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N = 306)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N = 304)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Mucositis/Stomatitis <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Abdominal pain <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Fatigue/Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Localized edema <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Pyrexia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Rash <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Skin discoloration/Yellow skin</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hypertension <sup>e</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Edema/Peripheral edema</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Altered taste <sup>f</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph> 19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hypothyroidism/TSH increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Bleeding events, all sites <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Anorexia/Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Includes abdominal pain, abdominal pain lower, and abdominal pain upper. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup>Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>e</sup>Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>f</sup>Includes ageusia, hypogeusia, and dysgeusia. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>g</sup>Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 8. Adverse Reactions Reported in &#x2265;10% of Patients with pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6</caption><col width=\"171.35pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N = 83)</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N = 82)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4 <sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>95</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>50</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Stomatitis/oral syndromes <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Bleeding events <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Epistaxis</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: N = number of patients; pNET = pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Includes abdominal discomfort, abdominal pain, and abdominal pain upper. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup>Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 9. Laboratory Abnormalities Reported in &#x2265;10% of Patients with pNET Who Received Sunitinib Malate in Study 6</caption><col width=\"146.15pt\"/><col width=\"101.4pt\"/><col width=\"101.4pt\"/><col width=\"101.4pt\"/><col width=\"101.4pt\"/><tbody><tr><td rowspan=\"3\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td colspan=\"4\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4* <sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3 to 4* <sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>72</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/><td align=\"center\" styleCode=\"Rrule Toprule\"/></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Magnesium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>* The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; pNET = pancreatic neuroendocrine tumors. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). </paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers : Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co\u2011administered with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.5 )] . Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co\u2011administered with CYP3A4 inducers [see Dosage and Administration ( 2.5 )] . 7.2 Drugs that Prolong QT Interval Sunitinib malate is associated with QTc interval prolongation [see Warnings and Precautions ( 5.3 ), Clinical Pharmacology ( 12.2 )] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 times and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5 mg/kg/day, 1.5 mg/kg/day, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3 mg/kg/day, 1.5 mg/kg/day, 3 mg/kg/day, 5 mg/kg/day) and rabbits (0.5 mg/kg/day, 1 mg/kg/day, 5 mg/kg/day, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3 mg/kg/day, 1 mg/kg/day, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3-month dosing 2 mg/kg/day, 6 mg/kg/day, 12 mg/kg/day; 8 cycles of dosing 0.3 mg/kg/day, 1.5 mg/kg/day, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5 mg/kg, 5.0 mg/kg, and 15.0 mg/kg) or 5 cycles (0.3 mg/kg/day, 1.5 mg/kg/day, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology ( 12.3 )] . Sunitinib malate was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 mL/min to 80 mL/min), moderate (CLcr 30 mL/min to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology ( 12.3 )] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 times and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5 mg/kg/day, 1.5 mg/kg/day, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3 mg/kg/day, 1.5 mg/kg/day, 3 mg/kg/day, 5 mg/kg/day) and rabbits (0.5 mg/kg/day, 1 mg/kg/day, 5 mg/kg/day, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3 mg/kg/day, 1 mg/kg/day, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3-month dosing 2 mg/kg/day, 6 mg/kg/day, 12 mg/kg/day; 8 cycles of dosing 0.3 mg/kg/day, 1.5 mg/kg/day, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5 mg/kg, 5.0 mg/kg, and 15.0 mg/kg) or 5 cycles (0.3 mg/kg/day, 1.5 mg/kg/day, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3,000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate acid. The molecular formula is C 22 H 27 FN 4 O 2 \u2022 C 4 H 6 O 5 and the molecular weight is 532.6 g/mol. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow or orange-yellow powder with a pKa of 8.95. The solubility of sunitinib malate is slightly soluble in water, practically insoluble in ethanol. Sunitinib malate capsules are supplied as printed hard-shell capsules containing 12.5 mg, 25 mg, 37.5 mg, and 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, and 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone. The orange gelatin capsule shells contain red iron oxide, and titanium dioxide; the caramel gelatin capsule shells contain black iron oxide, red iron oxide, titanium dioxide, and yellow iron oxide; and the yellow gelatin capsule shells contain titanium dioxide, and yellow iron oxide. The white printing ink contains potassium hydroxide, propylene glycol, shellac, and titanium dioxide and the black printing ink contains black iron oxide, potassium hydroxide, propylene glycol, and shellac. image description"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions ( 5.3 )]. 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 times to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3-fold to 4-fold while the primary metabolite accumulates 7-fold to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 days to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 ng/mL to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 hours to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2,230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 ng/mL to 4,000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 hours to 60 hours and 80 hours to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 L/h to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radio-labeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radio-labeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 years to 84 years), body weight (34 kg to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 mL/min to 80 mL/min), moderate (CLcr 30 mL/min to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions ( 5.3 )]."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 times to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3-fold to 4-fold while the primary metabolite accumulates 7-fold to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 days to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 ng/mL to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 hours to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2,230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 ng/mL to 4,000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 hours to 60 hours and 80 hours to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 L/h to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radio-labeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radio-labeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 years to 84 years), body weight (34 kg to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 mL/min to 80 mL/min), moderate (CLcr 30 mL/min to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 month or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5 mg/kg/day, 1.5 mg/kg/day, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2 mg/kg/day, 6 mg/kg/day, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3 mg/kg/day, 1.5 mg/kg/day, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1 mg/kg/day, 3 mg/kg/day, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 month or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5 mg/kg/day, 1.5 mg/kg/day, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2 mg/kg/day, 6 mg/kg/day, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3 mg/kg/day, 1.5 mg/kg/day, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1 mg/kg/day, 3 mg/kg/day, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double\u2011blind, placebo\u2011controlled trial of sunitinib malate in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression\u2011free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate and patients randomized to sunitinib malate were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate and placebo groups with regard to age (69% versus 72% <65 years for sunitinib malate versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results from Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib Malate (N = 207) Placebo (N = 105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) <0.0001 A comparison is considered statistically significant if the p-value is <0.00417 (O'Brien Fleming stopping boundary). 0.33 (0.23, 0.47) Progression-free survival Time from randomization to progression or death due to any cause. [median, weeks (95% CI)] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) <0.0001 0.33 (0.24, 0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7, 11.1) 0 0.006 Pearson chi-square test. Abbreviations: CI = confidence interval; GIST = gastrointestinal stromal tumor; HR = hazard ratio; N = number of patients; PR = partial response. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI = confidence interval; GIST = gastrointestinal stromal tumor; N = number of patients; TTP = time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis , the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate in the open\u2011label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate arm and 64.9 weeks for the placebo arm [hazard ratio (HR) = 0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). image description 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate and interferon alfa groups with regard to age (59% versus 67% <65 years for sunitinib malate versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \u22641.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate over interferon alfa. The ORR was higher in the sunitinib malate arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib Malate (N = 375) Interferon Alfa (N = 375) p-value (log-rank test) HR (95% CI) Progression-free survival a 47.3 22.0 <0.000001 b 0.415 [median, weeks (95% CI)] (42.6, 50.7) (16.4, 24.0) (0.320, 0.539) Objective response rate a 27.5 5.3 <0.001 c NA [%, (95% CI)] (23.0, 32.3) (3.3, 8.1) Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; RCC = renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is <0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI = confidence interval; IFN-\u03b1 = interferon-alfa; N = number of patients; PFS = progression-free survival; RCC = renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR = 0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib malate. Cytokine-Refractory The use of single-agent sunitinib malate in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 years to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N = 106) Study 5 (N = 63) Objective response rate [%, (95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR * (42.0, * ) 54 b (34.3, 70.1) * Data not mature enough to determine upper confidence limit. Abbreviations: CI = confidence interval; N = number of patients; NR = not reached; RCC = renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib Malate N = 309 Placebo N = 306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR = blinded independent central review; CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; RCC = renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/ Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Malate Placebo Sunitinib Malate Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; n = number of events; NR = not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u2265 1 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u2265 2, ECOG PS \u2265 1 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR = blinded independent central review; CI = confidence interval; N = number of patients. image description image description 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate (N = 86) or placebo (N = 85) once daily without a scheduled off- treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate and placebo groups. Additionally, 49% of sunitinib malate patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib Malate (N = 86) Placebo (N = 85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 a 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; pNET = pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI = confidence interval; N = number of patients; PFS = progression-free survival; pNET = pancreatic neuroendocrine tumors. image description"
    ],
    "clinical_studies_table": [
      "<table width=\"100%\"><caption> Table 10. GIST Efficacy Results from Study 1 (Double-Blind Treatment Phase)</caption><tbody><tr><td align=\"center\"><content styleCode=\"bold\"> Efficacy Parameter</content></td><td align=\"center\"><content styleCode=\"bold\">Sunitinib Malate</content> <content styleCode=\"bold\">(N = 207) </content></td><td align=\"center\"><content styleCode=\"bold\"> Placebo</content> <content styleCode=\"bold\">(N = 105)</content></td><td align=\"center\"><content styleCode=\"bold\">p-value (log-rank test)</content></td><td align=\"center\"><content styleCode=\"bold\"> HR</content> <content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td> Time-to-tumor progression <footnote ID=\"La5e466a8-a3c9-4dd1-9a61-ace5f05492a0\">Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation.</footnote>  [median, weeks (95% CI)] </td><td align=\"center\"> 27.3   (16.0, 32.1) </td><td align=\"center\"> 6.4   (4.4, 10.0) </td><td align=\"center\">&lt;0.0001 <footnote ID=\"L97ff0c70-4531-4ef4-b738-989dabc2b65d\">A comparison is considered statistically significant if the p-value is &lt;0.00417 (O&apos;Brien Fleming stopping boundary).</footnote></td><td align=\"center\"> 0.33   (0.23, 0.47) </td></tr><tr><td> Progression-free survival <footnote ID=\"La09d2b23-7a0b-4f5c-ae31-afd33bb25e97\">Time from randomization to progression or death due to any cause.</footnote>  [median, weeks (95% CI)] </td><td align=\"center\"> 24.1   (11.1, 28.3) </td><td align=\"center\"> 6.0   (4.4, 9.9) </td><td align=\"center\">&lt;0.0001</td><td align=\"center\"> 0.33   (0.24, 0.47) </td></tr><tr><td> Objective response rate (PR)   [%, (95% CI)] </td><td align=\"center\"> 6.8   (3.7, 11.1) </td><td align=\"center\"> 0</td><td align=\"center\">0.006 <footnote ID=\"L8b3e64ac-ed98-49a4-82c5-5d68d89d243b\">Pearson chi-square test.</footnote></td><td/></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 11. Treatment-Na&#xEF;ve RCC Efficacy Results (Interim Analysis) from Study 3</caption><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph>Progression-free survival <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>47.3</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>22.0</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>&lt;0.000001 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>0.415</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>(42.6, 50.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>(16.4, 24.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"><paragraph>(0.320, 0.539)</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule Toprule\"><paragraph>Objective response rate <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"><paragraph>27.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"><paragraph>5.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"><paragraph>&lt;0.001 <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Lrule Rrule\"><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>(23.0, 32.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule\"><paragraph>(3.3, 8.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule\"/><td align=\"center\" styleCode=\"Rrule\"/></tr><tr><td colspan=\"5\" styleCode=\"Toprule\"><paragraph>Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; RCC = renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Assessed by blinded core radiology laboratory; 90 patients&#x2019; scans had not been read at time of analysis. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>A comparison is considered statistically significant if the p-value is &lt;0.0042 (O&#x2019;Brien Fleming stopping boundary). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Pearson chi-square test. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5</caption><col width=\"192pt\"/><col width=\"192pt\"/><col width=\"192pt\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Study 4</content></paragraph><paragraph><content styleCode=\"bold\">(N = 106)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Study 5</content></paragraph><paragraph><content styleCode=\"bold\">(N = 63)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>34.0 <sup>a</sup></paragraph><paragraph>(25.0, 43.8)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>36.5 <sup>b</sup></paragraph><paragraph>(24.7, 49.6)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Duration of response</paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>NR <sup>*</sup></paragraph><paragraph>(42.0, <sup>*</sup>) </paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>54 <sup>b</sup></paragraph><paragraph>(34.3, 70.1)</paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>*</sup>Data not mature enough to determine upper confidence limit. </paragraph></td></tr><tr><td colspan=\"3\"><paragraph>Abbreviations: CI = confidence interval; N = number of patients; NR = not reached; RCC = renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>a</sup>Assessed by blinded core radiology laboratory. </paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>b</sup>Assessed by investigators. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC</caption><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">N = 309</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">N = 306</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value <sup>a</sup></content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR <sup>a</sup>(95% CI) </content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Median DFS [years (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>6.8 (5.8, NR)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>5.6 (3.8, 6.6)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.03</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.76 (0.59, 0.98)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>DFS Events</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>113 (36.6%)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>144 (47.1%)</paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>5 Year DFS Rate</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>59.3%</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>51.3%</paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"/></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group </paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: BICR = blinded independent central review; CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; RCC = renal cell carcinoma.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 14. Disease-free Survival by Baseline Disease Characteristics</caption><col width=\"164.85pt\"/><col width=\"158px\"/><col width=\"158px\"/><col width=\"158px\"/><col width=\"158px\"/><col width=\"158px\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"/><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Number of Events/ Total</content></paragraph><paragraph><content styleCode=\"bold\">n/N</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Median DFS</content></paragraph><paragraph><content styleCode=\"bold\">[years (95% CI)]</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR <sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"/><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"/></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>T3 Intermediate <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>35/115</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>46/112</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>NR</paragraph><paragraph>(5.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>6.4</paragraph><paragraph>(4.7, NR)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.82</paragraph><paragraph>(0.53, 1.28)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>T3 High <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>63/165</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>79/166</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>6.8</paragraph><paragraph>(5.0, NR)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>5.3</paragraph><paragraph>(2.9, NR)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.77</paragraph><paragraph>(0.55, 1.07)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>T4/Node Positive <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>15/29</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>19/28</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>3.5</paragraph><paragraph>(1.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>1.7</paragraph><paragraph>(0.4, 3.0)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.62</paragraph><paragraph>(0.31, 1.23)</paragraph></td></tr><tr><td colspan=\"6\"><paragraph>Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; n = number of events; NR = not reached</paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>a</sup>HR based on a Cox proportional hazards model </paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>b</sup>T3 Intermediate: T3, N0 or NX, M0, any Fuhrman&#x2019;s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman&#x2019;s grade 1, ECOG PS &#x2265; 1 </paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>c</sup>T3 High: T3, N0 or NX, M0, Fuhrman&#x2019;s grade &#x2265; 2, ECOG PS &#x2265; 1 </paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>d</sup>T4/Node Positive: T4, N0 or NX, M0, any Fuhrman&#x2019;s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman&#x2019;s grade, any ECOG PS </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 15. pNET Efficacy Results from Study 6</caption><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N = 86)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 85)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Progression-free survival</paragraph><paragraph>[median, months (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>10.2</paragraph><paragraph>(7.4, 16.9)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>5.4</paragraph><paragraph>(3.4, 6.0)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.000146 <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.427</paragraph><paragraph>(0.271, 0.673)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>9.3</paragraph><paragraph>(3.2, 15.4)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>0.0066 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph>NA</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; pNET = pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>2-sided unstratified log-rank test. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Fisher&#x2019;s Exact test. </paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Sunitinib malate capsules, 12.5 mg are supplied as yellow to orange-yellow granules filled in hard gelatin capsule with orange opaque cap and orange opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c12.5 mg\u201d on the body with white ink. Bottles of 28 capsules: NDC 82293-014-10 Sunitinib malate capsules, 25 mg are supplied as yellow to orange-yellow granules filled in hard gelatin capsule with caramel opaque cap and orange opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c25 mg\u201d on the body with white ink. Bottles of 28 capsules: NDC 82293-015-10 Sunitinib malate capsules, 37.5 mg are supplied as yellow to orange-yellow granules filled in hard gelatin capsule with yellow opaque cap and yellow opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c37.5 mg\u201d on the body with black ink. Bottles of 28 capsules: NDC 82293-016-10 Sunitinib malate capsules, 50 mg are supplied as yellow to orange-yellow granules filled in hard gelatin capsule with caramel opaque cap and caramel opaque body, imprinted with \u201cSTN\u201d on the cap and \u201c50 mg\u201d on the body with white ink. Bottles of 28 capsules: NDC 82293-017-10 Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Dispense in tight containers (USP)."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions ( 5.1 )] . Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions ( 5.2 )] . QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions ( 5.3 )] . Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions ( 5.4 )] . Hemorrhagic Events Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions ( 5.5 )] . Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate capsules treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate capsules [see Warnings and Precautions ( 5.5 ), Adverse Reactions ( 6.1 )] . Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate capsules due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions ( 5.9 ), Adverse Reactions ( 6.1 )] . Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] . Thyroid Dysfunction Advise patients that sunitinib malate capsules can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions ( 5.11 )] . Hypoglycemia Advise patients that sunitinib malate capsules can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions ( 5.12 )] . Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] . Impaired Wound Healing Advise patients that sunitinib malate capsules impairs wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions ( 5.14 )] . Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions ( 7 )] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.15 ), Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations ( 8.3 )] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations ( 8.3 )] . Lactation Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [see Use in Specific Populations ( 8.2 )] . Infertility Advise patients that sunitinib malate capsules may impair male and female fertility [see Use in Specific Populations ( 8.3 ), Nonclinical Toxicology ( 13.1 )] . Missed Dose Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time. Distributed by: Novugen Pharma (USA) LLC 100 Overlook Center Princeton, NJ 08540, USA MADE IN INDIA Revised: 4/2023"
    ],
    "spl_medguide": [
      "MEDICATION GUIDE Sunitinib Malate (soo ni\u2032 ti nib mal\u2032 ate) Capsules What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201c What are the possible side effects of sunitinib malate capsules? \u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are a prescription medicine used to treat: a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate. advanced kidney cancer (advanced renal cell carcinoma or RCC). adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: have any heart problems have high blood pressure have thyroid problems have a history of low blood sugar or diabetes have kidney function problems (other than cancer) have liver problems have any bleeding problem plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d have seizures have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsules 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too much sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules you feel faint or lightheaded, or you pass out dizziness feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache lightheadedness dizziness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) vomiting blood coughing up blood black, sticky stools bloody urine headache change in your mental status Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away loss of appetite problems with heat feeling nervous or agitated, tremors sweating nausea or vomiting diarrhea fast heat rate weight gain or weight loss feeling depressed irregular menstrual periods or no menstrual periods headache hair loss Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: headache drowsiness weakness dizziness confusion irritability hunger fast heart beat sweating feeling jittery Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness weakness diarrhea pain, swelling or sores inside of your mouth nausea loss of appetite indigestion vomiting stomach-area (abdominal) pain blisters or rash on the palms of your hands and soles of your feet high blood pressure taste changes low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone. Orange gelatin capsule shells: red iron oxide, and titanium dioxide. Caramel gelatin capsule shells: black iron oxide, red iron oxide, titanium dioxide, and yellow iron oxide. Yellow gelatin capsule shells: titanium dioxide, and yellow iron oxide. White printing ink: potassium hydroxide, propylene glycol, shellac, and titanium dioxide. Black printing ink: black iron oxide, potassium hydroxide, propylene glycol, and shellac. Distributed by: Novugen Pharma (USA) LLC 100 Overlook Center Princeton, NJ 08540, USA MADE IN INDIA For more information, call Novugen Pharma (USA) LLC at 1-888-966-8843. This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: April 2023"
    ],
    "spl_medguide_table": [
      "<table width=\"1000px\" cellspacing=\"0\" cellpadding=\"5\"><col width=\"500px\"/><col width=\"500px\"/><tbody><tr><td colspan=\"2\" align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">MEDICATION GUIDE</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib Malate (soo ni&#x2032; ti nib mal&#x2032; ate)</content></paragraph><paragraph><content styleCode=\"bold\">Capsules</content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules can cause serious side effects including:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content><list listType=\"unordered\" styleCode=\"Circle\"><item>itching</item><item>yellow eyes or skin</item><item>dark urine</item><item>pain or discomfort in the right upper stomach area</item></list></item></list><paragraph>Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems.</paragraph>See <content styleCode=\"bold\">&#x201C;</content><content styleCode=\"bold\">What are the possible side effects of sunitinib malate capsules?</content><content styleCode=\"bold\">&#x201D;</content>for more information about side effects. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">What are sunitinib malate capsules?</content></paragraph><paragraph>Sunitinib malate capsules are a prescription medicine used to treat:</paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: <list listType=\"unordered\" styleCode=\"Circle\"><item>you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or</item><item>you cannot take imatinib mesylate.</item></list></item><item>advanced kidney cancer (advanced renal cell carcinoma or RCC).</item><item>adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.</item><item>a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.</item></list>It is not known if sunitinib malate capsules are safe and effective in children. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>have any heart problems</item><item>have high blood pressure</item><item>have thyroid problems</item><item>have a history of low blood sugar or diabetes</item><item>have kidney function problems (other than cancer)</item><item>have liver problems</item><item>have any bleeding problem</item><item>plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D;</content></item><item>have seizures</item><item>have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth</item><item>are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. <paragraph><content styleCode=\"bold\">Females</content>who are able to become pregnant: </paragraph><list listType=\"unordered\" styleCode=\"Circle\"><item>Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules.</item><item>You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules.</item><item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.</item></list></item></list><paragraph><content styleCode=\"bold\">Males</content>with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. </paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose.</item></list>Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any</content>surgery, or medical or dental procedure. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content>including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. </paragraph><paragraph>You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell</content>your healthcare provider if you are taking or have taken an osteoporosis medicine. </paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">How should I take sunitinib malate capsules?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Take sunitinib malate capsules exactly the way your healthcare provider tells you.</item><item>Take sunitinib malate capsules 1 time each day with or without food.</item><item>If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks   (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. </item><item>If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.</item><item>Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body.</item><item>Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.</item><item>If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.</item><item>Call your healthcare provider right away, if you take too much sunitinib malate capsules.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">What are possible side effects of sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules may cause serious side effects, including:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>See <content styleCode=\"bold\">&#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content></item><item><content styleCode=\"bold\">Heart problems.</content>Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. </item><item><content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening.</content>Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules </item></list></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>you feel faint or lightheaded, or you pass out</item><item>dizziness</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item> feel your heart beat is irregular or fast</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\"><item><content styleCode=\"bold\">High blood pressure.</content>High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: </item></list></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>severe headache</item><item>lightheadedness</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>dizziness</item><item>change in vision</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><paragraph>Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed.</paragraph><list listType=\"unordered\"><item><content styleCode=\"bold\">Bleeding problems.</content>Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: </item></list></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>painful, swollen stomach (abdomen)</item><item>vomiting blood</item><item>coughing up blood</item><item>black, sticky stools</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>bloody urine</item><item>headache </item><item>change in your mental status</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Serious stomach and intestinal problems, that can sometimes lead to death.</content>Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. </item><item><content styleCode=\"bold\">Tumor lysis syndrome (TLS).</content>TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. </item><item><content styleCode=\"bold\">Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]).</content>RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. </item><item><content styleCode=\"bold\">Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS).</content>TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brain and kidneys, and can sometimes lead to death. </item><item><content styleCode=\"bold\">Protein in your urine.</content>Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. </item><item><content styleCode=\"bold\">Serious skin and mouth reactions. </content>Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: <list listType=\"unordered\" styleCode=\"Circle\"><item>severe rash with blisters or peeling of the skin.</item><item>painful sores or ulcers on the skin, lips or inside the mouth.</item><item>tissue damage (necrotizing fasciitis).</item></list></item></list><paragraph>If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away.</paragraph><list listType=\"unordered\"><item><content styleCode=\"bold\">Thyroid problems.</content>Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: </item></list></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>tiredness that gets worse and does not go away</item><item>loss of appetite</item><item>problems with heat</item><item>feeling nervous or agitated, tremors</item><item>sweating</item><item>nausea or vomiting</item><item>diarrhea</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>fast heat rate</item><item>weight gain or weight loss</item><item>feeling depressed</item><item>irregular menstrual periods or no menstrual periods</item><item>headache</item><item>hair loss</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\"><item><content styleCode=\"bold\"><content styleCode=\"bold\">Low blood sugar (hypoglycemia). </content></content>Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: </item></list></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>headache</item><item>drowsiness</item><item>weakness</item><item>dizziness</item><item>confusion</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>irritability</item><item>hunger</item><item>fast heart beat</item><item>sweating</item><item>feeling jittery</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Jawbone problems (osteonecrosis).</content>Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.</item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures.</item></list></item><item><content styleCode=\"bold\">Wound healing problems. </content>Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.</item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.</item></list></item></list><paragraph><content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects.</content></paragraph><content styleCode=\"bold\">Common side effects of sunitinib malate capsules include:</content></td></tr><tr><td styleCode=\"Lrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>tiredness</item><item>weakness</item><item>diarrhea</item><item>pain, swelling or sores inside of your mouth</item><item>nausea</item><item>loss of appetite</item><item>indigestion</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>vomiting</item><item>stomach-area (abdominal) pain</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>high blood pressure</item><item>taste changes</item><item>low platelet counts</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule\"><paragraph>The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.</paragraph><paragraph>These are not all of the possible side effects of sunitinib malate capsules.</paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule\"><paragraph><content styleCode=\"bold\">How do I store sunitinib malate capsules?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Store sunitinib malate capsules at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item></list><paragraph><content styleCode=\"bold\"><content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content></content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">What are the ingredients in sunitinib malate capsules?</content></paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\">Active ingredient:</content>sunitinib malate </paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\">Inactive ingredients:</content>croscarmellose sodium, magnesium stearate, mannitol, and povidone. </paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\">Orange gelatin capsule shells:</content>red iron oxide, and titanium dioxide. </paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\"> Caramel gelatin capsule shells:</content>black iron oxide, red iron oxide, titanium dioxide, and yellow iron oxide. </paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\"> Yellow gelatin capsule shells:</content>titanium dioxide, and yellow iron oxide. </paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\"> White printing ink:</content>potassium hydroxide, propylene glycol, shellac, and titanium dioxide. </paragraph><paragraph styleCode=\"TableParagraph\"><content styleCode=\"bold\"> Black printing ink:</content>black iron oxide, potassium hydroxide, propylene glycol, and shellac. </paragraph><paragraph/><paragraph>Distributed by:  <content styleCode=\"bold\">Novugen Pharma (USA) LLC</content>  100 Overlook Center   Princeton, NJ 08540, USA  <content styleCode=\"bold\">MADE IN INDIA</content>  For more information, call Novugen Pharma (USA) LLC at 1-888-966-8843. </paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "Principal Display Panel NDC 82293-014-10 Sunitinib Malate Capsules 12.5 mg* Dispense the accompanying Medication Guide to each patient. 28 Capsules Rx only image description",
      "Principal Display Panel NDC 82293-015-10 Sunitinib Malate Capsules 25 mg* Dispense the accompanying Medication Guide to each patient. 28 Capsules Rx only image description",
      "Principal Display Panel NDC 82293-016-10 Sunitinib Malate Capsules 37.5 mg* Dispense the accompanying Medication Guide to each patient. 28 Capsules Rx only image description",
      "Principal Display Panel NDC 82293-017-10 Sunitinib Malate Capsules 50 mg* Dispense the accompanying Medication Guide to each patient. 28 Capsules Rx only image description"
    ],
    "set_id": "04d34bce-1296-d2b9-e063-6394a90a7018",
    "id": "21d0ff80-d937-abb3-e063-6394a90af4b7",
    "effective_time": "20240910",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA218012"
      ],
      "brand_name": [
        "Sunitinib Malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Novugen Pharma (USA) LLC."
      ],
      "product_ndc": [
        "82293-014",
        "82293-015",
        "82293-016",
        "82293-017"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "21d0ff80-d937-abb3-e063-6394a90af4b7"
      ],
      "spl_set_id": [
        "04d34bce-1296-d2b9-e063-6394a90a7018"
      ],
      "package_ndc": [
        "82293-014-10",
        "82293-015-10",
        "82293-016-10",
        "82293-017-10"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0382293017102",
        "0382293015108"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE RED TITANIUM DIOXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque reddish brown cap opaque reddish brown body RM53;RM53 Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE RED FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE TITANIUM DIOXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque caramel cap opaque reddish brown body RM54;RM54 Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE YELLOW TITANIUM DIOXIDE FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque yellow cap opaque yellow body RM55;RM55 Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE RED FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE TITANIUM DIOXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque caramel cap opaque caramel body RM56;RM56"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib as recommended [see Warnings and Precautions (5.1)] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib as recommended [see Warnings and Precautions (5.1)]."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1) treatment of adult patients with advanced renal cell carcinoma (RCC). (1.2) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. (1.3) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. (1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). (2.1) Adjuvant Treatment of RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. (2.2) pNET : The recommended dosage is 37.5 mg orally once daily. (2.3) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions (5.1)] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. For recurring Grade 3 permanently discontinue. Grade 4 Permanently discontinue. Cardiovascular events [see Warnings and Precautions (5.2)] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) Withhold until resolution to Grade 0 to 1 or baseline. Resume at reduced dose. Clinically manifested congestive heart failure (CHF) Permanently discontinue. Hypertension [see Warnings and Precautions (5.4)] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Grade 4 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions (5.5)] Grade 3 or 4 Withhold until resolution to Grade 0 to 1 or baseline. Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions (5.7)] Any Grade Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8)] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9)] Any Grade Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] Any Grade Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions (5.13)] Any Grade The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions (5.14)] Any Grade The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions (7.1)] : GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1)] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"18%\"/><col width=\"18%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indications</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">RCC</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Advanced RCC</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adjuvant RCC</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>First dose reduction</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25 mg once daily</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Second dose reduction</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>25 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>25 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NA</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" width=\"100%\"><col width=\"28%\"/><col width=\"28%\"/><col width=\"44%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Adverse Reaction</content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Severity</content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dosage Modifications for Sunitinib Malate Capsules</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item>Hepatotoxicity <content styleCode=\"italics\">[see Warnings and Precautions (5.1)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Grade 3</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item><item>For recurring Grade 3 permanently discontinue.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Grade 4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item>Cardiovascular events <content styleCode=\"italics\">[see Warnings and Precautions (5.2)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than</item><item>20% but less than</item><item>50% below baseline or below the lower limit of normal if baseline was not obtained)</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at reduced dose.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Clinically manifested congestive heart failure (CHF)</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item>Hypertension <content styleCode=\"italics\">[see Warnings and Precautions (5.4)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Grade 3</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Grade 4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Hemorrhagic events <content styleCode=\"italics\">[see Warnings and Precautions (5.5)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Grade 3 or 4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Thrombotic microangiopathy <content styleCode=\"italics\">[see Warnings and Precautions (5.7)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Any Grade</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see Warnings and Precautions (5.8)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">3 or more grams proteinuria in</content></item><item><content styleCode=\"xmChange\">24 hours in the absence of nephrotic syndrome</content></item></list></td><td styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Nephrotic syndrome or recurrent proteinuria of 3 or more grams per</content></item><item><content styleCode=\"xmChange\">24 hours despite dose reductions</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see Warnings and Precautions (5.9)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see Warnings and Precautions (5.10)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Osteonecrosis of the jaw <content styleCode=\"italics\">[see Warnings and Precautions (5.13)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Impaired wound healing <content styleCode=\"italics\">[see Warnings and Precautions (5.14)]</content></content></item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS 12.5 mg capsules Hard gelatin capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM53\u2019 on cap and \u2018RM53\u2019 on body in white ink, containing yellow to orange colored powder. 25 mg capsules Hard gelatin capsule with opaque caramel cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM54\u2019 on cap and \u2018RM54\u2019 on body in white ink, containing yellow to orange colored powder. 37.5 mg capsules Hard gelatin capsule with opaque yellow cap and opaque yellow body, self-lock capsule, imprinted with \u2018RM55\u2019 on cap and \u2018RM55\u2019 on body in black ink, containing yellow to orange colored powder. 50 mg capsules Hard gelatin capsule with opaque caramel cap and opaque caramel body, self-lock capsule, imprinted with \u2018RM56\u2019 on cap and \u2018RM56\u2019 on body in white ink, containing yellow to orange colored powder. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib (3)"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib for Grade 3 hepatotoxicity until resolution Grade \u2264 1 or baseline and resume sunitinib at a reduced dose; discontinue if no resolution. Discontinue sunitinib in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. (2.4, 5.1) Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. (5.2) QT Interval Prolongation and Torsade de Pointes : Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. (5.3) Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients who develop Grade 4 hypertension. (5.4) Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. (5.5) Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. (5.6) Thrombotic microangiopathy (TMA) : TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib for TMA. (5.7) Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. (5.8) Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib for these events. (5.9) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib until resolution. (5.10) Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. (5.11) Hypoglycemia: Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (5.12) Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib for at least 3 weeks prior to invasive dental procedure and development of ONJ until complete resolution. (5.13) Impaired Wound Healing : Withhold sunitinib for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib after resolution of wound healing complications has not been established. (5.14) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (5.15, 8.1, 8.3) 5.1 Hepatotoxicity Sunitinib can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in < 1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib for Grade 3 hepatotoxicity until resolution to Grade \u2264 1 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST > 2.5 times upper limit of normal (ULN) or with > 5.0 times ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in < 1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u2265 50% or baseline by the time of last measurement. No patients who received sunitinib were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib in patients who experience clinical manifestations of CHF. Interrupt sunitinib and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in < 0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib. Monitor QT interval more frequently when sunitinib is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib [see Dosage and Administration (2.5) , Drug Interactions (7.2)]. 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib until resolution to Grade \u2264 1 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3-5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib for Grade 3 or 4 hemorrhagic events until resolution to Grade \u2264 1 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib as monotherapy and administered in combination with bevacizumab. Sunitinib is not approved for use in combination with bevacizumab. Discontinue sunitinib in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein 3 or more grams despite dose reductions. The safety of continued sunitinib treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib, including of the perineum and secondary to fistula formation. Discontinue sunitinib in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib for advanced RCC (Study 3) and GIST (Study 1) (n = 577) and in approximately 10% of the patients treated with sunitinib for pNET (Study 6) (n = 83). For patients being treated with sunitinib for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib and periodically during sunitinib therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib for development of ONJ until complete resolution.The safety of resumption of sunitinib after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib [see Adverse Reactions (6.2)]. Withhold sunitinib for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib and for 4 weeks following the final dose [see Use in Specific Populations (8.1, 8.3)] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions (5.1)] Cardiovascular Events [see Warnings and Precautions (5.2)] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3)] Hypertension [see Warnings and Precautions (5.4)] Hemorrhagic Events [see Warnings and Precautions (5.5)] Tumor Lysis Syndrome [see Warnings and Precautions (5.6)] Thrombotic Microangiopathy [see Warnings and Precautions (5.7)] Proteinuria [see Warnings and Precautions (5.8)] Dermatologic Toxicities [see Warnings and Precautions (5.9)] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.10)] Thyroid Dysfunction [see Warnings and Precautions (5.11)] Hypoglycemia [see Warnings and Precautions (5.12)] Osteonecrosis of the Jaw [see Warnings and Precautions (5.13)] Impaired Wound Healing [see Warnings and Precautions (5.14)] The most common adverse reactions (\u2265 25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u2265 25%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib 50 mg daily on Schedule 4/2 (n = 202) or placebo (n = 102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib (mean: 3.0; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u2265 10% of GIST Patients Who Received Sunitinib in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reactions GIST Sunitinib (N = 202) Placebo (N = 102) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia a 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u2265 10% of GIST Patients Who Received Sunitinib or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib (N = 202) Placebo (N = 102) All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis , the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib [see Clinical Studies (14.1)] . For 241 patients randomized to the sunitinib arm, including 139 who received sunitinib in both the double-blind and open-label phases, the median duration of sunitinib treatment was 6 cycles (mean: 8.5; range: 1 to 44). For the 255 patients who ultimately received open-label sunitinib treatment, median duration of study treatment was 6 cycles (mean: 7.8; range: 1 to 37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib 50 mg daily on Schedule 4/2 (n = 375) or interferon alfa 9 million International Units (MIU) (n = 360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib (N = 375) Interferon Alfa (N = 360) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 < 1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 < 1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain c 30 5 12 1 Constipation 23 1 14 < 1 Dry mouth 13 0 7 < 1 Oral pain 14 < 1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 < 1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 < 1 Weight decreased 16 < 1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 < 1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e 47 < 1 15 0 Headache 23 1 19 0 Dizziness 11 < 1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension 34 13 4 < 1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 < 1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 < 1 0 0 Dry skin 23 < 1 7 0 Hair color changes 20 0 < 1 0 Alopecia 14 0 9 0 Erythema 12 < 1 1 0 Pruritus 12 < 1 7 < 1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 < 1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 < 1 2 0 Upper respiratory tract infection 11 < 1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 < 1 10 0 Depression g 11 0 14 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib included back pain (1%), arthralgia (< 1%), dyspnea (< 1%), asthenia (< 1%), fatigue (< 1%), limb pain (< 1%) and rash (< 1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (< 1%), and depression (< 1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u2265 10% of RCC Patients Who Received Sunitinib or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib (N = 375) Interferon Alfa (N = 360) All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 < 1 51 < 1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 < 1 Potassium increased 16 3 17 4 Calcium increased 13 < 1 10 1 Potassium decreased 13 1 2 < 1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (< 1%), creatine kinase (< 1%), creatinine (< 1%), glucose increased (< 1%), calcium decreased (< 1%), phosphorous (< 1%), potassium increased (< 1%), and sodium decreased (< 1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (< 1%), calcium increased (< 1%), glucose decreased (< 1%), potassium increased (< 1%), and hemoglobin (< 1%). Long-Term Safety in RCC The long-term safety of sunitinib in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib 50 mg daily on Schedule 4/2 (n=306) or placebo (n = 304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib arm. Adverse reactions leading to permanent discontinuation in > 2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in (54%) and dose reductions occurred in 46% of patients who received sunitinib. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib (N = 306) Placebo (N = 304) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a 61 6 15 0 Diarrhea 57 4 22 < 1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain b 25 2 9 < 1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema c 18 < 1 < 1 0 Pyrexia 12 < 1 6 0 Dermatology Hand-foot syndrome 50 16 10 < 1 Rash d 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension e 39 8 14 1 Edema/Peripheral edema 10 < 1 7 0 Neurology Altered taste f 38 < 1 6 0 Headache 19 < 1 12 0 Endocrine Hypothyroidism/TSH increased 24 < 1 4 0 Hemorrhage/Bleeding Bleeding events, all sites g 24 < 1 5 < 1 Metabolism/Nutrition Anorexia/Decreased appetite 19 < 1 5 0 Musculoskeletal Pain in extremity 15 < 1 7 0 Arthralgia 11 < 1 10 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, hematuria. Grade 4 adverse reactions in patients on sunitinib included hand-foot syndrome (1%), fatigue (< 1%), abdominal pain (< 1%), stomatitis (< 1%), and pyrexia (< 1%). Grade 3 to 4 laboratory abnormalities that occurred in \u2265 2% of patients receiving sunitinib include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib 37.5 mg once daily (n = 83) or placebo (n = 82). The median number of days on treatment was 139 days (range: 13 to 532 days) for patients on sunitinib and 113 days (range: 1 to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib and 4 patients (5%) on placebo were on study for > 1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u2265 10% of Patients With pNET Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib (N = 83) Placebo (N = 82) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes b 48 6 18 0 Nausea 45 1 29 1 Abdominal pain c 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage /Bleeding Bleeding events d 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u2265 10% of Patients With pNET Who Received Sunitinib in Study 6 Laboratory Abnormality pNET Sunitinib Placebo All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3 to 4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (< 1%) in the adjuvant treatment for RCC study on sunitinib. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of sunitinib. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema . Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. *including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table width=\"100%\"><col width=\"23%\"/><col width=\"22%\"/><col width=\"19%\"/><col width=\"18%\"/><col width=\"18%\"/><thead><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reactions</content></th><th align=\"left\" colspan=\"4\" styleCode=\"Toprule \" valign=\"middle\"><content styleCode=\"bold\">GIST</content></th></tr><tr><th align=\"left\" colspan=\"2\" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 202)</content></th><th align=\"left\" colspan=\"2\" valign=\"middle\"><content styleCode=\"bold\">Placebo (N = 102)</content></th></tr><tr><th align=\"left\" styleCode=\"Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades %</content></th><th align=\"left\" styleCode=\"Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 %</content></th><th align=\"left\" styleCode=\"Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades %</content></th><th align=\"left\" styleCode=\"Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 %</content></th></tr></thead><tbody><tr><td styleCode=\"Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td styleCode=\"Toprule Botrule \" valign=\"middle\"><paragraph>94</paragraph></td><td styleCode=\"Toprule Botrule \" valign=\"middle\"><paragraph>56</paragraph></td><td styleCode=\"Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>97</item></list></td><td styleCode=\"Toprule Botrule \" valign=\"middle\"><paragraph>51</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Diarrhea</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>40</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>27</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Mucositis/stomatitis</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>29</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>18</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Constipation</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>20</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Anorexia <sup>a</sup></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>33</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>29</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Asthenia</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Skin discoloration</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>30</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>23</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Rash</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hand-foot syndrome</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Altered taste</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>21</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>12</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypertension</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Myalgia/limb pain</paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"24%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"18%\"/><col width=\"16%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 4. Laboratory Abnormalities Reported in &#x2265; 10% of GIST Patients Who Received Sunitinib or Placebo in the Double-Blind Treatment Phase* in Study 1</content></th></tr><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Laboratory Abnormality</content></th><th align=\"left\" colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">GIST</content></th></tr><tr><th align=\"left\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 202)</content></th><th align=\"left\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo (N = 102)</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Any Laboratory Abnormality</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>34</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>22</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Hematology</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Neutrophils decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>53</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Lymphocytes decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>38</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>16</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Platelets decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>38</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>5</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Hemoglobin decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>26</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>3</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>22</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>2</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Gastrointestinal</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>AST/ALT increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>39</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>2</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>23</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>1</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Lipase increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>25</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>17</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>7</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Alkaline phosphatase increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>24</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>21</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>4</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Amylase increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>17</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>5</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>12</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>3</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Total bilirubin increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>16</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>8</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Indirect bilirubin increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Renal/Metabolic</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Creatinine increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>12</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>7</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Potassium decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>12</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Sodium increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>1</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Cardiac</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item>Decreased LVEF</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>11</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>3</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"23%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"18%\"/><col width=\"17%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 5. Adverse Reactions Reported in &#x2265; 10% of Patients With RCC Who Received Sunitinib or Interferon Alfa* in Study 3</content></th></tr><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></th></tr><tr><th align=\"left\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 375)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Interferon Alfa (N = 360)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>55</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>66</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>58</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Mucositis/stomatitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>47</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>39</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dyspepsia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Constipation</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dry mouth</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Oral pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Flatulence</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>GERD/reflux esophagitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Glossodynia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hemorrhoids</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fatigue</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>62</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Asthenia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>26</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fever</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Weight decreased</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Chills</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Chest Pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Influenza like illness</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Anorexia <sup>d</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>48</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Altered taste <sup>e</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>47</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dizziness</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding, all sites</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4 <sup>f</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hypertension</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Edema peripheral</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Ejection fraction decreased</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Rash</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Skin discoloration/yellow skin</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>25</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dry skin</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hair color changes</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Alopecia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Erythema</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pruritus</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Pain in extremity/limb discomfort</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Arthralgia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Back pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Cough</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>27</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dyspnea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>26</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nasopharyngitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Oropharyngeal pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Upper respiratory tract infection</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypothyroidism</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Insomnia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Depression <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 6. Laboratory Abnormalities Reported in &#x2265; 10% of RCC Patients Who Received Sunitinib or Interferon Alfa in Study 3</content></th></tr><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Laboratory Abnormality</content></th><th align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></th></tr><tr><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 375)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Interferon Alfa (N = 360)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Creatine kinase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Uric acid increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Calcium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Sodium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"22%\"/><col width=\"21%\"/><col width=\"20%\"/><col width=\"19%\"/><col width=\"19%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 7. Adverse Reactions Reported in &#x2265; 10% of Patients With RCC Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in S-TRAC</content></th></tr><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">Adjuvant Treatment of RCC</content></th></tr><tr><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 306)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo (N = 304)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4</content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Mucositis/Stomatitis <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Abdominal pain <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fatigue/Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Localized edema <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pyrexia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Rash <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Skin discoloration/Yellow skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hypertension <sup>e</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Edema/Peripheral edema</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Altered taste <sup>f</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypothyroidism/TSH increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding events, all sites <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Anorexia/Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 8. Adverse Reactions Reported in &#x2265; 10% of Patients With pNET Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in Study 6</content></th></tr><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">pNET</content></th></tr><tr><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content> <content styleCode=\"bold\">(N = 83)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 82)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4</content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>95</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>50</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>59</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Stomatitis/oral syndromes <sup>b</sup></paragraph></td><td align=\"center\" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dyspepsia</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/><td styleCode=\"Rrule Lrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Asthenia</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fatigue</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Weight decreased</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hair color changes</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Rash</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dry skin</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Hypertension</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>27</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>10</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Hemorrhage /Bleeding</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Bleeding events <sup>d</sup></paragraph></td><td align=\"center\" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Epistaxis</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dysgeusia</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Insomnia</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>18</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"bottom\"><paragraph>Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 9. Laboratory Abnormalities Reported in &#x2265; 10% of Patients With pNET Who Received Sunitinib in Study 6</content></th></tr><tr><th align=\"left\" rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Laboratory Abnormality</content></th><th align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">pNET</content></th></tr><tr><th align=\"left\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>72</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>18</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Magnesium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib when administered with strong CYP3A4 inhibitors. (7.1) CYP3A4 Inducers : Consider dose increase of sunitinib when administered with strong CYP3A4 inducers. (7.1) 7.1 Effect of Other Drugs on Sunitinib Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3)] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5)] . Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3)] . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5)] . 7.2 Drugs that Prolong QT Interval Sunitinib is associated with QTc interval prolongation [see Warnings and Precautions (5.3), Clinical Pharmacology (12.2)] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. (8.2) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u2264 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u2265 1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u2265 1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u2264 1 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib may impair male and female fertility [see Nonclinical Toxicology (13.1)] . 8.4 Pediatric Use The safety and effectiveness of sunitinib in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to < 17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to < 17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u2265 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were > 0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u2265 5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at > 5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u2264 2 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib were 65 years and older. Clinical studies of sunitinib did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology (12.3)] . Sunitinib was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CL cr 50 to 80 mL/min), moderate (CL cr 30 to < 50 mL/min), or severe (CL cr < 30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology (12.3)] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology (12.3)] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u2264 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u2265 1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u2265 1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u2264 1 mg/kg/day."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to < 17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to < 17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u2265 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were > 0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u2265 5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at > 5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u2264 2 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib were 65 years and older. Clinical studies of sunitinib did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, compound with (S)-2-hydroxybutanedioic acid. The molecular formula is C 22 H 27 FN 4 O 2 .C 4 H 6 O 5 and the molecular weight is 532.57 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is light yellow to brownish orange colored powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in the range of 12 to 70 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively) together with croscarmellose sodium, magnesium stearate, mannitol and povidone (K-30) as inactive ingredients. The reddish brown gelatin capsule shells contain ferric oxide red and titanium dioxide. The caramel gelatin capsule shells contain ferric oxide red, ferric oxide yellow, ferrosoferric oxide and titanium dioxide. The yellow gelatin capsule shells contain ferric oxide yellow and titanium dioxide. The white printing ink contains potassium hydroxide, shellac and titanium dioxide. The black printing ink contains ferrosoferric oxide, potassium hydroxide and shellac. spl-sunitinib-malate-structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (> 80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2-and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Cardiac Electrophysiology Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)]. 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr > 80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitini b : Co-administration of a single sunitinib dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (> 80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2-and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Cardiac Electrophysiology Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)]."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr > 80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitini b : Co-administration of a single sunitinib dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u2265 25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u2264 1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u2265 2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u2264 10 mg/kg/day (approximately \u2265 26 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u2265 25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u2264 1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u2265 2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u2264 10 mg/kg/day (approximately \u2265 26 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib and patients randomized to sunitinib were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib and placebo groups with regard to age (69% versus 72% < 65 years for sunitinib versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib (N = 207) Placebo (N = 105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression a [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) < 0.0001* 0.33 (0.23, 0.47) Progression-free survival b [median, weeks (95% CI)] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) < 0.0001 0.33 (0.24, 0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7, 11.1) 0 0.006 c * A comparison is considered statistically significant if the p-value is < 0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis , the study was unblinded, and patients on the placebo arm were offered open-label sunitinib treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib arm and 64.9 weeks for the placebo arm [hazard ratio (HR) = 0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). spl-sunitinib-figure1 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib and interferon alfa groups with regard to age (59% versus 67% < 65 years for sunitinib versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib over interferon alfa in the endpoint of PFS (see Table 9 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (> 1.5 ULN versus \u2264 1.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib over interferon alfa. The ORR was higher in the sunitinib arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib (N = 375) Interferon Alfa (N = 375) p-value (log-rank test) HR (95% CI) Progression-free survival a [median, weeks (95% CI)] 47.3 (42.6, 50.7) 22.0 (16.4, 24.0) < 0.000001 b 0.415 (0.320, 0.539) Objective response rate a [%, (95% CI)] 27.5 (23.0, 32.3) 5.3 (3.3, 8.1) < 0.001 c NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is < 0.0042 (O\u2019Brien Fleming stopping boundary). Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; INF-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib arm and 94.9 weeks for the interferon alfa arm (HR = 0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib. Cytokine-Refractory The use of single-agent sunitinib in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status < 2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (> 90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N = 106) Study 5 (N = 63) Objective response rate [%, (95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR * (42.0, * ) 54 b (34.3, 70.1) * Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265 T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib N = 309 Placebo N = 306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Placebo Sunitinib Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u2265 1 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u2265 2, ECOG PS \u2265 1 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. spl-sunitinib-figure2 spl-sunitinib-figure3 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib (N = 86) or placebo (N = 85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib and placebo groups. Additionally, 49% of sunitinib patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib (N = 86) Placebo (N = 85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 a 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors. spl-sunitinib-figure4"
    ],
    "clinical_studies_table": [
      "<table cellpadding=\"0pt\" width=\"100%\"><col width=\"42%\"/><col width=\"17%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"14%\"/><thead><tr><th align=\"left\" colspan=\"5\" styleCode=\"Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase)</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Efficacy Parameter</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content> <content styleCode=\"bold\">(N = 207)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 105)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">p-value</content> <content styleCode=\"bold\">(log-rank test)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">HR</content> <content styleCode=\"bold\">(95% CI)</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>Time-to-tumor progression <sup>a</sup>[median, weeks (95% CI)] </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>27.3</paragraph><paragraph>(16.0, 32.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6.4</paragraph><paragraph>(4.4, 10.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt; 0.0001*</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.33</paragraph><paragraph>(0.23, 0.47)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Progression-free survival <sup>b</sup>[median, weeks (95% CI)] </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>24.1</paragraph><paragraph>(11.1, 28.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>6.0</paragraph><paragraph>(4.4, 9.9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 0.0001</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.33</paragraph><paragraph>(0.24, 0.47)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Objective response rate (PR) [%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>6.8</paragraph><paragraph>(3.7, 11.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0.006 <sup>c</sup></paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"27%\"/><col width=\"21%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"19%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Sunitinib</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Progression-free survival <sup>a</sup>[median, weeks (95% CI)] </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>47.3</paragraph><paragraph>(42.6, 50.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22.0</paragraph><paragraph>(16.4, 24.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 0.000001 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.415</paragraph><paragraph>(0.320, 0.539)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Objective response rate <sup>a</sup></paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>27.5</paragraph><paragraph>(23.0, 32.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>5.3</paragraph><paragraph>(3.3, 8.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>&lt; 0.001 <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>NA</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"33%\"/><col width=\"34%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 4</content></paragraph><paragraph><content styleCode=\"bold\">(N = 106)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 5</content></paragraph><paragraph><content styleCode=\"bold\">(N = 63)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34.0 <sup>a</sup></paragraph><paragraph>(25.0, 43.8)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>36.5 <sup>b</sup></paragraph><paragraph>(24.7, 49.6)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"bottom\"><paragraph>Duration of response</paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NR <sup>*</sup></paragraph><paragraph>(42.0, <sup>*</sup>) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>54 <sup>b</sup></paragraph><paragraph>(34.3, 70.1)</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"29%\"/><col width=\"19%\"/><col width=\"18%\"/><col width=\"15%\"/><col width=\"18%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Sunitinib</content></item></list><paragraph><content styleCode=\"bold\">N = 309</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">N = 306</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">p-value <sup>a</sup></content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">HR <sup>a</sup>(95% CI) </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Median DFS [years (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6.8 (5.8, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5.6 (3.8, 6.6)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.03</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.76</paragraph><paragraph>(0.59, 0.98)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>DFS Events</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>113 (36.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>144 (47.1%)</paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>5 Year DFS Rate</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>59.3%</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>51.3%</paragraph></td><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"18%\"/><col width=\"12%\"/><col width=\"18%\"/><thead><tr><th align=\"left\" colspan=\"6\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 14. Disease-free Survival by Baseline Disease Characteristics</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Number of Events/Total</content> <content styleCode=\"bold\">n/N</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Median DFS</content> <content styleCode=\"bold\">[years (95% CI)]</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">HR <sup>a</sup></content> <content styleCode=\"bold\">(95% CI)</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>T3 Intermediate <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>35/115</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>46/112</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>NR</paragraph><paragraph>(5.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6.4</paragraph><paragraph>(4.7, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.82</paragraph><paragraph>(0.53, 1.28)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>T3 High <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>63/165</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>79/166</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>6.8</paragraph><paragraph>(5.0, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5.3</paragraph><paragraph>(2.9, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.77 (0.55, 1.07)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>T4/Node Positive <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>15/29</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>19/28</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>3.5</paragraph><paragraph>(1.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1.7</paragraph><paragraph>(0.4, 3.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0.62</paragraph><paragraph>(0.31, 1.23)</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"31%\"/><col width=\"20%\"/><col width=\"16%\"/><col width=\"16%\"/><col width=\"17%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Sunitinib</content></paragraph><paragraph><content styleCode=\"bold\">(N = 86)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 85)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Progression-free survival</paragraph><paragraph>[median, months (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10.2</paragraph><paragraph>(7.4, 16.9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5.4</paragraph><paragraph>(3.4, 6.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.000146 <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.427</paragraph><paragraph>(0.271, 0.673)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>9.3</paragraph><paragraph>(3.2, 15.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0.0066 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>NA</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 12.5 mg capsules Hard gelatin capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM53\u2019 on cap and \u2018RM53\u2019 on body in white ink, containing yellow to orange colored powder; available in: Bottles of 28 capsules with child-resistant closure: NDC 63304-091-27 Carton of 28 capsules (4 x 7 Unit-dose): NDC 63304-091-86 25 mg capsules Hard gelatin capsule with opaque caramel cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM54\u2019 on cap and \u2018RM54\u2019 on body in white ink, containing yellow to orange colored powder; available in: Bottles of 28 capsules with child-resistant closure: NDC 63304-092-27 Carton of 28 capsules (4 x 7 Unit-dose): NDC 63304-092-86 37.5 mg capsules Hard gelatin capsule with opaque yellow cap and opaque yellow body, self-lock capsule, imprinted with \u2018RM55\u2019 on cap and \u2018RM55\u2019 on body in black ink, containing yellow to orange colored powder; available in: Bottles of 28 capsules with child-resistant closure: NDC 63304-093-27 Carton of 28 capsules (4 x 7 Unit-dose): NDC 63304-093-86 50 mg capsules Hard gelatin capsule with opaque caramel cap and opaque caramel body, self-lock capsule, imprinted with \u2018RM56\u2019 on cap and \u2018RM56\u2019 on body in white ink, containing Yellow to orange colored powder ; available in: Bottles of 28 capsules with child-resistant closure: NDC 63304-094-27 Carton of 28 capsules (4 x 7 Unit-dose): NDC 63304-094-86 Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [See USP Controlled Room Temperature]. Keep out of reach of children."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.1)] . Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.2)] . QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions (5.3)] . Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions (5.4)] . Hemorrhagic Events Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions (5.5)] . Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate capsules treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate capsules [see Warnings and Precautions (5.5), and Adverse Reactions (6.1)]. Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate capsules due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions (5.9), and Adverse Reactions (6.1)]. Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] . Thyroid Dysfunction Advise patients that sunitinib malate capsules can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions (5.11)] . Hypoglycemia Advise patients that sunitinib malate capsules can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions (5.12)] . Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions (5.13)] . Impaired Wound Healing Advise patients that sunitinib malate capsules impairs wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions (5.14)] . Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions (7)] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.15), Use in Specific Populations (8.1)] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations (8.3)] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations (8.3)] . Lactation Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [see Use in Specific Populations (8.2)] . Infertility Advise patients that sunitinib malate capsules may impair male and female fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)] . Missed Dose Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time. Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 1012, Dadra-396 193, U.T. of D & NH and Daman & Diu, India. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 October 2023 FDA-05"
    ],
    "spl_medguide": [
      "Medication Guide MEDICATION GUIDE Sunitinib Malate (soo ni\u2019 ti nib mal\u2019 ate) Capsules Rx only What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are prescription medicine used to treat: a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate. advanced kidney cancer (advanced renal cell carcinoma or RCC). adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: have any heart problems have high blood pressure have thyroid problems have a history of low blood sugar or diabetes have kidney function problems (other than cancer) have liver problems have any bleeding problem plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d have seizures have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsule 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too much sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201c What is the most important information I should know about sunitinib malate capsules? \u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules you feel faint or lightheaded, or you pass out dizziness feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with sunitinib malate capsules, and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache dizziness lightheadedness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems . Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) bloody urine vomiting blood coughing up blood headache change in your mental status black, sticky stools Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome[RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS) . TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away loss of appetite problems with heat feeling nervous or agitated, tremors sweating nausea or vomiting diarrhea fast heart beat weight gain or weight loss feeling depressed irregular menstrual periods or no menstrual periods headache hair loss Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: headache irritability drowsiness hunger weakness fast heart beat dizziness sweating confusion feeling jittery Jawbone problems (osteonecrosis). Severe jaw bone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems . Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness weakness diarrhea pain, swelling or sores inside of your mouth nausea loss of appetite indigestion vomiting stomach-area (abdominal) pain blisters or rash on the palms of your hands and soles of your feet high blood pressure taste changes low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, povidone (K-30). Reddish brown gelatin capsule shells: ferric oxide red and titanium dioxide. Caramel gelatin capsule shells: ferric oxide red, ferric oxide yellow, ferrosoferric oxide and titanium dioxide. Yellow gelatin capsule shells: ferric oxide yellow and titanium dioxide. White printing ink: potassium hydroxide, shellac and titanium dioxide. Black printing ink: ferrosoferric oxide, potassium hydroxide and shellac. All trademarks are property of their respective owners. Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 1012, Dadra-396 193, U.T. of D & NH and Daman & Diu, India. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 085122 October 2023 FDA-05 For more information, call 1-800-818-4555. This Medication Guide has been approved by the U.S. Food and Drug Administration"
    ],
    "spl_medguide_table": [
      "<table width=\"100%\"><colgroup><col width=\"100%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (soo ni&#x2019; ti nib mal&#x2019; ate) Capsules</content></paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"52%\"/><col width=\"48%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>you feel faint or lightheaded, or you pass out</item><item>dizziness</item></list></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>feel your heart beat is irregular or fast</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"55%\"/><col width=\"45%\"/></colgroup><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>severe headache</item></list></td><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>dizziness</item></list></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>lightheadedness</item></list></td><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>change in vision</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"48%\"/><col width=\"52%\"/></colgroup><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>painful, swollen stomach (abdomen)</item></list></td><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>bloody urine</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>vomiting blood</item><item>coughing up blood</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>headache</item><item>change in your mental status</item></list></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>black, sticky stools</item></list></td><td styleCode=\"Botrule \" valign=\"top\"/></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"56%\"/><col width=\"44%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>tiredness that gets worse and does not go away</item><item>loss of appetite</item><item>problems with heat</item><item>feeling nervous or agitated, tremors</item><item>sweating</item><item>nausea or vomiting</item><item>diarrhea</item></list></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>fast heart beat</item><item>weight gain or weight loss</item><item>feeling depressed</item><item>irregular menstrual periods or no menstrual periods</item><item>headache</item><item>hair loss</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"50%\"/><col width=\"50%\"/></colgroup><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>headache</item></list></td><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>irritability</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>drowsiness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>hunger</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>weakness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>fast heart beat</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>dizziness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>sweating</item></list></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>confusion</item></list></td><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>feeling jittery</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"55%\"/><col width=\"45%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>tiredness</item><item>weakness</item><item>diarrhea</item><item>pain, swelling or sores inside of your mouth</item><item>nausea</item><item>loss of appetite</item><item>indigestion</item></list></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>vomiting</item><item>stomach-area (abdominal) pain</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>high blood pressure</item><item>taste changes</item><item>low platelet counts</item></list></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 63304-091-27 Sunitinib Malate Capsules 12.5 mg PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules SUN PHARMA 12.5mg-28s",
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 63304-092-27 Sunitinib Malate Capsules 25 mg PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules SUN PHARMA 25mg-28s",
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 63304-093-27 Sunitinib Malate Capsules 37.5 mg PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules SUN PHARMA 37.5mg-28s",
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 63304-094-27 Sunitinib Malate Capsules 50 mg PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules SUN PHARMA 50mg-28s"
    ],
    "set_id": "06e0ad28-6637-4f54-879c-2c194aece5fd",
    "id": "2971c7ca-50dc-e36c-e063-6294a90a4b7d",
    "effective_time": "20241217",
    "version": "8",
    "openfda": {
      "application_number": [
        "ANDA213914"
      ],
      "brand_name": [
        "Sunitinib malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Sun Pharmaceutical Industries Inc."
      ],
      "product_ndc": [
        "63304-091",
        "63304-092",
        "63304-093",
        "63304-094"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "2971c7ca-50dc-e36c-e063-6294a90a4b7d"
      ],
      "spl_set_id": [
        "06e0ad28-6637-4f54-879c-2c194aece5fd"
      ],
      "package_ndc": [
        "63304-091-27",
        "63304-091-11",
        "63304-091-86",
        "63304-092-27",
        "63304-092-11",
        "63304-092-86",
        "63304-093-27",
        "63304-093-11",
        "63304-093-86",
        "63304-094-27",
        "63304-094-11",
        "63304-094-86"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0363304092271"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 D&C RED NO. 28 FD&C BLUE NO. 1 FD&C RED NO. 40 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE SHELLAC PROPYLENE GLYCOL SUNITINIB MALATE SUNITINIB maroon TEVA;8199;TEVA;8199 Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 D&C RED NO. 28 FD&C BLUE NO. 1 FD&C RED NO. 40 FD&C YELLOW NO. 6 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE SHELLAC PROPYLENE GLYCOL SUNITINIB MALATE SUNITINIB light brown maroon TEVA;8224;TEVA;8224 Sunitinib Malate Sunitinib Malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE FD&C RED NO. 40 SHELLAC PROPYLENE GLYCOL SUNITINIB MALATE SUNITINIB TEVA;8229;TEVA;8229 Sunitinib Malate Sunitinib Malate FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE SHELLAC PROPYLENE GLYCOL SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FD&C BLUE NO. 1 FD&C RED NO. 40 FD&C YELLOW NO. 6 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE light brown TEVA;8231;TEVA;8231"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions ( 5.1 )] ."
    ],
    "recent_major_changes": [
      "Dosage and Administration, Dosage Modifications for Adverse Reactions ( 2.4 ) 8/2021 Dosage and Administration, Dosage Modification for Drug Interactions ( 2.5 ) 8/2021 Warnings and Precautions, Hepatotoxicity ( 5.1 ) 8/2021 Warnings and Precautions, Hypertension ( 5.4 ) 8/2021 Warnings and Precautions, Hemorrhagic Events and Viscous Perforation ( 5.5 ) 8/2021 Warnings and Precautions, Reversible Posterior Leukoencephalopathy Syndrome ( 5.10 ) 8/2021 Warnings and Precautions, Hypoglycemia ( 5.12 ) 8/2021 Warnings and Precautions, Osteonecrosis of the Jaw ( 5.13 ) 8/2021"
    ],
    "recent_major_changes_table": [
      "<table width=\"600px\" cellspacing=\"0\" cellpadding=\"5\"><col width=\"500px\"/><col width=\"100px\"/><tbody><tr><td> Dosage and Administration, Dosage Modifications for Adverse Reactions ( <linkHtml href=\"#LINK_dd07798e-bcdf-43e2-a8eb-6e239c6330fa\">2.4</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Dosage and Administration, Dosage Modification for Drug Interactions ( <linkHtml href=\"#LINK_ba250466-d19c-4f8f-8a41-30a384cdca6f\">2.5</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Warnings and Precautions, Hepatotoxicity ( <linkHtml href=\"#LINK_adcd7799-f2c5-4708-963e-7af21e95b4ed\">5.1</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Warnings and Precautions, Hypertension ( <linkHtml href=\"#LINK_8b54ae79-2b4a-4eca-a38b-c48f77974d9e\">5.4</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Warnings and Precautions, Hemorrhagic Events and Viscous Perforation ( <linkHtml href=\"#LINK_9e057e6e-d9e9-4ce3-a0fa-df7074545b8c\">5.5</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Warnings and Precautions, Reversible Posterior Leukoencephalopathy Syndrome ( <linkHtml href=\"#LINK_65feff95-8f29-45e4-8b52-21fca7397c30\">5.10</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Warnings and Precautions, Hypoglycemia ( <linkHtml href=\"#LINK_93d6041b-85f9-495a-8f6c-756f0429387d\">5.12</linkHtml>) </td><td> 8/2021</td></tr><tr><td> Warnings and Precautions, Osteonecrosis of the Jaw ( <linkHtml href=\"#LINK_a43314d2-d140-45b9-ab5f-b9462ff61c38\">5.13</linkHtml>) </td><td> 8/2021</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET : The recommended dosage is 37.5 mg orally once daily. ( 2.3 ) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. For recurring Grade 3 permanently discontinue. Grade 4 Permanently discontinue. Cardiovascular events [see Warnings and Precautions ( 5.2 )] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) Withhold until resolution to Grade 0 to 1 or baseline. Resume at reduced dose. Clinically manifested congestive heart failure (CHF) Permanently discontinue. Hypertension [see Warnings and Precautions ( 5.4 )] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Grade 4 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions ( 5.5 )] Grade 3 or 4 Withhold until resolution to Grade 0 to 1 or baseline. Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions ( 5.7 )] Any Grade Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions ( 5.8 )] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions ( 5.9 )] Any Grade Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] Any Grade Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] Any Grade The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions ( 5.14 )] Any Grade The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions ( 7.1 )] : GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions ( 7.1 )] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions</caption><col width=\"110.15pt\"/><col width=\"110.2pt\"/><col width=\"110.2pt\"/><col width=\"110.2pt\"/><col width=\"110.2pt\"/><tbody><tr><td rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Indications</content></content></paragraph></td><td align=\"center\" rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">GIST</content></content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">RCC</content></content></paragraph></td><td align=\"center\" rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">pNET</content></content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Advanced RCC</content></content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Adjuvant RCC</content></content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">First dose reduction</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">37.5 mg once daily</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">37.5 mg once</content></paragraph><paragraph><content styleCode=\"xmChange\">daily</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">37.5 mg once daily</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">25 mg once daily</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Second dose reduction</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">25 mg once daily</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">25 mg once</content></paragraph><paragraph><content styleCode=\"xmChange\">daily</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">NA</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">NA</content></paragraph></td></tr></tbody></table>",
      "<table width=\"1000px\" cellspacing=\"0\" cellpadding=\"5\"><col width=\"114.3pt\"/><col width=\"114.3pt\"/><col width=\"114.3pt\"/><tbody><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Adverse Reaction</content></content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Severity</content></content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Dosage Modifications for</content><content styleCode=\"bold\">Sunitinib Malate Capsules</content></content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Hepatotoxicity <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_adcd7799-f2c5-4708-963e-7af21e95b4ed\">5.1</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Grade 3</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item><item><content styleCode=\"xmChange\">For recurring Grade 3 permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Grade 4</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Cardiovascular events <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_e28ea320-c7d4-4290-b82d-b37625f4861e\">5.2</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at reduced dose.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Clinically manifested congestive heart failure (CHF)</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Hypertension <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_8b54ae79-2b4a-4eca-a38b-c48f77974d9e\">5.4</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Grade 3</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Grade 4</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Hemorrhagic events <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_9e057e6e-d9e9-4ce3-a0fa-df7074545b8c\">5.5</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Grade 3 or 4</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Thrombotic microangiopathy <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_69b88b83-66d6-43fe-b7fb-5ba05af6a6d9\">5.7</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Any Grade</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_467fcc32-240a-4366-9c44-0a4177c41cff\">5.8</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_af3a4849-07cd-47ff-9078-da48eaff362b\">5.9</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Any Grade</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_65feff95-8f29-45e4-8b52-21fca7397c30\">5.10</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Any Grade</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Osteonecrosis of the jaw <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_a43314d2-d140-45b9-ab5f-b9462ff61c38\">5.13</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Any Grade</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Impaired wound healing <content styleCode=\"italics\">[see Warnings and Precautions ( <linkHtml href=\"#LINK_42c613d0-91d5-4619-bc04-0febeb1be906\">5.14</linkHtml>)] </content></content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"xmChange\">Any Grade</content></paragraph></td><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS 12.5 mg capsules Hard gelatin capsule with maroon opaque cap and body, imprinted with TEVA over 8199 on both cap and body in black ink. 25 mg capsules Hard gelatin capsule with light brown opaque cap and maroon opaque body, imprinted with TEVA over 8224 on both cap and body in black ink. 37.5 mg capsules Hard gelatin capsule with yellow opaque cap and body, imprinted with TEVA over 8229 on both cap and body in black ink. 50 mg capsules Hard gelatin capsule with light brown opaque cap and body, imprinted with TEVA over 8231 on both cap and body in black ink. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline and resume sunitinib malate at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. ( 2.4 , 5.1 ) Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) QT Interval Prolongation and Torsade de Pointes : Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib malate for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients who develop Grade 4 hypertension. ( 5.4 ) Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ) Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) Thrombotic microangiopathy (TMA) : TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate for TMA. ( 5.7 ) Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate for these events. ( 5.9 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate until resolution. ( 5.10 ) Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib malate for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 ) Impaired Wound Healing : Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. ( 5.14 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u226550% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate. Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration ( 2.5 ), Drug Interactions ( 7.2 )] . 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3-5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib malate. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib malate. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate as monotherapy and administered in combination with bevacizumab. Sunitinib malate is not approved for use in combination with bevacizumab. Discontinue sunitinib malate in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n=83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate and periodically during sunitinib malate therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate for development of ONJ until complete resolution. The safety of resumption of sunitinib malate after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate [see Adverse Reactions ( 6.2 )] . Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for 4 weeks following the final dose [see Use in Specific Populations ( 8.1 , 8.3 )] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Cardiovascular Events [see Warnings and Precautions ( 5.2 )] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions ( 5.3 )] Hypertension [see Warnings and Precautions ( 5.4 )] Hemorrhagic Events [see Warnings and Precautions ( 5.5 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.6 )] Thrombotic Microangiopathy [see Warnings and Precautions ( 5.7 )] Proteinuria [see Warnings and Precautions ( 5.8 )] Dermatologic Toxicities [see Warnings and Precautions ( 5.9 )] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions ( 5.10 )] Thyroid Dysfunction [see Warnings and Precautions ( 5.11 )] Hypoglycemia [see Warnings and Precautions ( 5.12 )] Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.13 )] Impaired Wound Healing [see Warnings and Precautions ( 5.14 )] The most common adverse reactions (\u226525%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u226525%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate (mean: 3.0; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u226510% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reaction GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia a 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u226510% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate [see Clinical Studies ( 14.1 )] . For 241 patients randomized to the sunitinib malate arm, including 139 who received sunitinib malate in both the double-blind and open-label phases, the median duration of sunitinib malate treatment was 6 cycles (mean: 8.5; range: 1 to 44). For the 255 patients who ultimately received open-label sunitinib malate treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1 to 37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades % Grade 3-4 a % All Grades % Grade 3-4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 <1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 <1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain c 30 5 12 1 Constipation 23 1 14 <1 Dry mouth 13 0 7 <1 Oral pain 14 <1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 <1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 <1 Weight decreased 16 <1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 <1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e 47 <1 15 0 Headache 23 1 19 0 Dizziness 11 <1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension 34 13 4 <1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 <1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 <1 0 0 Dry skin 23 <1 7 0 Hair color changes 20 0 <1 0 Alopecia 14 0 9 0 Erythema 12 <1 1 0 Pruritus 12 <1 7 <1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 <1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 <1 2 0 Upper respiratory tract infection 11 <1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 <1 10 0 Depression g 11 0 14 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u226510% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 <1 51 <1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 <1 Potassium increased 16 3 17 4 Calcium increased 13 <1 10 1 Potassium decreased 13 1 2 <1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). Long-Term Safety in RCC The long-term safety of sunitinib malate in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib Malate (N=306) Placebo (N=304) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a 61 6 15 0 Diarrhea 57 4 22 <1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain b 25 2 9 <1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema c 18 <1 <1 0 Pyrexia 12 <1 6 0 Dermatology Hand-foot syndrome 50 16 10 <1 Rash d 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension e 39 8 14 1 Edema/Peripheral edema 10 <1 7 0 Neurology Altered taste f 38 <1 6 0 Headache 19 <1 12 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage/Bleeding Bleeding events, all sites g 24 <1 5 <1 Metabolism/Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Pain in extremity 15 <1 7 0 Arthralgia 11 <1 10 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. Grade 4 adverse reactions in patients on sunitinib malate included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (<1%), stomatitis (<1%), and pyrexia (<1%). Grade 3-4 laboratory abnormalities that occurred in \u22652% of patients receiving sunitinib malate include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13 to 532 days) for patients on sunitinib malate and 113 days (range: 1 to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib Malate (N=83) Placebo (N=82) All Grades % Grade 3-4 a % All Grades % Grade 3-4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes b 48 6 18 0 Nausea 45 1 29 1 Abdominal pain c 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events d 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate in Study 6 Laboratory Abnormality pNET Sunitinib Malate Placebo All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3-4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on sunitinib malate. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema. Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib malate include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. *including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 3. Adverse Reactions Reported in &#x2265;10% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1</caption><col width=\"171.35pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=202)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N=102)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4 %</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4 %</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>94</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>97</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>51</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Anorexia <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Skin discoloration</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Altered taste</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Myalgia/limb pain</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Includes decreased appetite. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 4. Laboratory Abnormalities Reported in &#x2265;10% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1</caption><col width=\"187.8pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=202)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N=102)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4* <sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4* <sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Any <content styleCode=\"bold\">Laboratory Abnormality</content></content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"/><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"/><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>22</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> AST/ALT increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Decreased LVEF</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 5. Adverse Reactions Reported in &#x2265;10% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3</caption><col width=\"183.95pt\"/><col width=\"91.7pt\"/><col width=\"91.7pt\"/><col width=\"91.7pt\"/><col width=\"91.7pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=375)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa (N=360)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4 <sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4 <sup>b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>55</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dry mouth</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Oral pain</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Flatulence</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> GERD/reflux esophagitis</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Glossodynia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hemorrhoids</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>62</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Fever</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Chills</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Chest Pain</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Influenza like illness</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Anorexia <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Altered taste <sup>e</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Bleeding, all sites</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4 <sup>f</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Edema peripheral</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Ejection fraction decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Skin discoloration/yellow skin</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Alopecia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Erythema</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Pruritus</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Pain in extremity/limb discomfort</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Back pain</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Respiratory</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Cough</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dyspnea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Oropharyngeal pain</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Upper respiratory tract infection</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hypothyroidism</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Depression <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (&lt;1%), dyspnea (&lt;1%), asthenia (&lt;1%), fatigue (&lt;1%), limb pain (&lt;1%), and rash (&lt;1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (&lt;1%), and depression (&lt;1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Includes flank pain. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup>Includes decreased appetite. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>e</sup>Includes ageusia, hypogeusia, and dysgeusia. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>f</sup>Includes 1 patient with Grade 5 gastric hemorrhage. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>g</sup>Includes depressed mood. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 6. Laboratory Abnormalities Reported in &#x2265;10% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3</caption><col width=\"187.8pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><col width=\"90.85pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=375)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa (N=360)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4* <sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4* <sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Creatine kinase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Uric acid increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Calcium increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (&lt;1%), creatine kinase (&lt;1%), creatinine (&lt;1%), glucose increased (&lt;1%), calcium decreased (&lt;1%), phosphorous (&lt;1%), potassium increased (&lt;1%), and sodium decreased (&lt;1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (&lt;1%), calcium increased (&lt;1%), glucose decreased (&lt;1%), potassium increased (&lt;1%), and hemoglobin (&lt;1%). </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 7. Adverse Reactions Reported in &#x2265;10% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC</caption><col width=\"187.45pt\"/><col width=\"90.7pt\"/><col width=\"90.7pt\"/><col width=\"90.7pt\"/><col width=\"90.7pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adjuvant Treatment of RCC</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=306)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N=304)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Mucositis/Stomatitis <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Abdominal pain <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Fatigue/Asthenia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Localized edema <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Pyrexia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Rash <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Skin discoloration/Yellow skin</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hypertension <sup>e</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Edema/Peripheral edema</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Altered taste <sup>f</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph> 19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hypothyroidism/TSH increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Bleeding events, all sites <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Anorexia/Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Includes abdominal pain, abdominal pain lower, and abdominal pain upper. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup>Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>e</sup>Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>f</sup>Includes ageusia, hypogeusia, and dysgeusia. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>g</sup>Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 8. Adverse Reactions Reported in &#x2265;10% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6</caption><col width=\"171.35pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><col width=\"94.95pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=83)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (N=82)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4 <sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>95</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>50</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Stomatitis/oral syndromes <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Bleeding events <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Epistaxis</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Includes abdominal discomfort, abdominal pain, and abdominal pain upper. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup>Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 9. Laboratory Abnormalities Reported in &#x2265;10% of Patients With pNET Who Received Sunitinib Malate in Study 6</caption><col width=\"146.15pt\"/><col width=\"101.4pt\"/><col width=\"101.4pt\"/><col width=\"101.4pt\"/><col width=\"101.4pt\"/><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4* <sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Grade 3-4* <sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>72</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Magnesium decreased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). </paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers : Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 Inhibitors Coadministration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.5 )] . Strong CYP3A4 Inducers Coadministration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers [see Dosage and Administration ( 2.5 )] . 7.2 Drugs that Prolong QT Interval Sunitinib malate is associated with QTc interval prolongation [see Warnings and Precautions ( 5.3 ), Clinical Pharmacology ( 12.2 )] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology ( 12.3 )] . Sunitinib malate was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology ( 12.3 )] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3,000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as (2 S )-2-hydroxybutanedoic acid with N -[2-(diethylamino)ethyl]-5-[( Z )-(5-fluoro-1,2-dihydro-2-oxo- 3H -indol-3-ylidine)methyl]-2,4-dimethyl- 1H -pyrrole-3-carboxamide (1:1). The molecular formula is C 22 H 27 FN 4 O 2 \u25cf C 4 H 6 O 5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 0.4 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. The 12.5 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, and titanium dioxide. The 25 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The 37.5 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide. The 50 mg capsule shell contains FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The black printing ink which is common for all strengths contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, shellac, and may also contain propylene glycol. 1"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions ( 5.3 )] . 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Coadministration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Coadministration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions ( 5.3 )] ."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Coadministration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Coadministration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib malate in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate and patients randomized to sunitinib malate were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate and placebo groups with regard to age (69% versus 72% <65 years for sunitinib malate versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib Malate (N=207) Placebo (N=105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression a 27.3 6.4 <0.0001* 0.33 [median, weeks (95% CI)] (16.0, 32.1) (4.4, 10.0) (0.23, 0.47) Progression-free survival b 24.1 6.0 <0.0001 0.33 [median, weeks (95% CI)] (11.1, 28.3) (4.4, 9.9) (0.24, 0.47) Objective response rate (PR) 6.8 0 0.006 c [%, (95% CI)] (3.7, 11.1) * A comparison is considered statistically significant if the p-value is <0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis, the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). 1 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate and interferon alfa groups with regard to age (59% versus 67% <65 years for sunitinib malate versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \u22641.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate over interferon alfa. The ORR was higher in the sunitinib malate arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib Malate (N=375) Interferon Alfa (N=375) p-value (log-rank test) HR (95% CI) Progression-free survival a 47.3 22.0 <0.000001 b 0.415 [median, weeks (95% CI)] (42.6, 50.7) (16.4, 24.0) (0.320, 0.539) Objective response rate a 27.5 5.3 <0.001 c NA [%, (95% CI)] (23.0, 32.3) (3.3, 8.1) Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is <0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; IFN-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib malate. Cytokine-Refractory The use of single-agent sunitinib malate in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N=106) Study 5 (N=63) Objective response rate [%, (95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR* (42.0, *) 54 b (34.3, 70.1) *Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib Malate N=309 Placebo N=306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Malate Placebo Sunitinib Malate Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u22651 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u22652, ECOG PS \u22651 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. 1 1 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate and placebo groups. Additionally, 49% of sunitinib malate patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib Malate (N=86) Placebo (N=85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 a 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors. 1"
    ],
    "clinical_studies_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase)</caption><col width=\"210.95pt\"/><col width=\"210.95pt\"/><col width=\"210.95pt\"/><col width=\"210.95pt\"/><col width=\"210.95pt\"/><tbody><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N=207)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N=105)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>Time-to-tumor progression <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>27.3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>6.4</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;0.0001*</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0.33</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(16.0, 32.1)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(4.4, 10.0)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(0.23, 0.47)</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph>Progression-free survival <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>24.1</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>6.0</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>&lt;0.0001</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>0.33</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(11.1, 28.3)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(4.4, 9.9)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(0.24, 0.47)</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph>Objective response rate (PR)</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>6.8</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>0.006 <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"/></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(3.7, 11.1)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>* A comparison is considered statistically significant if the p-value is &lt;0.00417 (O&#x2019;Brien Fleming stopping boundary).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Time from randomization to progression or death due to any cause. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Pearson chi-square test. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 11. Treatment-Na&#xEF;ve RCC Efficacy Results (Interim Analysis) from Study 3</caption><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><tbody><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N=375)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N=375)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>Progression-free survival <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>47.3</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>22.0</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>&lt;0.000001 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>0.415</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(42.6, 50.7)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(16.4, 24.0)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(0.320, 0.539)</paragraph></td></tr><tr><td styleCode=\"     Toprule         Lrule          Rrule     \"><paragraph>Objective response rate <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>27.5</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>5.3</paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>&lt;0.001 <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"     Toprule          Rrule     \"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"    Lrule          Rrule     \"><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(23.0, 32.3)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"><paragraph>(3.3, 8.1)</paragraph></td><td align=\"center\" styleCode=\"     Rrule     \"/><td align=\"center\" styleCode=\"     Rrule     \"/></tr><tr><td colspan=\"5\" styleCode=\"     Toprule     \"><paragraph>Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>Assessed by blinded core radiology laboratory; 90 patients&#x2019; scans had not been read at time of analysis. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>A comparison is considered statistically significant if the p-value is &lt;0.0042 (O&#x2019;Brien Fleming stopping boundary). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup>Pearson chi-square test. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5</caption><col width=\"192pt\"/><col width=\"192pt\"/><col width=\"192pt\"/><tbody><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Study 4</content></paragraph><paragraph><content styleCode=\"bold\">(N=106)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Study 5</content></paragraph><paragraph><content styleCode=\"bold\">(N=63)</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>34.0 <sup>a</sup></paragraph><paragraph>(25.0, 43.8)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>36.5 <sup>b</sup></paragraph><paragraph>(24.7, 49.6)</paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Duration of response</paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>NR*</paragraph><paragraph>(42.0, *)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>54 <sup>b</sup></paragraph><paragraph>(34.3, 70.1)</paragraph></td></tr><tr><td colspan=\"3\"><paragraph>*Data not mature enough to determine upper confidence limit.</paragraph></td></tr><tr><td colspan=\"3\"><paragraph>Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>a</sup>Assessed by blinded core radiology laboratory. </paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>b</sup>Assessed by investigators. </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC</caption><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><tbody><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"/><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">N=309</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">N=306</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value <sup>a</sup></content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR <sup>a</sup>(95% CI) </content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Median DFS [years (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>6.8 (5.8, NR)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>5.6 (3.8, 6.6)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.03</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.76 (0.59, 0.98)</paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>DFS Events</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>113 (36.6%)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>144 (47.1%)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"/></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>5 Year DFS Rate</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>59.3%</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>51.3%</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"/></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group </paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 14. Disease-free Survival by Baseline Disease Characteristics</caption><col width=\"164.85pt\"/><col width=\"158px\"/><col width=\"158px\"/><col width=\"158px\"/><col width=\"158px\"/><col width=\"158px\"/><tbody><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"/><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Number of Events/Total</content></paragraph><paragraph><content styleCode=\"bold\">n/N</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Median DFS</content></paragraph><paragraph><content styleCode=\"bold\">[years (95% CI)]</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR <sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"/><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Sunitinib Malate</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Placebo</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Sunitinib Malate</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Placebo</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"/></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>T3 Intermediate <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>35/115</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>46/112</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>NR</paragraph><paragraph>(5.2, NR)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>6.4</paragraph><paragraph>(4.7, NR)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.82</paragraph><paragraph>(0.53, 1.28)</paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>T3 High <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>63/165</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>79/166</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>6.8</paragraph><paragraph>(5.0, NR)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>5.3</paragraph><paragraph>(2.9, NR)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.77</paragraph><paragraph>(0.55, 1.07)</paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>T4/Node Positive <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>15/29</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>19/28</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>3.5</paragraph><paragraph>(1.2, NR)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>1.7</paragraph><paragraph>(0.4, 3.0)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.62</paragraph><paragraph>(0.31, 1.23)</paragraph></td></tr><tr><td colspan=\"6\"><paragraph>Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached</paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>a</sup>HR based on a Cox proportional hazards model </paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>b</sup>T3 Intermediate: T3, N0 or NX, M0, any Fuhrman&#x2019;s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman&#x2019;s grade 1, ECOG PS &#x2265;1 </paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>c</sup>T3 High: T3, N0 or NX, M0, Fuhrman&#x2019;s grade &#x2265;2, ECOG PS &#x2265;1 </paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>d</sup>T4/Node Positive: T4, N0 or NX, M0, any Fuhrman&#x2019;s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman&#x2019;s grade, any ECOG PS </paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 15. pNET Efficacy Results from Study 6</caption><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><tbody><tr><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N=86)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N=85)</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Progression-free survival</paragraph><paragraph>[median, months (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>10.2</paragraph><paragraph>(7.4, 16.9)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>5.4</paragraph><paragraph>(3.4, 6.0)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.000146 <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.427</paragraph><paragraph>(0.271, 0.673)</paragraph></td></tr><tr><td styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>9.3</paragraph><paragraph>(3.2, 15.4)</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>0.0066 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"     Botrule          Toprule         Lrule          Rrule     \"><paragraph>NA</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup>2-sided unstratified log-rank test. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup>Fisher&#x2019;s Exact test. </paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 12.5 mg capsules Hard gelatin capsule with maroon opaque cap and body, imprinted with TEVA over 8199 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 42291-901-28 25 mg capsules Hard gelatin capsule with light brown opaque cap and maroon opaque body, imprinted with TEVA over 8224 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 42291-902-28 37.5 mg capsules Hard gelatin capsule with yellow opaque cap and body, imprinted with TEVA over 8229 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 42291-903-28 50 mg capsules Hard gelatin capsule with light brown opaque cap and body, imprinted with TEVA over 8231 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 42291-904-28 Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions ( 5.1 )] . Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions ( 5.2 )] . QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions ( 5.3 )] . Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions ( 5.4 )] . Hemorrhagic Events Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions ( 5.5 )] . Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate capsules treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate capsules [see Warnings and Precautions ( 5.5 ), Adverse Reactions ( 6.1 )] . Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate capsules due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions ( 5.9 ), Adverse Reactions ( 6.1 )] . Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] . Thyroid Dysfunction Advise patients that sunitinib malate capsules can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions ( 5.11 )] . Hypoglycemia Advise patients that sunitinib malate capsules can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions ( 5.12 )] . Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] . Impaired Wound Healing Advise patients that sunitinib malate capsules impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions ( 5.14 )] . Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions ( 7 )] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.15 ), Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations ( 8.3 )] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations ( 8.3 )] . Lactation Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [see Use in Specific Populations ( 8.2 )] . Infertility Advise patients that sunitinib malate capsules may impair male and female fertility [see Use in Specific Populations ( 8.3 ), Nonclinical Toxicology ( 13.1 )] . Missed Dose Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time. Manufactured By: AvKARE Pulaski, TN 38478 Mfg. Iss. 9/2021 AV 08/23 (M)"
    ],
    "spl_medguide": [
      "MEDICATION GUIDE Sunitinib Malate (soo ni' ti nib mal' ate) Capsules What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are a prescription medicine used to treat: a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate. advanced kidney cancer (advanced renal cell carcinoma or RCC). adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: have any heart problems have high blood pressure have thyroid problems have a history of low blood sugar or diabetes have kidney function problems (other than cancer) have liver problems have any bleeding problem plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d have seizures have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth are pregnant or plan to become pregnant. Sunitinib malate can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsules 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too many sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules you feel faint or lightheaded, or you pass out dizziness feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache lightheadedness dizziness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) vomiting blood coughing up blood black, sticky stools bloody urine headache change in your mental status Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away loss of appetite problems with heat feeling nervous or agitated, tremors sweating nausea or vomiting diarrhea fast heat rate weight gain or weight loss feeling depressed irregular menstrual periods or no menstrual periods headache hair loss Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: headache drowsiness weakness dizziness confusion irritability hunger fast heart beat sweating feeling jittery Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness weakness diarrhea pain, swelling or sores inside of your mouth nausea loss of appetite indigestion vomiting stomach-area (abdominal) pain blisters or rash on the palms of your hands and soles of your feet high blood pressure taste changes low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which they were not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. The 12.5 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, and titanium dioxide. The 25 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The 37.5 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide. The 50 mg capsule shell contains FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The black printing ink which is common for all strengths contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, shellac, and may also contain propylene glycol. Manufactured By: AvKARE Pulaski, TN 38478 Mfg. Iss. 9/2021 AV 08/23 (M) This Medication Guide has been approved by the U.S. Food and Drug Administration. Iss. 9/2021"
    ],
    "spl_medguide_table": [
      "<table cellpadding=\"5\" cellspacing=\"0\" width=\"1000px\"><colgroup><col width=\"500px\"/><col width=\"500px\"/></colgroup><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><content styleCode=\"bold\">Sunitinib Malate (soo ni&apos; ti nib mal&apos; ate) Capsules</content></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules can cause serious side effects including:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content><list listType=\"unordered\" styleCode=\"Circle\"><item>itching</item><item>yellow eyes or skin</item><item>dark urine</item><item>pain or discomfort in the right upper stomach area</item></list></item></list><paragraph>Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems.</paragraph> See &#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D; for more information about side effects. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">What are sunitinib malate capsules?</content></paragraph><paragraph>Sunitinib malate capsules are a prescription medicine used to treat:</paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: <list listType=\"unordered\" styleCode=\"Circle\"><item>you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or</item><item>you cannot take imatinib mesylate.</item></list></item><item>advanced kidney cancer (advanced renal cell carcinoma or RCC).</item><item>adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.</item><item>a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.</item></list> It is not known if sunitinib malate capsules are safe and effective in children. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>have any heart problems</item><item>have high blood pressure</item><item>have thyroid problems</item><item>have a history of low blood sugar or diabetes</item><item>have kidney function problems (other than cancer)</item><item>have liver problems</item><item>have any bleeding problem</item><item>plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D;</content></item><item>have seizures</item><item>have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth</item><item>are pregnant or plan to become pregnant. Sunitinib malate can harm your unborn baby. <paragraph><content styleCode=\"bold\">Females</content>who are able to become pregnant: </paragraph><list listType=\"unordered\" styleCode=\"Circle\"><item>Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules.</item><item>You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules.</item><item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.</item></list></item></list><paragraph><content styleCode=\"bold\">Males</content>with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. </paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose.</item></list> Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any</content>surgery, or medical or dental procedure. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content>including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. </paragraph><paragraph>You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell</content>your healthcare provider if you are taking or have taken an osteoporosis medicine. </paragraph> Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">How should I take sunitinib malate capsules?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Take sunitinib malate capsules exactly the way your healthcare provider tells you.</item><item>Take sunitinib malate capsules 1 time each day with or without food.</item><item>If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks   (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. </item><item>If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.</item><item>Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body.</item><item>Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.</item><item>If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.</item><item>Call your healthcare provider right away, if you take too many sunitinib malate capsules.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">What are possible side effects of sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules may cause serious side effects, including:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>See <content styleCode=\"bold\">&#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content></item><item><content styleCode=\"bold\">Heart problems.</content>Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. </item><item><content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening.</content>Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules </item></list></td></tr><tr><td styleCode=\"Lrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>you feel faint or lightheaded, or you pass out</item><item>dizziness</item></list></td><td styleCode=\"Rrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item> feel your heart beat is irregular or fast</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule          Rrule     \"><list listType=\"unordered\"><item><content styleCode=\"bold\">High blood pressure.</content>High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: </item></list></td></tr><tr><td styleCode=\"Lrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>severe headache</item><item>lightheadedness</item></list></td><td styleCode=\"Rrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>dizziness</item><item>change in vision</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule          Rrule     \"><paragraph>Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed.</paragraph><list listType=\"unordered\"><item><content styleCode=\"bold\">Bleeding problems.</content>Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: </item></list></td></tr><tr><td styleCode=\"Lrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>painful, swollen stomach (abdomen)</item><item>vomiting blood</item><item>coughing up blood</item><item>black, sticky stools</item></list></td><td styleCode=\"Rrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>bloody urine</item><item>headache </item><item>change in your mental status</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Serious stomach and intestinal problems, that can sometimes lead to death.</content>Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. </item><item><content styleCode=\"bold\">Tumor lysis syndrome (TLS).</content>TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. </item><item><content styleCode=\"bold\">Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]).</content>RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. </item><item><content styleCode=\"bold\">Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS).</content>TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brain and kidneys, and can sometimes lead to death. </item><item><content styleCode=\"bold\">Protein in your urine.</content>Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. </item><item><content styleCode=\"bold\">Serious skin and mouth reactions.</content>Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: <list listType=\"unordered\" styleCode=\"Circle\"><item>severe rash with blisters or peeling of the skin.</item><item>painful sores or ulcers on the skin, lips or inside the mouth.</item><item>tissue damage (necrotizing fasciitis).</item></list></item></list><paragraph>If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away.</paragraph><list listType=\"unordered\"><item><content styleCode=\"bold\">Thyroid problems.</content>Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: </item></list></td></tr><tr><td styleCode=\"Lrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>tiredness that gets worse and does not go away</item><item>loss of appetite</item><item>problems with heat</item><item>feeling nervous or agitated, tremors</item><item>sweating</item><item>nausea or vomiting</item><item>diarrhea</item></list></td><td styleCode=\"Rrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>fast heat rate</item><item>weight gain or weight loss</item><item>feeling depressed</item><item>irregular menstrual periods or no menstrual periods</item><item>headache</item><item>hair loss</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule          Rrule     \"><list listType=\"unordered\"><item><content styleCode=\"bold\"><content styleCode=\"bold\">Low blood sugar (hypoglycemia). </content></content>Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: </item></list></td></tr><tr><td styleCode=\"Lrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>headache</item><item>drowsiness</item><item>weakness</item><item>dizziness</item><item>confusion</item></list></td><td styleCode=\"Rrule     \"><list listType=\"unordered\" styleCode=\"Circle\"><item>irritability</item><item>hunger</item><item>fast heart beat</item><item>sweating</item><item>feeling jittery</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule          Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Jawbone problems (osteonecrosis).</content>Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.</item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures.</item></list></item><item><content styleCode=\"bold\">Wound healing problems.</content>Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.</item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.</item></list></item></list><paragraph><content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects.</content></paragraph><content styleCode=\"bold\">Common side effects of sunitinib malate capsules include:</content></td></tr><tr><td styleCode=\"Lrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item>tiredness</item><item>weakness</item><item>diarrhea</item><item>pain, swelling or sores inside of your mouth</item><item>nausea</item><item>loss of appetite</item><item>indigestion</item></list></td><td styleCode=\"Rrule     \"><list listType=\"unordered\" styleCode=\"Disc\"><item>vomiting</item><item>stomach-area (abdominal) pain</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>high blood pressure</item><item>taste changes</item><item>low platelet counts</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule         Lrule          Rrule     \"><paragraph>The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.</paragraph><paragraph>These are not all of the possible side effects of sunitinib malate capsules.</paragraph> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">How do I store sunitinib malate capsules?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Store sunitinib malate capsules at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item></list><paragraph><content styleCode=\"bold\"><content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content></content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which they were not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them.</paragraph> You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. </td></tr><tr><td colspan=\"2\" styleCode=\"Botrule          Toprule         Lrule          Rrule     \"><paragraph><content styleCode=\"bold\">What are the ingredients in sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content>sunitinib malate </paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content>croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. </paragraph><paragraph>The 12.5 mg capsule shell contains D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, and titanium dioxide.</paragraph><paragraph>The 25 mg capsule shell contains D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, gelatin, and titanium dioxide.</paragraph><paragraph>The 37.5 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide.</paragraph><paragraph>The 50 mg capsule shell contains FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, gelatin, and titanium dioxide.</paragraph><paragraph>The black printing ink which is common for all strengths contains black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, shellac, and may also contain propylene glycol.</paragraph><paragraph>Manufactured By:   AvKARE </paragraph><paragraph>Pulaski, TN 38478</paragraph><paragraph>Mfg. Iss. 9/2021</paragraph><paragraph>AV 08/23 (M)</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 12.5",
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 25",
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 37.5",
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 50"
    ],
    "set_id": "0772eb61-ca42-39de-e063-6294a90a6632",
    "id": "4884360d-03d2-1af6-e063-6294a90aedf6",
    "effective_time": "20260116",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA213803"
      ],
      "brand_name": [
        "Sunitinib Malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "AvKARE"
      ],
      "product_ndc": [
        "42291-901",
        "42291-902",
        "42291-903",
        "42291-904"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "4884360d-03d2-1af6-e063-6294a90aedf6"
      ],
      "spl_set_id": [
        "0772eb61-ca42-39de-e063-6294a90a6632"
      ],
      "package_ndc": [
        "42291-901-28",
        "42291-902-28",
        "42291-903-28",
        "42291-904-28"
      ],
      "original_packager_product_ndc": [
        "0093-8199",
        "0093-8224",
        "0093-8229",
        "0093-8231"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE TITANIUM DIOXIDE FERRIC OXIDE RED STARCH, CORN SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE 6;MS Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE TITANIUM DIOXIDE FERRIC OXIDE RED FERRIC OXIDE YELLOW STARCH, CORN FERROSOFERRIC OXIDE SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE caramel 7;MS Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE FERROSOFERRIC OXIDE STARCH, CORN 8;MS Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE FERRIC OXIDE RED SHELLAC PROPYLENE GLYCOL POTASSIUM HYDROXIDE STARCH, CORN caramel 9;MS"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate as recommended [ see Warnings and Precautions (5.1) ]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate as recommended [ see Warnings and Precautions (5.1) ]."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate capsule is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET: The recommended dosage is 37.5 mg orally once daily. ( 2.3 ) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction S e verity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [ see Warnings and Precautions (5.1) ] Grade 3 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. \u2022 For recurring Grade 3 permanently discontinue. Grade 4 \u2022 Permanently discontinue. Cardiovascular events [ see Warnings and Precautions (5.2) ] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at reduced dose. Clinically manifested congestive heart failure (CHF) \u2022 Permanently discontinue. Hypertension [ see Warnings and Precautions (5.4) ] Grade 3 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. Grade 4 \u2022 Permanently discontinue. Hemorrhagic events [ see Warnings and Precautions (5.5) ] Grade 3 or 4 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [ see Warnings and Precautions (5.7) ] Any Grade \u2022 Permanently discontinue. Proteinuria or Nephrotic syndrome [ see Warnings and Precautions (5.8) ] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions \u2022 Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [ see Warnings and Precautions (5.9) ] Any Grade \u2022 Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [ see Warnings and Precautions (5.10) ] Any Grade \u2022 Permanently discontinue. Osteonecrosis of the jaw [ see Warnings and Precautions (5.13) ] Any Grade \u2022 The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. \u2022 Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [ see Warnings and Precautions (5.14) ] Any Grade \u2022 The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. \u2022 Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential, If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [ see Drug Interactions (7.1) ]: GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [ see Drug Interactions (7.1) ]. 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)]."
    ],
    "dosage_and_administration_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"16.96%\"/><col width=\"18.14%\"/><col width=\"17.94%\"/><col width=\"25.22%\"/><col width=\"21.74%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\"> <content styleCode=\"bold\">Indications</content>  </td><td styleCode=\"Rrule\" rowspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">GIST</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">RCC</content>  </td><td styleCode=\"Rrule\" rowspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">pNET</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Advanced RCC</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Adjuvant RCC</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> First dose reduction  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 37.5 mg once daily  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 37.5 mg once daily  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 37.5 mg once daily  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 25 mg once daily  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Second dose reduction  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 25 mg once daily  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 25 mg once daily  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> NA  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> NA  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"30.32%\"/><col width=\"22.82%\"/><col width=\"46.86%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Adverse Reaction</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> <content styleCode=\"bold\">S</content><content styleCode=\"bold\">e</content><content styleCode=\"bold\">verity</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Dosage Modifications for </content><content styleCode=\"bold\">Sunitinib Malate Capsules</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\"> Hepatotoxicity <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.1\">see Warnings and Precautions (5.1)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Grade 3  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Withhold until resolution to Grade 0 to 1 or baseline.  &#x2022; Resume at a reduced dose.  &#x2022; For recurring Grade 3 permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Grade 4  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\"> Cardiovascular events <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.2\">see Warnings and Precautions (5.2)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than  20% but less than  50% below baseline or below the lower limit of normal if baseline was not obtained)  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Withhold until resolution to Grade 0 to 1 or baseline.  &#x2022; Resume at reduced dose.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Clinically manifested congestive heart failure (CHF)  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\"> Hypertension <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.4\">see Warnings and Precautions (5.4)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Grade 3  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Withhold until resolution to Grade 0 to 1 or baseline.  &#x2022; Resume at a reduced dose.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Grade 4  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Hemorrhagic events <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.5\">see Warnings and Precautions (5.5)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Grade 3 or 4  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Withhold until resolution to Grade 0 to 1 or baseline.  &#x2022; Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Thrombotic microangiopathy <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.7\">see Warnings and Precautions (5.7)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.8\">see Warnings and Precautions (5.8)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> 3 or more grams proteinuria in  24 hours in the absence of nephrotic syndrome  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Withhold until resolution to Grade 0 to 1 or baseline.  &#x2022; Resume at a reduced dose.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">   </td><td styleCode=\"Rrule\" valign=\"top\"> Nephrotic syndrome or recurrent proteinuria of 3 or more grams per  24 hours despite dose reductions  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.9\">see Warnings and Precautions (5.9)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.15\">see Warnings and Precautions (5.10)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Osteonecrosis of the jaw <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.12\">see Warnings and Precautions (5.13)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.  &#x2022; Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Impaired wound healing <content styleCode=\"italics\">[<linkHtml href=\"#Section_5.13\">see Warnings and Precautions (5.14)</linkHtml>]</content>  </td><td styleCode=\"Rrule\" valign=\"top\"> Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"> &#x2022; The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established.  &#x2022; Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.  </td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Capsules, hard gelatin: 12.5 mg sunitinib: Size \u201c4\u201d hard gelatin capsules with orange opaque body imprinted with \u201c6\u201d and orange opaque cap imprinted with \u201cMS\u201d in white ink. 25 mg sunitinib: Size \u201c3\u201d hard gelatin capsules with orange opaque body imprinted with \u201c7\u201d and caramel opaque cap imprinted with \u201cMS\u201d in white ink. 37.5 mg sunitinib: Size \u201c3\u201d hard gelatin capsules with yellow opaque body imprinted with \u201c8\u201d and yellow opaque cap imprinted with \u201cMS\u201d in black ink. 50 mg sunitinib: Size \u201c2\u201d hard gelatin capsules with caramel opaque body imprinted with \u201c9\u201d and carmel opaque cap imprinted with \u201cMS\u201d in white ink. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline and resume sunitinib malate at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. ( 2.4 , 5.1 ) Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) QT Interval Prolongation and Torsade de Pointes: Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib malate for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients who develop Grade 4 hypertension. ( 5.4 ) Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ) Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) Thrombotic microangiopathy (TMA) : TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate for TMA. ( 5.7 ) Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate for these events. ( 5.9 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate until resolution. ( 5.10 ) Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib malate for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 ) Impaired Wound Healing : Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. ( 5.14 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u226550% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes.Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate. Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration (2.5) , Drug Interactions (7.2) ]. 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3-5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib malate. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib malate. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome (TLS) Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate as monotherapy and administered in combination with bevacizumab. Sunitinib malate is not approved for use in combination with bevacizumab. Discontinue sunitinib malate in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n=83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw (ONJ) Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate and periodically during sunitinib malate therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate for development of ONJ until complete resolution. The safety of resumption of sunitinib malate after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate [see Adverse Reactions (6.2) ]. Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for 4 weeks following the final dose [see Use in Specific Populations (8.1 , 8.3 )]."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [ see Warnings and Precautions (5.1) ] Cardiovascular Events [ see Warnings and Precautions (5.2) ] QT Interval Prolongation and Torsade de Pointes [ see Warnings and Precautions (5.3) ] Hypertension [ see Warnings and Precautions (5.4) ] Hemorrhagic Events [ see Warnings and Precautions (5.5) ] Tumor Lysis Syndrome [ see Warnings and Precautions (5.6) ] Thrombotic Microangiopathy [ see Warnings and Precautions (5.7) ] Proteinuria [ see Warnings and Precautions (5.8) ] Dermatologic Toxicities [ see Warnings and Precautions (5.9) ] Reversible Posterior Leukoencephalopathy Syndrome [ see Warnings and Precautions (5.10) ] Thyroid Dysfunction [ see Warnings and Precautions (5.11) ] Hypoglycemia [ see Warnings and Precautions (5.12) ] Osteonecrosis of the Jaw [ see Warnings and Precautions (5.13) ] Impaired Wound Healing [ see Warnings and Precautions (5.14) ] The most common adverse reactions (\u226525%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u226525%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate (mean: 3.0; range: 1-9) and 1 cycle (mean; 1.8; range: 1-6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u226510% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reaction GIST Sunitinib malate (N=202) Placebo (N=102) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea Mucositis/stomatitis Constipation 40 29 20 4 1 0 27 18 14 0 2 2 Metabolism/Nutrition Anorexia a Asthenia 33 22 1 5 29 11 5 3 Dermatology Skin discoloration Rash Hand-foot syndrome 30 14 14 0 1 4 23 9 10 0 0 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u226510% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib malate (N=202) Placebo (N=102) All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased Lymphocytes decreased Platelets decreased Hemoglobin decreased 53 38 38 26 10 0 5 3 4 16 4 22 0 0 0 2 Gastrointestinal AST/ALT increased Lipase increased Alkaline phosphatase increased Amylase increased Total bilirubin increased Indirect bilirubin increased 39 25 24 17 16 10 2 10 4 5 1 0 23 17 21 12 8 4 1 7 4 3 0 0 Renal/Metabolic Creatinine increased Potassium decreased Sodium increased 12 12 10 1 1 0 7 4 4 0 0 1 Cardiac Decreased LVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate [ see Clinical Studies (14.1) ]. For 241 patients randomized to the sunitinib malate arm, including 139 who received sunitinib malate in both the double-blind and open-label phases, the median duration of sunitinib malate treatment was 6 cycles (mean: 8.5; range: 1\u201344). For the 255 patients who ultimately received open-label sunitinib malate treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1\u201337) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib malate (N=375) Interferon Alfa (N=360) All Grades % Grade 3-4 a % All Grades % Grade 3-4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea Nausea Mucositis/stomatitis Vomiting Dyspepsia Abdominal pain c Constipation Dry mouth Oral pain Flatulence GERD/reflux esophagitis Glossodynia Hemorrhoids 66 58 47 39 34 30 23 13 14 14 12 11 10 10 6 3 5 2 5 1 0 <1 0 <1 0 0 21 41 5 17 4 12 14 7 1 2 1 1 2 <1 2 <1 1 0 1 <1 <1 0 0 0 0 0 Constitutional Fatigue Asthenia Fever Weight decreased Chills Chest Pain Influenza like illness 62 26 22 16 14 13 5 15 11 1 <1 1 2 0 56 22 37 17 31 7 15 15 6 <1 1 0 1 <1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e Headache Dizziness 47 23 11 <1 1 <1 15 19 14 0 0 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension Edema peripheral Ejection fraction decreased 34 24 16 13 2 3 4 5 5 <1 1 2 Dermatology Rash Hand-foot syndrome Skin discoloration/yellow skin Dry skin Hair color changes Alopecia Erythema Pruritus 29 29 25 23 20 14 12 12 2 8 <1 <1 0 0 <1 <1 11 1 0 7 <1 9 1 7 <1 0 0 0 0 0 0 <1 Musculoskeletal Pain in extremity/limb discomfort Arthralgia Back pain 40 30 28 5 3 5 30 19 14 2 1 2 Respiratory Cough Dyspnea Nasopharyngitis Oropharyngeal pain Upper respiratory tract infection 27 26 14 14 11 1 6 0 <1 <1 14 20 2 2 2 <1 4 0 0 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia Depression g 15 11 <1 0 10 14 0 1 *Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u226510% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib malate (N=375) Interferon Alfa ( N=360) All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Hematology Hemoglobin decreased Neutrophils decreased Platelets decreased Lymphocytes decreased 79 77 68 68 8 17 9 18 69 49 24 68 5 9 1 26 Renal/Metabolic Creatinine increased Creatine kinase increased Uric acid increased Calcium increased Phosphorus decreased Albumin decreased Glucose increased Sodium decreased Glucose decreased Potassium increased Calcium increased Potassium decreased Sodium increased 70 49 46 42 31 28 23 20 17 16 13 13 13 <1 2 14 1 6 1 6 8 0 3 <1 1 0 51 11 33 40 24 20 15 15 12 17 10 2 10 <1 1 8 1 6 0 6 4 <1 4 1 <1 0 Gastrointestinal AST increased Lipase increased ALT increased Alkaline phosphatase increased Amylase increased Total bilirubin increased Indirect bilirubin increased 56 56 51 46 35 20 13 2 18 3 2 6 1 1 38 46 40 37 32 2 1 2 8 2 2 3 0 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). Long-Term Safety in RCC The long-term safety of sunitinib malate in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings.The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate did not appear to be associated with new types of adverse reactions.There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304).The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib malate (N=306) Placebo (N=304) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a Diarrhea Nausea Dyspepsia Abdominal pain b Vomiting Constipation 61 57 34 27 25 19 12 6 4 2 1 2 2 0 15 22 15 7 9 7 11 0 <1 0 0 <1 0 0 Constitutional Fatigue/Asthenia Localized edema c Pyrexia 57 18 12 8 <1 <1 34 <1 6 2 0 0 Dermatology Hand-foot syndrome Rash d Hair color changes Skin discoloration/Yellow skin Dry skin 50 24 22 18 14 16 2 0 0 0 10 12 2 1 6 <1 0 0 0 0 Cardiac Hypertension e Edema/Peripheral edema 39 10 8 <1 14 7 1 0 Neurology Altered taste f Headache 38 19 <1 <1 6 12 0 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage /Bleeding Bleeding events, all sites g 24 <1 5 <1 Metabolism/Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Pain in extremity Arthralgia 15 11 <1 <1 7 10 0 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingiva lbleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. Grade 4 adverse reactions in patients on sunitinib malate included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%). Grade 3-4 laboratory abnormalities that occurred in \u22652% of patients receiving sunitinib malate include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13-532 days) for patients on sunitinib malate and 113 days (range: 1-614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib malate (N=83) Placebo (N=82) All Grades % Grade 3-4 a % All Grades % Grade 3-4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea Stomatitis/oral syndromes b Nausea Abdominal pain c Vomiting Dyspepsia 59 48 45 39 34 15 5 6 1 5 0 0 39 18 29 34 31 6 2 0 1 10 2 0 Constitutional Asthenia Fatigue Weight decreased 34 33 16 5 5 1 27 27 11 4 9 0 Dermatology Hair color changes Hand-foot syndrome Rash Dry skin 29 23 18 15 1 6 0 0 1 2 5 11 0 0 0 0 Cardiac Hypertension 27 10 5 1 Hemorrhage /Bleeding Bleeding events d Epistaxis 22 21 0 1 10 5 4 0 Neurology Dysgeusia Headache 21 18 0 0 5 13 0 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate in Study 6 Laboratory Abnormality pNET Sunitinib malate Placebo All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Gastrointestinal AST increased Alkaline phosphatase increased ALT increased Total bilirubin increased Amylase increased Lipase increased 72 63 61 37 20 17 5 10 4 1 4 5 70 70 55 28 10 11 3 11 3 4 1 4 Hematology Neutrophils decreased Hemoglobin decreased Platelets decreased Lymphocytes decreased 71 65 60 56 16 0 5 7 16 55 15 35 0 1 0 4 Renal/Metabolic Glucose increased Albumin decreased Phosphorus decreased Calcium decreased Sodium decreased Creatinine increased Glucose decreased Potassium decreased Magnesium decreased Potassium increased 71 41 36 34 29 27 22 21 19 18 12 1 7 0 2 5 2 4 0 1 78 37 22 19 34 28 15 14 10 11 18 1 5 0 3 5 4 0 0 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3-4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on sunitinib malate. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema. Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib malate include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. *including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"31.18%\"/><col width=\"17.12%\"/><col width=\"17.28%\"/><col width=\"17.12%\"/><col width=\"17.28%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Adverse Reaction</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">GIST</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> Sunitinib <content styleCode=\"bold\">malate</content><content styleCode=\"bold\"> (N=202)</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Placebo (N=102)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades %</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4 %</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades %</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4 %</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Any Adverse Reaction</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 94  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 56  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 97  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 51  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  Diarrhea   Mucositis/stomatitis   Constipation  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   40  29  20  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  1  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   27  18  14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  2  2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Metabolism/Nutrition </content>  Anorexia<sup>a </sup>  Asthenia  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   33   22  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   29  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  3  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Dermatology </content>  Skin discoloration   Rash  Hand-foot syndrome  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   30  14  14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  1  4  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   23  9  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  3  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Neurology</content>  Altered taste  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   21  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   12  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Cardiac</content>  Hypertension  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Musculoskeletal</content>  Myalgia/limb pain  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   9  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"34.1%\"/><col width=\"16.54%\"/><col width=\"16.4%\"/><col width=\"16.4%\"/><col width=\"16.56%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Laboratory Abnormality</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">GIST</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Sunitinib </content><content styleCode=\"bold\">malate</content><content styleCode=\"bold\"> (N=202)</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Placebo (N=102)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades*</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4*<sup>,a</sup></content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades*</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4*<sup>,b</sup></content>  <content styleCode=\"bold\">%</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Any <content styleCode=\"bold\">Laboratory Abnormality</content></content>  </td><td styleCode=\"Rrule\" valign=\"top\">   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 34  </td><td styleCode=\"Rrule\" valign=\"top\">   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 22  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Hematology</content>  Neutrophils decreased  Lymphocytes decreased  Platelets decreased  Hemoglobin decreased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   53  38  38  26  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  0  5  3  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  16  4  22  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  0  2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  AST/ALT increased  Lipase increased  Alkaline phosphatase increased  Amylase increased  Total bilirubin increased  Indirect bilirubin increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   39  25  24  17  16  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  10  4  5  1  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   23  17  21  12  8  4  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  7  4  3  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Renal/Metabolic</content>  Creatinine increased  Potassium decreased   Sodium increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   12  12  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  1  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   7  4  4  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  1  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Cardiac</content>  Decreased LVEF  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   3  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"36.74%\"/><col width=\"15.86%\"/><col width=\"15.86%\"/><col width=\"15.7%\"/><col width=\"15.84%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Adverse Reaction</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Sunitinib </content><content styleCode=\"bold\">malate</content><content styleCode=\"bold\"> </content> <content styleCode=\"bold\">(N=375)</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Interferon Alfa </content>  <content styleCode=\"bold\">(N=360)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4<sup>a</sup></content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4<sup>b</sup></content>  <content styleCode=\"bold\">%</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Any Adverse Reaction</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 99  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 77  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 99  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 55  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  Diarrhea  Nausea  Mucositis/stomatitis  Vomiting  Dyspepsia  Abdominal pain<sup>c</sup>  Constipation  Dry mouth  Oral pain  Flatulence  GERD/reflux esophagitis  Glossodynia  Hemorrhoids  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   66  58  47  39  34  30  23  13  14  14  12  11  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  6  3  5  2  5  1  0  &lt;1  0  &lt;1  0  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   21  41  5  17  4  12  14  7  1  2  1  1  2  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  2  &lt;1  1  0  1  &lt;1  &lt;1  0  0  0  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Constitutional</content>  Fatigue  Asthenia  Fever  Weight decreased  Chills  Chest Pain  Influenza like illness  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   62  26  22  16  14  13  5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  11  1  &lt;1  1  2  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   56  22  37  17  31  7  15  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  6  &lt;1  1  0  1  &lt;1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Metabolism/Nutrition</content>  Anorexia<sup>d</sup>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   48  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   3  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   42  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Neurology </content>  Altered taste<sup>e</sup>  Headache   Dizziness  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   47  23  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  1  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  19  14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Hemorrhage/Bleeding</content>  Bleeding, all sites  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   37  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4<sup>f</sup>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Cardiac</content>  Hypertension  Edema peripheral  Ejection fraction decreased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   34  24  16  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   13  2  3  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  5  5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  1  2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Dermatology</content>  Rash  Hand-foot syndrome  Skin discoloration/yellow skin   Dry skin  Hair color changes   Alopecia  Erythema   Pruritus  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   29  29  25  23  20  14  12  12  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  8  &lt;1  &lt;1  0  0  &lt;1  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   11  1  0  7  &lt;1  9  1  7  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  0  0  0  0  0  0  &lt;1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Musculoskeletal </content>  Pain in extremity/limb discomfort   Arthralgia  Back pain   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   40  30  28   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  3  5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   30  19  14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  1  2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Respiratory</content>  Cough   Dyspnea  Nasopharyngitis   Oropharyngeal pain  Upper respiratory tract infection  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   27  26  14  14  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  6  0  &lt;1  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   14  20  2  2  2  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  4  0  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Endocrine</content>  Hypothyroidism  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   16  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Psychiatric </content>  Insomnia   Depression<sup>g</sup>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  1  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"34.1%\"/><col width=\"16.54%\"/><col width=\"16.4%\"/><col width=\"16.4%\"/><col width=\"16.56%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Laboratory Abnormality</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Sunitinib malate (N=375)</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Interferon Alfa (</content><content styleCode=\"bold\">N=360)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades*</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4*<sup>,a</sup></content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades*</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4*<sup>,b</sup></content>  <content styleCode=\"bold\">%</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Hematology</content>  Hemoglobin decreased  Neutrophils decreased  Platelets decreased  Lymphocytes decreased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   79  77  68  68  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   8  17  9  18  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   69  49  24  68  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  9  1  26  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Renal/Metabolic</content>  Creatinine increased  Creatine kinase increased  Uric acid increased  Calcium increased  Phosphorus decreased  Albumin decreased  Glucose increased  Sodium decreased  Glucose decreased  Potassium increased  Calcium increased  Potassium decreased  Sodium increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   70  49  46  42  31  28  23  20  17  16  13  13  13  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  2  14  1  6  1  6  8  0  3  &lt;1  1  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   51  11  33  40  24  20  15  15  12  17  10  2  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  1  8  1  6  0  6  4  &lt;1  4  1  &lt;1  0  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  AST increased  Lipase increased  ALT increased  Alkaline phosphatase increased  Amylase increased  Total bilirubin increased  Indirect bilirubin increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   56  56  51  46  35  20  13  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  18  3  2  6  1  1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   38  46  40  37  32  2  1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  8  2  2  3  0  0  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"35.06%\"/><col width=\"16.16%\"/><col width=\"16.98%\"/><col width=\"15.48%\"/><col width=\"16.32%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Adverse Reaction</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Adjuvant Treatment of RCC</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Sunitinib</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">malate</content><content styleCode=\"bold\"> (N=306)</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Placebo (N=304)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4</content>  <content styleCode=\"bold\">%</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Any Adverse Reaction</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 99  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 60  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 88  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 15  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  Mucositis/Stomatitis<sup> a </sup>  Diarrhea   Nausea   Dyspepsia   Abdominal pain <sup>b</sup>  Vomiting   Constipation  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   61  57  34  27  25  19  12  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   6  4  2  1  2  2  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  22  15  7  9  7  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  &lt;1  0  0  &lt;1  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Constitutional </content>  Fatigue/Asthenia   Localized edema <sup>c</sup>  Pyrexia  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   57  18  12  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   8  &lt;1  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   34  &lt;1  6  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Dermatology</content>  Hand-foot syndrome   Rash<sup> d</sup>  Hair color changes  Skin discoloration/Yellow skin   Dry skin  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   50  24  22  18  14  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   16  2  0  0  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  12  2  1  6  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  0  0  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Cardiac</content>  Hypertension<sup> e</sup>  Edema/Peripheral edema  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   39  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   8  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   14  7  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Neurology</content>  Altered taste<sup>f</sup>  Headache  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   38  19  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   6  12  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Endocrine</content>  Hypothyroidism/TSH increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   24  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Hemorrhage /Bleeding</content>  Bleeding events, all sites<sup>g</sup>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   24  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Metabolism/Nutrition</content>  Anorexia/Decreased appetite  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   19  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Musculoskeletal </content>  Pain in extremity   Arthralgia  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   &lt;1  &lt;1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   7  10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"34.32%\"/><col width=\"16.34%\"/><col width=\"16.5%\"/><col width=\"16.34%\"/><col width=\"16.5%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Adverse Reaction</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">pNET</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Sunitinib malate (N=83)</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Placebo (N=82)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4<sup>a</sup></content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4</content>  <content styleCode=\"bold\">%</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Any Adverse Reaction</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 99  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 54  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 95  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 50  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  Diarrhea  Stomatitis/oral syndromes<sup>b</sup>  Nausea  Abdominal pain<sup>c</sup>  Vomiting   Dyspepsia  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   59  48  45  39  34  15  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  6  1  5  0  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   39  18  29  34  31  6  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   2  0  1  10  2  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Constitutional</content>   Asthenia   Fatigue  Weight decreased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   34  33  16  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  5  1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   27  27  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  9  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Dermatology</content>  Hair color changes   Hand-foot syndrome   Rash  Dry skin  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   29  23  18  15  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  6  0  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  2  5  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  0  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Cardiac</content>  Hypertension  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   27  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Hemorrhage /Bleeding</content>  Bleeding events<sup>d</sup>  Epistaxis  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   22  21  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   10  5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   4  0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Neurology</content>   Dysgeusia   Headache  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   21  18  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   5  13  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  1  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Psychiatric</content>  Insomnia  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   18  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   12  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Musculoskeletal</content>  Arthralgia  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   15  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   6  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"27.3%\"/><col width=\"19.62%\"/><col width=\"17.1%\"/><col width=\"18.38%\"/><col width=\"17.6%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"> <content styleCode=\"bold\">Laboratory Abnormality</content>  </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">pNET</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Sunitinib malate</content>  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Placebo</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades*</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4*<sup>,a</sup></content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All Grades*</content>  <content styleCode=\"bold\">%</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">Grade 3-4*<sup>,b</sup></content>  <content styleCode=\"bold\">%</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> AST increased  Alkaline phosphatase  increased  ALT increased  Total bilirubin increased  Amylase increased  Lipase increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 72  63    61  37  20  17  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 5  10    4  1  4  5  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 70  70    55  28  10  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 3  11    3  4  1  4  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Hematology</content>  Neutrophils decreased  Hemoglobin decreased  Platelets decreased  Lymphocytes decreased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   71  65  60  56  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   16  0  5  7  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   16  55  15  35  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0  1  0  4  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"> <content styleCode=\"bold\">Renal/Metabolic</content>  Glucose increased  Albumin decreased  Phosphorus decreased  Calcium decreased  Sodium decreased  Creatinine increased  Glucose decreased  Potassium decreased  Magnesium decreased  Potassium increased  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   71  41  36  34  29  27  22  21  19  18  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   12  1  7  0  2  5  2  4  0  1  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   78  37  22  19  34  28  15  14  10  11  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   18  1  5  0  3  5  4  0  0  1  </td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers : Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [ see Clinical Pharmacology (12.3) ]. Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors [ see Dosage and Administration (2.5) ]. Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [ see Clinical Pharmacology (12.3) ]. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers [ see Dosage and Administration (2.5) ]. 7.2 Drugs that Prolong QT Interval Sunitinib malate is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ]. Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ]. There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data). Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Use in Specific Populations (8.1) ]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [ see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6 mg/kg/day) at doses that were >0.4 times the the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5, and 15 mg/kg) or 5 cycles (0.3, 1.5, and 6 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [ see Clinical Pharmacology (12.3) ]. Sunitinib malate was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [ see Clinical Pharmacology (12.3) ]. No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [ see Clinical Pharmacology (12.3) ]."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ]. There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day."
    ],
    "labor_and_delivery": [
      "8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data). Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma."
    ],
    "nursing_mothers": [
      "8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Use in Specific Populations (8.1) ]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [ see Nonclinical Toxicology (13.1) ]."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6 mg/kg/day) at doses that were >0.4 times the the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5, and 15 mg/kg) or 5 cycles (0.3, 1.5, and 6 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3,000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as (2S)-2-hydroxybutanedoic acid with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1). The molecular formula is C 22 H 27 FN 4 O 2 \u2022 C 4 H 6 O 5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow to orange powder with a pKa of 8.56.The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules, for oral use, are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, mannitol, magnesium stearate and pregelatinized starch as inactive ingredients. In addition 12.5 mg capsule shell contains gelatin, titanium dioxide and red iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide. In addition 25 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide and red iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide. In addition 37.5 mg capsule shell contains gelatin, titanium dioxide and yellow iron oxide. The black printing ink contains shellac, propylene glycol, potassium hydroxide and black iron oxide. In addition 50 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, red iron oxide and black iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide. sunitinib-structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [ see Warnings and Precautions (5.3) ]. 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4,000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib: Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib: Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [ see Warnings and Precautions (5.3) ]."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4,000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib: Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib: Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib malate in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate and patients randomized to sunitinib malate were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate and placebo groups with regard to age (69% versus 72% <65 years for sunitinib malate versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib malate (N=207) Placebo (N=105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression a [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) <0.0001* 0.33 (0.23, 0.47) Progression-free survival b [median, weeks (95% CI)] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) <0.0001 0.33 (0.24, 0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7, 11.1) 0 0.006 c * A comparison is considered statistically significant if the p-value is <0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis, the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). sunitinib-figure-1 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate and interferon alfa groups with regard to age (59% versus 67% <65 years for sunitinib malate versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \u22641.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate over interferon alfa. The ORR was higher in the sunitinib malate arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib malate (N=375) Interferon Alfa (N=375) p-value (log-rank test) HR (95% CI) Progression-free survival a [median, weeks (95% CI)] 47.3 (42.6, 50.7) 22.0 (16.4, 24.0) <0.000001 b 0.415 (0.320, 0.539) Objective response rate a [%, (95% CI)] 27.5 (23.0, 32.3) 5.3 (3.3, 8.1) <0.001 c NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is <0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; INF-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib malate. Cytokine-Refractory The use of single-agent sunitinib malate in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86%-94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N=106) Study 5 (N=63) Objective response rate [%, (95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR* (42.0, *) 54 b (34.3, 70.1) *Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib malate N = 309 Placebo N = 306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System(UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/ Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib malate Placebo Sunitinib malate Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u2265 1 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u2265 2, ECOG PS \u2265 1 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. sunitinib-figure-3 sunitinib-figure-2 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate and placebo groups. Additionally, 49% of sunitinib malate patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an over estimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib malate (N=86) Placebo (N=85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 a 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors. sunitinib-figure-4"
    ],
    "clinical_studies_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"38%\"/><col width=\"15%\"/><col width=\"13%\"/><col width=\"15%\"/><col width=\"15%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Efficacy Parameter</content><content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> Sunitinib malate</content><content styleCode=\"bold\"> (N=207)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo (N=105)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">p-value (log-rank test)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">HR (95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Time-to-tumor progression<sup>a</sup> [median, weeks (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">27.3 (16.0, 32.1) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.4 (4.4, 10.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">&lt;0.0001* </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.33 (0.23, 0.47) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Progression-free survival<sup>b</sup> [median, weeks (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">24.1 (11.1, 28.3) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.0 (4.4, 9.9) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">&lt;0.0001 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.33 (0.24, 0.47) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Objective response rate (PR)  [%, (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.8 (3.7, 11.1) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.006<sup>c</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"35%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"18%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Efficacy Parameter</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib malate (N=375)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Interferon Alfa</content> <content styleCode=\"bold\">(N=375)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">p-value (log-rank test)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">HR (95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Progression-free survival<sup>a</sup> [median, weeks (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">47.3 (42.6, 50.7) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">22.0 (16.4, 24.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">&lt;0.000001<sup>b</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.415 (0.320, 0.539) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Objective response rate<sup>a</sup> [%, (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">27.5 (23.0, 32.3) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.3 (3.3, 8.1) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">&lt;0.001<sup>c</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">NA </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"35%\"/><col width=\"31%\"/><col width=\"33%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Efficacy Parameter</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Study 4</content> <content styleCode=\"bold\">(N=106)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Study 5</content> <content styleCode=\"bold\">(N=63)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Objective response rate [%, (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">34.0<sup>a</sup> (25.0, 43.8) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">36.5<sup>b</sup> (24.7, 49.6) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Duration of response [median, weeks (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">NR* (42.0, *) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">54<sup>b</sup> (34.3, 70.1) </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"36%\"/><col width=\"16%\"/><col width=\"18%\"/><col width=\"11%\"/><col width=\"17%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib malate</content> <content styleCode=\"bold\">N = 309</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">N = 306</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">p-value<sup>a</sup></content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">HR<sup>a</sup></content> <content styleCode=\"bold\">(95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Median DFS [years (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.8 (5.8, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.6 (3.8, 6.6) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.03 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.76 (0.59, 0.98) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">DFS Events </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">113 (36.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">144 (47.1%) </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">5 Year DFS Rate </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">59.3% </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">51.3% </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"30%\"/><col width=\"12%\"/><col width=\"12%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"17%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Number of Events/ Total n/N</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Median DFS</content> <content styleCode=\"bold\">[years (95% CI)]</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">HR<sup>a</sup></content> <content styleCode=\"bold\">(95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">Sunitinib malate </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">Placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">Sunitinib malate </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">Placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">T3 Intermediate<sup>b</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">35/115 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">46/112 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">NR (5.2, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.4 (4.7, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.82 (0.53, 1.28) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">T3 High<sup>c</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">63/165 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">79/166 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.8 (5.0, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.3 (2.9, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.77 (0.55, 1.07) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">T4/Node Positive<sup>d</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">15/29 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">19/28 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3.5 (1.2, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1.7 (0.4, 3.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.62 (0.31, 1.23) </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"35%\"/><col width=\"16%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"16%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Efficacy Parameter</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib malate</content> <content styleCode=\"bold\">(N=86)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N=85)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">p-value</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">HR (95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Progression-free survival [median, months (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">10.2 (7.4, 16.9) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.4 (3.4, 6.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.000146<sup>a</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.427 (0.271, 0.673) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Objective response rate [%, (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">9.3 (3.2, 15.4) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.0066<sup>b</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">NA </td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Sunitinib malate 12.5 mg capsules are supplied as Size \u201c4\u201d hard gelatin capsules with orange opaque body imprinted with \u201c6\u201d and orange opaque cap imprinted with \u201cMS\u201d in white ink: Bottles of 28 capsules: NDC 72205-116-28 Sunitinib malate 25 mg capsules are supplied as Size \u201c3\u201d hard gelatin capsules with orange opaque body imprinted with \u201c7\u201d and caramel opaque cap imprinted with \u201cMS\u201d in white ink: Bottles of 28 capsules: NDC 72205-117-28 Sunitinib malate 37.5 mg capsules are supplied as Size \u201c3\u201d hard gelatin capsules with yellow opaque body imprinted with \u201c8\u201d and yellow opaque cap imprinted with \u201cMS\u201d in black ink: Bottles of 28 capsules: NDC 72205-118-28 Sunitinib malate 50 mg capsules are supplied as Size \u201c2\u201d hard gelatin capsules with caramel opaque body imprinted with \u201c9\u201d and caramel opaque cap imprinted with \u201cMS\u201d in white ink: Bottles of 28 capsules: NDC 72205-119-28 Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [ see Warnings and Precautions (5.1) ]. Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [ see Warnings and Precautions (5.2) ]. QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [ see Warnings and Precautions (5.3) ]. Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [ see Warnings and Precautions (5.4) ]. Hemorrhagic Events Advise patients that sunitinib malate can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [ see Warnings and Precautions (5.5) ]. Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate [ see Warnings and Precautions (5.5) , Adverse Reactions (6.1) ]. Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [ see Warnings and Precautions (5.9) , Adverse Reactions (6.1) ]. Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [ see Warnings and Precautions (5.10) ]. Thyroid Dysfunction Advise patients that sunitinib malate can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions (5.11) ]. Hypoglycemia Advise patients that sunitinib malate can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions (5.12) ]. Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [ see Warnings and Precautions (5.13) ]. Impaired Wound Healing Advise patients that sunitinib malate impairs wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [ see Warnings and Precautions (5.14) ]. Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [ see Drug Interactions (7) ]. Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [ see Warnings and Precautions (5.15) , Use in Specific Populations (8.1) ]. Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate [ see Use in Specific Populations (8.3) ]. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate [ see Use in Specific Populations (8.3) ]. Lactation Advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose [ see Use in Specific Populations (8.2) ]. Infertility Advise patients that sunitinib malate may impair male and female fertility [ see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ]. Missed Dose Advise patients that miss a dose of sunitinib malate by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate by more than 12 hours to take the next scheduled dose at its regular time. This product\u2019s labeling may have been updated. For the most recent prescribing information, please visit http://www.msnlabs.com. Manufactured by: MSN Laboratories Private Limited Telangana \u2013 509 228, INDIA Distributed by: Novadoz Pharmaceuticals LLC Piscataway, NJ 08854 -3714 Issued on: February 2025"
    ],
    "spl_unclassified_section": [
      "MEDICATION GUIDE Sunitinib Malate (soo ni\u02ca ti nib mal eyt) capsules What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are a prescription medicine used to treat: a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate. advanced kidney cancer (advanced renal cell carcinoma or RCC). adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: have any heart problems have high blood pressure have thyroid problems have a history of low blood sugar or diabetes have kidney function problems (other than cancer) have liver problems have any bleeding problem plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d have seizures have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsule 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too much sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules you feel faint or lightheaded, or you pass out feel your heart beat is irregular or fast dizziness High blood pressure. High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache dizziness lightheadedness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems . Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) bloody urine vomiting blood headache coughing up blood change in your mental status black, sticky stools Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome[RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away fast heat rate loss of appetite weight gain or weight loss problems with heat feeling depressed feeling nervous or agitated, tremors irregular menstrual periods or no menstrual periods sweating headache nausea or vomiting hair loss diarrhea Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: headache irritability drowsiness hunger weakness fast heart beat dizziness sweating confusion feeling jittery Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. o You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. o Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. o You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. o Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness vomiting weakness stomach-area (abdominal) pain diarrhea blisters or rash on the palms of your hands and soles of your feet pain, swelling or sores inside of your mouth high blood pressure nausea taste changes loss of appetite low platelet counts indigestion The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, mannitol, magnesium stearate and pregelatinized starch. In addition 12.5 mg capsule shell contains gelatin, titanium dioxide and red iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide. In addition 25 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide and red iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide. In addition 37.5 mg capsule shell contains gelatin, titanium dioxide and yellow iron oxide. The black printing ink contains shellac, propylene glycol, potassium hydroxide and black iron oxide. In addition 50 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, red iron oxide and black iron oxide. The white printing ink, contains shellac, propylene glycol, potassium hydroxide and titanium dioxide. For more information go to www.novadozpharma.com or call 1-855-668-2369. Manufactured by: MSN Laboratories Private Limited Telangana \u2013 509 228, INDIA Distributed by: Novadoz Pharmaceuticals LLC Piscataway, NJ 08854-3714 Issued on: February 2025 This Medication Guide has been approved by the U.S. Food and Drug Administration."
    ],
    "spl_unclassified_section_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> <content styleCode=\"bold\">Sunitinib Malate (soo ni&#x2CA; ti nib mal eyt)  capsules</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules?   Sunitinib malate capsules can cause serious side effects including: </content><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content><list listType=\"unordered\" styleCode=\"disc\"><item>itching </item><item>yellow eyes or skin</item><item>dark urine</item><item>pain or discomfort in the right upper stomach area</item></list></item></list>Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems.  See &#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D; for more information about side effects. </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">What are sunitinib malate capsules?</content>  Sunitinib malate capsules are a prescription medicine used to treat: <list listType=\"unordered\" styleCode=\"disc\"><item>a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: <list listType=\"unordered\" styleCode=\"disc\"><item>you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or </item><item>you cannot take imatinib mesylate.</item></list></item></list><list listType=\"unordered\" styleCode=\"disc\"><item>advanced kidney cancer (advanced renal cell carcinoma or RCC).</item><item>adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.</item><item>a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.</item></list>It is not known if sunitinib malate capsules are safe and effective in children. </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> <content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content> <list listType=\"unordered\" styleCode=\"disc\"><item>have any heart problems</item><item>have high blood pressure</item><item>have thyroid problems</item><item>have a history of low blood sugar or diabetes</item><item>have kidney function problems (other than cancer)</item><item>have liver problems</item><item>have any bleeding problem</item><item>plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D; </content></item><item>have seizures</item><item>have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth</item><item>are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby.</item></list><content styleCode=\"bold\">Females</content> who are able to become pregnant: <list listType=\"unordered\" styleCode=\"disc\"><item><list listType=\"unordered\" styleCode=\"disc\"><item>Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules.</item><item>You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules.</item><item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.</item></list></item></list><content styleCode=\"bold\">Males</content> with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules.  Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. <list listType=\"unordered\" styleCode=\"disc\"><item><list listType=\"unordered\" styleCode=\"disc\"><item>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose.</item></list></item></list>Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any</content> surgery, or medical or dental procedure. <content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects.  You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell</content> your healthcare provider if you are taking or have taken an osteoporosis medicine.  Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> <content styleCode=\"bold\">How should I take sunitinib malate capsules?</content> <list listType=\"unordered\" styleCode=\"disc\"><item>Take sunitinib malate capsules exactly the way your healthcare provider tells you.</item><item>Take sunitinib malate capsule 1 time each day with or without food.</item><item>If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to.</item><item>If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.</item><item>Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body.</item><item>Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.</item><item>If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.</item><item>Call your healthcare provider right away, if you take too much sunitinib malate capsules.</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">What are possible side effects of sunitinib malate capsules?   Sunitinib malate capsules may cause serious side effects, including:</content> <list listType=\"unordered\" styleCode=\"disc\"><item>See<content styleCode=\"bold\"> &#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content></item><item><content styleCode=\"bold\">Heart problems.</content> Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. </item><item><content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening.</content> Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules <list listType=\"unordered\" styleCode=\"disc\"><item>you feel faint or lightheaded, or you pass out </item><item>feel your heart beat is irregular or fast</item><item>dizziness</item></list></item><item><content styleCode=\"bold\">High blood pressure.</content> High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: <list listType=\"unordered\" styleCode=\"disc\"><item>severe headache </item><item>dizziness</item><item>lightheadedness </item><item>change in vision  Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. </item></list></item><item><content styleCode=\"bold\">Bleeding problems</content>. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: <list listType=\"unordered\" styleCode=\"disc\"><item>painful, swollen stomach (abdomen) </item><item>bloody urine </item><item>vomiting blood </item><item>headache </item><item>coughing up blood</item><item>change in your mental status </item><item>black, sticky stools </item></list></item><item><content styleCode=\"bold\">Serious stomach and intestinal problems, that can sometimes lead to death.</content> Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. </item><item><content styleCode=\"bold\">Tumor lysis syndrome (TLS).</content> TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.</item><item><content styleCode=\"bold\">Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome[RPLS]). </content>RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. </item><item><content styleCode=\"bold\">Thrombotic microangiopathy (TMA)</content><content styleCode=\"bold\">including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS).</content> TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brain and kidneys, and can sometimes lead to death. </item><item><content styleCode=\"bold\">Protein in your urine.</content> Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. </item><item><content styleCode=\"bold\">Serious skin and mouth reactions.</content> Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: </item><item>severe rash with blisters or peeling of the skin. </item><item>painful sores or ulcers on the skin, lips or inside the mouth. </item><item>tissue damage (necrotizing fasciitis).  If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. </item><item><content styleCode=\"bold\">Thyroid problems.</content> Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules:<list listType=\"unordered\" styleCode=\"disc\"><item>tiredness that gets worse and does not go away </item><item>fast heat rate</item><item>loss of appetite </item><item>weight gain or weight loss</item><item>problems with heat </item><item>feeling depressed</item><item>feeling nervous or agitated, tremors </item><item>irregular menstrual periods or no menstrual periods</item><item>sweating </item><item>headache</item><item>nausea or vomiting </item><item>hair loss</item><item>diarrhea </item></list></item><item><content styleCode=\"bold\">Low blood sugar (hypoglycemia).</content> Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: <list listType=\"unordered\" styleCode=\"disc\"><item>headache </item><item>irritability</item><item>drowsiness </item><item>hunger</item><item>weakness </item><item>fast heart beat</item><item>dizziness </item><item>sweating</item><item>confusion </item><item>feeling jittery</item></list></item></list><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">Jawbone problems (osteonecrosis).</content> Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules.  o You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.  o Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures.</item><item><content styleCode=\"bold\">Wound healing problems.</content> Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules.  o You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.  o Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.</item></list><content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects.</content> <content styleCode=\"bold\">Common side effects of sunitinib malate capsules include: </content> <list listType=\"unordered\" styleCode=\"disc\"><item>tiredness </item><item>vomiting </item><item>weakness</item><item>stomach-area (abdominal) pain</item><item>diarrhea</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>pain, swelling or sores inside of your mouth</item><item>high blood pressure</item><item>nausea</item><item>taste changes</item><item>loss of appetite</item><item>low platelet counts</item><item>indigestion</item></list>The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.  These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">How do I store sunitinib malate capsules?</content> <list listType=\"unordered\" styleCode=\"disc\"><item>Store sunitinib malate capsules at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item></list><content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules. </content>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals.</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">What are the ingredients in sunitinib malate capsules?   Active ingredient:</content> sunitinib malate <content styleCode=\"bold\">Inactive ingredients:</content> croscarmellose sodium, mannitol, magnesium stearate and pregelatinized starch.  In addition 12.5 mg capsule shell contains gelatin, titanium dioxide and red iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide.  In addition 25 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide and red iron oxide. The white printing ink contains shellac, propylene glycol, potassium hydroxide and titanium dioxide.  In addition 37.5 mg capsule shell contains gelatin, titanium dioxide and yellow iron oxide. The black printing ink contains shellac, propylene glycol, potassium hydroxide and black iron oxide.  In addition 50 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, red iron oxide and black iron oxide. The white printing ink, contains shellac, propylene glycol, potassium hydroxide and titanium dioxide.   For more information go to www.novadozpharma.com or call 1-855-668-2369.  <content styleCode=\"bold\">Manufactured by:  MSN Laboratories Private Limited</content>  Telangana &#x2013; 509 228,  INDIA <content styleCode=\"bold\">Distributed by:  Novadoz Pharmaceuticals LLC</content>  Piscataway, NJ 08854-3714 <content styleCode=\"bold\">Issued on:</content> February 2025 </td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Sunitinib Capsules 12.5 mg Container Label Sunitinib Capsules 25 mg Container Label Sunitinib Capsules 37.5 mg Container Label Sunitinib Capsules 50 mg Container Label sunitinib-capsules-12-5mg-cntr-label sunitinib-capsules-25mg-cntr-label. sunitinib-capsules-37-5mg-cntr-label sunitinib-capsules-50mg-cntr-label"
    ],
    "set_id": "15dd0555-b33f-4f56-94d3-0f4ce888df01",
    "id": "15dd0555-b33f-4f56-94d3-0f4ce888df01",
    "effective_time": "20250210",
    "version": "1",
    "openfda": {
      "application_number": [
        "ANDA214824"
      ],
      "brand_name": [
        "Sunitinib Malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Novadoz Pharmaceuticals LLC"
      ],
      "product_ndc": [
        "72205-116",
        "72205-117",
        "72205-118",
        "72205-119"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "15dd0555-b33f-4f56-94d3-0f4ce888df01"
      ],
      "spl_set_id": [
        "15dd0555-b33f-4f56-94d3-0f4ce888df01"
      ],
      "package_ndc": [
        "72205-116-28",
        "72205-117-28",
        "72205-118-28",
        "72205-119-28"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0372205118287",
        "0372205116283",
        "0372205119284",
        "0372205117280"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Sunitinib Malate sunitinib malate SUNITINIB MALATE SUNITINIB SILICON DIOXIDE CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE MANNITOL SODIUM LAURYL SULFATE TITANIUM DIOXIDE FERRIC OXIDE RED AMMONIA FERROSOFERRIC OXIDE PROPYLENE GLYCOL SHELLAC pink-brown opaque MYLAN;SM;12;5 Sunitinib Malate sunitinib malate SUNITINIB MALATE SUNITINIB SILICON DIOXIDE CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE MANNITOL SODIUM LAURYL SULFATE TITANIUM DIOXIDE FERRIC OXIDE RED FERRIC OXIDE YELLOW AMMONIA FERROSOFERRIC OXIDE PROPYLENE GLYCOL SHELLAC yellow opaque pink-brown opaque MYLAN;SM;25 Sunitinib Malate sunitinib malate SUNITINIB MALATE SUNITINIB SILICON DIOXIDE CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE MANNITOL SODIUM LAURYL SULFATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW AMMONIA FERROSOFERRIC OXIDE PROPYLENE GLYCOL SHELLAC ivory opaque MYLAN;SM;37;5 Sunitinib Malate sunitinib malate SUNITINIB MALATE SUNITINIB SILICON DIOXIDE CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED MAGNESIUM STEARATE MANNITOL SODIUM LAURYL SULFATE TITANIUM DIOXIDE FERRIC OXIDE YELLOW AMMONIA FERROSOFERRIC OXIDE PROPYLENE GLYCOL SHELLAC yellow opaque MYLAN;SM;50"
    ],
    "recent_major_changes": [
      "Dosage and Administration, Dosage Modifications for Adverse Reactions ( 2.4 ) 8/2021 Dosage and Administration, Dosage Modification for Drug Interactions ( 2.5 ) 8/2021 Warnings and Precautions, Hepatotoxicity ( 5.1 ) 8/2021 Warnings and Precautions, Hypertension ( 5.4 ) 8/2021 Warnings and Precautions, Hemorrhagic Events and Viscous Perforation ( 5.5 ) 8/2021 Warnings and Precautions, Reversible Posterior Leukoencephalopathy Syndrome ( 5.10 ) 8/2021 Warnings and Precautions, Hypoglycemia ( 5.12 ) 8/2021 Warnings and Precautions, Osteonecrosis of the Jaw ( 5.13 ) 8/2021"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions (5.1) ]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions (5.1) ]."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: \u2022 treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) \u2022 treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) \u2022 adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) \u2022 treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC : \u2022 The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC : \u2022 The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET : \u2022 The recommended dosage is 37.5 mg orally once daily. ( 2.3 ) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions . Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions (5.1) ] Grade 3 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. \u2022 For recurring Grade 3 permanently discontinue. Grade 4 \u2022 Permanently discontinue. Cardiovascular events [see Warnings and Precautions (5.2) ] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at reduced dose. Clinically manifested congestive heart failure (CHF) \u2022 Permanently discontinue. Hypertension [see Warnings and Precautions (5.4) ] Grade 3 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. Grade 4 \u2022 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions (5.5) ] Grade 3 or 4 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions (5.7) ] Any Grade \u2022 Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8) ] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions \u2022 Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9) ] Any Grade \u2022 Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10) ] Any Grade \u2022 Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions (5.13) ] Any Grade \u2022 The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. \u2022 Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions (5.14) ] Any Grade \u2022 The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. \u2022 Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions (7.1) ]: \u2022 GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) \u2022 pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: \u2022 GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) \u2022 pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1) ] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3) ]."
    ],
    "dosage_and_administration_table": [
      "<table ID=\"_Ref_Hlk81573337\" width=\"100%\"><caption>Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions</caption><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Indications</content></content></paragraph></td><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">GIST</content></content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">RCC</content></content></paragraph></td><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">pNET</content></content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Advanced RCC</content></content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Adjuvant RCC</content></content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">First dose reduction </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">37.5 mg once daily</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">37.5 mg once daily</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">37.5 mg once daily</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">25 mg once daily</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Second dose reduction </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">25 mg once</content></paragraph><paragraph><content styleCode=\"xmChange\">daily</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">25 mg once</content></paragraph><paragraph><content styleCode=\"xmChange\">daily</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">NA</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">NA</content></paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EN4AE\" width=\"100.02%\"><caption>Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Adverse Reaction </content></content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Severity</content></content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\"><content styleCode=\"bold\">Dosage Modifications for Sunitinib Malate Capsules</content></content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Hepatotoxicity <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_7ccbe498-19c8-47cf-afef-18d1fe03051b\">Warnings and Precautions (5.1)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Grade 3 </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">For recurring Grade 3 permanently discontinue. </content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Grade 4 </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue. </content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Cardiovascular events <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_18a10325-d093-407f-940b-f5baa194d65e\">Warnings and Precautions (5.2)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Resume at reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Clinically manifested congestive heart failure (CHF)</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Hypertension <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_fa94c84b-a681-496e-b4b7-911b0e350816\">Warnings and Precautions (5.4)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Grade 3</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline. </content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Grade 4</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Hemorrhagic events <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_2ce48d3b-7068-4be8-bab7-d35035024bf5\">Warnings and Precautions (5.5)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Grade 3 or 4</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline. </content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Thrombotic microangiopathy <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_5c5113a5-8a36-4d53-92a3-3307a51f228d\">Warnings and Precautions (5.7)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Any Grade </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue. </content></item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_4c5a877b-efb2-491b-9f80-45fe8ce4815e\">Warnings and Precautions (5.8)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue. </content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_86834ceb-e95a-412b-9cd1-428f6d15f6c5\">Warnings and Precautions (5.9)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Any Grade </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue. </content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_c258c76c-cc9d-4169-8674-22044b0c8694\">Warnings and Precautions (5.10)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Any Grade </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Permanently discontinue. </content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Osteonecrosis of the jaw <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_fb686339-98b2-4fe8-92b5-c2fc88de7f59\">Warnings and Precautions (5.13)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Any Grade </content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.</content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. </content></item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Impaired wound healing <content styleCode=\"italics\">[see </content></content><content styleCode=\"italics\"><linkHtml href=\"#ID_ab253aed-12e0-43d3-9a17-fd47622b8c33\">Warnings and Precautions (5.14)</linkHtml><content styleCode=\"xmChange\">]</content></content></paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Any Grade </content></paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. </content></item><item><caption>&#x2022;</caption><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. </content></item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Sunitinib Malate Capsules are available containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib equivalent to 16.7 mg, 33.4 mg, 50.1 mg or 66.8 mg of sunitinib malate, respectively. \u2022 The 12.5 mg capsules are hard-shell gelatin capsules with a pink-brown opaque cap and pink-brown opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 12.5 in black ink on cap and body. \u2022 The 25 mg capsules are hard-shell gelatin capsules with a yellow opaque cap and pink-brown opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 25 in black ink on cap and body. \u2022 The 37.5 mg capsules are hard-shell gelatin capsules with an ivory opaque cap and ivory opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 37.5 in black ink on cap and body. \u2022 The 50 mg capsules are hard-shell gelatin capsules with a yellow opaque cap and yellow opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 50 in black ink on cap and body. \u2022 Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. \u2022 None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate capsules for Grade 3 hepatotoxicity until resolution to Grade \u2264 1 or baseline and resume sunitinib malate capsules at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate capsules in patients with Grade 4 hepatotoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. ( 2.4 , 5.1 ) \u2022 Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate capsules for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) \u2022 QT Interval Prolongation and Torsade de Pointes : Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) \u2022 Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib malate capsules for Grade 3 hypertension until resolution to Grade \u2264 1 or baseline, then resume sunitinib malate capsules at a reduced dose. Discontinue sunitinib malate capsules in patients who develop Grade 4 hypertension. ( 5.4 ) \u2022 Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate capsules for Grade 3 or 4 hemorrhagic events until resolution to Grade \u2264 1 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ) \u2022 Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) \u2022 Thrombotic Microangiopathy (TMA): TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate capsules for TMA. ( 5.7 ) \u2022 Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) \u2022 Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate capsules for these events. ( 5.9 ) \u2022 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate capsules until resolution. ( 5.10 ) \u2022 Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) \u2022 Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) \u2022 Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib malate capsules for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 ) \u2022 Impaired Wound Healing : Withhold sunitinib malate capsules for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate capsules after resolution of wound healing complications has not been established. ( 5.14 ) \u2022 Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate capsules can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in < 1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate capsules for Grade 3 hepatotoxicity until resolution to Grade \u2264 1 or baseline, then resume sunitinib malate capsules at a reduced dose. Discontinue sunitinib malate capsules in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST > 2.5 x upper limit of normal (ULN) or with > 5 x ULN and liver metastases has not been established . 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in < 1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u2265 50% or baseline by the time of last measurement. No patients who received sunitinib malate capsules were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate capsules administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate capsules clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate capsules in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate capsules and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate capsules can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in < 0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate capsules. Monitor QT interval more frequently when sunitinib malate capsules are concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate capsules [see Dosage and Administration (2.5) , Drug Interactions (7.2) ] . 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate capsules until resolution to Grade \u2264 1 or baseline, then resume sunitinib malate capsules at a reduced dose. Discontinue sunitinib malate capsules in patients who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3-5 event . Tumor-related hemorrhage was observed in patients treated with sunitinib malate capsules. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate capsules for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate capsules are not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib malate capsules. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate capsules for Grade 3 or 4 hemorrhagic events until resolution to Grade \u2264 1 or baseline, then resume sunitinib malate capsules at a reduced dose. Discontinue sunitinib malate capsules in patients without resolution of Grade 3 or 4 hemorrhagic events . 5.6 Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate capsules as monotherapy and administered in combination with bevacizumab. Sunitinib malate capsules are not approved for use in combination with bevacizumab. Discontinue sunitinib malate capsules in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate capsules were discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate capsules and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate capsules for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate capsules treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate capsules for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate capsules, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate capsules in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in < 1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate capsules in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate capsules. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate capsules. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate capsules can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate capsules. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate capsules for advanced RCC (Study 3) and GIST (Study 1) (n = 577) and in approximately 10% of the patients treated with sunitinib malate capsules for pNET (Study 6) (n = 83). For patients being treated with sunitinib malate capsules for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes . Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate capsules. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate capsules. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate capsules and periodically during sunitinib malate capsules therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate capsules treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate capsules for development of ONJ until complete resolution. The safety of resumption of sunitinib malate capsules after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate capsules [see Adverse Reactions (6.2) ] . Withhold sunitinib malate capsules for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate capsules after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate capsules can cause fetal harm when administered to a pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate capsules and for 4 weeks following the final dose [see Use in Specific Populations (8.1 , 8.3) ] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. \u2022 Hepatotoxicity [see Warnings and Precautions (5.1) ] \u2022 Cardiovascular Events [see Warnings and Precautions (5.2) ] \u2022 QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3) ] \u2022 Hypertension [see Warnings and Precautions (5.4) ] \u2022 Hemorrhagic Events [see Warnings and Precautions (5.5) ] \u2022 Tumor Lysis Syndrome [see Warnings and Precautions (5.6) ] \u2022 Thrombotic Microangiopathy [see Warnings and Precautions (5.7) ] \u2022 Proteinuria [see Warnings and Precautions (5.8) ] \u2022 Dermatologic Toxicities [see Warnings and Precautions (5.9) ] \u2022 Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.10) ] \u2022 Thyroid Dysfunction [see Warnings and Precautions (5.11) ] \u2022 Hypoglycemia [see Warnings and Precautions (5.12) ] \u2022 Osteonecrosis of the Jaw [see Warnings and Precautions (5.13) ] \u2022 Impaired Wound Healing [see Warnings and Precautions (5.14) ] \u2022 The most common adverse reactions (\u2265 25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET . In this pooled safety population, the most common adverse reactions (\u2265 25%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate capsules was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate capsules 50 mg daily on Schedule 4/2 (n = 202) or placebo (n = 102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate capsules (mean: 3.0; range: 1-9) and 1 cycle (mean; 1.8; range: 1-6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate capsules arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate capsules. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u2265 10% of GIST Patients Who Received Sunitinib Malate Capsules in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 1 Abbreviations: GIST = gastrointestinal stromal tumor; N = number of patients. Adverse Reaction GIST Sunitinib Malate Capsules (N = 202) Placebo (N = 102) All Grades % Grade 3-4% All Grades % Grade 3-4% Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia Includes decreased appetite. 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate capsules. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u2265 10% of GIST Patients Who Received Sunitinib Malate Capsules or Placebo in the Double-Blind Treatment Phase Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 1 Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; GIST = gastrointestinal stromal tumor; LVEF = left ventricular ejection fraction; N = number of patients. Laboratory Abnormality GIST Sunitinib Malate Capsules (N = 202) Placebo (N = 102) All Grades % Grade 3-4 , Grade 4 laboratory abnormalities in patients on sunitinib malate capsules included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). % All Grades % Grade 3-4 , Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 After an interim analysis , the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate capsules [see Clinical Studies (14.1) ] . For 241 patients randomized to the sunitinib malate capsules arm, including 139 who received sunitinib malate capsules in both the double-blind and open-label phases, the median duration of sunitinib malate capsules treatment was 6 cycles (mean: 8.5; range: 1\u201344). For the 255 patients who ultimately received open-label sunitinib malate capsules treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1\u201337) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate capsules. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate capsules. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate capsules in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate capsules was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate capsules 50 mg daily on Schedule 4/2 (n = 375) or interferon alfa 9 million International Units (MIU) (n = 360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate capsules treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate capsules arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate capsules. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib Malate Capsules or Interferon Alfa Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 3 Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma. Adverse Reaction Treatment-Na\u00efve RCC Sunitinib Malate Capsules (N = 375) Interferon Alfa (N = 360) All Grades % Grade 3-4 Grade 4 ARs in patients on sunitinib malate capsules included back pain (1%), arthralgia (< 1%), dyspnea (< 1%), asthenia (< 1%), fatigue (< 1%), limb pain (< 1%), and rash (< 1%). % All Grades % Grade 3-4 Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (< 1%), and depression (< 1%). % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 < 1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 < 1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain Includes flank pain. 30 5 12 1 Constipation 23 1 14 < 1 Dry mouth 13 0 7 < 1 Oral pain 14 < 1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 < 1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 < 1 Weight decreased 16 < 1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 < 1 Metabolism/Nutrition Anorexia Includes decreased appetite. 48 3 42 2 Neurology Altered taste Includes ageusia, hypogeusia, and dysgeusia. 47 < 1 15 0 Headache 23 1 19 0 Dizziness 11 < 1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 Includes 1 patient with Grade 5 gastric hemorrhage. 10 1 Cardiac Hypertension 34 13 4 < 1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 < 1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 < 1 0 0 Dry skin 23 < 1 7 0 Hair color changes 20 0 < 1 0 Alopecia 14 0 9 0 Erythema 12 < 1 1 0 Pruritus 12 < 1 7 < 1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 < 1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 < 1 2 0 Upper respiratory tract infection 11 < 1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 < 1 10 0 Depression Includes depressed mood. 11 0 14 1 Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u2265 10% of RCC Patients Who Received Sunitinib Malate Capsules or Interferon Alfa in Study 3 Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; RCC = renal cell carcinoma. Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib Malate Capsules (N = 375) Interferon Alfa (N = 360) All Grades Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. % Grade 3/4 , Grade 4 laboratory abnormalities in patients on sunitinib malate capsules included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (< 1%), creatine kinase (< 1%), creatinine (< 1%), glucose increased (< 1%), calcium decreased (< 1%), phosphorous (< 1%), potassium increased (< 1%), and sodium decreased (< 1%). % All Grades % Grade 3/4 , Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (< 1%), calcium increased (< 1%), glucose decreased (< 1%), potassium increased (< 1%), and hemoglobin (< 1%). % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 < 1 51 < 1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 < 1 Potassium increased 16 3 17 4 Calcium increased 13 < 1 10 1 Potassium decreased 13 1 2 < 1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 Long-Term Safety in RCC The long-term safety of sunitinib malate capsules in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate capsules did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate capsules was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate capsules 50 mg daily on Schedule 4/2 (n = 306) or placebo (n = 304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate capsules and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate capsules arm. Adverse reactions leading to permanent discontinuation in > 2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate capsules. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib Malate Capsules and More Commonly Than in Patients Given Placebo Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in S-TRAC Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma. Adverse Reaction Adjuvant Treatment of RCC Sunitinib Malate Capsules (N = 306) Placebo (N = 304) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. 61 6 15 0 Diarrhea 57 4 22 < 1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain Includes abdominal pain, abdominal pain lower, and abdominal pain upper. 25 2 9 < 1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. 18 < 1 < 1 0 Pyrexia 12 < 1 6 0 Dermatology Hand-foot syndrome 50 16 10 < 1 Rash Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/ Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. 39 8 14 1 Edema/Peripheral edema 10 < 1 7 0 Neurology Altered taste Includes ageusia, hypogeusia, and dysgeusia. 38 < 1 6 0 Headache 19 < 1 12 0 Endocrine Hypothyroidism/TSH increased 24 < 1 4 0 Hemorrhage/Bleeding Bleeding events, all sites Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. 24 < 1 5 < 1 Metabolism/Nutrition Anorexia/Decreased appetite 19 < 1 5 0 Musculoskeletal Pain in extremity 15 < 1 7 0 Arthralgia 11 < 1 10 0 Grade 4 adverse reactions in patients on sunitinib malate capsules included hand-foot syndrome (1%), fatigue (< 1%), abdominal pain (< 1%), stomatitis (< 1%), and pyrexia (< 1%). Grade 3-4 laboratory abnormalities that occurred in \u2265 2% of patients receiving sunitinib malate capsules include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate capsules was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate capsules 37.5 mg once daily (n = 83) or placebo (n = 82). The median number of days on treatment was 139 days (range: 13-532 days) for patients on sunitinib malate capsules and 113 days (range: 1-614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate capsules and 4 patients (5%) on placebo were on study for > 1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate capsules arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate capsules. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u2265 10% of Patients With pNET Who Received Sunitinib Malate Capsules and More Commonly Than in Patients Given Placebo Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. in Study 6 Abbreviations: N = number of patients; pNET = pancreatic neuroendocrine tumors. Adverse Reaction pNET Sunitinib Malate Capsules (N = 83) Placebo (N = 82) All Grades % Grade 3-4 Grade 4 adverse reactions in patients on sunitinib malate capsules included fatigue (1%). % All Grades % Grade 3-4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. 48 6 18 0 Nausea 45 1 29 1 Abdominal pain Includes abdominal discomfort, abdominal pain, and abdominal pain upper. 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u2265 10% of Patients With pNET Who Received Sunitinib Malate Capsules in Study 6 Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; pNET = pancreatic neuroendocrine tumors. Laboratory Abnormality pNET Sunitinib Malate Capsules Placebo All Grades The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate capsules and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. % Grade 3-4 , Grade 4 laboratory abnormalities in patients on sunitinib malate capsules included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). % All Grades % Grade 3-4 , Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3-4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (< 1%) in the adjuvant treatment for RCC study on sunitinib malate capsules. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: hemorrhage associated with thrombocytopenia * . Gastrointestinal Disorders: esophagitis. Hepatobiliary Disorders: cholecystitis, particularly acalculous cholecystitis. Immune System Disorders: hypersensitivity reactions, including angioedema. Infections and Infestations: serious infection (with or without neutropenia) * . The infections most commonly observed with sunitinib malate capsules include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and Connective Tissue Disorders: fistula formation, sometimes associated with tumor necrosis and/or regression * ; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and Urinary Disorders: renal impairment and/or failure * . Respiratory Disorders: pulmonary embolism * , pleural effusion * . Skin and Subcutaneous Tissue Disorders: pyoderma gangrenosum, including positive de-challenges. Vascular Disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events * . The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General Disorders and Administration Site Conditions: impaired wound healing. * including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table ID=\"_RefID0EBGBG\" width=\"100%\"><caption>Table 3. Adverse Reactions Reported in &#x2265; 10% of GIST Patients Who Received Sunitinib Malate Capsules in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo<footnote ID=\"_Ref58326369\">Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</footnote> in Study 1</caption><col width=\"27%\"/><col width=\"27%\"/><col width=\"16%\"/><col width=\"16%\"/><col width=\"16%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: GIST = gastrointestinal stromal tumor; N = number of patients.</td></tr></tfoot><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 202)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 102)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>94</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>97</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>51</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anorexia<footnote ID=\"_Ref58326383\">Includes decreased appetite.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Skin discoloration</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Altered taste</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Myalgia/limb pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EDWBG\" width=\"100%\"><caption>Table 4. Laboratory Abnormalities Reported in &#x2265; 10% of GIST Patients Who Received Sunitinib Malate Capsules or Placebo in the Double-Blind Treatment Phase<footnote ID=\"_Ref58332364\">Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</footnote> in Study 1</caption><col width=\"27%\"/><col width=\"27%\"/><col width=\"16%\"/><col width=\"15%\"/><col width=\"15%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; GIST = gastrointestinal stromal tumor; LVEF = left ventricular ejection fraction; N = number of patients.</td></tr></tfoot><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory Abnormality</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 202)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 102)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content><footnoteRef IDREF=\"_Ref58332364\"/></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnoteRef IDREF=\"_Ref58332364\"/><content styleCode=\"bold\"><sup>,</sup></content><footnote ID=\"_Ref58332397\">Grade 4 laboratory abnormalities in patients on sunitinib malate capsules included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content><footnoteRef IDREF=\"_Ref58332364\"/><content styleCode=\"bold\"> %</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnoteRef IDREF=\"_Ref58332364\"/><content styleCode=\"bold\"><sup>,</sup></content><footnote ID=\"_Ref58332429\">Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%).</footnote> <content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Laboratory Abnormality</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> AST/ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Decreased LVEF</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EJJAI\" width=\"100%\"><caption>Table 5. Adverse Reactions Reported in &#x2265; 10% of Patients With RCC Who Received Sunitinib Malate Capsules or Interferon Alfa<footnote ID=\"_Ref58333346\">Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</footnote> in Study 3</caption><col width=\"27%\"/><col width=\"27%\"/><col width=\"16%\"/><col width=\"15%\"/><col width=\"15%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma.</td></tr></tfoot><tbody><tr><td align=\"center\" rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N = 360)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnote ID=\"_Ref58333483\">Grade 4 ARs in patients on sunitinib malate capsules included back pain (1%), arthralgia (&lt; 1%), dyspnea (&lt; 1%), asthenia (&lt; 1%), fatigue (&lt; 1%), limb pain (&lt; 1%), and rash (&lt; 1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnote ID=\"_Ref58333494\">Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (&lt; 1%), and depression (&lt; 1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>55</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Abdominal pain<footnote ID=\"_Ref58333506\">Includes flank pain.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dry mouth</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Oral pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Flatulence</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> GERD/reflux esophagitis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Glossodynia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hemorrhoids</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>62</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fever</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Chills</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Chest Pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Influenza like illness</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anorexia<footnote ID=\"_Ref58333519\">Includes decreased appetite.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Altered taste<footnote ID=\"_Ref58333619\">Includes ageusia, hypogeusia, and dysgeusia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Bleeding, all sites</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4<footnote ID=\"_Ref58333667\">Includes 1 patient with Grade 5 gastric hemorrhage.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Edema peripheral</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Ejection fraction decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Skin discoloration/yellow skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Alopecia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Erythema</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Pruritus</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Pain in extremity/limb discomfort</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Back pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Cough</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dyspnea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Oropharyngeal pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Upper respiratory tract infection</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hypothyroidism</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Depression<footnote ID=\"_Ref58333635\">Includes depressed mood.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EKZBI\" width=\"100%\"><caption>Table 6. Laboratory Abnormalities Reported in &#x2265; 10% of RCC Patients Who Received Sunitinib Malate Capsules or Interferon Alfa in Study 3 </caption><col width=\"26%\"/><col width=\"26%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"14%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; RCC = renal cell carcinoma.</td></tr></tfoot><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory Abnormality</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N = 360)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content><footnote ID=\"_Ref58333947\">Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. </footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3/4</content><footnoteRef IDREF=\"_Ref58333947\"/><content styleCode=\"bold\"><sup>,</sup></content><footnote ID=\"_Ref58333964\">Grade 4 laboratory abnormalities in patients on sunitinib malate capsules included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (&lt; 1%), creatine kinase (&lt; 1%), creatinine (&lt; 1%), glucose increased (&lt; 1%), calcium decreased (&lt; 1%), phosphorous (&lt; 1%), potassium increased (&lt; 1%), and sodium decreased (&lt; 1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content><footnoteRef IDREF=\"_Ref58333947\"/></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3/4</content><footnoteRef IDREF=\"_Ref58333947\"/><content styleCode=\"bold\"><sup>,</sup></content><footnote ID=\"_Ref58333987\">Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (&lt; 1%), calcium increased (&lt; 1%), glucose decreased (&lt; 1%), potassium increased (&lt; 1%), and hemoglobin (&lt; 1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Creatine kinase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Uric acid increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Calcium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0ECTCI\" width=\"100%\"><caption>Table 7. Adverse Reactions Reported in &#x2265; 10% of Patients With RCC Who Received Sunitinib Malate Capsules and More Commonly Than in Patients Given Placebo<footnote ID=\"_Ref58334166\">Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</footnote> in S-TRAC</caption><col width=\"27%\"/><col width=\"27%\"/><col width=\"16%\"/><col width=\"16%\"/><col width=\"14%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: ARs = adverse reactions; N = number of patients; RCC = renal cell carcinoma.</td></tr></tfoot><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adjuvant Treatment of RCC</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 306)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 304)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Mucositis/Stomatitis<footnote ID=\"_Ref58334190\">Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Abdominal pain<footnote ID=\"_Ref58334203\">Includes abdominal pain, abdominal pain lower, and abdominal pain upper.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue/Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Localized edema<footnote ID=\"_Ref58334213\">Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Pyrexia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Rash<footnote ID=\"_Ref58334225\">Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Skin discoloration/ Yellow skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hypertension<footnote ID=\"_Ref58334240\">Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Edema/Peripheral edema</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Altered taste<footnote ID=\"_Ref58334250\">Includes ageusia, hypogeusia, and dysgeusia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hypothyroidism/TSH increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Bleeding events, all sites<footnote ID=\"_Ref58334259\">Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anorexia/Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EZQDI\" width=\"100%\"><caption>Table 8. Adverse Reactions Reported in &#x2265; 10% of Patients With pNET Who Received Sunitinib Malate Capsules and More Commonly Than in Patients Given Placebo<footnote ID=\"_Ref58334424\">Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</footnote> in Study 6</caption><col width=\"29%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"13%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: N = number of patients; pNET = pancreatic neuroendocrine tumors.</td></tr></tfoot><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 83)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 82)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnote ID=\"_Ref58334444\">Grade 4 adverse reactions in patients on sunitinib malate capsules included fatigue (1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>95</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>50</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Stomatitis/oral syndromes<footnote ID=\"_Ref58334473\">Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Abdominal pain<footnote ID=\"_Ref58334482\">Includes abdominal discomfort, abdominal pain, and abdominal pain upper.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Bleeding events<footnote ID=\"_Ref58334494\">Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Epistaxis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EWJAK\" width=\"100%\"><caption>Table 9. Laboratory Abnormalities Reported in &#x2265; 10% of Patients With pNET Who Received Sunitinib Malate Capsules in Study 6</caption><col width=\"27%\"/><col width=\"26%\"/><col width=\"15%\"/><col width=\"16%\"/><col width=\"15%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; N = number of patients; pNET = pancreatic neuroendocrine tumors.</td></tr></tfoot><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Laboratory Abnormality</content></paragraph></td><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content><footnote ID=\"_Ref58334653\">The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate capsules and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnoteRef IDREF=\"_Ref58334653\"/><content styleCode=\"bold\"><sup>,</sup></content><footnote ID=\"_Ref58334674\">Grade 4 laboratory abnormalities in patients on sunitinib malate capsules included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content><footnoteRef IDREF=\"_Ref58334653\"/></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3-4</content><footnoteRef IDREF=\"_Ref58334653\"/><content styleCode=\"bold\"><sup>,</sup></content><footnote ID=\"_Ref58334701\">Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%).</footnote></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>72</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>18</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Magnesium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS \u2022 CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate capsules when administered with strong CYP3A4 inhibitors. ( 7.1 ) \u2022 CYP3A4 Inducers : Consider dose increase of sunitinib malate capsules when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Capsules Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3) ] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate capsules when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5) ] . Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3) ]. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate capsules when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5) ] . 7.2 Drugs that Prolong QT Interval Sunitinib malate capsules are associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data ) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u2264 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u2265 1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u2265 1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u2264 1 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data ) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate capsules. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate capsules and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate capsules may impair male and female fertility [see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use The safety and effectiveness of sunitinib malate capsules in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to < 17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to < 17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate capsules has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u2265 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were > 0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u2265 5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at > 5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u2264 2 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate capsules, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate capsules were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate capsules were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate capsules were 65 years and older. Clinical studies of sunitinib malate capsules did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology (12.3) ] . Sunitinib malate capsules were not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology (12.3) ] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology (12.3) ] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data ) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u2264 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u2265 1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u2265 1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u2264 1 mg/kg/day."
    ],
    "risks": [
      "Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data ) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate capsules in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to < 17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to < 17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate capsules has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u2265 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were > 0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u2265 5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at > 5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u2264 2 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate capsules, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate capsules were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate capsules were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate capsules were 65 years and older. Clinical studies of sunitinib malate capsules did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate capsules should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate capsules. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate capsules, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as N -[2-(Diethylamino)ethyl]-5-[( Z )-(5-fluoro-2-oxo-1,2-dihydro-3 H -indol-3-ylidene)methyl]-2,4-dimethyl-1 H -pyrrole-3-carboxamide hydrogen (2 S )-2-hydroxybutanedioate. The molecular formula is C 22 H 27 FN 4 O 2 \u2022 C 4 H 6 O 5 and the molecular weight is 532.6. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules are supplied as printed hard-shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, gelatin, magnesium stearate, mannitol, sodium lauryl sulfate and titanium dioxide. The 12.5 mg and 25 mg strengths also contain red iron oxide. The 25 mg, 37.5 mg and 50 mg strengths also contain yellow iron oxide. In addition, the black imprinting ink contains the following: ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze. Sunitinib Structural Formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (> 80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate capsules can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3) ] . 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate capsules 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr > 80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of Strong CYP3A4 Inhibitors on Sunitinib Co-administration of a single sunitinib malate capsule dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of Strong CYP3A4 Inducers on Sunitinib Co-administration of a single sunitinib malate capsule dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (> 80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate capsules can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3) ] ."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate capsules 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr > 80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of Strong CYP3A4 Inhibitors on Sunitinib Co-administration of a single sunitinib malate capsule dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of Strong CYP3A4 Inducers on Sunitinib Co-administration of a single sunitinib malate capsule dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "clinical_studies": [
      "Clinical Studies Effect of Strong CYP3A4 Inhibitors on Sunitinib Co-administration of a single sunitinib malate capsule dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of Strong CYP3A4 Inducers on Sunitinib Co-administration of a single sunitinib malate capsule dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations.",
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib malate capsules in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate capsules plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate capsules or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate capsules and patients randomized to sunitinib malate capsules were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate capsules arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate capsules and placebo groups with regard to age (69% versus 72% < 65 years for sunitinib malate capsules versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate capsules over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Abbreviations: CI = confidence interval; GIST = gastrointestinal stromal tumor; HR = hazard ratio; N = number of patients; PR = partial response. Efficacy Parameter Sunitinib Malate Capsules (N = 207) Placebo (N = 105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) < 0.0001 A comparison is considered statistically significant if the p-value is < 0.00417 (O\u2019Brien Fleming stopping boundary). 0.33 (0.23, 0.47) Progression-free survival Time from randomization to progression or death due to any cause. [median, weeks (95% CI)] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) < 0.0001 0.33 (0.24, 0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7, 11.1) 0 0.006 Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI = confidence interval; GIST = gastrointestinal stromal tumor; N = number of patients; TTP = time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate capsules arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis , the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate capsules treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate capsules in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate capsules arm and 64.9 weeks for the placebo arm [hazard ratio (HR) = 0.876, 95% confidence interval (CI) (0.679, 1.129)]. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate capsules on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate capsules with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate capsules versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate capsules once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate capsules and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate capsules and interferon alfa groups with regard to age (59% versus 67% < 65 years for sunitinib malate capsules versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate capsules over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (> 1.5 ULN versus \u2264 1.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate capsules over interferon alfa. The ORR was higher in the sunitinib malate capsules arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; RCC = renal cell carcinoma. Efficacy Parameter Sunitinib Malate Capsules (N = 375) Interferon Alfa (N = 375) p-value (log-rank test) HR (95% CI) Progression-free survival Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. [median, weeks (95% CI)] 47.3 (42.6, 50.7) 22.0 (16.4, 24.0) < 0.000001 A comparison is considered statistically significant if the p-value is < 0.0042 (O\u2019Brien Fleming stopping boundary). 0.415 (0.320, 0.539) Objective response rate [%, (95% CI)] 27.5 (23.0, 32.3) 5.3 (3.3, 8.1) < 0.001 Pearson chi-square test. NA Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI = confidence interval; IFN-\u03b1 = interferon-alfa; N = number of patients; PFS = progression-free survival; RCC = renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR = 0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate capsules as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib malate capsules. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Cytokine-Refractory The use of single-agent sunitinib malate capsules in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate capsules on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86%-94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status < 2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (> 90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Abbreviations: CI = confidence interval; N = number of patients; NR = not reached; RCC = renal cell carcinoma. Efficacy Parameter Study 4 (N = 106) Study 5 (N = 63) Objective response rate [%, (95% CI)] 34.0 Assessed by blinded core radiology laboratory. (25.0, 43.8) 36.5 Assessed by investigators. (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR Data not mature enough to determine upper confidence limit. (42.0, ) 54 (34.3, 70.1) Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate capsules were investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265 T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate capsules once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate capsules and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate capsules and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate capsules had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate capsules versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate capsules compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Abbreviations: BICR = blinded independent central review; CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; RCC = renal cell carcinoma. Sunitinib Malate Capsules N = 309 Placebo N = 306 p-value P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group HR (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% Table 14. Disease-free Survival by Baseline Disease Characteristics Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; n = number of events; NR = not reached Number of Events/ Total n/N Median DFS [years (95% CI)] HR HR based on a Cox proportional hazards model (95% CI) Sunitinib Malate Capsules Placebo Sunitinib Malate Capsules Placebo T3 Intermediate T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u2265 1 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u2265 2, ECOG PS \u2265 1 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR = blinded independent central review; CI = confidence interval; N = number of patients. Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate capsules conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate capsules (N = 86) or placebo (N = 85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate capsules versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate capsules and placebo groups. Additionally, 49% of sunitinib malate capsules patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate capsules patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate capsules patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate capsules in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate capsules over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate capsules was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate capsules arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate capsules over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; pNET = pancreatic neuroendocrine tumors. Efficacy Parameter Sunitinib Malate Capsules (N = 86) Placebo (N = 85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 2-sided unstratified log-rank test. 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 Fisher\u2019s Exact test. NA Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI = confidence interval; N = number of patients; PFS = progression-free survival; pNET = pancreatic neuroendocrine tumors. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6"
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u2265 25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u2264 1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u2265 2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u2264 10 mg/kg/day (approximately \u2265 26 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u2265 25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u2264 1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u2265 2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u2264 10 mg/kg/day (approximately \u2265 26 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies_table": [
      "<table ID=\"_RefID0E5FCK\" width=\"100%\"><caption>Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase)</caption><col width=\"31%\"/><col width=\"20%\"/><col width=\"15%\"/><col width=\"19%\"/><col width=\"15%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: CI = confidence interval; GIST = gastrointestinal stromal tumor; HR = hazard ratio; N = number of patients; PR = partial response.</td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 207)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 105)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Time-to-tumor progression<footnote ID=\"_Ref58334974\">Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation.</footnote></paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>27.3</paragraph><paragraph>(16.0, 32.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6.4</paragraph><paragraph>(4.4, 10.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 0.0001<footnote ID=\"_Ref58335005\">A comparison is considered statistically significant if the p-value is &lt; 0.00417 (O&#x2019;Brien Fleming stopping boundary).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.33</paragraph><paragraph>(0.23, 0.47)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Progression-free survival<footnote ID=\"_Ref58334987\">Time from randomization to progression or death due to any cause.</footnote></paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>24.1</paragraph><paragraph>(11.1, 28.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6.0</paragraph><paragraph>(4.4, 9.9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 0.0001</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.33</paragraph><paragraph>(0.24, 0.47)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Objective response rate (PR)</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>6.8</paragraph><paragraph>(3.7, 11.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0.006<footnote ID=\"_Ref58335024\">Pearson chi-square test.</footnote></paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/></tr></tbody></table>",
      "<table ID=\"_RefID0EUNCK\" width=\"100%\"><caption>Table 11. Treatment-Na&#xEF;ve RCC Efficacy Results (Interim Analysis) from Study 3</caption><col width=\"28%\"/><col width=\"24%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"15%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; RCC = renal cell carcinoma.</td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Progression-free survival<footnote ID=\"_Ref58335159\">Assessed by blinded core radiology laboratory; 90 patients&#x2019; scans had not been read at time of analysis.</footnote></paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>47.3</paragraph><paragraph>(42.6, 50.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>22.0</paragraph><paragraph>(16.4, 24.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 0.000001<footnote ID=\"_Ref58335190\">A comparison is considered statistically significant if the p-value is &lt; 0.0042 (O&#x2019;Brien Fleming stopping boundary).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.415</paragraph><paragraph>(0.320, 0.539)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Objective response rate<footnoteRef IDREF=\"_Ref58335159\"/></paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>27.5</paragraph><paragraph>(23.0, 32.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>5.3</paragraph><paragraph>(3.3, 8.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>&lt; 0.001<footnote ID=\"_Ref58335196\">Pearson chi-square test.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0EITCK\" width=\"100%\"><caption>Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Abbreviations: CI = confidence interval; N = number of patients; NR = not reached; RCC = renal cell carcinoma.</td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 4</content></paragraph><paragraph><content styleCode=\"bold\">(N = 106)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 5</content></paragraph><paragraph><content styleCode=\"bold\">(N = 63)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34.0<footnote ID=\"_Ref58335314\">Assessed by blinded core radiology laboratory.</footnote></paragraph><paragraph>(25.0, 43.8)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>36.5<footnote ID=\"_Ref58335321\">Assessed by investigators.</footnote></paragraph><paragraph>(24.7, 49.6)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Duration of response</paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NR<footnote ID=\"_Ref58335331\">Data not mature enough to determine upper confidence limit.</footnote></paragraph><paragraph>(42.0, <footnoteRef IDREF=\"_Ref58335331\"/>)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>54<footnoteRef IDREF=\"_Ref58335321\"/></paragraph><paragraph>(34.3, 70.1)</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0ECXCK\" width=\"100%\"><caption>Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC</caption><col width=\"26%\"/><col width=\"24%\"/><col width=\"18%\"/><col width=\"13%\"/><col width=\"19%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: BICR = blinded independent central review; CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; RCC = renal cell carcinoma.</td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">N = 309</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">N = 306</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">p-value</content><footnote ID=\"_Ref58335463\">P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content><footnoteRef IDREF=\"_Ref58335463\"/><content styleCode=\"bold\"> (95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Median DFS [years (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>6.8 (5.8, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5.6 (3.8, 6.6)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.03</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.76 (0.59, 0.98)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>DFS Events</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>113 (36.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>144 (47.1%)</paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>5 Year DFS Rate</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>59.3%</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>51.3%</paragraph></td><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"/></tr></tbody></table>",
      "<table ID=\"_RefID0EG2CK\" width=\"100%\"><caption>Table 14. Disease-free Survival by Baseline Disease Characteristics</caption><col width=\"26%\"/><col width=\"16%\"/><col width=\"13%\"/><col width=\"16%\"/><col width=\"13%\"/><col width=\"17%\"/><tfoot><tr><td align=\"left\" colspan=\"6\" valign=\"top\">Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; N = number of patients; n = number of events; NR = not reached</td></tr></tfoot><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Number of Events/ Total</content></paragraph><paragraph><content styleCode=\"bold\">n/N</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Median DFS</content></paragraph><paragraph><content styleCode=\"bold\">[years (95% CI)]</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content><footnote ID=\"_Ref58335591\">HR based on a Cox proportional hazards model</footnote></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>T3 Intermediate<footnote ID=\"_Ref58335618\">T3 Intermediate: T3, N0 or NX, M0, any Fuhrman&#x2019;s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman&#x2019;s grade 1, ECOG PS &#x2265; 1</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>35/115</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>46/112</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>NR</paragraph><paragraph>(5.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6.4</paragraph><paragraph>(4.7, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.82</paragraph><paragraph>(0.53, 1.28)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>T3 High<footnote ID=\"_Ref58335629\">T3 High: T3, N0 or NX, M0, Fuhrman&#x2019;s grade &#x2265; 2, ECOG PS &#x2265; 1</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>63/165</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>79/166</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6.8</paragraph><paragraph>(5.0, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5.3</paragraph><paragraph>(2.9, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.77</paragraph><paragraph>(0.55, 1.07)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>T4/Node Positive<footnote ID=\"_Ref58335646\">T4/Node Positive: T4, N0 or NX, M0, any Fuhrman&#x2019;s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman&#x2019;s grade, any ECOG PS</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>15/29</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>19/28</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>3.5</paragraph><paragraph>(1.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>1.7</paragraph><paragraph>(0.4, 3.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0.62</paragraph><paragraph>(0.31, 1.23)</paragraph></td></tr></tbody></table>",
      "<table ID=\"_RefID0ESCDK\" width=\"100%\"><caption>Table 15. pNET Efficacy Results from Study 6</caption><col width=\"30%\"/><col width=\"26%\"/><col width=\"14%\"/><col width=\"12%\"/><col width=\"17%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">Abbreviations: CI = confidence interval; HR = hazard ratio; N = number of patients; NA = not applicable; pNET = pancreatic neuroendocrine tumors.</td></tr></tfoot><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph><paragraph><content styleCode=\"bold\">(N = 86)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 85)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Progression-free survival</paragraph><paragraph>[median, months (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10.2</paragraph><paragraph>(7.4, 16.9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5.4</paragraph><paragraph>(3.4, 6.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.000146<footnote ID=\"_Ref58335886\">2-sided unstratified log-rank test.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.427</paragraph><paragraph>(0.271, 0.673)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>9.3</paragraph><paragraph>(3.2, 15.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0.0066<footnote ID=\"_Ref58335897\">Fisher&#x2019;s Exact test.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Sunitinib Malate Capsules are available containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib equivalent to 16.7 mg, 33.4 mg, 50.1 mg or 66.8 mg of sunitinib malate, respectively. The 12.5 mg capsules are hard-shell gelatin capsules with a pink-brown opaque cap and pink-brown opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 12.5 in black ink on cap and body. They are available as follows: NDC 0378-6678-28 bottles of 28 capsules The 25 mg capsules are hard-shell gelatin capsules with a yellow opaque cap and pink-brown opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 25 in black ink on cap and body. They are available as follows: NDC 0378-6679-28 bottles of 28 capsules The 37.5 mg capsules are hard-shell gelatin capsules with an ivory opaque cap and ivory opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 37.5 in black ink on cap and body. They are available as follows: NDC 0378-6681-28 bottles of 28 capsules The 50 mg capsules are hard-shell gelatin capsules with a yellow opaque cap and yellow opaque body filled with yellow to orange powder. The capsules are axially printed with MYLAN over SM 50 in black ink on cap and body. They are available as follows: NDC 0378-6680-28 bottles of 28 capsules Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Dispense a Medication Guide with each prescription."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Hepatotoxicity: Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.1) ]. Cardiovascular Events: Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.2) ]. QT Prolongation and Torsade de Pointes: Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions (5.3) ]. Hypertension: Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions (5.4) ]. Hemorrhagic Events: Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions (5.5) ]. Gastrointestinal Disorders: Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate capsules treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate capsules [see Warnings and Precautions (5.5) , Adverse Reactions (6.1) ]. Dermatologic Effects and Toxicities: Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate capsules due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions (5.9) , Adverse Reactions (6.1) ]. Reversible Posterior Leukoencephalopathy Syndrome: Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10) ]. Thyroid Dysfunction: Advise patients that sunitinib malate capsules can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions (5.11) ] . Hypoglycemia: Advise patients that sunitinib malate capsules can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions (5.12) ] . Osteonecrosis of the Jaw: Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions (5.13) ] . Impaired Wound Healing: Advise patients that sunitinib malate capsules impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions (5.14) ] . Concomitant Medications: Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions (7) ] . Embryo-Fetal Toxicity: Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.15) , Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations (8.3) ] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations (8.3) ] . Lactation: Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [see Use in Specific Populations (8.2) ]. Infertility: Advise patients that sunitinib malate capsules may impair male and female fertility [see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ] . Missed Dose: Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time."
    ],
    "spl_medguide": [
      "Medication Guide Sunitinib Malate Capsules (soo ni\u2032 ti nib mal eyt) What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: \u2022 Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: o itching o yellow eyes or skin o dark urine o pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are a prescription medicine used to treat: \u2022 a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: o you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or o you cannot take imatinib mesylate. \u2022 advanced kidney cancer (advanced renal cell carcinoma or RCC). \u2022 adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. \u2022 a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: \u2022 have any heart problems \u2022 have high blood pressure \u2022 have thyroid problems \u2022 have a history of low blood sugar or diabetes \u2022 have kidney function problems (other than cancer) \u2022 have liver problems \u2022 have any bleeding problem \u2022 plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d \u2022 have seizures \u2022 have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth \u2022 are pregnant or plan to become pregnant. Sunitinib malate can harm your unborn baby. Females who are able to become pregnant: o Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. o You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. o Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. \u2022 are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? \u2022 Take sunitinib malate capsules exactly the way your healthcare provider tells you. \u2022 Take sunitinib malate capsules 1 time each day with or without food. \u2022 If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. \u2022 If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. \u2022 Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body. \u2022 Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. \u2022 If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. \u2022 Call your healthcare provider right away, if you take too many sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: \u2022 See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d \u2022 Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. \u2022 Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules. o you feel faint or lightheaded, or you pass out o dizziness o feel your heart beat is irregular or fast \u2022 High blood pressure. High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure: o severe headache o lightheadedness o dizziness o change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. \u2022 Bleeding problems . Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: o painful, swollen stomach (abdomen) o vomiting blood o coughing up blood o black, sticky stools o bloody urine o headache o change in your mental status \u2022 Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation) or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. \u2022 Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. \u2022 Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. \u2022 Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS) . TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys and can sometimes lead to death. \u2022 Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. \u2022 Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: o severe rash with blisters or peeling of the skin. o painful sores or ulcers on the skin, lips or inside the mouth. o tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. \u2022 Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: o tiredness that gets worse and does not go away o loss of appetite o problems with heat o feeling nervous or agitated, tremors o sweating o nausea or vomiting o diarrhea o fast heart rate o weight gain or weight loss o feeling depressed o irregular menstrual periods or no menstrual periods o headache o hair loss \u2022 Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: o headache o drowsiness o weakness o dizziness o confusion o irritability o hunger o fast heart beat o sweating o feeling jittery \u2022 Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. o You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. o Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. \u2022 Wound healing problems . Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. o You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. o Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: \u2022 tiredness \u2022 weakness \u2022 diarrhea \u2022 pain, swelling or sores inside of your mouth \u2022 nausea \u2022 loss of appetite \u2022 indigestion \u2022 vomiting \u2022 stomach-area (abdominal) pain \u2022 blisters or rash on the palms of your hands and soles of your feet \u2022 high blood pressure \u2022 taste changes \u2022 low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? \u2022 Store sunitinib malate capsules at room temperature, between 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which they were not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, gelatin, magnesium stearate, mannitol, sodium lauryl sulfate and titanium dioxide. The 12.5 mg and 25 mg strengths also contain red iron oxide. The 25 mg, 37.5 mg and 50 mg strengths also contain yellow iron oxide. In addition, the black imprinting ink contains the following: ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze. Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). This Medication Guide has been approved by the U.S. Food and Drug Administration. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Societal CDMO Gainesville, LLC Gainesville, GA 30504, U.S.A. Revised: 8/2023 SOC:SUNI:R1 6003299-00"
    ],
    "spl_medguide_table": [
      "<table width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sunitinib Malate Capsules</content> <content styleCode=\"bold\">(soo ni&#x2032; ti nib mal eyt)</content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules can cause serious side effects including:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content><list listType=\"unordered\"><item><caption>o</caption>itching</item><item><caption>o</caption>yellow eyes or skin</item><item><caption>o</caption>dark urine</item><item><caption>o</caption>pain or discomfort in the right upper stomach area</item></list></item></list><paragraph>Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems.</paragraph><paragraph> </paragraph><paragraph>See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D;</content> for more information about side effects.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are sunitinib malate capsules?</content></paragraph><paragraph>Sunitinib malate capsules are a prescription medicine used to treat:</paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when:<list listType=\"unordered\"><item><caption>o</caption>you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or</item><item><caption>o</caption>you cannot take imatinib mesylate.</item></list></item><item><caption>&#x2022;</caption>advanced kidney cancer (advanced renal cell carcinoma or RCC).</item><item><caption>&#x2022;</caption>adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.</item><item><caption>&#x2022;</caption>a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.</item></list><paragraph>It is not known if sunitinib malate capsules are safe and effective in children.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have any heart problems</item><item><caption>&#x2022;</caption>have high blood pressure</item><item><caption>&#x2022;</caption>have thyroid problems</item><item><caption>&#x2022;</caption>have a history of low blood sugar or diabetes</item><item><caption>&#x2022;</caption>have kidney function problems (other than cancer)</item><item><caption>&#x2022;</caption>have liver problems</item><item><caption>&#x2022;</caption>have any bleeding problem</item><item><caption>&#x2022;</caption>plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D;</content></item><item><caption>&#x2022;</caption>have seizures</item><item><caption>&#x2022;</caption>have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. Sunitinib malate can harm your unborn baby. <content styleCode=\"bold\">Females</content> who are able to become pregnant:<list listType=\"unordered\"><item><caption>o</caption>Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules.</item><item><caption>o</caption>You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules.</item><item><caption>o</caption>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.</item></list></item><item><caption> </caption><content styleCode=\"bold\">Males</content> with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose.</item></list><paragraph>Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any </content>surgery, or medical or dental procedure.</paragraph><paragraph> </paragraph><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take, </content>including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects.</paragraph><paragraph> </paragraph><paragraph>You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell </content>your healthcare provider if you are taking or have taken an osteoporosis medicine.</paragraph><paragraph> </paragraph><paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I take sunitinib malate capsules?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Take sunitinib malate capsules exactly the way your healthcare provider tells you.</item><item><caption>&#x2022;</caption>Take sunitinib malate capsules 1 time each day with or without food.</item><item><caption>&#x2022;</caption>If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to.</item><item><caption>&#x2022;</caption>If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.</item><item><caption>&#x2022;</caption>Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body.</item><item><caption>&#x2022;</caption>Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.</item><item><caption>&#x2022;</caption>If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.</item><item><caption>&#x2022;</caption>Call your healthcare provider right away, if you take too many sunitinib malate capsules.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are possible side effects of sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules may cause serious side effects, including:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>See <content styleCode=\"bold\">&#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Heart problems. </content>Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. </content>Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules.</item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>you feel faint or lightheaded, or you pass out</item><item><caption>o</caption>dizziness</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>feel your heart beat is irregular or fast</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">High blood pressure. </content>High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:</item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>severe headache</item><item><caption>o</caption>lightheadedness</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>dizziness</item><item><caption>o</caption>change in vision</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Bleeding problems</content>. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including:</item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>painful, swollen stomach (abdomen)</item><item><caption>o</caption>vomiting blood</item><item><caption>o</caption>coughing up blood</item><item><caption>o</caption>black, sticky stools</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>bloody urine</item><item><caption>o</caption>headache</item><item><caption>o</caption>change in your mental status</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\"> </content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Serious stomach and intestinal problems, that can sometimes lead to death. </content>Some people have had tears in their stomach or intestine (perforation) or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Tumor lysis syndrome (TLS). </content>TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]).</content> RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS)</content>. TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brain and kidneys and can sometimes lead to death.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Protein in your urine. </content>Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Serious skin and mouth reactions. </content>Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including:<list listType=\"unordered\"><item><caption>o</caption>severe rash with blisters or peeling of the skin.</item><item><caption>o</caption>painful sores or ulcers on the skin, lips or inside the mouth.</item><item><caption>o</caption>tissue damage (necrotizing fasciitis).</item></list></item><item><caption> </caption>If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Thyroid problems. </content>Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules:</item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>tiredness that gets worse and does not go away</item><item><caption>o</caption>loss of appetite</item><item><caption>o</caption>problems with heat</item><item><caption>o</caption>feeling nervous or agitated, tremors</item><item><caption>o</caption>sweating</item><item><caption>o</caption>nausea or vomiting</item><item><caption>o</caption>diarrhea</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>fast heart rate</item><item><caption>o</caption>weight gain or weight loss</item><item><caption>o</caption>feeling depressed</item><item><caption>o</caption>irregular menstrual periods or no menstrual periods</item><item><caption>o</caption>headache</item><item><caption>o</caption>hair loss</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Low blood sugar (hypoglycemia). </content>Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules:</item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>headache</item><item><caption>o</caption>drowsiness</item><item><caption>o</caption>weakness</item><item><caption>o</caption>dizziness</item><item><caption>o</caption>confusion</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>o</caption>irritability</item><item><caption>o</caption>hunger</item><item><caption>o</caption>fast heart beat</item><item><caption>o</caption>sweating</item><item><caption>o</caption>feeling jittery</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Jawbone problems (osteonecrosis). </content>Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules.<list listType=\"unordered\"><item><caption>o</caption>You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.</item><item><caption>o</caption>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures.</item></list></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Wound healing problems</content>. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. <list listType=\"unordered\"><item><caption>o</caption>You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.</item><item><caption>o</caption>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.</item></list></item></list><paragraph><content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects.</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph><paragraph><content styleCode=\"bold\">Common side effects of sunitinib malate capsules include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>tiredness</item><item><caption>&#x2022;</caption>weakness</item><item><caption>&#x2022;</caption>diarrhea</item><item><caption>&#x2022;</caption>pain, swelling or sores inside of your mouth</item><item><caption>&#x2022;</caption>nausea</item><item><caption>&#x2022;</caption>loss of appetite</item><item><caption>&#x2022;</caption>indigestion</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>vomiting</item><item><caption>&#x2022;</caption>stomach-area (abdominal) pain</item><item><caption>&#x2022;</caption>blisters or rash on the palms of your hands and soles of your feet</item><item><caption>&#x2022;</caption>high blood pressure</item><item><caption>&#x2022;</caption>taste changes</item><item><caption>&#x2022;</caption>low platelet counts</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.</paragraph><paragraph> </paragraph><paragraph>These are not all of the possible side effects of sunitinib malate capsules. <content styleCode=\"bold\">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How do I store sunitinib malate capsules?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Store sunitinib malate capsules at room temperature, between 20&#xB0; to 25&#xB0;C (68&#xB0; to 77&#xB0;F).</item></list><paragraph><content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which they were not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient: </content>sunitinib malate</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients: </content>colloidal silicon dioxide, croscarmellose sodium, gelatin, magnesium stearate, mannitol, sodium lauryl sulfate and titanium dioxide. The 12.5 mg and 25 mg strengths also contain red iron oxide. The 25 mg, 37.5 mg and 50 mg strengths also contain yellow iron oxide.</paragraph><paragraph> </paragraph><paragraph>In addition, the black imprinting ink contains the following: ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze.</paragraph><paragraph> </paragraph><paragraph>Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.</paragraph><paragraph> </paragraph><paragraph>For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). </paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL \u2013 12.5 mg NDC 0378-6678-28 Sunitinib Malate Capsules 12.5 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules * Each capsule contains 12.5 mg sunitinib equivalent to 16.7 mg sunitinib malate. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed. Keep this and all medication out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Usual Dosage: See accompanying prescribing information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Societal CDMO Gainesville, LLC Gainesville, GA 30504 U.S.A. RSOC6678BD 6003295-00 Mylan.com Sunitinib Malate Capsules 12.5 mg Bottle Label",
      "PRINCIPAL DISPLAY PANEL \u2013 25 mg NDC 0378-6679-28 Sunitinib Malate Capsules 25 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules * Each capsule contains 25 mg sunitinib equivalent to 33.4 mg sunitinib malate. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed. Keep this and all medication out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Usual Dosage: See accompanying prescribing information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Societal CDMO Gainesville, LLC Gainesville, GA 30504 U.S.A. RSOC6679BD 6003296-00 Mylan.com Sunitinib Malate Capsules 25 mg Bottle Label",
      "PRINCIPAL DISPLAY PANEL \u2013 37.5 mg NDC 0378-6681-28 Sunitinib Malate Capsules 37.5 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules * Each capsule contains 37.5 mg sunitinib equivalent to 50.1 mg sunitinib malate. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed. Keep this and all medication out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Usual Dosage: See accompanying prescribing information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Societal CDMO Gainesville, LLC Gainesville, GA 30504 U.S.A. RSOC6681BD 6003297-00 Mylan.com Sunitinib Malate Capsules 37.5 mg Bottle Label",
      "PRINCIPAL DISPLAY PANEL \u2013 50 mg NDC 0378-6680-28 Sunitinib Malate Capsules 50 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules * Each capsule contains 50 mg sunitinib equivalent to 66.8 mg sunitinib malate. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed. Keep this and all medication out of the reach of children. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Usual Dosage: See accompanying prescribing information. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Societal CDMO Gainesville, LLC Gainesville, GA 30504 U.S.A. RSOC6680BD 6003298-00 Mylan.com Sunitinib Malate Capsules 50 mg Bottle Label"
    ],
    "set_id": "4dbfcc02-dacc-4f0c-9f41-095783b68e27",
    "id": "9e441770-fe62-43c0-b293-7ebc8f753ebc",
    "effective_time": "20230815",
    "version": "3",
    "openfda": {
      "application_number": [
        "ANDA201275"
      ],
      "brand_name": [
        "Sunitinib Malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Mylan Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "0378-6678",
        "0378-6679",
        "0378-6681",
        "0378-6680"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "9e441770-fe62-43c0-b293-7ebc8f753ebc"
      ],
      "spl_set_id": [
        "4dbfcc02-dacc-4f0c-9f41-095783b68e27"
      ],
      "package_ndc": [
        "0378-6678-28",
        "0378-6679-28",
        "0378-6681-28",
        "0378-6680-28"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE RED TITANIUM DIOXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque reddish brown cap opaque reddish brown body RM53;RM53 Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE RED FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE TITANIUM DIOXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque caramel cap opaque reddish brown body RM54;RM54 Sunitinib malate Sunitinib malate GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE YELLOW TITANIUM DIOXIDE FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE SHELLAC opaque yellow cap opaque yellow body RM55;RM55 Sunitinib malate Sunitinib malate CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FERRIC OXIDE RED FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE TITANIUM DIOXIDE POTASSIUM HYDROXIDE SHELLAC GELATIN, UNSPECIFIED SUNITINIB MALATE SUNITINIB opaque caramel cap opaque caramel body RM56;RM56"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib recommended [see Warnings and Precautions (5.1)]."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1) treatment of adult patients with advanced renal cell carcinoma (RCC). (1.2) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. (1.3) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. (1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). (2.1) Adjuvant Treatment of RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. (2.2) pNET: The recommended dosage is 37.5 mg orally once daily. (2.3) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions (5.1)] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. For recurring Grade 3 permanently discontinue. Grade 4 Permanently discontinue. Cardiovascular events [see Warnings and Precautions (5.2)] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) Withhold until resolution to Grade 0 to 1 or baseline. Resume at reduced dose. Clinically manifested congestive heart failure (CHF) Permanently discontinue. Hypertension [see Warnings and Precautions (5.4)] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Grade 4 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions (5.5)] Grade 3 or 4 Withhold until resolution to Grade 0 to 1 or baseline. Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions (5.7)] Any Grade Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8)] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9)] Any Grade Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] Any Grade Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions (5.13) ] Any Grade The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions (5.14)] Any Grade The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions (7.1)] : GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1)] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"18%\"/><col width=\"18%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indications</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td><td colspan=\"2\" align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">RCC</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Advanced RCC</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adjuvant RCC</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>First dose reduction</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>25 mg once daily</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Second dose reduction</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>25 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>25 mg once daily</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NA</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\" cellpadding=\"0pt\"><col width=\"28%\"/><col width=\"28%\"/><col width=\"43%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Adverse Reaction</content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Severity</content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dosage Modifications for Sunitinib Malate Capsules</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item>Hepatotoxicity <content styleCode=\"italics\">[see Warnings and Precautions (5.1)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Grade 3</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item><item>For recurring Grade 3 permanently discontinue.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Grade 4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item>Cardiovascular events <content styleCode=\"italics\">[see Warnings and Precautions (5.2)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than</item><item>20% but less than</item><item>50% below baseline or below the lower limit of normal if baseline was not obtained)</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at reduced dose.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Clinically manifested congestive heart failure (CHF)</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item>Hypertension <content styleCode=\"italics\">[see Warnings and Precautions (5.4)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Grade 3</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Grade 4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Hemorrhagic events <content styleCode=\"italics\">[see Warnings and Precautions (5.5)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Grade 3 or 4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Thrombotic microangiopathy <content styleCode=\"italics\">[see Warnings and Precautions (5.7)]</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item>Any Grade</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see Warnings and Precautions (5.8)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">3 or more grams proteinuria in</content></item><item><content styleCode=\"xmChange\">24 hours in the absence of nephrotic syndrome</content></item></list></td><td styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Withhold until resolution to Grade 0 to 1 or baseline.</content></item><item><content styleCode=\"xmChange\">Resume at a reduced dose.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Nephrotic syndrome or recurrent proteinuria of 3 or more grams per</content></item><item><content styleCode=\"xmChange\">24 hours despite dose reductions</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see Warnings and Precautions (5.9)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see Warnings and Precautions (5.10)]</content></content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">Permanently discontinue.</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Osteonecrosis of the jaw <content styleCode=\"italics\">[see Warnings and Precautions (5.13)</content>] </content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Impaired wound healing <content styleCode=\"italics\">[see Warnings and Precautions (5.14)]</content></content></item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"ordered\"><item><content styleCode=\"xmChange\">Any Grade</content></item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"xmChange\">The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established.</content></item><item><content styleCode=\"xmChange\">Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</content></item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS 12.5 mg capsules Hard gelatin capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM53\u2019 on cap and \u2018RM53\u2019 on body in white ink, containing yellow to orange colored powder. 25 mg capsules Hard gelatin capsule with opaque caramel cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM54\u2019 on cap and \u2018RM54\u2019 on body in white ink, containing yellow to orange colored powder. 37.5 mg capsules Hard gelatin capsule with opaque yellow cap and opaque yellow body, self-lock capsule, imprinted with \u2018RM55\u2019 on cap and \u2018RM55\u2019 on body in black ink, containing yellow to orange colored powder. 50 mg capsules Hard gelatin capsule with opaque caramel cap and opaque caramel body, self-lock capsule, imprinted with \u2018RM56\u2019 on cap and \u2018RM56\u2019 on body in white ink, containing yellow to orange colored powder. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib (3)"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None None (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib for Grade 3 hepatotoxicity until resolution Grade \u2264 1 or baseline and resume sunitinib at a reduced dose; discontinue if no resolution. Discontinue sunitinib in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. (2.4, 5.1) Cardiovascular Events: Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. (5.2) QT Interval Prolongation and Torsade de Pointes: Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. (5.3) Hypertension: Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients who develop Grade 4 hypertension. (5.4) Hemorrhagic Events: Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. (5.5) Tumor Lysis Syndrome (TLS): TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. (5.6) Thrombotic microangiopathy (TMA): TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib for TMA. (5.7) Proteinuria: Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. (5.8) Dermatologic Toxicities: Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib for these events. (5.9) Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib until resolution. (5.10) Thyroid Dysfunction: Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. (5.11) Hypoglycemia: Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (5.12) Osteonecrosis of the Jaw (ONJ): Withhold sunitinib for at least 3 weeks prior to invasive dental procedure and development of ONJ until complete resolution. (5.13) Impaired Wound Healing: Withhold sunitinib for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib after resolution of wound healing complications has not been established. (5.14) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (5.15, 8.1, 8.3) 5.1 Hepatotoxicity Sunitinib can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in < 1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib for Grade 3 hepatotoxicity until resolution to Grade \u2264 1 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST > 2.5 times upper limit of normal (ULN) or with > 5.0 times ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in < 1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u2265 50% or baseline by the time of last measurement. No patients who received sunitinib were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib in patients who experience clinical manifestations of CHF. Interrupt sunitinib and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in < 0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib. Monitor QT interval more frequently when sunitinib is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib [see Dosage and Administration (2.5), Drug Interactions (7.2)] 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib until resolution to Grade \u2264 1 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3-5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib for Grade 3 or 4 hemorrhagic events until resolution to Grade \u2264 1 or baseline, then resume sunitinib at a reduced dose. Discontinue sunitinib in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib as monotherapy and administered in combination with bevacizumab. Sunitinib is not approved for use in combination with bevacizumab. Discontinue sunitinib in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein 3 or more grams despite dose reductions. The safety of continued sunitinib treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib, including of the perineum and secondary to fistula formation. Discontinue sunitinib in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib for advanced RCC (Study 3) and GIST (Study 1) (n = 577) and in approximately 10% of the patients treated with sunitinib for pNET (Study 6) (n = 83). For patients being treated with sunitinib for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib and periodically during sunitinib therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib for development of ONJ until complete resolution. The safety of resumption of sunitinib after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib [see Adverse Reactions (6.2)] . Withhold sunitinib for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib and for 4 weeks following the final dose [see Use in Specific Populations (8.1, 8.3)] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions (5.1)] Cardiovascular Events [see Warnings and Precautions (5.2)] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3)] Hypertension [see Warnings and Precautions (5.4)] Hemorrhagic Events [see Warnings and Precautions (5.5)] Tumor Lysis Syndrome [see Warnings and Precautions (5.6)] Thrombotic Microangiopathy [see Warnings and Precautions (5.7)] Proteinuria [see Warnings and Precautions (5.8)] Dermatologic Toxicities [see Warnings and Precautions (5.9)] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.10)] Thyroid Dysfunction [see Warnings and Precautions (5.11)] Hypoglycemia [see Warnings and Precautions (5.12)] Osteonecrosis of the Jaw [see Warnings and Precautions (5.13)] Impaired Wound Healing [see Warnings and Precautions (5.14)] The most common adverse reactions (\u2265 25%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u2265 25%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib 50 mg daily on Schedule 4/2 (n = 202) or placebo (n = 102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib (mean: 3.0; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u2265 10% of GIST Patients Who Received Sunitinib in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reactions GIST Sunitinib (N = 202) Placebo (N = 102) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia a 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u2265 10% of GIST Patients Who Received Sunitinib or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib (N = 202) Placebo (N = 102) All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis , the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib [see Clinical Studies (14.1)] . For 241 patients randomized to the sunitinib arm, including 139 who received sunitinib in both the double-blind and open-label phases, the median duration of sunitinib treatment was 6 cycles (mean: 8.5; range: 1 to 44). For the 255 patients who ultimately received open-label sunitinib treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1 to 37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib 50 mg daily on Schedule 4/2 (n = 375) or interferon alfa 9 million International Units (MIU) (n = 360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib (N = 375) Interferon Alfa (N = 360) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 < 1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 < 1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain c 30 5 12 1 Constipation 23 1 14 < 1 Dry mouth 13 0 7 < 1 Oral pain 14 < 1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 < 1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 < 1 Weight decreased 16 < 1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 < 1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e 47 < 1 15 0 Headache 23 1 19 0 Dizziness 11 < 1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension 34 13 4 < 1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 < 1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 < 1 0 0 Dry skin 23 < 1 7 0 Hair color changes 20 0 < 1 0 Alopecia 14 0 9 0 Erythema 12 < 1 1 0 Pruritus 12 < 1 7 < 1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 < 1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 < 1 2 0 Upper respiratory tract infection 11 < 1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 < 1 10 0 Depression g 11 0 14 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib included back pain (1%), arthralgia (< 1%), dyspnea (< 1%), asthenia (< 1%), fatigue (< 1%), limb pain (< 1%) and rash (< 1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (< 1%), and depression (< 1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u2265 10% of RCC Patients Who Received Sunitinib or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib (N = 375) Interferon Alfa (N = 360) All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 < 1 51 < 1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 < 1 Potassium increased 16 3 17 4 Calcium increased 13 < 1 10 1 Potassium decreased 13 1 2 < 1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (< 1%), creatine kinase (< 1%), creatinine (< 1%), glucose increased (< 1%), calcium decreased (< 1%), phosphorous (< 1%), potassium increased (< 1%), and sodium decreased (< 1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (< 1%), calcium increased (< 1%), glucose decreased (< 1%), potassium increased (< 1%), and hemoglobin (< 1%). Long-Term Safety in RCC The long-term safety of sunitinib in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib 50 mg daily on Schedule 4/2 (n = 306) or placebo (n = 304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib arm. Adverse reactions leading to permanent discontinuation in > 2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib (N = 306) Placebo (N = 304) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a 61 6 15 0 Diarrhea 57 4 22 < 1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain b 25 2 9 < 1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema c 18 < 1 < 1 0 Pyrexia 12 < 1 6 0 Dermatology Hand-foot syndrome 50 16 10 < 1 Rash d 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension e 39 8 14 1 Edema/Peripheral edema 10 < 1 7 0 Neurology Altered taste f 38 < 1 6 0 Headache 19 < 1 12 0 Endocrine Hypothyroidism/TSH increased 24 < 1 4 0 Hemorrhage/Bleeding Bleeding events, all sites g 24 < 1 5 < 1 Metabolism/Nutrition Anorexia/Decreased appetite 19 < 1 5 0 Musculoskeletal Pain in extremity 15 < 1 7 0 Arthralgia 11 < 1 10 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, hematuria. Grade 4 adverse reactions in patients on sunitinib included hand-foot syndrome (1%), fatigue (< 1%), abdominal pain (< 1%), stomatitis (< 1%), and pyrexia (< 1%). Grade 3 to 4 laboratory abnormalities that occurred in \u2265 2% of patients receiving sunitinib include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib 37.5 mg once daily (n = 83) or placebo (n = 82). The median number of days on treatment was 139 days (range: 13 to 532 days) for patients on sunitinib and 113 days (range: 1 to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib and 4 patients (5%) on placebo were on study for > 1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u2265 10% of Patients With pNET Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib (N = 83) Placebo (N = 82) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes b 48 6 18 0 Nausea 45 1 29 1 Abdominal pain c 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage /Bleeding Bleeding events d 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u2265 10% of Patients With pNET Who Received Sunitinib in Study 6 Laboratory Abnormality pNET Sunitinib Placebo All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3 to 4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (< 1%) in the adjuvant treatment for RCC study on sunitinib. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of sunitinib. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema . Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. *including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table width=\"100%\"><col width=\"23%\"/><col width=\"22%\"/><col width=\"19%\"/><col width=\"18%\"/><col width=\"18%\"/><thead><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reactions</content></th><th colspan=\"4\" align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">GIST</content></th></tr><tr><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 202)</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo (N = 102)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades %</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 %</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades %</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 %</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>94</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>56</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>97</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>51</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Mucositis/stomatitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Constipation</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Anorexia <sup>a</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>33</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Asthenia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Skin discoloration</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Rash</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Altered taste</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>21</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hypertension</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Myalgia/limb pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"24%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"18%\"/><col width=\"16%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 4. Laboratory Abnormalities Reported in &#x2265; 10% of GIST Patients Who Received Sunitinib or Placebo in the Double-Blind Treatment Phase* in Study 1</content></th></tr><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Laboratory Abnormality</content></th><th colspan=\"4\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">GIST</content></th></tr><tr><th colspan=\"2\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 202)</content></th><th colspan=\"2\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo (N = 102)</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Any Laboratory Abnormality</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>34</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>22</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Hematology</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Neutrophils decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>53</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Lymphocytes decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>38</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>16</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Platelets decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>38</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>5</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Hemoglobin decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>26</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>3</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>22</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>2</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Gastrointestinal</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>AST/ALT increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>39</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>2</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>23</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>1</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Lipase increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>25</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>17</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>7</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Alkaline phosphatase increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>24</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>21</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>4</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Amylase increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>17</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>5</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>12</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>3</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Total bilirubin increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>16</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>8</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Indirect bilirubin increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Renal/Metabolic</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Creatinine increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>12</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>7</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Potassium decreased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>12</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Sodium increased</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>10</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>0</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>4</item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item>1</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Cardiac</content></item></list></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item>Decreased LVEF</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>11</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>1</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>3</item></list></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><list listType=\"unordered\"><item>0</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"23%\"/><col width=\"22%\"/><col width=\"20%\"/><col width=\"18%\"/><col width=\"17%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 5. Adverse Reactions Reported in &#x2265; 10% of Patients With RCC Who Received Sunitinib or Interferon Alfa* in Study 3</content></th></tr><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content></th><th colspan=\"4\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></th></tr><tr><th colspan=\"2\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 375)</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Interferon Alfa (N = 360)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>55</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>66</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>58</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Mucositis/stomatitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>47</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>39</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dyspepsia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Constipation</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dry mouth</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Oral pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Flatulence</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>GERD/reflux esophagitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Glossodynia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hemorrhoids</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fatigue</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>62</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Asthenia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>26</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fever</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Weight decreased</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Chills</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Chest Pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Influenza like illness</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Anorexia <sup>d</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>48</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Altered taste <sup>e</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>47</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dizziness</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding, all sites</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4 <sup>f</sup></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hypertension</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Edema peripheral</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Ejection fraction decreased</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Rash</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Skin discoloration/yellow skin</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>25</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dry skin</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hair color changes</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Alopecia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Erythema</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pruritus</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Pain in extremity/limb discomfort</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Arthralgia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>30</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Back pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Cough</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>27</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dyspnea</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>26</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nasopharyngitis</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Oropharyngeal pain</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Upper respiratory tract infection</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypothyroidism</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td valign=\"middle\"/><td valign=\"middle\"/><td valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Insomnia</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Depression <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 6. Laboratory Abnormalities Reported in &#x2265; 10% of RCC Patients Who Received Sunitinib or Interferon Alfa in Study 3</content></th></tr><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Laboratory Abnormality</content></th><th colspan=\"4\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></th></tr><tr><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 375)</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Interferon Alfa (N = 360)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Creatine kinase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Uric acid increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Calcium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Sodium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"22%\"/><col width=\"21%\"/><col width=\"20%\"/><col width=\"19%\"/><col width=\"19%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 7. Adverse Reactions Reported in &#x2265; 10% of Patients With RCC Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in S-TRAC</content></th></tr><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content></th><th colspan=\"4\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><content styleCode=\"bold\">Adjuvant Treatment of RCC</content></th></tr><tr><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib (N = 306)</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo (N = 304)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4</content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Mucositis/Stomatitis <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Abdominal pain <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fatigue/Asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Localized edema <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pyrexia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Rash <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hair color changes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Skin discoloration/Yellow skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry skin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hypertension <sup>e</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Edema/Peripheral edema</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Altered taste <sup>f</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypothyroidism/TSH increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding events, all sites <sup>g</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Anorexia/Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Pain in extremity</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>&lt; 1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 8. Adverse Reactions Reported in &#x2265; 10% of Patients With pNET Who Received Sunitinib and More Commonly Than in Patients Given Placebo* in Study 6</content></th></tr><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content></th><th colspan=\"4\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">pNET</content></th></tr><tr><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content> <content styleCode=\"bold\">(N = 83)</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 82)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4</content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>95</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>50</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>59</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Stomatitis/oral syndromes <sup>b</sup></paragraph></td><td align=\"center\" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Abdominal pain <sup>c</sup></paragraph></td><td align=\"center\" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>10</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dyspepsia</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/><td styleCode=\"Rrule Lrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Asthenia</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Fatigue</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Weight decreased</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hair color changes</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Hand-foot syndrome</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Rash</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dry skin</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Hypertension</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>27</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>10</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Hemorrhage /Bleeding</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Bleeding events <sup>d</sup></paragraph></td><td align=\"center\" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Epistaxis</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Dysgeusia</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Insomnia</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>18</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>0</paragraph></td><td align=\"center\" valign=\"bottom\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td valign=\"bottom\"/><td valign=\"bottom\"/><td valign=\"bottom\"/><td styleCode=\"Rrule Lrule \" valign=\"bottom\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"bottom\"><paragraph>Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"bottom\"><paragraph>0</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 9. Laboratory Abnormalities Reported in &#x2265; 10% of Patients With pNET Who Received Sunitinib in Study 6</content></th></tr><tr><th rowspan=\"3\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Laboratory Abnormality</content></th><th colspan=\"4\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">pNET</content></th></tr><tr><th colspan=\"2\" align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,a</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">All Grades <sup>*</sup></content> <content styleCode=\"bold\">%</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Grade 3 to 4 <sup>*,b</sup></content> <content styleCode=\"bold\">%</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>AST increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>72</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>ALT increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Amylase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Lipase increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Platelets decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Glucose increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>18</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Albumin decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Calcium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Sodium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Glucose decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Potassium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Magnesium decreased</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Potassium increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors: Consider dose reduction of sunitinib when administered with strong CYP3A4 inhibitors. (7.1) CYP3A4 Inducers: Consider dose increase of sunitinib when administered with strong CYP3A4 inducers. (7.1) 7.1 Effect of Other Drugs on Sunitinib Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3)] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5)] . Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3)] . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5)] . 7.2 Drugs that Prolong QT Interval Sunitinib is associated with QTc interval prolongation [see Warnings and Precautions (5.3), Clinical Pharmacology (12.2)] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. (8.2) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u2264 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u2265 1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u2265 1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u2264 1 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib may impair male and female fertility [see Nonclinical Toxicology (13.1)] . 8.4 Pediatric Use The safety and effectiveness of sunitinib in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to < 17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to < 17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u2265 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were > 0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u2265 5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at > 5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u2264 2 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib were 65 years and older. Clinical studies of sunitinib did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology (12.3)] . Sunitinib was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CL cr 50 to 80 mL/min), moderate (CL cr 30 to < 50 mL/min), or severe (CL cr < 30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology (12.3)] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology (12.3)] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u2264 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u2265 1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u2265 1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u2264 1 mg/kg/day."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to < 17 years of age (n = 29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to < 17 years of age (n = 27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u2265 3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were > 0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u2265 5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at > 5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u2264 2 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib were 65 years and older. Clinical studies of sunitinib did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, compound with (S)-2-hydroxybutanedioic acid. The molecular formula is C 22 H 27 FN 4 O 2 .C 4 H 6 O 5 and the molecular weight is 532.57 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is light yellow to brownish orange colored powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in the range of 12 to 70 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively) together with croscarmellose sodium, magnesium stearate, mannitol and povidone (K-30) as inactive ingredients. The reddish brown gelatin capsule shells contain ferric oxide red and titanium dioxide. The caramel gelatin capsule shells contain ferric oxide red, ferric oxide yellow, ferrosoferric oxide and titanium dioxide. The yellow gelatin capsule shells contain ferric oxide yellow and titanium dioxide. The white printing ink contains potassium hydroxide, shellac and titanium dioxide. The black printing ink contains ferrosoferric oxide, potassium hydroxide and shellac. SPL-Sunitinib-Northstar-Molecular structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (> 80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)]. 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr > 80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (> 80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)]."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to < 50 mL/min), or severe (CLcr < 30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr > 80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u2265 25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u2264 1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u2265 2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u2264 10 mg/kg/day (approximately \u2265 26 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u2265 25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u2264 1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u2265 2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u2264 10 mg/kg/day (approximately \u2265 26 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib and patients randomized to sunitinib were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib and placebo groups with regard to age (69% versus 72% < 65 years for sunitinib versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib (N = 207) Placebo (N = 105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression a [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) < 0.0001* 0.33 (0.23, 0.47) Progression-free survival b [median, weeks (95% CI)] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) < 0.0001 0.33 (0.24, 0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7, 11.1) 0 0.006 c * A comparison is considered statistically significant if the p-value is < 0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis , the study was unblinded, and patients on the placebo arm were offered open-label sunitinib treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib arm and 64.9 weeks for the placebo arm [hazard ratio (HR) = 0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). SPL-Sunitinib-Northstar-Figure-1 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib and interferon alfa groups with regard to age (59% versus 67% < 65 years for sunitinib versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (> 1.5 ULN versus \u2264 1.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib over interferon alfa. The ORR was higher in the sunitinib arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib (N = 375) Interferon Alfa (N = 375) p-value (log-rank test) HR (95% CI) Progression-free survival a [median, weeks (95% CI)] 47.3 (42.6, 50.7) 22.0 (16.4, 24.0) < 0.000001 b 0.415 (0.320, 0.539) Objective response rate a [%, (95% CI)] 27.5 (23.0, 32.3) 5.3 (3.3, 8.1) < 0.001 c NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is < 0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; INF-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib arm and 94.9 weeks for the interferon alfa arm (HR = 0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib. Cytokine-Refractory The use of single-agent sunitinib in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status < 2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (> 90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N = 106) Study 5 (N = 63) Objective response rate [%, (95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR * (42.0, * ) 54 b (34.3, 70.1) * Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265 T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib N = 309 Placebo N = 306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Placebo Sunitinib Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u2265 1 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u2265 2, ECOG PS \u2265 1 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. SPL-Sunitinib-Northstar-Figure-2 SPL-Sunitinib-Northstar-figure 3 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib (N = 86) or placebo (N = 85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib and placebo groups. Additionally, 49% of sunitinib patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib (N = 86) Placebo (N = 85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 a 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors SPL-Sunitinib-Northstar-Figure-4"
    ],
    "clinical_studies_table": [
      "<table width=\"100%\" cellpadding=\"0pt\"><col width=\"42%\"/><col width=\"17%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"14%\"/><thead><tr><th colspan=\"5\" align=\"left\" styleCode=\"Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase)</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><content styleCode=\"bold\">Efficacy Parameter</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content> <content styleCode=\"bold\">(N = 207)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N = 105)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">p-value</content> <content styleCode=\"bold\">(log-rank test)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">HR</content> <content styleCode=\"bold\">(95% CI)</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>Time-to-tumor progression <sup>a</sup>[median, weeks (95% CI)] </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>27.3</paragraph><paragraph>(16.0, 32.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6.4</paragraph><paragraph>(4.4, 10.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt; 0.0001*</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.33</paragraph><paragraph>(0.23, 0.47)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Progression-free survival <sup>b</sup>[median, weeks (95% CI)] </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>24.1</paragraph><paragraph>(11.1, 28.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>6.0</paragraph><paragraph>(4.4, 9.9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 0.0001</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.33</paragraph><paragraph>(0.24, 0.47)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Objective response rate (PR) [%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>6.8</paragraph><paragraph>(3.7, 11.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0.006 <sup>c</sup></paragraph></td><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"27%\"/><col width=\"21%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"19%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Sunitinib</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N = 375)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Progression-free survival <sup>a</sup>[median, weeks (95% CI)] </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>47.3</paragraph><paragraph>(42.6, 50.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>22.0</paragraph><paragraph>(16.4, 24.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>&lt; 0.000001 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.415</paragraph><paragraph>(0.320, 0.539)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>Objective response rate <sup>a</sup></paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>27.5</paragraph><paragraph>(23.0, 32.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>5.3</paragraph><paragraph>(3.3, 8.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>&lt; 0.001 <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>NA</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"33%\"/><col width=\"34%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 4</content></paragraph><paragraph><content styleCode=\"bold\">(N = 106)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Study 5</content></paragraph><paragraph><content styleCode=\"bold\">(N = 63)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>34.0 <sup>a</sup></paragraph><paragraph>(25.0, 43.8)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>36.5 <sup>b</sup></paragraph><paragraph>(24.7, 49.6)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"bottom\"><paragraph>Duration of response</paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>NR <sup>*</sup></paragraph><paragraph>(42.0, <sup>*</sup>) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>54 <sup>b</sup></paragraph><paragraph>(34.3, 70.1)</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"29%\"/><col width=\"19%\"/><col width=\"18%\"/><col width=\"15%\"/><col width=\"18%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><content styleCode=\"bold\">Sunitinib</content></item></list><paragraph><content styleCode=\"bold\">N = 309</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">N = 306</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">p-value <sup>a</sup></content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">HR <sup>a</sup>(95% CI) </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Median DFS [years (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>6.8 (5.8, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>5.6 (3.8, 6.6)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.03</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.76</paragraph><paragraph>(0.59, 0.98)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>DFS Events</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>113 (36.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>144 (47.1%)</paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>5 Year DFS Rate</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>59.3%</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>51.3%</paragraph></td><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"20%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"18%\"/><col width=\"12%\"/><col width=\"18%\"/><thead><tr><th colspan=\"6\" align=\"left\" styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Table 14. Disease-free Survival by Baseline Disease Characteristics</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Number of Events/Total</content> <content styleCode=\"bold\">n/N</content></th><th colspan=\"2\" align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Median DFS</content> <content styleCode=\"bold\">[years (95% CI)]</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">HR <sup>a</sup></content> <content styleCode=\"bold\">(95% CI)</content></th></tr><tr><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content></th><th align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></th><th align=\"left\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"/></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>T3 Intermediate <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>35/115</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>46/112</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>NR</paragraph><paragraph>(5.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6.4</paragraph><paragraph>(4.7, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.82</paragraph><paragraph>(0.53, 1.28)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>T3 High <sup>c</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>63/165</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>79/166</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>6.8</paragraph><paragraph>(5.0, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5.3</paragraph><paragraph>(2.9, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.77 (0.55, 1.07)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>T4/Node Positive <sup>d</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>15/29</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>19/28</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>3.5</paragraph><paragraph>(1.2, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1.7</paragraph><paragraph>(0.4, 3.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0.62</paragraph><paragraph>(0.31, 1.23)</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"31%\"/><col width=\"20%\"/><col width=\"16%\"/><col width=\"16%\"/><col width=\"17%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Sunitinib</content></paragraph><paragraph><content styleCode=\"bold\">(N = 86)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N = 85)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Progression-free survival</paragraph><paragraph>[median, months (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>10.2</paragraph><paragraph>(7.4, 16.9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>5.4</paragraph><paragraph>(3.4, 6.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.000146 <sup>a</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>0.427</paragraph><paragraph>(0.271, 0.673)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>Objective response rate</paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>9.3</paragraph><paragraph>(3.2, 15.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>0.0066 <sup>b</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>NA</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 12.5 mg capsules Hard gelatin capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM53\u2019 on cap and \u2018RM53\u2019 on body in white ink, containing yellow to orange colored powder; available in: Bottles of 28 capsules with child-resistant closure: NDC 16714-676-01 25 mg capsules Hard gelatin capsule with opaque caramel cap and opaque reddish brown body, self-lock capsule, imprinted with \u2018RM54\u2019 on cap and \u2018RM54\u2019 on body in white ink, containing yellow to orange colored powder; available in: Bottles of 28 capsules with child-resistant closure: NDC 16714-677-01 37.5 mg capsules Hard gelatin capsule with opaque yellow cap and opaque yellow body, self-lock capsule, imprinted with \u2018RM55\u2019 on cap and \u2018RM55\u2019 on body in black ink, containing yellow to orange colored powder; available in: Bottles of 28 capsules with child-resistant closure: NDC 16714-678-01 50 mg capsules Hard gelatin capsule with opaque caramel cap and opaque caramel body, self-lock capsule, imprinted with \u2018RM56\u2019 on cap and \u2018RM56\u2019 on body in white ink, containing Yellow to orange colored powder ; available in: Bottles of 28 capsules with child-resistant closure: NDC 16714-679-01 Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [See USP Controlled Room Temperature]. Keep out of reach of children."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.1)] . Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.2)] . QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions (5.3)] . Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions (5.4)] . Hemorrhagic Events Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions (5.5)] . Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate capsules treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate capsules [see Warnings and Precautions (5.5), and Adverse Reactions (6.1)]. Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate capsules due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions (5.9), and Adverse Reactions (6.1)]. Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] . Thyroid Dysfunction Advise patients that sunitinib malate capsules can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions (5.11)] . Hypoglycemia Advise patients that sunitinib malate capsules can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions (5.12)] . Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions (5.13)] . Impaired Wound Healing Advise patients that sunitinib malate capsules impairs wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions (5.14)] . Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions (7)] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.15), Use in Specific Populations (8.1)] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations (8.3)] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations (8.3)] . Lactation Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [see Use in Specific Populations (8.2)] . Infertility Advise patients that sunitinib malate capsules may impair male and female fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)] . Missed Dose Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time. Medication Guides available at http://www.northstarrxllc.com/products or call 1-800-206-7821 Manufactured for: NorthStar Rx LLC Memphis, TN 38141 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 1012, Dadra-396 193, U.T. of D & NH and Daman & Diu, India. October 2023 FDA-02"
    ],
    "spl_medguide": [
      "Medication Guide MEDICATION GUIDE Sunitinib Malate (soo ni\u2019 ti nib mal\u2019 ate) Capsules Rx only What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are prescription medicine used to treat: a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate. advanced kidney cancer (advanced renal cell carcinoma or RCC). adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: have any heart problems have high blood pressure have thyroid problems have a history of low blood sugar or diabetes have kidney function problems (other than cancer) have liver problems have any bleeding problem plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d have seizures have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsule 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too much sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201cWhat is the most important information I should know about sunitinib malate capsules? \u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules you feel faint or lightheaded, or you pass out dizziness feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with sunitinib malate capsules, and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache dizziness lightheadedness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems . Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) bloody urine vomiting blood headache coughing up blood change in your mental status black, sticky stools Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome[RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS) . TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away loss of appetite problems with heat feeling nervous or agitated, tremors sweating nausea or vomiting diarrhea fast heart beat weight gain or weight loss feeling depressed irregular menstrual periods or no menstrual periods headache hair loss Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: headache irritability drowsiness hunger weakness fast heart beat dizziness sweating confusion feeling jittery Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems . Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness weakness diarrhea pain, swelling or sores inside of your mouth nausea loss of appetite indigestion vomiting stomach-area (abdominal) pain blisters or rash on the palms of your hands and soles of your feet high blood pressure taste changes low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, povidone (K-30). Reddish brown gelatin capsule shells: ferric oxide red and titanium dioxide. Caramel gelatin capsule shells: ferric oxide red, ferric oxide yellow, ferrosoferric oxide and titanium dioxide. Yellow gelatin capsule shells: ferric oxide yellow and titanium dioxide. White printing ink: potassium hydroxide, shellac and titanium dioxide. Black printing ink: ferrosoferric oxide, potassium hydroxide and shellac. All trademarks are property of their respective owners. Medication Guides available at http://www.northstarrxllc.com/products or call 1-800-206-7821 Manufactured for: NorthStar Rx LLC Memphis, TN 38141 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 1012, Dadra-396 193, U.T. of D & NH and Daman & Diu, India. October 2023 FDA-02 For more information, call 1-800-206-7821. This Medication Guide has been approved by the U.S. Food and Drug Administration"
    ],
    "spl_medguide_table": [
      "<table width=\"100%\"><colgroup><col width=\"52%\"/><col width=\"48%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>you feel faint or lightheaded, or you pass out</item><item>dizziness</item></list></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>feel your heart beat is irregular or fast</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"55%\"/><col width=\"45%\"/></colgroup><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>severe headache</item></list></td><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>dizziness</item></list></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>lightheadedness</item></list></td><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>change in vision</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"48%\"/><col width=\"52%\"/></colgroup><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>painful, swollen stomach (abdomen)</item></list></td><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>bloody urine</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>vomiting blood</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>headache</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>coughing up blood</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>change in your mental status</item></list></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>black, sticky stools</item></list></td><td styleCode=\"Botrule \" valign=\"top\"/></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"56%\"/><col width=\"44%\"/></colgroup><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>tiredness that gets worse and does not go away</item><item>loss of appetite</item><item>problems with heat</item><item>feeling nervous or agitated, tremors</item><item>sweating</item><item>nausea or vomiting</item><item>diarrhea</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>fast heart beat</item><item>weight gain or weight loss</item><item>feeling depressed</item><item>irregular menstrual periods or no menstrual periods</item><item>headache</item><item>hair loss</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"50%\"/><col width=\"50%\"/></colgroup><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>headache</item></list></td><td styleCode=\"Toprule \" valign=\"top\"><list listType=\"unordered\"><item>irritability</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>drowsiness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>hunger</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>weakness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>fast heart beat</item></list></td></tr><tr><td valign=\"top\"><list listType=\"unordered\"><item>dizziness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item>sweating</item></list></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>confusion</item></list></td><td styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>feeling jittery</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><colgroup><col width=\"53%\"/><col width=\"47%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>tiredness</item><item>weakness</item><item>diarrhea</item><item>pain, swelling or sores inside of your mouth</item><item>nausea</item><item>loss of appetite</item><item>indigestion</item></list></td><td styleCode=\"Botrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item>vomiting</item><item>stomach-area (abdominal) pain</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>high blood pressure</item><item>taste changes</item><item>low platelet counts</item></list></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 16714-676-01 Sunitinib Malate Capsules 12.5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. 28 Capsules NorthStar Rx only 12.5mg-28s-label",
      "Package/Label Display Panel NDC 16714-677-01 Sunitinib Malate Capsules 25 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. 28 Capsules NorthStar Rx only 25mg-28s-label",
      "Package/Label Display Panel NDC 16714-678-01 Sunitinib Malate Capsules 37.5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. 28 Capsules NorthStar Rx only 37.5mg-28s-label",
      "Package/Label Display Panel NDC 16714-679-01 Sunitinib Malate Capsules 50 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. 28 Capsules NorthStar Rx only 50mg-28s-label"
    ],
    "set_id": "7579e3d0-2de6-4239-a7a8-118ed92075f5",
    "id": "2a3c27a8-20ee-4a18-e063-6294a90acd54",
    "effective_time": "20241227",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA213914"
      ],
      "brand_name": [
        "Sunitinib malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "NorthStar RxLLC"
      ],
      "product_ndc": [
        "16714-676",
        "16714-677",
        "16714-678",
        "16714-679"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "2a3c27a8-20ee-4a18-e063-6294a90acd54"
      ],
      "spl_set_id": [
        "7579e3d0-2de6-4239-a7a8-118ed92075f5"
      ],
      "package_ndc": [
        "16714-676-01",
        "16714-677-01",
        "16714-678-01",
        "16714-679-01"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0316714678016",
        "0316714679013"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K25 GELATIN, UNSPECIFIED FERRIC OXIDE RED TITANIUM DIOXIDE POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC Red Opaque Cap, Red Opaque Body S12;5 SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K25 FD&C BLUE NO. 2 GELATIN, UNSPECIFIED FERRIC OXIDE RED FERRIC OXIDE YELLOW TITANIUM DIOXIDE POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC Olive Green Opaque Cap Red Opaque Body S25 SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K25 FD&C BLUE NO. 2 GELATIN, UNSPECIFIED FERRIC OXIDE YELLOW TITANIUM DIOXIDE FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC Light Green Opaque Cap, Light Green Opaque Body S37;5 SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K25 FD&C BLUE NO. 2 GELATIN, UNSPECIFIED FERRIC OXIDE RED FERRIC OXIDE YELLOW TITANIUM DIOXIDE FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE PROPYLENE GLYCOL SHELLAC Olive Green Opaque Cap, Olive Green Opaque Body S50"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate as recommended [see Warnings and Precautions (5.1) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate as recommended [see Warnings and Precautions (5.1) ]."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC: The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET: The recommended dosage is 37.5 mg orally once daily. ( 2.3) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions (5.1) ] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. For recurring Grade 3 permanently discontinue. Grade 4 \u2022 Permanently discontinue. Cardiovascular events [see Warnings and Precautions (5.2) ] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) Withhold until resolution to Grade 0 to 1 or baseline. Resume at reduced dose. Clinically manifested congestive heart failure (CHF) Permanently discontinue. Hypertension [see Warnings and Precautions (5.4) ] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Grade 4 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions (5.5) ] Grade 3 or 4 Withhold until resolution to Grade 0 to 1 or baseline. Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions (5.7) ] Any Grade Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8) ] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9) ] Any Grade Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10) ] Any Grade Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions (5.13) ] Any Grade The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions (5.14) ] Any Grade The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions (7.1)] : GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1) ] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3) ]."
    ],
    "dosage_and_administration_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"19%\"/><col width=\"18%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"21%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Indications</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">GIST</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">RCC</content> </td><td styleCode=\"Rrule\" rowspan=\"2\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">pNET</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Advanced RCC</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Adjuvant RCC</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">First dose reduction </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">37.5 mg once daily </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">37.5 mg once daily </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">37.5 mg once daily </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">25 mg once daily </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">Second dose reduction </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">25 mg once daily </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">25 mg once daily </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">NA </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">NA </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"41%\"/><col width=\"20%\"/><col width=\"38%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Adverse Reaction</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Severity</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Dosage Modifications for Sunitinib Malate Capsules</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\">Hepatotoxicity  <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.1\">Warnings and Precautions (5.1)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Grade 3  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose. </item><item>For recurring Grade 3 permanently discontinue. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Grade 4 </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">&#x2022; Permanently discontinue.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\">Cardiovascular events <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.2\">Warnings and Precautions (5.2)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline. </item><item>Resume at reduced dose. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Clinically manifested congestive heart failure (CHF) </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Permanently discontinue. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\">Hypertension <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.4\">Warnings and Precautions (5.4)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Grade 3  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline. </item><item>Resume at a reduced dose. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Grade 4 </td><td styleCode=\"Rrule\" valign=\"middle\"><list listType=\"unordered\" styleCode=\"disc\"><item>Permanently discontinue. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Hemorrhagic events <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.5\">Warnings and Precautions (5.5)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Grade 3 or 4  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline. </item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Thrombotic microangiopathy <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.7\">Warnings and Precautions (5.7)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Permanently discontinue. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"top\">Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.8\">Warnings and Precautions (5.8)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline. </item><item>Resume at a reduced dose. </item></list>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Permanently discontinue. </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.9\">Warnings and Precautions (5.9)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Any Grade    </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Permanently discontinue.</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.10\">Warnings and Precautions (5.10)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Permanently discontinue.</item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Osteonecrosis of the jaw <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.13\">Warnings and Precautions (5.13)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. </item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. </item></list></td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Impaired wound healing <content styleCode=\"italics\">[see <linkHtml href=\"#Section_5.14\">Warnings and Precautions (5.14)</linkHtml>] </content> </td><td styleCode=\"Rrule\" valign=\"top\">Any Grade  </td><td styleCode=\"Rrule\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. </item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. </item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Capsules, hard gelatin: \u2022 12.5 mg sunitinib: red opaque cap and red opaque body imprinted \u2018S12.5\u2019 on body with white ink and plain cap, containing yellow to orange granules. \u2022 25 mg sunitinib: olive green opaque cap and red opaque body imprinted \u2018S25\u2019 on body with white ink and plain cap, containing yellow to orange granules. \u2022 37.5 mg sunitinib: light green opaque cap and light green opaque body imprinted \u2018S37.5\u2019 on body with black ink and plain cap, containing yellow to orange granules. \u2022 50 mg sunitinib: olive green opaque cap and olive green opaque body imprinted \u2018S50\u2019 on body with black ink and plain cap, containing yellow to orange granules. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline and resume sunitinib malate at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. ( 2.4 , 5.1 ) Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) QT Interval Prolongation and Torsade de Pointes : Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib malate for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients who develop Grade 4 hypertension. ( 5.4 ) Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ) Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) Thrombotic microangiopathy (TMA) : TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate for TMA. ( 5.7 ) Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate for these events. ( 5.9 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate until resolution. ( 5.10 ) Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib malate for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 ) Impaired Wound Healing : Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. ( 5.14 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u226550% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate. Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration (2.5) , Drug Interactions (7.2) ] . 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3 to 5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib malate. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib malate. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome (TLS) Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate as monotherapy and administered in combination with bevacizumab. Sunitinib malate is not approved for use in combination with bevacizumab. Discontinue sunitinib malate in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n=83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw (ONJ) Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate and periodically during sunitinib malate therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate for development of ONJ until complete resolution. The safety of resumption of sunitinib malate after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate [see Adverse Reactions (6.2) ] . Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for 4 weeks following the final dose [see Use in Specific Populations (8.1 , 8.3) ] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions (5.1) ] Cardiovascular Events [see Warnings and Precautions (5.2) ] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3) ] Hypertension [see Warnings and Precautions (5.4) ] Hemorrhagic Events [see Warnings and Precautions (5.5) ] Tumor Lysis Syndrome [see Warnings and Precautions (5.6) ] Thrombotic Microangiopathy [see Warnings and Precautions (5.7) ] Proteinuria [see Warnings and Precautions (5.8) ] Dermatologic Toxicities [see Warnings and Precautions (5.9) ] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.10) ] Thyroid Dysfunction [see Warnings and Precautions (5.11) ] Hypoglycemia [see Warnings and Precautions (5.12) ] Osteonecrosis of the Jaw [see Warnings and Precautions (5.13) ] Impaired Wound Healing [see Warnings and Precautions (5.14) ] The most common adverse reactions (\u226525%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u226525%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate (mean: 3.0; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u2265 10% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo * in Study 1 Adverse Reaction GIST Sunitinib Malate (N=202) Placebo (N=102) All Grade s % Grade 3 to 4 % All Grade s % Grade 3 to 4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea Mucositis/stomatitis Constipation 40 29 20 4 1 0 27 18 14 0 2 2 Metabolism/Nutrition Anorexia a Asthenia 33 22 1 5 29 11 5 3 Dermatology Skindiscoloration Rash Hand-footsyndrome 30 14 14 0 1 4 23 9 10 0 0 3 Neurology Alteredtaste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u2265 10% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase * in Study 1 Laboratory Abnormality GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *, b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased Lymphocytes decreased Platelets decreased Hemoglobindecreased 53 38 38 26 10 0 5 3 4 16 4 22 0 0 0 2 Gastrointestinal AST/ALT increased Lipase increased Alkalinephosphatase increased Amylase increased Totalbilirubin increased Indirectbilirubin increased 39 25 24 17 16 10 2 10 4 5 1 0 23 17 21 12 8 4 1 7 4 3 0 0 Renal/Metabolic Creatinine increased Potassiumdecreased Sodiumincreased 12 12 10 1 1 0 7 4 4 0 0 1 Cardiac DecreasedLVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis , the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate [see Clinical Studies (14.1)] . For 241 patients randomized to the sunitinib malate arm, including 139 who received sunitinib malate in both the double-blind and open-label phases, the median duration of sunitinib malate treatment was 6 cycles (mean: 8.5; range: 1 to 44). For the 255 patients who ultimately received open-label sunitinib malate treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1 to 37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u2265 10% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa * in Study 3 Adverse Reaction Treatment -Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea Nausea Mucositis/stomatitis Vomiting Dyspepsia Abdominal pain c Constipation Dry mouth Oral pain Flatulence GERD/reflux esophagitis Glossodynia Hemorrhoids 66 58 47 39 34 30 23 13 14 14 12 11 10 10 6 3 5 2 5 1 0 <1 0 <1 0 0 21 41 5 17 4 12 14 7 1 2 1 1 2 <1 2 <1 1 0 1 <1 <1 0 0 0 0 0 Constitutional Fatigue Asthenia Fever Weightdecreased Chills ChestPain Influenzalikeillness 62 26 22 16 14 13 5 15 11 1 <1 1 2 0 56 22 37 17 31 7 15 15 6 <1 1 0 1 <1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e Headache Dizziness 47 23 11 <1 1 <1 15 19 14 0 0 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension Edemaperipheral Ejectionfractiondecreased 34 24 16 13 2 3 4 5 5 <1 1 2 Dermatology Rash Hand-footsyndrome Skin discoloration/yellow skin Dry skin Haircolorchanges Alopecia Erythema Pruritus 29 29 25 23 20 14 12 12 2 8 <1 <1 0 0 <1 <1 11 1 0 7 <1 9 1 7 <1 0 0 0 0 0 0 <1 Musculoskeletal Paininextremity/limbdiscomfort Arthralgia Backpain 40 30 28 5 3 5 30 19 14 2 1 2 Respiratory Cough Dyspnea Nasopharyngitis Oropharyngealpain Upperrespiratorytract infection 27 26 14 14 11 1 6 0 <1 <1 14 20 2 2 2 <1 4 0 0 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia Depression g 15 11 <1 0 10 14 0 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u2265 10% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3 Laboratory Abnormality Treatment -Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Hematology Hemoglobin decreased Neutrophils decreased Platelets decreased Lymphocytes decreased 79 77 68 68 8 17 9 18 69 49 24 68 5 9 1 26 Renal/Metabolic Creatinine increased Creatinekinase increased Uricacid increased Calciumdecreased Phosphorus decreased Albumin decreased Glucose increased Sodiumdecreased Glucosedecreased Potassium increased Calcium increased Potassiumdecreased Sodiumincreased 70 49 46 42 31 28 23 20 17 16 13 13 13 <1 2 14 1 6 1 6 8 0 3 <1 1 0 51 11 33 40 24 20 15 15 12 17 10 2 10 <1 1 8 1 6 0 6 4 <1 4 1 <1 0 Gastrointestinal AST increased Lipase increased ALT increased Alkalinephosphatase increased Amylase increased Totalbilirubin increased Indirectbilirubin increased 56 56 51 46 35 20 13 2 18 3 2 6 1 1 38 46 40 37 32 2 1 2 8 2 2 3 0 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). Long-Term Safety in RCC The long-term safety of sunitinib malate in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo * in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib Malate (N=306) Pl a c e b o (N=304) All Grade s % Grade 3 to 4 % All Grade s % Grade 3 to 4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a Diarrhea Nausea Dyspepsia Abdominalpain b Vomiting Constipation 61 57 34 27 25 19 12 6 4 2 1 2 2 0 15 22 15 7 9 7 11 0 <1 0 0 <1 0 0 Constitutional Fatigue/Asthenia Localizededema c Pyrexia 57 18 12 8 <1 <1 34 <1 6 2 0 0 Dermatology Hand-footsyndrome Rash d Haircolorchanges Skindiscoloration/Yellow skin Dry skin 50 24 22 18 14 16 2 0 0 0 10 12 2 1 6 <1 0 0 0 0 Cardiac Hypertension e Edema/Peripheral edema 39 10 8 <1 14 7 1 0 Neurology Alteredtaste f Headache 38 19 <1 <1 6 12 0 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage /Bleeding Bleeding events, all sites g 24 <1 5 <1 Metabolism /Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Paininextremity Arthralgia 15 11 <1 <1 7 10 0 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. Grade 4 adverse reactions in patients on sunitinib malate included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%). Grade 3 to 4 laboratory abnormalities that occurred in \u22652% of patients receiving sunitinib malate include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13 to 532 days) for patients on sunitinib malate and 113 days (range: 1 to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u2265 10% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo * in Study 6 Adverse Reaction pNET Sunitinib Malate (N=83) Placebo (N=82) All Grade s % Grade 3 to 4 a % All Grade s % Grade 3 to 4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea Stomatitis/oral syndromes b Nausea Abdominalpain c Vomiting Dyspepsia 59 48 45 39 34 15 5 6 1 5 0 0 39 18 29 34 31 6 2 0 1 10 2 0 Constitutional Asthenia Fatigue Weightdecreased 34 33 16 5 5 1 27 27 11 4 9 0 Dermatology Haircolorchanges Hand-footsyndrome Rash Dry skin 29 23 18 15 1 6 0 0 1 2 5 11 0 0 0 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events d Epistaxis 22 21 0 1 10 5 4 0 Neurology Dysgeusia Headache 21 18 0 0 5 13 0 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u2265 10% of Patients With pNET Who Received Sunitinib Malate in Study 6 Laboratory Abnormality pNET Sunitinib Malate Placebo All Grades * % Grade 3 to 4 *,a % All Grades * % Grade 3 to 4 *,b % Gastrointestinal AST increased Alkalinephosphatase increased ALT increased Totalbilirubin increased Amylase increased Lipase increased 72 63 61 37 20 17 5 10 4 1 4 5 70 70 55 28 10 11 3 11 3 4 1 4 Hematology Neutrophilsdecreased Hemoglobindecreased Plateletsdecreased Lymphocytesdecreased 71 65 60 56 16 0 5 7 16 55 15 35 0 1 0 4 Renal/Me tabolic Glucose increased Albumin decreased Phosphorusdecreased Calciumdecreased Sodiumdecreased Creatinine increased Glucosedecreased Potassiumdecreased Magnesiumdecreased Potassium increased 71 41 36 34 29 27 22 21 19 18 12 1 7 0 2 5 2 4 0 1 78 37 22 19 34 28 15 14 10 11 18 1 5 0 3 5 4 0 0 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3 to 4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on sunitinib malate. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema. Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib malate include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. *including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"31.2%\"/><col width=\"17.12%\"/><col width=\"17.28%\"/><col width=\"17.12%\"/><col width=\"17.28%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\">    <content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">GIST</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"/><content styleCode=\"bold\">(N=202)</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo (N=102)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\">s %</content></td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4</content><content styleCode=\"bold\"/><content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> <content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\">s %</content></td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4</content><content styleCode=\"bold\"/><content styleCode=\"bold\">%</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Any</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">94 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">56 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">97 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">51 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Gastrointestinal</content>  Diarrhea  Mucositis/stomatitis  Constipation </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  40 29 20 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  4 1 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  27 18 14 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 2 2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Metabolism/Nutrition </content>  Anorexia<sup>a</sup>  Asthenia </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  33 22 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  1 5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  29 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  5 3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Dermatology</content>  Skindiscoloration  Rash  Hand-footsyndrome </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  30 14 14 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 1 4 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  23 9 10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 0 3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Neurology</content>  Alteredtaste </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  21 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  12 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Cardiac</content>  Hypertension </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  15 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  4 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Musculoskeletal</content>  Myalgia/limb pain </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  14 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  9 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  1 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"34.1%\"/><col width=\"16.54%\"/><col width=\"16.4%\"/><col width=\"16.4%\"/><col width=\"16.56%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Laboratory</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Abnormality</content> </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">GIST</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"/><content styleCode=\"bold\">(N=202)</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo (N=102)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content><content styleCode=\"bold\">*</content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>*,a</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content><content styleCode=\"bold\"><sup>*</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>*,</sup></content><content styleCode=\"bold\"><sup>b</sup></content> <content styleCode=\"bold\">%</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Any </content><content styleCode=\"bold\">Laboratory</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Abnormality</content> </td><td styleCode=\"Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 34</td><td styleCode=\"Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"> 22</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Hematology </content>  Neutrophils decreased   Lymphocytes decreased  Platelets decreased  Hemoglobindecreased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  53 38 38 26 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  10 0 5 3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  4 16 4 22 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  0 0 0 2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Gastrointestinal</content>  AST/ALT increased  Lipase increased  Alkalinephosphatase increased  Amylase increased  Totalbilirubin increased  Indirectbilirubin increased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 39 25 24 17 16 10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 10 4 5 1 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 23 17 21 12 8 4 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 7 4 3 0 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Renal/Metabolic</content>  Creatinine increased  Potassiumdecreased  Sodiumincreased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 12 12 10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 1 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 7 4 4 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 0 1 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Cardiac</content>  DecreasedLVEF </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"27.9%\"/><col width=\"19.98%\"/><col width=\"17.98%\"/><col width=\"16.98%\"/><col width=\"17.16%\"/></colgroup><thead><tr><th styleCode=\"Lrule Rrule Toprule\" rowspan=\"3\" align=\"center\"><content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content><content styleCode=\"bold\"/> </th><th styleCode=\"Lrule Rrule Toprule\" colspan=\"4\" align=\"center\"><content styleCode=\"bold\">Treatment</content><content styleCode=\"bold\">-Na&#xEF;ve</content><content styleCode=\"bold\"/><content styleCode=\"bold\">RCC</content> </th></tr><tr><th styleCode=\"Lrule Rrule Toprule\" colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"/><content styleCode=\"bold\">(N=375)</content> </th><th styleCode=\"Lrule Rrule Toprule\" colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Interferon Alfa (N=360)</content> </th></tr><tr><th styleCode=\"Lrule Rrule Toprule\" align=\"center\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content> <content styleCode=\"bold\">%</content> </th><th styleCode=\"Lrule Rrule Toprule\" align=\"center\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>a</sup></content> <content styleCode=\"bold\">%</content> </th><th styleCode=\"Lrule Rrule Toprule\" align=\"center\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content> <content styleCode=\"bold\">%</content> </th><th styleCode=\"Lrule Rrule Toprule\" align=\"center\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>b</sup></content> <content styleCode=\"bold\">%</content> </th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Any</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Adverse </content><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">99 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">77 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">99 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">55 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Gastrointestinal</content>  Diarrhea  Nausea  Mucositis/stomatitis  Vomiting  Dyspepsia  Abdominal pain<sup>c</sup>  Constipation  Dry mouth  Oral pain  Flatulence  GERD/reflux esophagitis  Glossodynia  Hemorrhoids </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 66 58 47 39 34 30 23 13 14 14 12 11 10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 10 6 3 5 2 5 1 0 &lt;1 0 &lt;1 0 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 21 41 5 17 4 12 14 7 1 2 1 1 2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 2 &lt;1 1 0 1 &lt;1 &lt;1 0 0 0 0 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Constitutional</content>  Fatigue  Asthenia  Fever  Weightdecreased  Chills  ChestPain  Influenzalikeillness<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  62 26 22 16 14 13 5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  15 11 1 &lt;1 1 2 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  56 22 37 17 31 7 15 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  15 6 &lt;1 1 0 1 &lt;1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Metabolism/Nutrition </content>  Anorexia<sup>d</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  48 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  42 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Neurology</content>  Altered taste<sup>e</sup>  Headache   Dizziness </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  47 23 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  &lt;1 1 &lt;1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  15 19 14 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 0 1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Hemorrhage/Bleeding</content><content styleCode=\"bold\"/>  Bleeding, all sites </td><td styleCode=\"Rrule\" align=\"center\" valign=\"bottom\">37 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"bottom\">4<sup>f</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"bottom\">10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"bottom\">1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Cardiac</content>  Hypertension  Edemaperipheral  Ejectionfractiondecreased<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 34 24 16 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 13 2 3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 4 5 5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 1 2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Dermatology</content>  Rash  Hand-footsyndrome  Skin discoloration/yellow skin  Dry skin  Haircolorchanges  Alopecia  Erythema  Pruritus<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 29 29 25 23 20 14 12 12 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 8 &lt;1 &lt;1 0 0 &lt;1 &lt;1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 11 1 0 7 &lt;1 9 1 7 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 0 0 0 0 0 0 &lt;1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Musculoskeletal</content>  Paininextremity/limbdiscomfort  Arthralgia  Backpain<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 40 30 28 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 5 3 5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 30 19 14 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 1 2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Respiratory</content>  Cough  Dyspnea  Nasopharyngitis  Oropharyngealpain  Upperrespiratorytract infection<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 27 26 14 14 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 6 0 &lt;1 &lt;1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 14 20 2 2 2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 4 0 0 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Endocrine</content>  Hypothyroidism </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 16 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Psychiatric</content>  Insomnia  Depression<sup>g</sup><content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 15 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 10 14 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 1 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"34.1%\"/><col width=\"16.54%\"/><col width=\"16.4%\"/><col width=\"16.4%\"/><col width=\"16.56%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Laboratory</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Abnormality</content> </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Treatment</content><content styleCode=\"bold\">-Na&#xEF;ve</content><content styleCode=\"bold\"/><content styleCode=\"bold\">RCC</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"/><content styleCode=\"bold\">(N=375)</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Interferon Alfa (N=360)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content><content styleCode=\"bold\"><sup>*</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>*,a</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content><content styleCode=\"bold\"><sup>*</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>*,b</sup></content> <content styleCode=\"bold\">%</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Hematology</content>  Hemoglobin decreased  Neutrophils decreased  Platelets decreased  Lymphocytes decreased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 79 77 68 68 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 8 17 9 18 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 69 49 24 68 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 5 9 1 26 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Renal/Metabolic</content>  Creatinine increased  Creatinekinase increased  Uricacid increased  Calciumdecreased  Phosphorus decreased  Albumin decreased  Glucose increased  Sodiumdecreased  Glucosedecreased  Potassium increased  Calcium increased  Potassiumdecreased  Sodiumincreased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 70 49 46 42 31 28 23 20 17 16 13 13 13 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 2 14 1 6 1 6 8 0 3 &lt;1 1 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 51 11 33 40 24 20 15 15 12 17 10 2 10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 1 8 1 6 0 6 4 &lt;1 4 1 &lt;1 0 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Gastrointestinal</content>  AST increased  Lipase increased  ALT increased  Alkalinephosphatase increased  Amylase increased  Totalbilirubin increased  Indirectbilirubin increased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 56 56 51 46 35 20 13 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 18 3 2 6 1 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 38 46 40 37 32 2 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 8 2 2 3 0 0 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"140%\"><colgroup><col width=\"16.2134944612286%\"/><col width=\"0.100704934541793%\"/><col width=\"12.7895266868077%\"/><col width=\"0.201409869083585%\"/><col width=\"12.7895266868077%\"/><col width=\"2.11480362537764%\"/><col width=\"0.201409869083585%\"/><col width=\"8.96273917421954%\"/><col width=\"10.8761329305136%\"/><col width=\"0.201409869083585%\"/><col width=\"6.94864048338369%\"/><col width=\"21.852970795569%\"/><col width=\"6.7472306143001%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" colspan=\"10\" valign=\"top\"><content styleCode=\"bold\"> Adjuvant Treatment of RCC</content> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"> (N=306)</content> </td><td styleCode=\"Rrule\" colspan=\"6\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Pl</content><content styleCode=\"bold\">a</content><content styleCode=\"bold\">c</content><content styleCode=\"bold\">e</content><content styleCode=\"bold\">b</content><content styleCode=\"bold\">o (N=304)</content> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\">s</content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4</content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\">s</content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4</content> <content styleCode=\"bold\">% </content> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Any</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">99 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">60 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">88 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">15 </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Gastrointestinal</content>  Mucositis/Stomatitis<sup>a</sup>  Diarrhea  Nausea  Dyspepsia  Abdominalpain<sup>b</sup>  Vomiting  Constipation </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 61 57 34 27 25 19 12 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 6 4 2 1 2 2 0 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 15 22 15 7 9 7 11 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 &lt;1 0 0 &lt;1 0 0<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Constitutional</content>  Fatigue/Asthenia  Localizededema<sup>c</sup>  Pyrexia </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 57 18 12 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 8 &lt;1 &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 34 &lt;1 6 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 0 0<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Dermatology</content>  Hand-footsyndrome  Rash<sup>d</sup>   Haircolorchanges  Skindiscoloration/Yellow skin  Dry skin </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 50 24 22 18 14 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 16 2 0 0 0 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 10 12 2 1 6 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 0 0 0 0<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Cardiac </content>  Hypertension<sup>e</sup>  Edema/Peripheral edema </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  39 10 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  8 &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  14 7 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  1 0 </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Neurology</content>  Alteredtaste<sup>f</sup>  Headache </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 38 19 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 6 12 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 0<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Endocrine </content>  Hypothyroidism/TSH increased </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  24 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  4 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  0 </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Hemorrhage</content><content styleCode=\"bold\">/Bleeding </content>  Bleeding events, all sites<sup>g</sup> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  24 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  5 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  &lt;1 </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Metabolism</content><content styleCode=\"bold\">/Nutrition </content>  Anorexia/Decreased appetite  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  19 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\">  &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  5 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\">  0 </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Musculoskeletal</content>  Paininextremity  Arthralgia </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 15 11 </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> &lt;1 &lt;1 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 7 10 </td><td styleCode=\"Rrule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 0<content styleCode=\"bold\"/> </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"middle\">  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"32.2%\"/><col width=\"16.86%\"/><col width=\"17.04%\"/><col width=\"16.86%\"/><col width=\"17.04%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">pNET</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"> (N=83)</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content><content styleCode=\"bold\"/><content styleCode=\"bold\">(N=82)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\">s</content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>a</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\">s</content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4</content> <content styleCode=\"bold\">%</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Any</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Adverse</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Reaction</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">99 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">54 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">95 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">50 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Gastrointestinal</content>  Diarrhea  Stomatitis/oral syndromes<sup>b</sup>  Nausea  Abdominalpain<sup>c</sup>  Vomiting  Dyspepsia </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 59 48 45 39 34 15 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 5 6 1 5 0 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 39 18 29 34 31 6 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 2 0 1 10 2 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Constitutional</content>  Asthenia  Fatigue  Weightdecreased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 34 33 16 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 5 5 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 27 27 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 4 9 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Dermatology</content>  Haircolorchanges  Hand-footsyndrome  Rash  Dry skin </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 29 23 18 15 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 6 0 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 1 2 5 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 0 0 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Cardiac </content>  Hypertension  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  27 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Hemorrhage/Bleeding </content>  Bleeding events<sup>d </sup>  Epistaxis </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  22 21 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  0 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  10 5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  4 0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Neurology</content>  Dysgeusia  Headache </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 21 18 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 5 13 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Psychiatric</content>  Insomnia </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 18 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 12 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Musculoskeletal</content>  Arthralgia </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 15 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 6 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"27.88%\"/><col width=\"15.68%\"/><col width=\"22.86%\"/><col width=\"14.58%\"/><col width=\"19%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\"> </content> <content styleCode=\"bold\">Laboratory</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Abnormality</content> </td><td styleCode=\"Rrule\" colspan=\"4\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">pNET</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"/><content styleCode=\"bold\">Grades</content><content styleCode=\"bold\"><sup>*</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>*,a</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">All</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Grades<sup>*</sup></content> <content styleCode=\"bold\">%</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Grade</content><content styleCode=\"bold\"/><content styleCode=\"bold\">3 to 4<sup>*,b</sup></content> <content styleCode=\"bold\">%</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> <content styleCode=\"bold\">Gastrointestinal</content>  AST increased  Alkalinephosphatase increased  ALT increased   Totalbilirubin increased  Amylase increased  Lipase increased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  72 63 61 37 20 17 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  5 10 4 1 4 5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  70 70 55 28 10 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  3 11 3 4 1 4 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Hematology</content>  Neutrophilsdecreased  Hemoglobindecreased  Plateletsdecreased  Lymphocytesdecreased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 71 65 60 56 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 16 0 5 7 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 16 55 15 35 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 0 1 0 4 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Renal/Me</content><content styleCode=\"bold\">tabolic</content>  Glucose increased  Albumin decreased  Phosphorusdecreased  Calciumdecreased  Sodiumdecreased  Creatinine increased  Glucosedecreased  Potassiumdecreased  Magnesiumdecreased  Potassium increased </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 71 41 36 34 29 27 22 21 19 18 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 12 1 7 0 2 5 2 4 0 1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 78 37 22 19 34 28 15 14 10 11 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\"> </content> 18 1 5 0 3 5 4 0 0 1 </td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers : Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 Inhibitors Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3) ] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5) ] . Strong CYP3A4 Inducers Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3) ] . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5) ] . 7.2 Drugs that Prolong QT Interval Sunitinib malate is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5, and 15 mg/kg) or 5 cycles (0.3, 1.5, and 6 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology (12.3) ] . Sunitinib malate was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology (12.3) ] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology (12.3) ] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day."
    ],
    "labor_and_delivery": [
      "8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma."
    ],
    "nursing_mothers": [
      "8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [see Nonclinical Toxicology (13.1) ] ."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5, and 15 mg/kg) or 5 cycles (0.3, 1.5, and 6 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capules as the malate salt. Sunitinib malate is described chemically as (2 S )-2-hydroxybutanedoic acid with N -[2-(diethylamino)ethyl]-5-[( Z )-(5-fluoro-1,2-dihydro-2-oxo- 3H -indol-3-ylidine)methyl]-2,4-dimethyl- 1H -pyrrole-3-carboxamide (1:1). The molecular formula is C 22 H 27 FN 4 O 2 \u2022 C 4 H 6 O 5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.71 mg, 33.41 mg, 50.12 mg, or 66.83 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone. The red opaque gelatin capsule shells contain gelatin, iron oxide red, and titanium dioxide; the olive green opaque gelatin capsule shells contain FD&C Blue 2, gelatin, iron oxide red, iron oxide yellow, and titanium dioxide; and the light green opaque gelatin capsule shells contain FD&C Blue 2, gelatin, iron oxide yellow, and titanium dioxide. The white printing ink contains potassium hydroxide, propylene glycol, shellac, and titanium dioxide and the black printing ink contains black iron oxide, potassium hydroxide, propylene glycol, and shellac. sunitinib-str"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3) ]. 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3) ]."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib malate in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate and patients randomized to sunitinib malate were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate and placebo groups with regard to age (69% versus 72% <65 years for sunitinib malate versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib Malate (N=207) Placebo (N=105) p-value (log-rank test ) HR (95% CI) Time-to-tumor progression a [median, weeks (95%CI)] 27.3 (16.0,32.1) 6.4 (4.4,10.0) <0.0001 * 0.33 (0.23,0.47) Progression-freesurvival b [median, weeks (95%CI)] 24.1 (11.1,28.3) 6.0 (4.4,9.9) <0.0001 0.33 (0.24,0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7,11.1) 0 0.006 c * A comparison is considered statistically significant if the p-value is <0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis , the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). sunitinib-fig1 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate and interferon alfa groups with regard to age (59% versus 67% <65 years for sunitinib malate versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \u22641.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate over interferon alfa. The ORR was higher in the sunitinib malate arm (see Table 11). Table11. Treatment-Na\u00efveRCCEfficacyResults(InterimAnalysis) from Study 3 Efficacy Parameter Sunitinib Malate (N=375) Interferon Alfa (N=375) p-value (log-rank test) HR (95% CI) Progression-freesurvival a 47.3 22.0 <0.000001 b 0.415 [median, weeks (95%CI)] (42.6,50.7) (16.4, 24.0) (0.320, 0.539) Objectiveresponserate a 27.5 5.3 <0.001 c NA [%,(95% CI)] (23.0,32.3) (3.3, 8.1) Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is <0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; IFN-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib malate. Cytokine-Refractory The use of single-agent sunitinib malate in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table12. Cytokine-Refractory RCCEfficacyResults from Study 4 and Study 5 Efficacy Parameter Study 4 (N=106) Study 5 (N=63) Objectiveresponserate [%,(95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Durationofresponse [median, weeks (95%CI)] NR* (42.0, *) 54 b (34.3, 70.1) *Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib Malate N=309 Placebo N=306 p-value a HR a (95% CI) MedianDFS [years (95% CI)] 6.8(5.8, NR) 5.6(3.8,6.6) 0.03 0.76(0.59,0.98) DFS Events 113(36.6%) 144(47.1%) 5 YearDFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number ofEvents/ Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Malate Placebo Sunitinib Malate Placebo T3Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/NodePositive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u2265 1 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u2265 2, ECOG PS \u2265 1 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1 to 2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. sunitinib-fig2 sunitinib-fig3 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate and placebo groups. Additionally, 49% of sunitinib malate patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib Malate (N=86) Placebo (N=85) p-value HR (95% CI) Progression-freesurvival [median,months(95%CI)] 10.2 (7.4,16.9) 5.4 (3.4,6.0) 0.000146 a 0.427 (0.271,0.673) Objectiveresponserate [%,(95% CI)] 9.3 (3.2,15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors. sunitinib-fig4"
    ],
    "clinical_studies_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"29.44%\"/><col width=\"23.88%\"/><col width=\"15.16%\"/><col width=\"16.62%\"/><col width=\"14.88%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Efficacy</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> Parameter</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\"><content styleCode=\"bold\">Sunitinib Malate</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> (N=207)</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\"><content styleCode=\"bold\">Placebo</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> (N=105)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">p-value </content><content styleCode=\"bold\">(log-rank test</content><content styleCode=\"bold\">)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">HR</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> (95%</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Time-to-tumor progression<sup>a</sup> [median, weeks (95%CI)] </td><td styleCode=\"Rrule\" align=\"left\" valign=\"middle\">27.3 (16.0,32.1) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.4 (4.4,10.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&lt;0.0001<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"middle\">0.33 (0.23,0.47) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Progression-freesurvival<sup>b</sup><sup/> [median, weeks (95%CI)] </td><td styleCode=\"Rrule\" align=\"left\" valign=\"middle\">24.1 (11.1,28.3) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.0 (4.4,9.9) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&lt;0.0001 </td><td styleCode=\"Rrule\" align=\"left\" valign=\"middle\">0.33 (0.24,0.47) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\">Objective response rate (PR)  [%, (95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.8 (3.7,11.1) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.006<sup>c</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"27.94%\"/><col width=\"22.88%\"/><col width=\"18.06%\"/><col width=\"16.22%\"/><col width=\"14.9%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"bottom\"> <content styleCode=\"bold\">Efficacy Parameter</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\">Sunitinib Malate (N=375)</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\">Interferon Alfa</content><content styleCode=\"bold\"> (N=375)</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\">p-value</content><content styleCode=\"bold\"/> <content styleCode=\"bold\"> (log-rank</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> test)</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\"> HR</content> <content styleCode=\"bold\"> (95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Progression-freesurvival<sup>a</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">47.3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">22.0 </td><td styleCode=\"Rrule\" rowspan=\"2\" align=\"center\" valign=\"top\">&lt;0.000001<sup>b</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.415 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">[median, weeks (95%CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">(42.6,50.7) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">(16.4, 24.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">(0.320, 0.539) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Objectiveresponserate<sup>a</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">27.5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.3 </td><td styleCode=\"Rrule\" rowspan=\"2\" align=\"center\" valign=\"top\">&lt;0.001<sup>c</sup> </td><td styleCode=\"Rrule\" rowspan=\"2\" align=\"center\" valign=\"top\">NA </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">[%,(95% CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">(23.0,32.3) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">(3.3, 8.1) </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"34.68%\"/><col width=\"32.88%\"/><col width=\"32.44%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\"/> <content styleCode=\"bold\">Efficacy</content><content styleCode=\"bold\"> Parameter</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\">Study </content><content styleCode=\"bold\">4</content> <content styleCode=\"bold\"> (N=106)</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"bottom\"><content styleCode=\"bold\">Study 5</content> <content styleCode=\"bold\"> (N=63)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Objectiveresponserate [%,(95% CI)] </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\">34.0<sup>a </sup>  (25.0, 43.8) </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\">36.5<sup>b</sup> (24.7, 49.6) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Durationofresponse   [median, weeks (95%CI)] </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\">NR*  (42.0, *) </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\">54<sup>b</sup> (34.3, 70.1) </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"35.16%\"/><col width=\"19.02%\"/><col width=\"18.14%\"/><col width=\"10.8%\"/><col width=\"16.88%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\"><content styleCode=\"bold\"> Sunitinib Malate</content><content styleCode=\"bold\"/> <content styleCode=\"bold\"> N=309</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\"><content styleCode=\"bold\">Placebo</content><content styleCode=\"bold\">  N=306</content> </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\"><content styleCode=\"bold\"> p-value</content><content styleCode=\"bold\"><sup>a</sup></content><sup/> </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\"><content styleCode=\"bold\"> HR<sup>a</sup></content><content styleCode=\"bold\"/><content styleCode=\"bold\"> (95%</content><content styleCode=\"bold\"/><content styleCode=\"bold\"> CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">MedianDFS [years (95% CI)] </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">6.8(5.8, NR) </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">5.6(3.8,6.6) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.03 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.76(0.59,0.98) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">DFS Events </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">113(36.6%) </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">144(47.1%) </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"justify\" valign=\"top\">  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">5 YearDFS Rate </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">59.3% </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">51.3% </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"justify\" valign=\"top\">  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"18.24%\"/><col width=\"18.12%\"/><col width=\"12.1%\"/><col width=\"18.14%\"/><col width=\"13.62%\"/><col width=\"19.8%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"left\" valign=\"top\"><content styleCode=\"bold\"> Number ofEvents/ Total </content> <content styleCode=\"bold\">n/N</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"left\" valign=\"middle\"><content styleCode=\"bold\">Median DFS</content> <content styleCode=\"bold\">[years (95% CI)]</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\"><content styleCode=\"bold\"> HR<sup>a</sup></content> <content styleCode=\"bold\"> (95% CI)<sup/></content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">Sunitinib Malate </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">Placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">Sunitinib Malate </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">Placebo </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">T3Intermediate<sup>b</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">35/115 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">46/112 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">NR  (5.2, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.4 (4.7, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.82 (0.53, 1.28) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">T3High<sup>c</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">63/165 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">79/166 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6.8 (5.0, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.3 (2.9, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.77 (0.55, 1.07) </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">T4/NodePositive<sup>d</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">15/29 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">19/28 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3.5 (1.2, NR) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1.7 (0.4, 3.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.62 (0.31, 1.23) </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"35.14%\"/><col width=\"16.28%\"/><col width=\"16.04%\"/><col width=\"14.94%\"/><col width=\"17.58%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"top\">    <content styleCode=\"bold\"> Efficacy Parameter</content> </td><td styleCode=\"Rrule\" align=\"left\" valign=\"middle\"><content styleCode=\"bold\">Sunitinib   Malate (N=86)</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo   (N=85)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">p-value</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">HR</content> <content styleCode=\"bold\">(95% CI)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Progression-freesurvival [median,months(95%CI)] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">10.2 (7.4,16.9) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">5.4 (3.4,6.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.000146<sup>a</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.427 (0.271,0.673) </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"top\">Objectiveresponserate [%,(95% CI)] </td><td styleCode=\"Rrule\" align=\"left\" valign=\"top\">9.3 (3.2,15.4) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.0066<sup>b</sup><sup/> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">NA </td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Sunitinib Malate Capsules, 12.5 mg are supplied as hard gelatin capsule with red opaque cap and red opaque body imprinted \u2018S12.5\u2019 on body with white ink and plain cap, containing yellow to orange granules; available in: Bottles of 28 capsules NDC 59651-464-28 Cartons of 28 Capsules (4 x 7 Unit-Dose) NDC 59651-464-29 Sunitinib Malate Capsules, 25 mg are supplied as hard gelatin capsule with olive green opaque cap and red opaque body imprinted \u2018S25\u2019 on body with white ink and plain cap, containing yellow to orange granules; available in: Bottles of 28 capsules NDC 59651-465-28 Cartons of 28 Capsules (4 x 7 Unit-Dose) NDC 59651-465-29 Sunitinib Malate Capsules, 37.5 mg are supplied as hard gelatin capsule with light green opaque cap and light green opaque body imprinted \u2018S37.5\u2019 on body with black ink and plain cap, containing yellow to orange granules; available in: Bottles of 28 capsules NDC 59651-466-28 Cartons of 28 Capsules (4 x 7 Unit-Dose) NDC 59651-466-29 Sunitinib Malate Capsules, 50 mg are supplied as hard gelatin capsule with olive green opaque cap and olive green opaque body imprinted \u2018S50\u2019 on body with black ink and plain cap, containing yellow to orange granules; available in: Bottles of 28 capsules NDC 59651-467-28 Cartons of 28 Capsules (4 x 7 Unit-Dose) NDC 59651-467-29 Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.1) ] . Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions (5.2) ] . QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions (5.3) ] . Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions (5.4) ] . Hemorrhagic Events Advise patients that sunitinib malate can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions (5.5) ] . Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate [see Warnings and Precautions (5.5), Adverse Reactions (6.1) ]. Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions (5.9) , Adverse Reactions (6.1 )]. Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10) ] . Thyroid Dysfunction Advise patients that sunitinib malate can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions (5.11) ] . Hypoglycemia Advise patients that sunitinib malate can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions (5.12) ] . Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions (5.13) ] . Impaired Wound Healing Advise patients that sunitinib malate impairs wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions (5.14) ] . Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions (7) ] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.15) , Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate [see Use in Specific Populations (8.3) ] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate [see Use in Specific Populations (8.3) ] . Lactation Advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose [see Use in Specific Populations (8.2) ] . Infertility Advise patients that sunitinib malate may impair male and female fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1) ] . Missed Dose Advise patients that miss a dose of sunitinib malate by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate by more than 12 hours to take the next scheduled dose at its regular time. Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Eugia Pharma Specialities Limited Hyderabad - 500032 India Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides"
    ],
    "spl_medguide": [
      "MEDICATION GUIDE Sunitinib Malate Capsules (soo ni\u2019 ti nib mal\u2019 ate) What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: \u2022 Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: o itching o yellow eyes or skin o dark urine o pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsule is a prescription medicine used to treat: \u2022 a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate . \u2022 advanced kidney cancer (advanced renal cell carcinoma or RCC). \u2022 adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. \u2022 a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: \u2022 have any heart problems \u2022 have high blood pressure \u2022 have thyroid problems \u2022 have a history of low blood sugar or diabetes \u2022 have kidney function problems (other than cancer) \u2022 have liver problems \u2022 have any bleeding problem \u2022 plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201c What are the possible side effects of sunitinib malate capsules?\u201d \u2022 have seizures \u2022 have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth \u2022 are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsules 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too much sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening . Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules o you feel faint or lightheaded, or you pass out o dizziness o feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache lightheadedness dizziness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) vomiting blood coughing up blood black, sticky stools bloody urine headache change in your mental status Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS) . TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away loss of appetite problems with heat feeling nervous or agitated, tremors sweating nausea or vomiting diarrhea fast heat rate weight gain or weight loss feeling depressed irregular menstrual periods or no menstrual periods headache hair loss Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: Headache Drowsiness Weakness Dizziness Confusion Irritability Hunger fast heart beat sweating feeling jittery Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness weakness diarrhea pain, swelling or sores inside of your mouth nausea loss of appetite indigestion vomiting stomach-area (abdominal) pain blisters or rash on the palms of your hands and soles of your feet high blood pressure taste changes low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone. Red opaque gelatin capsule shells: gelatin, iron oxide red, and titanium dioxide. Olive green opaque gelatin capsule shells: FD&C Blue 2, gelatin, iron oxide red, iron oxide yellow, and titanium dioxide. Light green opaque gelatin capsule shells: Light green opaque gelatin capsule shells: FD&C Blue 2, gelatin, iron oxide yellow, and titanium dioxide. White printing ink: potassium hydroxide, propylene glycol, shellac, and titanium dioxide. Black printing ink: black iron oxide, potassium hydroxide, propylene glycol, and shellac. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Eugia Pharma Specialities Limited Hyderabad \u2013 500032 India For more information call Aurobindo Pharma USA, Inc. at 1-866-850-2876. This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: May 2024"
    ],
    "spl_medguide_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"100%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> <content styleCode=\"bold\">MEDICATION GUIDE</content>  <content styleCode=\"bold\">Sunitinib Malate Capsules</content>  <content styleCode=\"bold\">(soo ni&#x2019; ti nib mal&#x2019; ate)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules?</content>  <content styleCode=\"bold\">Sunitinib malate capsules can cause serious side effects including:</content>  <content styleCode=\"bold\">&#x2022; Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content>  o itching  o yellow eyes or skin  o dark urine  o pain or discomfort in the right upper stomach area    Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems.    See &#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D; for more information about side effects.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">What are sunitinib malate capsules?</content>    Sunitinib malate capsule is a prescription medicine used to treat:    <content styleCode=\"bold\">&#x2022; </content>a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when:  <list listType=\"unordered\" styleCode=\"Circle\"><item>you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or  </item><item>you cannot take imatinib mesylate<content styleCode=\"bold\">.</content></item></list> <content styleCode=\"bold\">&#x2022; </content>advanced kidney cancer (advanced renal cell carcinoma or RCC).  <content styleCode=\"bold\">&#x2022; </content>adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.  <content styleCode=\"bold\">&#x2022; </content>a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.    It is not known if sunitinib malate capsules are safe and effective in children.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content>    <content styleCode=\"bold\">&#x2022; </content>have any heart problems  &#x2022; have high blood pressure  &#x2022; have thyroid problems  &#x2022; have a history of low blood sugar or diabetes  &#x2022; have kidney function problems (other than cancer)  &#x2022; have liver problems  &#x2022; have any bleeding problem  <content styleCode=\"bold\">&#x2022; </content>plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See &#x201C;<content styleCode=\"bold\">What are the possible side effects of sunitinib malate capsules?&#x201D;</content>  &#x2022; have seizures  &#x2022; have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth  &#x2022; are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby.    <content styleCode=\"bold\">Females who are able to become pregnant:</content>  <list listType=\"unordered\" styleCode=\"Circle\"><item>Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules.  </item><item>You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules.  </item><item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.</item></list>   <content styleCode=\"bold\">Males</content> with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules.    Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you.    <list listType=\"unordered\" styleCode=\"Disc\"><item>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose.</item></list>   Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any</content> surgery, or medical or dental procedure.    <content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects.    You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell</content> your healthcare provider if you are taking or have taken an osteoporosis medicine.    Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">How should I take sunitinib malate capsules?</content>  <list listType=\"unordered\" styleCode=\"Disc\"><item>Take sunitinib malate capsules exactly the way your healthcare provider tells you.  </item><item>Take sunitinib malate capsules 1 time each day with or without food.  </item><item>If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to.  </item><item>If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.  </item><item>Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body.  </item><item>Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.  </item><item>If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.  </item><item>Call your healthcare provider right away, if you take too much sunitinib malate capsules.</item></list> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">What are possible side effects of sunitinib malate capsules?</content>    <content styleCode=\"bold\">Sunitinib malate capsules may cause serious side effects, including:</content>  <list listType=\"unordered\" styleCode=\"Disc\"><item>See<content styleCode=\"bold\"> &#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content>  </item><item><content styleCode=\"bold\">Heart problems.</content> Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles.  </item><item><content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening</content>. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules  o you feel faint or lightheaded, or you pass out o dizziness o feel your heart beat is irregular or fast   </item><item><content styleCode=\"bold\">High blood pressure.</content> High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure:  <list listType=\"unordered\" styleCode=\"Circle\"><item>severe headache</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>lightheadedness</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>dizziness</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>change in vision</item></list>  Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed.   </item><item><content styleCode=\"bold\">Bleeding problems.</content> Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including:  <list listType=\"unordered\" styleCode=\"Circle\"><item>painful, swollen stomach (abdomen)</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>vomiting blood</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>coughing up blood</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>black, sticky stools</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>bloody urine</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>headache</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>change in your mental status</item></list>  </item><item><content styleCode=\"bold\">Serious stomach and intestinal problems, that can sometimes lead to death.</content> Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules.  </item><item><content styleCode=\"bold\">Tumor lysis syndrome (TLS)</content>. TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.  </item><item><content styleCode=\"bold\">Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]).</content> RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death.  </item><item><content styleCode=\"bold\">Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS).</content> TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brain and kidneys, and can sometimes lead to death.  </item><item><content styleCode=\"bold\">Protein in your urine.</content> Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem.  </item><item><content styleCode=\"bold\">Serious skin and mouth reactions.</content> Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including:</item></list> <list listType=\"unordered\" styleCode=\"Circle\"><item>severe rash with blisters or peeling of the skin.</item><item>painful sores or ulcers on the skin, lips or inside the mouth.</item><item>tissue damage (necrotizing fasciitis).</item></list>   If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away.    <list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Thyroid problems.</content> Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules:</item></list> <list listType=\"unordered\" styleCode=\"Circle\"><item>tiredness that gets worse and does not go away</item><item>loss of appetite</item><item>problems with heat</item><item>feeling nervous or agitated, tremors</item><item>sweating</item><item>nausea or vomiting</item><item>diarrhea</item><item>fast heat rate</item><item>weight gain or weight loss</item><item>feeling depressed</item><item>irregular menstrual periods or no menstrual periods</item><item>headache</item><item>hair loss</item></list> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Low blood sugar (hypoglycemia).</content> Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules:  <list listType=\"unordered\" styleCode=\"Circle\"><item>Headache</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>Drowsiness</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>Weakness</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>Dizziness</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>Confusion</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>Irritability</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>Hunger</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>fast heart beat</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>sweating</item></list><list listType=\"unordered\" styleCode=\"Circle\"><item>feeling jittery</item></list>  </item><item><content styleCode=\"bold\">Jawbone problems (osteonecrosis). </content>Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules.  <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.</item></list>  <list listType=\"unordered\" styleCode=\"Circle\"><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures.</item></list>  </item><item><content styleCode=\"bold\">Wound healing problems.</content> Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules.</item></list>   <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.  </item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.</item></list>   <content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects.</content>    Common side effects of sunitinib malate capsules include:    <list listType=\"unordered\" styleCode=\"Circle\"><item>tiredness</item><item>weakness</item><item>diarrhea</item><item>pain, swelling or sores inside of your mouth</item><item>nausea</item><item>loss of appetite</item><item>indigestion</item><item>vomiting</item><item>stomach-area (abdominal) pain</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>high blood pressure</item><item>taste changes</item><item>low platelet counts</item></list>   The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.    These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">How do I store sunitinib malate capsules?</content>  <list listType=\"unordered\" styleCode=\"Disc\"><item>Store sunitinib malate capsules at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item></list> <content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules.</content>  Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them.    You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals.  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> <content styleCode=\"bold\">What are the ingredients in sunitinib malate capsules?</content>  <content styleCode=\"bold\">Active ingredient: </content>sunitinib malate  <content styleCode=\"bold\">Inactive ingredients: </content>croscarmellose sodium, magnesium stearate, mannitol, and povidone.  <content styleCode=\"bold\">Red opaque gelatin capsule shells: </content>gelatin, iron oxide red, and titanium dioxide.  <content styleCode=\"bold\">Olive green opaque gelatin capsule shells: </content>FD&amp;C Blue 2, gelatin, iron oxide red, iron oxide yellow, and titanium dioxide.  <content styleCode=\"bold\">Light green opaque gelatin capsule shells: </content><content styleCode=\"bold\">Light green opaque gelatin capsule shells:</content> FD&amp;C Blue 2, gelatin, iron oxide yellow, and titanium dioxide.   <content styleCode=\"bold\">White printing ink:</content> potassium hydroxide, propylene glycol, shellac, and titanium dioxide.  <content styleCode=\"bold\">Black printing ink:</content> black iron oxide, potassium hydroxide, propylene glycol, and shellac.    Distributed by:  <content styleCode=\"bold\">Aurobindo Pharma USA, Inc.</content>  279 Princeton-Hightstown Road  East Windsor, NJ 08520    Manufactured by:  <content styleCode=\"bold\">Eugia Pharma Specialities Limited</content>  Hyderabad &#x2013; 500032  India    For more information call Aurobindo Pharma USA, Inc. at 1-866-850-2876.  </td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 12.5 mg (28 Capsules Bottle) NDC 59651-464-28 Sunitinib Malate Capsules 12.5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. Rx only 28 Capsules AUROBINDO sunitinib-fig5",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 12.5 mg 28 Capsules (4 x 7 Unit-Dose) NDC 59651-464-29 Rx only Sunitinib Malate Capsules 12.5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. AUROBINDO 28 Capsules (4 x 7 Unit-Dose) sunitinib-fig6",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 25 mg (28 Capsules Bottle) NDC 59651-465-28 Sunitinib Malate Capsules 25 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. Rx only 28 Capsules AUROBINDO sunitinib-fig7",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 25 mg 28 Capsules (4 x 7 Unit-Dose) NDC 59651-465-29 Rx only Sunitinib Malate Capsules 2 5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. AUROBINDO 28 Capsules (4 x 7 Unit-Dose) sunitinib-fig8",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 37.5 mg (28 Capsules Bottle) NDC 59651-466-28 Sunitinib Malate Capsules 37.5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. Rx only 28 Capsules AUROBINDO sunitinib-fig9",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 37.5 mg 28 Capsules (4 x 7 Unit-Dose) NDC 59651-466-29 Rx only Sunitinib Malate Capsules 37.5 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. AUROBINDO 28 Capsules (4 x 7 Unit-Dose) sunitinib-fig10",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (28 Capsules Bottle) NDC 59651-467-28 Sunitinib Malate Capsules 50 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. Rx only 28 Capsules AUROBINDO sunitinib-fig11",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg 28 Capsules (4 x 7 Unit-Dose) NDC 59651-467-29 Rx only Sunitinib Malate Capsules 50 mg* PHARMACIST: Dispense the Medication Guide provided separately to each patient. AUROBINDO 28 Capsules (4 x 7 Unit-Dose) sunitinib-fig12"
    ],
    "set_id": "810dfcb2-d35b-4971-887c-2e78e82e9e07",
    "id": "a3d2b07e-f9d2-4f17-9a80-025d77ff8f7e",
    "effective_time": "20250417",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA218615"
      ],
      "brand_name": [
        "SUNITINIB MALATE"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Aurobindo Pharma Limited"
      ],
      "product_ndc": [
        "59651-464",
        "59651-465",
        "59651-466",
        "59651-467"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "a3d2b07e-f9d2-4f17-9a80-025d77ff8f7e"
      ],
      "spl_set_id": [
        "810dfcb2-d35b-4971-887c-2e78e82e9e07"
      ],
      "package_ndc": [
        "59651-464-28",
        "59651-464-29",
        "59651-465-28",
        "59651-465-29",
        "59651-466-28",
        "59651-466-29",
        "59651-467-28",
        "59651-467-29"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0359651466292",
        "0359651465295",
        "0359651467299"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM POVIDONE K25 MAGNESIUM STEARATE TITANIUM DIOXIDE FERRIC OXIDE RED POVIDONE FERROSOFERRIC OXIDE FERRIC OXIDE YELLOW GELATIN SODIUM LAURYL SULFATE ISOPROPYL ALCOHOL BUTYL ALCOHOL PROPYLENE GLYCOL SHELLAC POTASSIUM HYDROXIDE SC;12;5 warm grey SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM POVIDONE K25 MAGNESIUM STEARATE TITANIUM DIOXIDE GELATIN POVIDONE FERROSOFERRIC OXIDE SODIUM LAURYL SULFATE ISOPROPYL ALCOHOL BUTYL ALCOHOL PROPYLENE GLYCOL SHELLAC POTASSIUM HYDROXIDE SC;25 SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM POVIDONE K25 MAGNESIUM STEARATE TITANIUM DIOXIDE GELATIN POVIDONE FERROSOFERRIC OXIDE SODIUM LAURYL SULFATE ISOPROPYL ALCOHOL BUTYL ALCOHOL PROPYLENE GLYCOL SHELLAC POTASSIUM HYDROXIDE SC;37;5 black colored cap grey colored body SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MALATE SUNITINIB MANNITOL CROSCARMELLOSE SODIUM POVIDONE K25 MAGNESIUM STEARATE TITANIUM DIOXIDE GELATIN SODIUM HYDROXIDE POVIDONE FERROSOFERRIC OXIDE SODIUM LAURYL SULFATE PROPYLENE GLYCOL ISOPROPYL ALCOHOL BUTYL ALCOHOL SHELLAC POTASSIUM HYDROXIDE SC;50 bottle1 bottle2 bottle3 bottle4 figure1 figure2 figure3 figure4 structure"
    ],
    "boxed_warning": [
      "BOXED WARNING SECTION WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate as recommended [see Warnings and Precautions ( 5.1 )]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate as recommended [ see Warnings and Precautions ( 5.1 )] ."
    ],
    "recent_major_changes": [
      "RECENT MAJOR CHANGES SECTION Dosage and Administration, Dosage Modifications for Adverse Reactions ( 2.4 ) 8/2021 Dosage and Administration, Dosage Modification for Drug Interactions ( 2.5 ) 8/2021 Warnings and Precautions, Hepatotoxicity ( 5.1 ) 8/2021 Warnings and Precautions, Hypertension ( 5.4 ) 8/2021 Warnings and Precautions, Hemorrhagic Events and Viscous Perforation ( 5.5 ) 8/2021 Warnings and Precautions, Reversible Posterior Leukoencephalopathy Syndrome ( 5.10 ) 8/2021 Warnings and Precautions, Hypoglycemia ( 5.12 ) 8/2021 Warnings and Precautions, Osteonecrosis of the Jaw ( 5.13 ) 8/2021"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC: \u2022 The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC: \u2022 The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET: \u2022 The recommended dosage is 37.5 mg orally once daily. ( 2.3 ) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Hepatotoxicity [see Warnings and Precautions (5.1 )] Grade 3 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. \u2022 For recurring Grade 3 permanently discontinue. Grade 4 \u2022 Permanently discontinue. Cardiovascular events[see Warnings and Precautions ( 5.2 )] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at reduced dose. Clinically manifested congestive heart failure(CHF) \u2022 Permanently discontinue. Hypertension [see Warnings and Precautions ( 5.4) ] Grade 3 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. Grade 4 \u2022 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions (5.5)] Grade 3 or4 \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Either resume at a reduced dose or discontinue depending on the severity andpersistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions (5. 7 )] Any Grade \u2022 Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions ( 5.8 )] 3 or more gramsproteinuria in 24 hours in theabsence of nephrotic syndrome \u2022 Withhold until resolution to Grade 0 to 1 or baseline. \u2022 Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per24 hoursdespite dose reductions \u2022 Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [seeWarnings and Precautions( 5.9) ] Any Grade \u2022 Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] Any Grade \u2022 Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] Any Grade \u2022 The safety of resumption of sunitinib malate afterosteonecrosis has not been established. \u2022 Either resume at a reduced dose or discontinue depending on the severity andpersistence of theadverse reaction. Impaired wound healing [see Warnings and Precautions ( 5.14 )] Any Grade \u2022 The safety of resumption of sunitinib malate afterresolution of wound healing has not been established. \u2022 Either resume at a reduced dose or discontinue depending on the severity andpersistence of theadverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate to a minimum dosage as follows [ see Drug Interactions ( 7.1 ) ]: GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate is increased, monitor patients carefully for adverse reactions [ see Drug Interactions ( 7.1 ) ]. 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "dosage_and_administration_table": [
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td rowspan=\"2\"><content styleCode=\"bold\">Indications</content></td><td rowspan=\"2\"><content styleCode=\"bold\">GIST</content></td><td colspan=\"2\"><content styleCode=\"bold\">RCC</content></td><td rowspan=\"2\"><content styleCode=\"bold\">pNET</content></td></tr><tr><td><content styleCode=\"bold\">Advanced RCC</content></td><td><content styleCode=\"bold\">Adjuvant RCC</content></td></tr><tr><td>First dose reduction</td><td>37.5 mg once daily</td><td>37.5 mg once daily</td><td>37.5 mg once daily</td><td>25 mg once daily</td></tr><tr><td>Second dose reduction</td><td>25 mg once daily</td><td>25 mg once daily</td><td>NA</td><td>NA</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">Adverse Reaction</content></td><td><content styleCode=\"bold\">Severity</content></td><td><content styleCode=\"bold\">Dosage Modifications for Sunitinib Malate</content></td></tr><tr><td rowspan=\"2\">Hepatotoxicity [see Warnings and Precautions <linkHtml href=\"#_bb38cd71-b7ca-5e84-4b5a-3b87d9be0e8d\">(5.1</linkHtml>)]</td><td>Grade 3</td><td>&#x2022; Withhold until resolution to Grade 0 to 1 or baseline. &#x2022; Resume at a reduced dose. &#x2022; For recurring Grade 3 permanently discontinue.</td></tr><tr><td>Grade 4</td><td>&#x2022; Permanently discontinue.</td></tr><tr><td rowspan=\"2\">Cardiovascular events[see Warnings and Precautions (<linkHtml href=\"#_490e56c0-884d-9b03-b05f-3f8d509d84fc\">5.2</linkHtml>)]</td><td>Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)</td><td>&#x2022; Withhold until resolution to Grade 0 to 1 or baseline. &#x2022; Resume at reduced dose.</td></tr><tr><td>Clinically manifested congestive heart failure(CHF)</td><td>&#x2022; Permanently discontinue.</td></tr><tr><td rowspan=\"2\">Hypertension [see Warnings and Precautions (<linkHtml href=\"#_8f57fa2f-dd06-ec83-46a1-0639463d2017\">5.4)</linkHtml>]</td><td>Grade 3</td><td>&#x2022; Withhold until resolution to Grade 0 to 1 or baseline. &#x2022; Resume at a reduced dose.</td></tr><tr><td>Grade 4</td><td>&#x2022; Permanently discontinue.</td></tr><tr><td>Hemorrhagic events [see Warnings and Precautions (5.5)]</td><td>Grade 3 or4</td><td>&#x2022; Withhold until resolution to Grade 0 to 1 or baseline. &#x2022; Either resume at a reduced dose or discontinue depending on the severity andpersistence of adverse reaction.</td></tr><tr><td>Thrombotic microangiopathy [see Warnings and Precautions (5.<linkHtml href=\"#_9817f06e-ac88-dfd9-1c9a-823429be8bcd\">7</linkHtml>)]</td><td>Any Grade</td><td>&#x2022; Permanently discontinue.</td></tr><tr><td rowspan=\"2\">Proteinuria or Nephrotic syndrome [see Warnings and Precautions (<linkHtml href=\"#_931ecf6d-fbaf-188d-21bf-85e6ea36fa08\">5.8</linkHtml>)]</td><td>3 or more gramsproteinuria in 24 hours in theabsence of nephrotic syndrome</td><td>&#x2022; Withhold until resolution to Grade 0 to 1 or baseline. &#x2022; Resume at a reduced dose.</td></tr><tr><td>Nephrotic syndrome or recurrent proteinuria of 3 or more grams per24 hoursdespite dose reductions</td><td><content styleCode=\"bold\"/>&#x2022; Permanently discontinue.</td></tr><tr><td>Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [seeWarnings and Precautions(<linkHtml href=\"#_dda7540c-85a4-6eb0-8036-f5e553344cef\">5.9)</linkHtml>]</td><td>Any Grade</td><td>&#x2022; Permanently discontinue.</td></tr><tr><td>Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (<linkHtml href=\"#_15420d11-ac50-ef25-0420-499657d9f04e\">5.10</linkHtml>)]</td><td>Any Grade</td><td>&#x2022; Permanently discontinue.</td></tr><tr><td>Osteonecrosis of the jaw [see Warnings and Precautions (<linkHtml href=\"#_8885d963-ceac-b352-928f-7fb7ee80961d\">5.13</linkHtml>)]</td><td>Any Grade</td><td>&#x2022; The safety of resumption of sunitinib malate afterosteonecrosis has not been established. &#x2022; Either resume at a reduced dose or discontinue depending on the severity andpersistence of theadverse reaction.</td></tr><tr><td>Impaired wound healing [see Warnings and Precautions (<linkHtml href=\"#_b96e55b3-fa0d-6309-b817-1e86b53aed3f\">5.14</linkHtml>)]</td><td>Any Grade</td><td>&#x2022; The safety of resumption of sunitinib malate afterresolution of wound healing has not been established. &#x2022; Either resume at a reduced dose or discontinue depending on the severity andpersistence of theadverse reaction. </td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Capsules, hard gelatin: 12.5 mg sunitinib: warm grey colored cap and warm grey colored body, printed with white imprinting ink \u201cSC\u201d on the cap and \u201c12.5 mg\u201d on the body. 25 mg sunitinib: black colored cap and black colored body, printed with white Imprinting ink \u201cSC\u201d on the cap and \u201c25 mg\u201d on the body. 37.5 mg sunitinib: black colored cap and grey colored body, printed with white imprinting ink \u201cSC\u201d on the cap and \u201c37.5 mg\u201d on the body. 50 mg sunitinib: grey colored cap and grey colored body, printed with white imprinting ink \u201cSC\u201d on the cap and \u201c50 mg\u201d on the body. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline and resume sunitinib malate at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. (2.4 , 5.1 ) Cardiovascular Events: Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) QT Interval Prolongation and Torsade de Pointes: Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) Hypertension: Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt. sunitinib malate for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients who develop Grade 4 hypertension. ( 5.4 ) Hemorrhagic Events: Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ). Tumor Lysis Syndrome (TLS): TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) Thrombotic microangiopathy (TMA): TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate for TMA. ( 5.7 ) Proteinuria: Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) Dermatologic Toxicities: Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate for these events. ( 5.9 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate until resolution. ( 5.10 ) Thyroid Dysfunction: Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) Hypoglycemia: Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) Osteonecrosis of the Jaw (ONJ): Withhold sunitinib malate for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 )Impaired Wound Healing: Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. ( 5.14 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u2264 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported.In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u226550% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate capsules in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate.Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration ( 2.5 ), Drug Interactions ( 7.2 )]. 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3 to 5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib malate. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib malate. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome (TLS) Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate as monotherapy and administered in combination with bevacizumab. Sunitinib malate is not approved for use in combination with bevacizumab.Discontinue sunitinib malate capsules in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes.Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate capsules for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate capsules for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate capsules in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate.Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n=83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of theJaw (ONJ) Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate and periodically during sunitinib malate therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate for development of ONJ until complete resolution. The safety of resumption of sunitinib malate after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate [see Adverse Reactions ( 6.2 )]. Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for 4 weeks following the final dose [ see Use in Specific Populations ( 8.1 , 8.3) ]."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Cardiovascular Events [see Warnings and Precautions ( 5.2 )] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions ( 5.3 )] Hypertension [ see Warnings and Precautions ( 5.4 ) ] Hemorrhagic Events [ see Warnings and Precautions ( 5.5 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.6 ) ] Thrombotic Microangiopathy [ see Warnings and Precautions ( 5.7 ) ] Proteinuria [ see Warnings and Precautions ( 5.8 )] Dermatologic Toxicities [ see Warnings and Precautions ( 5.9) ] Reversible Posterior Leukoencephalopathy Syndrome [ see Warnings and Precautions ( 5.10) ] Thyroid Dysfunction [ see Warnings and Precautions (5.11) ] Hypoglycemia [ see Warnings and Precautions ( 5.12 ) ] Osteonecrosis of the Jaw [ see Warnings and Precautions ( 5.13 )] Impaired Wound Healing [ see Warnings and Precautions ( 5.14 ) ] The most common adverse reactions (\u226525%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy\u2019s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u226525%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate (mean: 3; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u226510% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reaction GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades % Grade 3 to 4 % All Grades % Grade 3 to 4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea Mucositis/stomatitis Constipation 40 29 20 4 1 0 27 18 14 0 2 2 Metabolism/Nutrition Anorexia a Asthenia 33 22 1 5 29 11 5 3 Dermatology Skin discoloration Rash Hand-foot syndrome 30 14 14 0 1 4 23 9 10 0 0 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u226510% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades* % Grade 3 to 4*, a % All Grades* % Grade 3 to 4 *,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased Lymphocytes decreased Platelets decreased Hemoglobin decreased 53 38 38 26 10 0 5 3 4 16 4 22 0 0 0 2 Gastrointestinal AST/ALT increased Lipase increased Alkaline phosphatase increased Amylase increased Total bilirubin increased Indirect bilirubin increased 39 25 24 17 16 10 2 10 4 5 10 23 17 21 12 8 4 1 7 4 3 0 0 Renal/Metabolic Creatinine increased Potassium decreased Sodium increased 12 12 10 1 1 0 7 4 4 0 0 1 Cardiac Decreased LVEF 11 1 3 0 *Common Terminology Criteria for Adverse Events (CTCAE), version 3 Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate [ see Clinical Studies (14.1 )]. For 241 patients randomized to the sunitinib malate arm, including 139 who received sunitinib malate in both the double-blind and open-label phases, the median duration of sunitinib malate treatment was 6 cycles (mean: 8.5; range: 1\u201344). For the 255 patients who ultimately received open-label sunitinib malate treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1\u201337) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades % Grade 3 to 4 a % All Grades % Grade 3 to 4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 <1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 <1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain c 30 5 12 1 Constipation 23 1 14 <1 Dry mouth 13 0 7 <1 Oral pain 14 <1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 <1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 <1 Weight decreased 16 <1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 <1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e 47 <1 15 0 Headache 23 1 19 0 Dizziness 11 <1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension 34 13 4 <1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 <1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 <1 0 0 Dry skin 23 <1 7 0 Hair color changes 20 0 <1 0 Alopecia 14 0 9 0 Erythema 12 <1 1 0 Pruritus 12 <1 7 <1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 <1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 <1 2 0 Upper respiratory tract infection 11 <1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia Depression g 15 11 <1 0 10 14 0 1 *Common Terminology Criteria for Adverse Events (CTCAE), version 3. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u226510% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades* % Grade 3 to 4 *,a % All Grades* % Grade 3 to 4 * ,b % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increases 70 <1 51 <1 Creatine kinase increases 49 2 11 1 Uric acid increases 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 <1 Potassium increased 16 3 17 4 Calcium increased 13 <1 10 1 Potassium decreased 13 1 2 <1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 *Common Terminology Criteria for Adverse Events (CTCAE), version 3. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). Long-Term Safety in RCC The long-term safety of sunitinib malate in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points.Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib Malate (N=306) Placebo (N=304) All Grades% Grade 3\u20134% All Grades% Grade 3\u20134% Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis \u2020 61 6 15 0 Diarrhea 57 4 22 <1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain \u2021 25 2 9 <1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema \u00a7 18 <1 <1 0 Pyrexia 12 <1 6 0 Dermatology Hand-foot syndrome 50 16 10 <1 Rash \u00b6 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension # 39 8 14 1 Edema/Peripheral edema 10 <1 7 0 Neurology Altered taste \u00de 38 <1 6 0 Headache 19 <1 12 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage/Bleeding Bleeding events, all sites S 24 <1 5 <1 Metabolism/Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Pain in extremity 15 <1 7 0 Arthralgia 11 <1 10 0 *Common Terminology Criteria for Adverse Events (CTCAE), version 3. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. Grade 4 adverse reactions in patients on sunitinib malate included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%). Grade 3 to 4 laboratory abnormalities that occurred in \u22652% of patients receiving sunitinib malate include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13 to 532 days) for patients on sunitinib malate and 113 days (range: 1 to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib Malate (N=83) Placebo (N=82) All Grades% Grade 3\u20134 \u2020 % All Grades% Grade 3\u20134% * Common Terminology Criteria for Adverse Events (CTCAE), version 3. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes \u2021 48 6 18 0 Nausea 45 1 29 1 Abdominal pain \u00a7 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 Table 9. Laboratory Abnormalities Reported in \u2265 10% of Patients With pNET Who Received Sunitinib Malate in Study 6 Laboratory Abnormality ET Sunitinib Malate Placebo All Grades* % Grade 3 to 4 *,a % All Grades* % Grade 3 to 4 *,b % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphataseincreased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3 Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic EventsIn pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3 to 4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on sunitinib malate. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema. Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib malate include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing.*including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table frame=\"box\" rules=\"all\"><tbody><tr align=\"center\"><td rowspan=\"3\"><content styleCode=\"bold\">Adverse Reaction</content></td><td colspan=\"4\" valign=\"middle\"><content styleCode=\"bold\">GIST</content></td></tr><tr><td colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate </content> <content styleCode=\"bold\">(N=202)</content></td><td colspan=\"2\"><content styleCode=\"bold\">Placebo </content> <content styleCode=\"bold\">(N=102)</content></td></tr><tr><td><content styleCode=\"bold\">All Grades %</content></td><td><content styleCode=\"bold\">Grade 3 to 4 %</content></td><td><content styleCode=\"bold\">All Grades %</content></td><td><content styleCode=\"bold\">Grade 3 to 4 %</content></td></tr><tr><td><content styleCode=\"bold\">Any Adverse Reaction</content></td><td>94</td><td>56</td><td>97</td><td>51</td></tr><tr><td><content styleCode=\"bold\">Gastrointestinal </content> Diarrhea  Mucositis/stomatitis  Constipation</td><td> 40  29  20</td><td> 4  1  0</td><td> 27  18  14</td><td> 0  2  2</td></tr><tr><td><content styleCode=\"bold\">Metabolism/Nutrition </content> Anorexia<sup>a</sup> Asthenia</td><td> 33  22</td><td> 1  5</td><td> 29  11</td><td> 5  3</td></tr><tr><td><content styleCode=\"bold\">Dermatology</content> Skin discoloration  Rash  Hand-foot syndrome</td><td> 30  14  14</td><td> 0  1  4</td><td> 23  9  10</td><td> 0  0  3</td></tr><tr><td><content styleCode=\"bold\">Neurology</content> Altered taste</td><td> 21</td><td> 0</td><td> 12</td><td> 0</td></tr><tr><td><content styleCode=\"bold\">Cardiac</content> Hypertension</td><td> 15</td><td> 4</td><td> 11</td><td> 0</td></tr><tr><td><content styleCode=\"bold\">Musculoskeletal</content> Myalgia/limb pain</td><td> 14</td><td> 1</td><td> 9</td><td> 1</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td rowspan=\"3\"><content styleCode=\"bold\">Laboratory Abnormality</content></td><td colspan=\"4\"><content styleCode=\"bold\">GIST</content></td></tr><tr><td colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate (N=202)</content></td><td colspan=\"2\"><content styleCode=\"bold\">Placebo (N=102)</content></td></tr><tr><td><content styleCode=\"bold\">All Grades*</content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4*,<sup>a</sup></content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">All Grades*</content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>*,b</sup></content><content styleCode=\"bold\">%</content></td></tr><tr><td><content styleCode=\"bold\">Any Laboratory Abnormality</content></td><td/><td>34</td><td/><td>22</td></tr><tr><td><content styleCode=\"bold\">Hematology</content> <content styleCode=\"bold\"/>Neutrophils decreased  Lymphocytes decreased  Platelets decreased  Hemoglobin decreased</td><td> 53  38  38  26</td><td> 10  0  5  3</td><td> 4  16  4  22</td><td> 0  0  0  2</td></tr><tr><td><content styleCode=\"bold\">Gastrointestinal</content> AST/ALT increased  Lipase increased  Alkaline phosphatase increased  Amylase increased  Total bilirubin increased  Indirect bilirubin increased</td><td> 39 25 24 17 16 10</td><td> 2  10  4  5  10</td><td> 23  17  21  12  8  4</td><td> 1  7  4  3  0  0</td></tr><tr><td><content styleCode=\"bold\">Renal/Metabolic </content>Creatinine increased  Potassium decreased  Sodium increased</td><td> 12  12  10</td><td> 1  1  0</td><td> 7  4  4</td><td> 0  0  1</td></tr><tr><td><content styleCode=\"bold\">Cardiac</content> Decreased LVEF</td><td> 11</td><td> 1</td><td> 3</td><td> 0</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr align=\"center\"><td rowspan=\"3\"><content styleCode=\"bold\">Adverse Reaction</content></td><td colspan=\"4\"><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></td></tr><tr><td colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate</content> <content styleCode=\"bold\">(N=375)</content></td><td colspan=\"2\"><content styleCode=\"bold\">Interferon Alfa</content> <content styleCode=\"bold\">(N=360)</content></td></tr><tr><td><content styleCode=\"bold\">All Grades</content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>a</sup></content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">All Grades</content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>b</sup></content><content styleCode=\"bold\">%</content></td></tr><tr><td><content styleCode=\"bold\">Any Adverse Reaction</content></td><td>99</td><td>77</td><td>99</td><td>55</td></tr><tr><td><content styleCode=\"bold\">Gastrointestinal</content></td><td/><td/><td/><td/></tr><tr><td>Diarrhea</td><td>66</td><td>10</td><td>21</td><td>&lt;1</td></tr><tr><td>Nausea</td><td>58</td><td>6</td><td>41</td><td>2</td></tr><tr><td>Mucositis/stomatitis</td><td>47</td><td>3</td><td>5</td><td>&lt;1</td></tr><tr><td>Vomiting</td><td>39</td><td>5</td><td>17</td><td>1</td></tr><tr><td>Dyspepsia</td><td>34</td><td>2</td><td>4</td><td>0</td></tr><tr><td>Abdominal pain<sup>c</sup></td><td>30</td><td>5</td><td>12</td><td>1</td></tr><tr><td>Constipation</td><td>23</td><td>1</td><td>14</td><td>&lt;1</td></tr><tr><td>Dry mouth</td><td>13</td><td>0</td><td>7</td><td>&lt;1</td></tr><tr><td>Oral pain</td><td>14</td><td>&lt;1</td><td>1</td><td>0</td></tr><tr><td>Flatulence</td><td>14</td><td>0</td><td>2</td><td>0</td></tr><tr><td>GERD/reflux esophagitis</td><td>12</td><td>&lt;1</td><td>1</td><td>0</td></tr><tr><td>Glossodynia</td><td>11</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Hemorrhoids</td><td>10</td><td>0</td><td>2</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Constitutional</content></td><td/><td/><td/><td/></tr><tr><td>Fatigue</td><td>62</td><td>15</td><td>56</td><td>15</td></tr><tr><td>Asthenia</td><td>26</td><td>11</td><td>22</td><td>6</td></tr><tr><td>Fever</td><td>22</td><td>1</td><td>37</td><td>&lt;1</td></tr><tr><td>Weight decreased</td><td>16</td><td>&lt;1</td><td>17</td><td>1</td></tr><tr><td>Chills</td><td>14</td><td>1</td><td>31</td><td>0</td></tr><tr><td>Chest Pain</td><td>13</td><td>2</td><td>7</td><td>1</td></tr><tr><td>Influenza like illness</td><td>5</td><td>0</td><td>15</td><td>&lt;1</td></tr><tr><td><content styleCode=\"bold\">Metabolism/Nutrition</content> Anorexia<sup>d</sup></td><td> 48</td><td> 3</td><td> 42</td><td> 2</td></tr><tr><td><content styleCode=\"bold\">Neurology</content></td><td/><td/><td/><td/></tr><tr><td>Altered taste<sup>e</sup></td><td>47</td><td>&lt;1</td><td>15</td><td>0</td></tr><tr><td>Headache</td><td>23</td><td>1</td><td>19</td><td>0</td></tr><tr><td>Dizziness</td><td>11</td><td>&lt;1</td><td>14</td><td>1</td></tr><tr><td><content styleCode=\"bold\">Hemorrhage/Bleeding</content> Bleeding, all sites</td><td> 37</td><td> 4<sup>f</sup></td><td> 10</td><td> 1</td></tr><tr><td><content styleCode=\"bold\">Cardiac</content></td><td/><td/><td/><td/></tr><tr><td>Hypertension</td><td>34</td><td>13</td><td>4</td><td>&lt;1</td></tr><tr><td>Edema peripheral</td><td>24</td><td>2</td><td>5</td><td>1</td></tr><tr><td>Ejection fraction decreased</td><td>16</td><td>3</td><td>5</td><td>2</td></tr><tr><td><content styleCode=\"bold\">Dermatology</content></td><td/><td/><td/><td/></tr><tr><td>Rash</td><td>29</td><td>2</td><td>11</td><td>&lt;1</td></tr><tr><td>Hand-foot syndrome</td><td>29</td><td>8</td><td>1</td><td>0</td></tr><tr><td>Skin discoloration/yellow skin</td><td>25</td><td>&lt;1</td><td>0</td><td>0</td></tr><tr><td>Dry skin</td><td>23</td><td>&lt;1</td><td>7</td><td>0</td></tr><tr><td>Hair color changes</td><td>20</td><td>0</td><td>&lt;1</td><td>0</td></tr><tr><td>Alopecia</td><td>14</td><td>0</td><td>9</td><td>0</td></tr><tr><td>Erythema</td><td>12</td><td>&lt;1</td><td>1</td><td>0</td></tr><tr><td>Pruritus</td><td>12</td><td>&lt;1</td><td>7</td><td>&lt;1</td></tr><tr><td><content styleCode=\"bold\">Musculoskeletal</content></td><td/><td/><td/><td/></tr><tr><td>Pain in extremity/limb discomfort</td><td>40</td><td>5</td><td>30</td><td>2</td></tr><tr><td>Arthralgia</td><td>30</td><td>3</td><td>19</td><td>1</td></tr><tr><td>Back pain</td><td>28</td><td>5</td><td>14</td><td>2</td></tr><tr><td><content styleCode=\"bold\">Respiratory</content></td><td/><td/><td/><td/></tr><tr><td>Cough</td><td>27</td><td>1</td><td>14</td><td>&lt;1</td></tr><tr><td>Dyspnea</td><td>26</td><td>6</td><td>20</td><td>4</td></tr><tr><td>Nasopharyngitis</td><td>14</td><td>0</td><td>2</td><td>0</td></tr><tr><td>Oropharyngeal pain</td><td>14</td><td>&lt;1</td><td>2</td><td>0</td></tr><tr><td>Upper respiratory tract infection</td><td>11</td><td>&lt;1</td><td>2</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Endocrine</content> Hypothyroidism</td><td> 16</td><td> 2</td><td> 1</td><td> 0</td></tr><tr><td><content styleCode=\"bold\">Psychiatric </content> Insomnia  Depression<sup>g</sup></td><td> 15  11</td><td> &lt;1  0</td><td> 10  14</td><td> 0  1</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody align=\"left\"><tr><td rowspan=\"3\"><content styleCode=\"bold\">Laboratory Abnormality</content></td><td align=\"center\" colspan=\"4\" valign=\"middle\"><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></td></tr><tr><td colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate (N=375)</content></td><td colspan=\"2\"><content styleCode=\"bold\">Interferon Alfa (N=360)</content></td></tr><tr><td><content styleCode=\"bold\">All Grades*</content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>*,a</sup></content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">All Grades*</content><content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>*</sup><sup>,b</sup></content><content styleCode=\"bold\">%</content></td></tr><tr align=\"left\"><td><content styleCode=\"bold\">Hematology</content></td><td/><td/><td/><td/></tr><tr align=\"left\" valign=\"middle\"><td>Hemoglobin decreased</td><td>79</td><td>8</td><td>69</td><td>5</td></tr><tr align=\"left\"><td>Neutrophils decreased</td><td>77</td><td>17</td><td>49</td><td>9</td></tr><tr align=\"left\"><td>Platelets decreased</td><td>68</td><td>9</td><td>24</td><td>1</td></tr><tr align=\"left\"><td>Lymphocytes decreased</td><td>68</td><td>18</td><td>68</td><td>26</td></tr><tr><td><content styleCode=\"bold\">Renal/Metabolic</content></td><td/><td/><td/><td/></tr><tr><td>Creatinine increases</td><td>70</td><td>&lt;1</td><td>51</td><td>&lt;1</td></tr><tr><td>Creatine kinase increases</td><td>49</td><td>2</td><td>11</td><td>1</td></tr><tr><td>Uric acid increases</td><td>46</td><td>14</td><td>33</td><td>8</td></tr><tr><td>Calcium decreased</td><td>42</td><td>1</td><td>40</td><td>1</td></tr><tr><td>Phosphorus decreased</td><td>31</td><td>6</td><td>24</td><td>6</td></tr><tr><td>Albumin decreased</td><td>28</td><td>1</td><td>20</td><td>0</td></tr><tr><td>Glucose increased</td><td>23</td><td>6</td><td>15</td><td>6</td></tr><tr><td>Sodium decreased</td><td>20</td><td>8</td><td>15</td><td>4</td></tr><tr><td>Glucose decreased</td><td>17</td><td>0</td><td>12</td><td>&lt;1</td></tr><tr><td>Potassium increased</td><td>16</td><td>3</td><td>17</td><td>4</td></tr><tr><td>Calcium increased</td><td>13</td><td>&lt;1</td><td>10</td><td>1</td></tr><tr><td>Potassium decreased</td><td>13</td><td>1</td><td>2</td><td>&lt;1</td></tr><tr><td>Sodium increased</td><td>13</td><td>0</td><td>10</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Gastrointestinal</content></td><td/><td/><td/><td/></tr><tr><td>AST increased </td><td>56</td><td>2</td><td>38</td><td>2</td></tr><tr><td>Lipase increased </td><td>56</td><td>18</td><td>46</td><td>8</td></tr><tr><td>ALT increased </td><td>51</td><td>3</td><td>40</td><td>2</td></tr><tr><td>Alkaline phosphatase increased </td><td>46</td><td>2</td><td>37</td><td>2</td></tr><tr><td>Amylase increased </td><td>35</td><td>6</td><td>32</td><td>3</td></tr><tr><td>Total bilirubin increased </td><td>20</td><td>1</td><td>2</td><td>0</td></tr><tr><td>Indirect bilirubin increased </td><td>13</td><td>1</td><td>1</td><td>0</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><thead><tr><th rowspan=\"3\">Adverse Reaction</th><th colspan=\"4\">Adjuvant Treatment of RCC</th></tr><tr><th colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate</content> (N=306)</th><th colspan=\"2\">Placebo (N=304)</th></tr><tr><th>All Grades% </th><th>Grade 3&#x2013;4%</th><th> All Grades%</th><th> Grade 3&#x2013;4%</th></tr></thead><tfoot><tr><td colspan=\"5\"/></tr></tfoot><tbody><tr><td><content styleCode=\"bold\">Any Adverse Reaction</content></td><td>99</td><td>60</td><td>88</td><td>15</td></tr><tr><td>Gastrointestinal</td><td/><td/><td/><td/></tr><tr><td> Mucositis/Stomatitis<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#x2020;</linkHtml></td><td>61</td><td>6</td><td>15</td><td>0</td></tr><tr><td> Diarrhea</td><td>57</td><td>4</td><td>22</td><td>&lt;1</td></tr><tr><td> Nausea</td><td>34</td><td>2</td><td>15</td><td>0</td></tr><tr><td> Dyspepsia</td><td>27</td><td>1</td><td>7</td><td>0</td></tr><tr><td> Abdominal pain<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#x2021;</linkHtml></td><td>25</td><td>2</td><td>9</td><td>&lt;1</td></tr><tr><td> Vomiting</td><td>19</td><td>2</td><td>7</td><td>0</td></tr><tr><td> Constipation</td><td>12</td><td>0</td><td>11</td><td>0</td></tr><tr><td>Constitutional</td><td/><td/><td/><td/></tr><tr><td> Fatigue/Asthenia</td><td>57</td><td>8</td><td>34</td><td>2</td></tr><tr><td> Localized edema<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#xA7;</linkHtml></td><td>18</td><td>&lt;1</td><td>&lt;1</td><td>0</td></tr><tr><td> Pyrexia</td><td>12</td><td>&lt;1</td><td>6</td><td>0</td></tr><tr><td>Dermatology</td><td/><td/><td/><td/></tr><tr><td> Hand-foot syndrome</td><td>50</td><td>16</td><td>10</td><td>&lt;1</td></tr><tr><td> Rash<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#xB6;</linkHtml></td><td>24</td><td>2</td><td>12</td><td>0</td></tr><tr><td> Hair color changes</td><td>22</td><td>0</td><td>2</td><td>0</td></tr><tr><td> Skin discoloration/Yellow skin</td><td>18</td><td>0</td><td>1</td><td>0</td></tr><tr><td> Dry skin</td><td>14</td><td>0</td><td>6</td><td>0</td></tr><tr><td>Cardiac</td><td/><td/><td/><td/></tr><tr><td> Hypertension<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">#</linkHtml></td><td>39</td><td>8</td><td>14</td><td>1</td></tr><tr><td> Edema/Peripheral edema</td><td>10</td><td>&lt;1</td><td>7</td><td>0</td></tr><tr><td>Neurology</td><td/><td/><td/><td/></tr><tr><td> Altered taste<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#xDE;</linkHtml></td><td>38</td><td>&lt;1</td><td>6</td><td>0</td></tr><tr><td> Headache</td><td>19</td><td>&lt;1</td><td>12</td><td>0</td></tr><tr><td>Endocrine</td><td/><td/><td/><td/></tr><tr><td> Hypothyroidism/TSH increased</td><td>24</td><td>&lt;1</td><td>4</td><td>0</td></tr><tr><td>Hemorrhage/Bleeding</td><td/><td/><td/><td/></tr><tr><td> Bleeding events, all sites<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">S</linkHtml></td><td>24</td><td>&lt;1</td><td>5</td><td>&lt;1</td></tr><tr><td>Metabolism/Nutrition</td><td/><td/><td/><td/></tr><tr><td> Anorexia/Decreased appetite</td><td>19</td><td>&lt;1</td><td>5</td><td>0</td></tr><tr><td>Musculoskeletal</td><td/><td/><td/><td/></tr><tr><td> Pain in extremity</td><td>15</td><td>&lt;1</td><td>7</td><td>0</td></tr><tr><td> Arthralgia</td><td>11</td><td>&lt;1</td><td>10</td><td>0</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><thead><tr><th rowspan=\"3\">Adverse Reaction</th><th colspan=\"4\">pNET</th></tr><tr><th colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate</content> (N=83)</th><th colspan=\"2\">Placebo (N=82)</th></tr><tr><th>All Grades%</th><th>Grade 3&#x2013;4<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#x2020;</linkHtml>%</th><th>All Grades%</th><th>Grade 3&#x2013;4%</th></tr></thead><tfoot><tr><td colspan=\"5\">* Common Terminology Criteria for Adverse Events (CTCAE), version 3. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors.<sup/> <sup>a</sup> Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). <sup>b</sup> Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. <sup>c</sup> Includes abdominal discomfort, abdominal pain, and abdominal pain upper. <sup>d</sup> Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. <content styleCode=\"bold\"> </content></td></tr></tfoot><tbody><tr><td>Any Adverse Reaction</td><td>99</td><td>54</td><td>95</td><td>50</td></tr><tr><td>Gastrointestinal</td><td/><td/><td/><td/></tr><tr><td> Diarrhea</td><td>59</td><td>5</td><td>39</td><td>2</td></tr><tr><td> Stomatitis/oral syndromes<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#x2021;</linkHtml></td><td>48</td><td>6</td><td>18</td><td>0</td></tr><tr><td> Nausea</td><td>45</td><td>1</td><td>29</td><td>1</td></tr><tr><td> Abdominal pain<linkHtml href=\"#_f35ff056-2ce8-29b3-80f7-2ce0d540e0d3\">&#xA7;</linkHtml></td><td>39</td><td>5</td><td>34</td><td>10</td></tr><tr><td> Vomiting</td><td>34</td><td>0</td><td>31</td><td>2</td></tr><tr><td> Dyspepsia</td><td>15</td><td>0</td><td>6</td><td>0</td></tr><tr><td>Constitutional</td><td/><td/><td/><td/></tr><tr><td> Asthenia</td><td>34</td><td>5</td><td>27</td><td>4</td></tr><tr><td> Fatigue</td><td>33</td><td>5</td><td>27</td><td>9</td></tr><tr><td> Weight decreased</td><td>16</td><td>1</td><td>11</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Dermatology</content></td><td/><td/><td/><td/></tr><tr><td> Hair color changes</td><td>29</td><td>1</td><td>1</td><td>0</td></tr><tr><td> Hand-foot syndrome</td><td>23</td><td>6</td><td>2</td><td>0</td></tr><tr><td> Rash</td><td>18</td><td>0</td><td>5</td><td>0</td></tr><tr><td> Dry skin</td><td>15</td><td>0</td><td>11</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Cardiac</content></td><td/><td/><td/><td/></tr><tr><td> Hypertension</td><td>27</td><td>10</td><td>5</td><td>1</td></tr><tr><td><content styleCode=\"bold\">Hemorrhage/Bleeding</content></td><td/><td/><td/><td/></tr><tr><td> Bleeding events </td><td>22</td><td>0</td><td>10</td><td>4</td></tr><tr><td> Epistaxis</td><td>21</td><td>1</td><td>5</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Neurology</content></td><td/><td/><td/><td/></tr><tr><td> Dysgeusia</td><td>21</td><td>0</td><td>5</td><td>0</td></tr><tr><td> Headache</td><td>18</td><td>0</td><td>13</td><td>1</td></tr><tr><td><content styleCode=\"bold\">Psychiatric</content></td><td/><td/><td/><td/></tr><tr><td> Insomnia</td><td>18</td><td>0</td><td>12</td><td>0</td></tr><tr><td><content styleCode=\"bold\">Musculoskeletal</content></td><td/><td/><td/><td/></tr><tr><td> Arthralgia</td><td>15</td><td>0</td><td>6</td><td>0</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td rowspan=\"3\">Laboratory Abnormality</td><td align=\"center\" colspan=\"4\"><content styleCode=\"bold\">ET</content></td></tr><tr><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Sunitinib Malate</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Placebo</content></td></tr><tr><td><content styleCode=\"bold\">All Grades*</content> <content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>*,a</sup></content> <content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">All Grades*</content> <content styleCode=\"bold\">%</content></td><td><content styleCode=\"bold\">Grade 3 to 4<sup>*,b</sup></content> <content styleCode=\"bold\">%</content></td></tr><tr><td><content styleCode=\"bold\">Gastrointestinal</content></td><td/><td/><td/><td/></tr><tr><td>AST increased</td><td>72</td><td>5</td><td>70</td><td>3</td></tr><tr><td>Alkaline phosphataseincreased</td><td>63</td><td>10</td><td>70</td><td>11</td></tr><tr><td>ALT increased</td><td>61</td><td>4</td><td>55</td><td>3</td></tr><tr><td>Total bilirubin increased</td><td>37</td><td>1</td><td>28</td><td>4</td></tr><tr><td>Amylase increased</td><td>20</td><td>4</td><td>10</td><td>1</td></tr><tr><td>Lipase increased</td><td>17</td><td>5</td><td>11</td><td>4</td></tr><tr><td><content styleCode=\"bold\">Hematology</content></td><td/><td/><td/><td/></tr><tr><td>Neutrophils decreased</td><td>71</td><td>16</td><td>16</td><td>0</td></tr><tr><td>Hemoglobin decreased</td><td>65</td><td>0</td><td>55</td><td>1</td></tr><tr><td>Platelets decreased</td><td>60</td><td>5</td><td>15</td><td>0</td></tr><tr><td> Lymphocytes decreased</td><td>56</td><td>7</td><td>35</td><td>4</td></tr><tr><td><content styleCode=\"bold\">Renal/Metabolic</content></td><td/><td/><td/><td/></tr><tr><td>Glucose increased</td><td>71</td><td>12</td><td>78</td><td>18</td></tr><tr><td>Albumin decreased</td><td>41</td><td>1</td><td>37</td><td>1</td></tr><tr><td>Phosphorus decreased</td><td>36</td><td>7</td><td>22</td><td>5</td></tr><tr><td>Calcium decreased</td><td>34</td><td>0</td><td>19</td><td>0</td></tr><tr><td>Sodium decreased</td><td>29</td><td>2</td><td>34</td><td>3</td></tr><tr><td>Creatinine increased</td><td>27</td><td>5</td><td>28</td><td>5</td></tr><tr><td>Glucose decreased</td><td>22</td><td>2</td><td>15</td><td>4</td></tr><tr><td>Potassium decreased</td><td>21</td><td>4</td><td>14</td><td>0</td></tr><tr><td>Magnesium decreased</td><td>19</td><td>0</td><td>10</td><td>0</td></tr><tr><td>Potassium increased</td><td>18</td><td>1</td><td>11</td><td>1</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors: Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers: Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 InhibitorsCo-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [ see Clinical Pharmacology ( 12.3 ) ]. Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors [ see Dosage and Administration ( 2.5) ]. Strong CYP3A4 InducersCo-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [ see Clinical Pharmacology ( 12.3 ) ]. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers [ see Dosage and Administration ( 2.5 ) ]. 7.2 Drugs that Prolong QT Interval Sunitinib malate is associated with QTc interval prolongation [ see Warnings and Precautions ( 5.3 ) , Clinical Pharmacology ( 12.2 ) ]. Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk SummaryBased on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal DataIn a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data). Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Use in Specific Populations ( 8.1) ]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception FemalesAdvise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [ see Nonclinical Toxicology ( 13.1 ) ]. 8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5, and 15 mg/kg) or 5 cycles (0.3, 1.5, and 6 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate, were 65 years and older. Clinical studies of sunitinib malate, did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [ see Clinical Pharmacology ( 12.3 ) ]. Sunitinib malate was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [ see Clinical Pharmacology ( 12.3 ) ].No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [ see Clinical Pharmacology ( 12.3 )]."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk SummaryBased on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal DataIn a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day"
    ],
    "labor_and_delivery": [
      "8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data). Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma."
    ],
    "nursing_mothers": [
      "8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [ see Use in Specific Populations ( 8.1) ]. Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception FemalesAdvise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [ see Nonclinical Toxicology ( 13.1 ) ]."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5, and 15 mg/kg) or 5 cycles (0.3, 1.5, and 6 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide(s)-2-hydroxysuccinate The molecular formula is C 22 H 27 FN 4 O 2 \u25cf C 4 H 6 O 5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient at pH 7 is 5.2. Sunitinib malate capsules for oral administration, are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone (K-25). The 12.5 mg capsules shells contains gelatin, iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate and titanium dioxide. The 25 mg, 37.5 mg and 50 mg capsule shells contains gelatin, iron oxide black, sodium lauryl sulfate and titanium dioxide. The white printing ink contains dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, shellac, strong ammonia solution, potassium hydroxide and titanium dioxide."
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)]. 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and Cmax increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (Tmax) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite Cmax and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib: Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite Cmax and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)]."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and Cmax increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (Tmax) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Co-administration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite Cmax and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib: Co-administration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite Cmax and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib malate in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate and patients randomized to sunitinib malate were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate and placebo groups with regard to age (69% versus 72% <65 years for sunitinib malate versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib Malate (N=207) Placebo (N=105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression a [median, weeks (95% CI)] 27.3 (16, 32.1) 6.4 (4.4, 10) <0.0001* 0.33 (0.23, 0.47) Progression-free survival b [median, weeks (95% CI)] 24.1 (11.1, 28.3) 6 (4.4, 9.9) <0.0001 0.33(0.24, 0.47) Objective response rate (PR) [%, (95% CI)] 6.8 (3.7, 11.1) 0 0.006 c * A comparison is considered statistically significant if the p-value is <0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis, the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3%, 20%). 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate and interferon alfa groups with regard to age (59% versus 67% <65 years for sunitinib malate versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \u22641.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate over interferon alfa. The ORR was higher in the sunitinib malate arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib Malate (N=375) Interferon Alfa (N=375) p-value (log-rank test) HR (95% CI) Progression-free survival a [median, weeks (95% CI)] 47.3 (42.6, 50.7) 22 (16.4, 24) <0.000001 b 0.415 (0.320, 0.539) Objective response rate a [%, (95% CI)] 27.5 (23, 32.3) 5.3 (3.3, 8.1) <0.001 c NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is <0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; IFN-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate as well as 121 patients (32%) on the interferon alfa arm who received post- study cancer treatment with sunitinib malate. Cytokine-Refractory The use of single-agent sunitinib malate in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies.The ORR and DR data from Studies 4 and 5 are provided in Table 10. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34% (95% CI: 25%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N=106) Study 5 (N=63) Objective response rate [%, (95% CI)] 34 a (25, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR* (42*) 54 b (34.3, 70.1) *Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib Malate N = 309 Placebo N = 306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/ Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Malate Placebo Sunitinib Malate Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS > 1 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade > 2, ECOG PS > 1 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate and placebo groups. Additionally, 49% of sunitinib malate patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib Malate (N=86) Placebo (N=85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6) 0.000146 a 0.427(0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors."
    ],
    "clinical_studies_table": [
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">Efficacy Parameter</content></td><td align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Sunitinib</content> <content styleCode=\"bold\"> Malate</content> <content styleCode=\"bold\"> (N=207)</content></td><td align=\"center\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N=105)</content></td><td align=\"center\"><content styleCode=\"bold\">p-value</content> <content styleCode=\"bold\"/><content styleCode=\"bold\">(log-rank test)</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">HR</content> <content styleCode=\"bold\"/><content styleCode=\"bold\">(95% CI)</content></td><td/></tr><tr><td>Time-to-tumor progression<sup>a</sup>[median, weeks (95% CI)]</td><td align=\"center\" valign=\"middle\">27.3 (16, 32.1)</td><td align=\"center\">6.4 (4.4, 10)</td><td align=\"center\" colspan=\"2\">&lt;0.0001*</td><td align=\"center\" colspan=\"2\">0.33 (0.23, 0.47)</td></tr><tr><td>Progression-free survival<sup>b</sup> [median, weeks (95% CI)]</td><td align=\"center\">24.1 (11.1, 28.3)</td><td align=\"center\">6 (4.4, 9.9)</td><td align=\"center\" colspan=\"2\">&lt;0.0001</td><td align=\"center\" colspan=\"2\">0.33(0.24, 0.47)</td></tr><tr><td>Objective response rate (PR) [%, (95% CI)]</td><td align=\"center\">6.8 (3.7, 11.1)</td><td align=\"center\">0</td><td align=\"center\" colspan=\"2\">0.006<sup>c</sup></td><td colspan=\"2\"/></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">Efficacy Parameter</content></td><td align=\"center\"><content styleCode=\"bold\">Sunitinib  Malate </content><content styleCode=\"bold\">(N=375)</content></td><td align=\"center\"><content styleCode=\"bold\">Interferon  Alfa </content><content styleCode=\"bold\">(N=375)</content></td><td align=\"center\"><content styleCode=\"bold\">p-value</content> <content styleCode=\"bold\">(log-rank test)</content></td><td align=\"center\"><content styleCode=\"bold\">HR </content><content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td>Progression-free survival<sup>a</sup> [median, weeks (95% CI)]</td><td align=\"center\">47.3 (42.6, 50.7)</td><td align=\"center\">22 (16.4, 24)</td><td align=\"center\">&lt;0.000001<sup>b</sup></td><td align=\"center\">0.415 (0.320, 0.539)</td></tr><tr><td>Objective response rate<sup>a</sup> [%, (95% CI)]</td><td align=\"center\">27.5 (23, 32.3)</td><td align=\"center\">5.3 (3.3, 8.1)</td><td align=\"center\">&lt;0.001<sup>c</sup></td><td align=\"center\">NA</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td align=\"center\"><content styleCode=\"bold\">Efficacy Parameter</content></td><td align=\"center\"><content styleCode=\"bold\">Study 4 </content><content styleCode=\"bold\">(N=106)</content></td><td align=\"center\"><content styleCode=\"bold\">Study 5 </content><content styleCode=\"bold\">(N=63)</content></td></tr><tr><td align=\"center\">Objective response rate  [%, (95% CI)]</td><td align=\"center\">34<sup>a</sup>  (25, 43.8)</td><td align=\"center\">36.5<sup>b</sup> (24.7, 49.6)</td></tr><tr><td align=\"center\">Duration of response [median, weeks (95% CI)]</td><td align=\"center\"> NR* (42*)</td><td align=\"center\">54<sup>b</sup> (34.3, 70.1)</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td/><td align=\"center\"><content styleCode=\"bold\">Sunitinib  Malate </content><content styleCode=\"bold\"> N = 309</content></td><td align=\"center\"><content styleCode=\"bold\">Placebo </content><content styleCode=\"bold\">N = 306</content></td><td><content styleCode=\"bold\">p-value<sup>a</sup></content></td><td align=\"center\"><content styleCode=\"bold\">HR<sup>a</sup></content><content styleCode=\"bold\"> (95% CI)</content></td></tr><tr><td>Median DFS [years (95% CI)]</td><td>6.8 (5.8, NR)</td><td>5.6 (3.8, 6.6)</td><td>0.03</td><td>0.76 (0.59, 0.98)</td></tr><tr><td align=\"center\">DFS Events</td><td>113 (36.6%)</td><td>144 (47.1%)</td><td colspan=\"2\"/></tr><tr><td align=\"center\">5 Year DFS Rate</td><td>59.3%</td><td>51.3%</td><td colspan=\"2\"/></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td/><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Number of Events/ Total  n/N</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Median DFS  [years </content><content styleCode=\"bold\">(95% CI)]</content></td><td><content styleCode=\"bold\">HR</content><content styleCode=\"bold\"><sup>a</sup></content> <content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td/><td align=\"center\">Sunitinib  Malate</td><td>Placebo</td><td align=\"center\">Sunitinib  Malate</td><td>Placebo</td><td/></tr><tr><td>T3 Intermediate<sup>b</sup></td><td align=\"center\">35/115</td><td align=\"center\">46/112</td><td align=\"center\">NR  (5.2, NR)</td><td align=\"center\">6.4 (4.7, NR)</td><td align=\"center\">0.82 (0.53, 1.28)</td></tr><tr><td>T3 High<sup>c</sup></td><td align=\"center\">63/165</td><td align=\"center\">79/166</td><td align=\"center\">6.8 (5, NR)</td><td align=\"center\">5.3 (2.9, NR)</td><td align=\"center\">0.77 (0.55, 1.07)</td></tr><tr><td>T4/Node Positive<sup>d</sup></td><td align=\"center\">15/29</td><td align=\"center\">19/28</td><td align=\"center\">3.5 (1.2, NR)</td><td align=\"center\">1.7 (0.4, 3)</td><td align=\"center\">0.62 (0.31, 1.23)</td></tr></tbody></table>",
      "<table frame=\"box\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">Efficacy Parameter</content></td><td><content styleCode=\"bold\">Sunitinib Malate</content> <content styleCode=\"bold\">(N=86)</content></td><td><content styleCode=\"bold\">Placebo </content> <content styleCode=\"bold\">(N=85)</content></td><td><content styleCode=\"bold\">p-value</content></td><td><content styleCode=\"bold\">HR (95% CI)</content></td></tr><tr><td>Progression-free survival [median,  months (95% CI)]</td><td>10.2 (7.4, 16.9)</td><td>5.4 (3.4, 6)</td><td>0.000146<sup>a</sup></td><td>0.427(0.271, 0.673)</td></tr><tr><td>Objective response rate [%, (95% CI)]</td><td>9.3 (3.2, 15.4)</td><td>0</td><td>0.0066<sup>b</sup></td><td>NA</td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Sunitinib malate 12.5 mg capsules are yellow to orange colored granules filled in hard gelatin capsules with warm grey colored cap and warm grey colored body, imprinted with \u2018SC\u2019 on the cap and \u201812.5\u2019 on body in white ink. Bottles of 28 NDC 43598-045-63 Unit-dose blister packages of 28 NDC 43598-045-28 Sunitinib malate 25 mg capsules are yellow to orange colored granules filled in hard gelatin capsules with black colored cap and black colored body, imprinted with \u2018SC\u2019 on the cap and \u201825\u2019 on body in white ink. Bottles of 28 NDC 43598-046-63 Unit-dose blister packages of 28 NDC 43598-046-28 Sunitinib malate 37.5 mg capsules are yellow to orange colored granules filled in hard gelatin capsules with black colored cap and grey colored body, imprinted with \u2018SC\u2019 on the cap and \u201837.5\u2019 on body in white ink. Bottles of 28 NDC 43598-047-63 Unit-dose blister packages of 28 NDC 43598-047-28 Sunitinib malate 50 mg capsules are yellow to orange colored granules filled in hard gelatin capsules with grey colored cap and grey colored body, imprinted with \u2018SC\u2019 on the cap and \u201850\u2019 on body in white ink. Bottles of 28 NDC 43598-048-63 Unit-dose blister packages of 28 NDC 43598-048-28 Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [ see Warnings and Precautions ( 5.1 ) ]. Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions ( 5.2 )]. QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [ see Warnings and Precautions ( 5.3) ]. Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [ see Warnings and Precautions ( 5.4 ) ]. Hemorrhagic EventsAdvise patients that sunitinib malate can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [ see Warnings and Precautions ( 5.5 ) ]. Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate [ see Warnings and Precautions ( 5.5 ), Adverse Reactions ( 6.1 ) ]. Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [ see Warnings and Precautions ( 5.9 ), Adverse Reactions ( 6.1 ) ]. Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [ see Warnings and Precautions ( 5.10 ) ]. Thyroid Dysfunction Advise patients that sunitinib malate can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [ see Warnings and Precautions ( 5.11) ]. Hypoglycemia Advise patients that sunitinib malate can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions ( 5.12) ]. Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [ see Warnings and Precautions ( 5.13 ) ]. Impaired Wound Healing Advise patients that sunitinib malate impairs wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions ( 5.14 )]. Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions (7)]. Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [ see Warnings and Precautions ( 5.15 ), Use in Specific Populations ( 8.1 )]. Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate [ see Use in Specific Populations ( 8.3 )]. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate [ see Use in Specific Populations ( 8.3) ]. Lactation Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [ see Use in Specific Populations ( 8.2 )]. Infertility Advise patients that sunitinib malate may impair male and female fertility [ see Use in Specific Populations ( 8.3 ) , Nonclinical Toxicology (13.1 ) ]. Missed Dose Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time. Rx Only Distributor: Dr. Reddy\u2019s Laboratories Inc., Princeton, NJ 08540 USA Made in India Issued: 03/2022"
    ],
    "spl_medguide": [
      "SPL MEDGUIDE SECTION MEDICATION GUIDE Sunitinib Malate (soo ni\u2032 ti nib mal eyt ) c apsules What is the most important information I should know about sunitinib malate capsules? sunitinib malate capsules can cause serious side effects including: \u2022Severe liver problems, that can leadto death. Tell your healthcare provider right awayif you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: \u2219itching \u2219yellow eyes or skin \u2219dark urine \u2219pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, orpermanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What is Sunitinib Malate Capsules? Sunitinib malate capsules is a prescription medicine used to treat: \u2022 a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: \u2219 you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or \u2219 you cannot take imatinib mesylate. \u2022 advanced kidney cancer (advanced renal cell carcinoma or RCC). \u2022 adults with kidneycancer that has not spread(localized), and who are at high riskof RCC coming back again after having kidney surgery. \u2022 a type of pancreatic cancercalled pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: \u2022 have any heart problems \u2022have high blood pressure \u2022have thyroid problems \u2022have a history of low blood sugar or diabetes \u2022have kidney function problems (other than cancer) \u2022have liver problems \u2022have any bleeding problem \u2022plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d \u2022 have seizures \u2022have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth \u2022 are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby. Females who are able to become pregnant: \u2022 Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. \u2022 You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. \u2022Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. \u2022are breastfeeding or plan to breastfeed. Do not breastfeed during treatment withsunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jaw bone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take Sunitinib Malate Capsules? \u2219 Take sunitinib malate capsules exactly the way your healthcare provider tells you. \u2022 Take sunitinib malate capsules 1 time each day with or without food.If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. \u2022 If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. \u2022 Do not drink grapefruit juice or eat grapefruit duringyour treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body. \u2022Your healthcare provider may do bloodtests before eachcycle of treatment to check you for side effects.If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. \u2022If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. \u2022Call your healthcare provider right away, if you take too much sunitinib malate capsules. What are possible side effects of Sunitinib Malate Capsules? Sunitinib malate capsules may cause serious side effects, including: \u2022See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d \u2022 Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy)that can lead to death.Tell your healthcare provider if you feel verytired, are short of breath, or have swollen feet and ankles. \u2022 Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms andblood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules \u2022you feel faint or lightheaded, or you pass out \u2219 feel your heart beat is irregular or fast \u2219dizziness \u2022 High blood pressure. High blood pressure is common with sunitinib malate capsules, and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: \u2022severe headache \u2022dizziness \u2022lightheadedness \u2022change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. \u2022 Bleeding problems . Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death.Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: \u2022painful, swollen stomach (abdomen) \u2022bloody urine \u2022vomiting blood \u2022headache \u2022change in your mental status \u2022black, sticky stools \u2022coughing up blood \u2022Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in theirstomach or intestine (perforation), or havedeveloped an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. \u2022Tumor lysis syndrome (TLS). TLS is caused by the fastbreakdown of cancer cellsand may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. \u2022Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. \u2022 Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS) . TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brainand kidneys, and can sometimes lead to death. \u2022 Protein in your urine. Some peoplewho have takensunitinib malate capsules have developed protein in theirurine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. \u2022Serious skin and mouth reactions. Treatment withsunitinib malate capsules havecaused severe skinreactions that can lead to death, including:severe rash with blisters or peeling of the skin.painful sores or ulcers on the skin, lips or inside the mouth.tissue damage (necrotizing fasciitis).If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. \u2022Thyroid problems. Your healthcare provider may do tests to check yourthyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: o tiredness that gets worse and does not go o fast heat rateaway o weight gain or weight loss loss of appetite o feeling depressed problems with heat o irregular menstrual periods or no feeling nervous oragitated, tremors menstrual periods sweating o headache nausea or vomiting o hair loss diarrhea \u2022Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people whohave diabetes andtake antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules. \u2022headache \u2022 irritability \u2022drowsiness \u2022hungerweakness \u2022fast heart beatdizziness \u2022sweatingconfusion \u2022feeling jittery \u2022 Jaw-bone problems (osteonecrosis). Severe jaw bone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tellyou to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules.You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. \u2022Wound healing problems. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery beforeor during treatment with sunitinib malate capsules.You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatmentwith sunitinib malate, if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness o vomitingweakness o stomach-area (abdominal) paindiarrhea o blisters or rash on the palms of your pain, swelling or sores inside of your hands and soles of your feet mouth high blood pressurenausea o taste changesloss of appetite o low platelet counts o indigestion The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store Sunitinib Malate Capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them.You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in Sunitinib Malate Capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone (K-25). Capsule shells: 12.5 mg capsules shells contains gelatin, iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate and titanium dioxide. The 25 mg, 37.5 mg and 50 mg capsule shells contains gelatin, iron oxide black, sodium lauryl sulfate and titanium dioxide. White printing ink: butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide propylene glycol, shellac, strong ammonia solution and titanium dioxide. Distributor: Dr. Reddy\u2019s Laboratories Inc., Princeton, NJ 08540 USA Made in India For more information, contact Dr. Reddy\u2019s Laboratories Inc., at 1-888-375-3784. This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: March 2022 To reorder additional Medication Guides contact Dr. Reddy\u2019s Customer Service at 1-866-733-3952."
    ],
    "spl_medguide_table": [
      "<table frame=\"border\" rules=\"all\"><tbody align=\"left\"><tr><td align=\"center\"><content styleCode=\"bold\"> MEDICATION GUIDE </content> <content styleCode=\"bold\">Sunitinib Malate (soo ni&#x2032; ti nib mal eyt )</content> c<content styleCode=\"bold\">apsules</content></td></tr><tr><td><content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules? sunitinib malate capsules can cause serious side effects including:</content>  <content styleCode=\"bold\">&#x2022;Severe liver problems, that can leadto death. Tell your healthcare provider right awayif you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content> &#x2219;itching  &#x2219;yellow eyes or skin  &#x2219;dark urine  &#x2219;pain or discomfort in the right upper stomach area  Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, orpermanently stop treatment with sunitinib malate capsules if you develop liver problems. See &#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D; for more information about side effects.</td></tr><tr><td><content styleCode=\"bold\">What is Sunitinib Malate Capsules?</content> Sunitinib malate capsules is a prescription medicine used to treat: &#x2022; a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: &#x2219; you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or &#x2219; you cannot take imatinib mesylate. &#x2022; advanced kidney cancer (advanced renal cell carcinoma or RCC). &#x2022; adults with kidneycancer that has not spread(localized), and who are at high riskof RCC coming back again after having kidney surgery. &#x2022; a type of pancreatic cancercalled pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children.</td></tr><tr><td><content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content> &#x2022; have any heart problems  &#x2022;have high blood pressure  &#x2022;have thyroid problems  &#x2022;have a history of low blood sugar or diabetes  &#x2022;have kidney function problems (other than cancer)  &#x2022;have liver problems  &#x2022;have any bleeding problem  &#x2022;plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D;</content> &#x2022; have seizures  &#x2022;have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth  &#x2022; are pregnant or plan to become pregnant. Sunitinib malate capsules can harm your unborn baby.<content styleCode=\"bold\"/> <content styleCode=\"bold\">Females </content>who are able to become pregnant:  &#x2022; Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. &#x2022; You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. &#x2022;Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.<content styleCode=\"bold\"/> <content styleCode=\"bold\">Males </content>with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. &#x2022;are breastfeeding or plan to breastfeed. Do not breastfeed during treatment withsunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any </content>surgery, or medical or dental procedure.</td></tr><tr><td><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take, </content>including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jaw bone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell </content>your healthcare provider if you are taking or have taken an osteoporosis medicine.  Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td></tr><tr><td><content styleCode=\"bold\">How should I take Sunitinib Malate Capsules?</content> &#x2219; Take sunitinib malate capsules exactly the way your healthcare provider tells you.  &#x2022; Take sunitinib malate capsules 1 time each day with or without food.If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to.  &#x2022; If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.  &#x2022; Do not drink grapefruit juice or eat grapefruit duringyour treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate capsules in your body.  &#x2022;Your healthcare provider may do bloodtests before eachcycle of treatment to check you for side effects.If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away.  &#x2022;If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.  &#x2022;Call your healthcare provider right away, if you take too much sunitinib malate capsules.</td></tr><tr><td><content styleCode=\"bold\">What are possible side effects of Sunitinib Malate Capsules? Sunitinib malate capsules may cause serious side effects, including:</content> &#x2022;See <content styleCode=\"bold\">&#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content> &#x2022;<content styleCode=\"bold\">Heart problems. </content>Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy)that can lead to death.Tell your healthcare provider if you feel verytired, are short of breath, or have swollen feet and ankles.  &#x2022;<content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. </content>Your healthcare provider may do electrocardiograms andblood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules  &#x2022;you feel faint or lightheaded, or you pass out  &#x2219; feel your heart beat is irregular or fast  &#x2219;dizziness<content styleCode=\"bold\"/> &#x2022;<content styleCode=\"bold\">High blood pressure. </content>High blood pressure is common with sunitinib malate capsules, and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: &#x2022;severe headache  &#x2022;dizziness  &#x2022;lightheadedness  &#x2022;change in vision  Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. &#x2022;<content styleCode=\"bold\">Bleeding problems</content>. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death.Your healthcare provider will monitor you for bleeding and may do blood tests if needed.  Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: &#x2022;painful, swollen stomach (abdomen)  &#x2022;bloody urine  &#x2022;vomiting blood  &#x2022;headache  &#x2022;change in your mental status  &#x2022;black, sticky stools  &#x2022;coughing up blood  <content styleCode=\"bold\">&#x2022;Serious stomach and intestinal problems, that can sometimes lead to death. </content>Some people have had tears in theirstomach or intestine (perforation), or havedeveloped an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules.<content styleCode=\"bold\"> &#x2022;Tumor lysis syndrome (TLS). </content>TLS is caused by the fastbreakdown of cancer cellsand may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.</td></tr><tr><td><content styleCode=\"bold\">&#x2022;Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). </content>RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death.  &#x2022;<content styleCode=\"bold\">Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS)</content>. TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brainand kidneys, and can sometimes lead to death. &#x2022;<content styleCode=\"bold\">Protein in your urine. </content>Some peoplewho have takensunitinib malate capsules have developed protein in theirurine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem.  <content styleCode=\"bold\">&#x2022;Serious skin and mouth reactions. </content>Treatment withsunitinib malate capsules havecaused severe skinreactions that can lead to death, including:severe rash with blisters or peeling of the skin.painful sores or ulcers on the skin, lips or inside the mouth.tissue damage (necrotizing fasciitis).If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away.<content styleCode=\"bold\"/> <content styleCode=\"bold\">&#x2022;Thyroid problems. </content>Your healthcare provider may do tests to check yourthyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: o tiredness that gets worse and does not go  o fast heat rateaway o weight gain or weight loss loss of appetite  o feeling depressed problems with heat  o irregular menstrual periods or no feeling nervous oragitated, tremors menstrual periods sweating  o headache nausea or vomiting  o hair loss diarrhea<content styleCode=\"bold\"/> <content styleCode=\"bold\">&#x2022;Low blood sugar (hypoglycemia). </content>Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people whohave diabetes andtake antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules. &#x2022;headache &#x2022; irritability  &#x2022;drowsiness  &#x2022;hungerweakness  &#x2022;fast heart beatdizziness  &#x2022;sweatingconfusion  &#x2022;feeling jittery  &#x2022;<content styleCode=\"bold\">Jaw-bone problems (osteonecrosis). </content>Severe jaw bone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tellyou to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules.You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. <content styleCode=\"bold\">&#x2022;Wound healing problems. </content>Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery beforeor during treatment with sunitinib malate capsules.You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.<content styleCode=\"bold\"/> <content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatmentwith sunitinib malate, if you develop serious side effects. Common side effects of sunitinib malate capsules include:</content> tiredness  o vomitingweakness  o stomach-area (abdominal) paindiarrhea  o blisters or rash on the palms of your pain, swelling or sores inside of your hands and soles of your feet mouth  high blood pressurenausea  o taste changesloss of appetite  o low platelet counts o indigestion <paragraph/>The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr><td><content styleCode=\"bold\">How do I store Sunitinib Malate Capsules? </content> Store sunitinib malate capsules at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C). <content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content></td></tr><tr><td><content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules.</content>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which it was not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. It may harm them.You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals.</td></tr><tr><td><content styleCode=\"bold\">What are the ingredients in Sunitinib Malate Capsules? </content> <content styleCode=\"bold\">Active ingredient: </content>sunitinib malate  <content styleCode=\"bold\">Inactive ingredients: </content>croscarmellose sodium, magnesium stearate, mannitol, and povidone (K-25).<content styleCode=\"bold\"> Capsule shells: </content>12.5 mg capsules shells contains gelatin, iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate and titanium dioxide. The 25 mg, 37.5 mg and 50 mg capsule shells contains gelatin, iron oxide black, sodium lauryl sulfate and titanium dioxide. <content styleCode=\"bold\"> White printing ink: </content>butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide propylene glycol, shellac, strong ammonia solution and titanium dioxide.  Distributor: <content styleCode=\"bold\">Dr. Reddy&#x2019;s Laboratories Inc.,</content>  Princeton, NJ 08540 USA  <content styleCode=\"bold\">Made in India</content>  For more information, contact Dr. Reddy&#x2019;s Laboratories Inc., at 1-888-375-3784.<paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration  Revised: March 2022 To reorder additional Medication Guides contact Dr. Reddy&#x2019;s Customer Service at 1-866-733-3952. </paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION",
      "",
      "",
      ""
    ],
    "set_id": "96ce8850-b5ae-382b-8433-04949533af44",
    "id": "664e6a61-82ff-5756-1fc1-9266090d901e",
    "effective_time": "20220316",
    "version": "5",
    "openfda": {
      "application_number": [
        "ANDA215843"
      ],
      "brand_name": [
        "SUNITINIB MALATE"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Dr.Reddys Laboratories Inc"
      ],
      "product_ndc": [
        "43598-045",
        "43598-046",
        "43598-047",
        "43598-048"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "664e6a61-82ff-5756-1fc1-9266090d901e"
      ],
      "spl_set_id": [
        "96ce8850-b5ae-382b-8433-04949533af44"
      ],
      "package_ndc": [
        "43598-045-63",
        "43598-045-70",
        "43598-045-28",
        "43598-046-63",
        "43598-046-70",
        "43598-046-28",
        "43598-047-63",
        "43598-047-70",
        "43598-047-28",
        "43598-048-63",
        "43598-048-70",
        "43598-048-28"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0343598048635",
        "0343598046631",
        "0343598045634",
        "0343598047638"
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 D&C RED NO. 28 FD&C BLUE NO. 1 FD&C RED NO. 40 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE SHELLAC PROPYLENE GLYCOL maroon TEVA;8199;TEVA;8199 Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 D&C RED NO. 28 FD&C BLUE NO. 1 FD&C RED NO. 40 FD&C YELLOW NO. 6 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE SHELLAC PROPYLENE GLYCOL light brown maroon TEVA;8224;TEVA;8224 Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE FD&C RED NO. 40 SHELLAC PROPYLENE GLYCOL TEVA;8229;TEVA;8229 Sunitinib Malate Sunitinib Malate SUNITINIB MALATE SUNITINIB CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL POVIDONE K30 FD&C BLUE NO. 1 FD&C RED NO. 40 FD&C YELLOW NO. 6 GELATIN, UNSPECIFIED TITANIUM DIOXIDE FERROSOFERRIC OXIDE D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 1 ALUMINUM LAKE FD&C BLUE NO. 2--ALUMINUM LAKE SHELLAC PROPYLENE GLYCOL light brown TEVA;8231;TEVA;8231"
    ],
    "boxed_warning": [
      "WARNING: HEPATOTOXICITY Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity may be severe, and in some cases fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue sunitinib malate capsules as recommended [see Warnings and Precautions ( 5.1 )] ."
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION GIST and Advanced RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC : The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET : The recommended dosage is 37.5 mg orally once daily. ( 2.3 ) 2.1 Recommended Dosage for GIST and Advanced RCC The recommended dosage of sunitinib malate capsules for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.2 Recommended Dosage for Adjuvant Treatment of RCC The recommended dosage of sunitinib malate capsules for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. Sunitinib malate capsules may be taken with or without food. 2.3 Recommended Dosage for pNET The recommended dosage of sunitinib malate capsules for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. Sunitinib malate capsules may be taken with or without food. 2.4 Dosage Modifications for Adverse Reactions To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of sunitinib malate capsules for adverse reactions. Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions Indications GIST RCC pNET Advanced RCC Adjuvant RCC First dose reduction 37.5 mg once daily 37.5 mg once daily 37.5 mg once daily 25 mg once daily Second dose reduction 25 mg once daily 25 mg once daily NA NA Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions Adverse Reaction Severity Dosage Modifications for Sunitinib Malate Capsules Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. For recurring Grade 3 permanently discontinue. Grade 4 Permanently discontinue. Cardiovascular events [see Warnings and Precautions ( 5.2 )] Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) Withhold until resolution to Grade 0 to 1 or baseline. Resume at reduced dose. Clinically manifested congestive heart failure (CHF) Permanently discontinue. Hypertension [see Warnings and Precautions ( 5.4 )] Grade 3 Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Grade 4 Permanently discontinue. Hemorrhagic events [see Warnings and Precautions ( 5.5 )] Grade 3 or 4 Withhold until resolution to Grade 0 to 1 or baseline. Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction. Thrombotic microangiopathy [see Warnings and Precautions ( 5.7 )] Any Grade Permanently discontinue. Proteinuria or Nephrotic syndrome [see Warnings and Precautions ( 5.8 )] 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome Withhold until resolution to Grade 0 to 1 or baseline. Resume at a reduced dose. Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions Permanently discontinue. Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions ( 5.9 )] Any Grade Permanently discontinue. Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] Any Grade Permanently discontinue. Osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] Any Grade The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. Impaired wound healing [see Warnings and Precautions ( 5.14 )] Any Grade The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established. Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction. 2.5 Dosage Modification for Drug Interactions Strong CYP3A4 Inhibitors Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for sunitinib malate capsules to a minimum dosage as follows [see Drug Interactions ( 7.1 )] : GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 25 mg orally once daily Strong CYP3A4 Inducers Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of sunitinib malate capsules with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for sunitinib malate capsules to a maximum dosage as follows: GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) pNET: 62.5 mg orally once daily If the dose of sunitinib malate capsules is increased, monitor patients carefully for adverse reactions [see Drug Interactions ( 7.1 )] . 2.6 Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "dosage_and_administration_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 1. Recommended Dosage Reductions of Sunitinib Malate Capsules for Adverse Reactions</caption><col width=\"110.15pt\"/><col width=\"110.15pt\"/><col width=\"110.15pt\"/><col width=\"110.15pt\"/><col/><tbody><tr><td valign=\"top\" rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Indications</content></paragraph></td><td align=\"center\" valign=\"top\" rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">RCC</content></paragraph></td><td align=\"center\" valign=\"top\" rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Advanced RCC</content></paragraph></td><td align=\"center\" valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adjuvant RCC</content></paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>First dose reduction</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>37.5 mg once</paragraph><paragraph>daily</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>37.5 mg once daily</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>25 mg once daily</paragraph></td></tr><tr><td valign=\"top\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Second dose reduction</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>25 mg once daily</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>25 mg once</paragraph><paragraph>daily</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NA</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NA</paragraph></td></tr></tbody></table>",
      "<table width=\"1000px\" cellspacing=\"0\" cellpadding=\"5\"><caption> Table 2. Recommended Dosage Modifications for Sunitinib Malate Capsules for Adverse Reactions</caption><col width=\"114.3pt\"/><col width=\"114.3pt\"/><col width=\"114.3pt\"/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Severity</content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Dosage Modifications for </content><content styleCode=\"bold\">Sunitinib Malate Capsules</content></paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Hepatotoxicity <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_adcd7799-f2c5-4708-963e-7af21e95b4ed\">5.1</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Grade 3</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item><item>For recurring Grade 3 permanently discontinue.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Grade 4</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Cardiovascular events <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_e28ea320-c7d4-4290-b82d-b37625f4861e\">5.2</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at reduced dose.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Clinically manifested congestive heart failure (CHF)</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Hypertension <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_8b54ae79-2b4a-4eca-a38b-c48f77974d9e\">5.4</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Grade 3</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Grade 4</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Hemorrhagic events <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_9e057e6e-d9e9-4ce3-a0fa-df7074545b8c\">5.5</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Grade 3 or 4</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Thrombotic microangiopathy <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_69b88b83-66d6-43fe-b7fb-5ba05af6a6d9\">5.7</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Any Grade</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td rowspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Proteinuria or Nephrotic syndrome <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_467fcc32-240a-4366-9c44-0a4177c41cff\">5.8</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Withhold until resolution to Grade 0 to 1 or baseline.</item><item>Resume at a reduced dose.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_af3a4849-07cd-47ff-9078-da48eaff362b\">5.9</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Any Grade</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Reversible posterior leukoencephalopathy syndrome <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_65feff95-8f29-45e4-8b52-21fca7397c30\">5.10</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Any Grade</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Permanently discontinue.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Osteonecrosis of the jaw <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_a43314d2-d140-45b9-ab5f-b9462ff61c38\">5.13</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Any Grade</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>The safety of resumption of sunitinib malate capsules after osteonecrosis has not been established.</item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</item></list></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Impaired wound healing <content styleCode=\"italics\">[see Warnings and Precautions (<linkHtml href=\"#www.splportal.comLINK_42c613d0-91d5-4619-bc04-0febeb1be906\">5.14</linkHtml>)]</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Any Grade</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>The safety of resumption of sunitinib malate capsules after resolution of wound healing has not been established.</item><item>Either resume at a reduced dose or discontinue depending on the severity and persistence of the adverse reaction.</item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS 12.5 mg capsules Hard gelatin capsule with maroon opaque cap and body, imprinted with TEVA over 8199 on both cap and body in black ink. 25 mg capsules Hard gelatin capsule with light brown opaque cap and maroon opaque body, imprinted with TEVA over 8224 on both cap and body in black ink. 37.5 mg capsules Hard gelatin capsule with yellow opaque cap and body, imprinted with TEVA over 8229 on both cap and body in black ink. 50 mg capsules Hard gelatin capsule with light brown opaque cap and body, imprinted with TEVA over 8231 on both cap and body in black ink. Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Fatal liver failure has been observed. Monitor liver function tests at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline and resume sunitinib malate at a reduced dose; discontinue if no resolution. Discontinue sunitinib malate in patients with Grade 4 hepatoxicity, in patients who have subsequent severe changes in liver function tests or other signs and symptoms of liver failure. ( 2.4 , 5.1 ) Cardiovascular Events : Myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal including death have occurred. Monitor for signs and symptoms of congestive heart failure and consider monitoring LVEF at baseline and periodically during treatment. Discontinue sunitinib malate for clinical manifestations of congestive heart failure. Interrupt and/or dose reduce for decreased LVEF. ( 5.2 ) QT Interval Prolongation and Torsade de Pointes : Monitor patients at higher risk for developing QT interval prolongation. Consider monitoring of electrocardiograms and electrolytes. ( 5.3 ) Hypertension : Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. Interrupt sunitinib malate for Grade 3 hypertension until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients who develop Grade 4 hypertension. ( 5.4 ) Hemorrhagic Events : Tumor-related hemorrhage and viscus perforation (both with fatal events) have occurred. Perform serial complete blood counts and physical examinations. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume at a reduced dose; discontinue if no resolution. ( 5.5 ) Tumor Lysis Syndrome (TLS) : TLS (some fatal) has been reported primarily in patients with RCC and GIST. Monitor these patients and treat as clinically indicated. ( 5.6 ) Thrombotic microangiopathy (TMA) : TMA, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, has been reported. Discontinue sunitinib malate for TMA. ( 5.7 ) Proteinuria : Renal failure or a fatal outcome has occurred. Monitor urine protein. Interrupt treatment for 24-hour urine protein of 3 or more grams. Discontinue for repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions or nephrotic syndrome. ( 5.8 ) Dermatologic Toxicities : Necrotizing fasciitis, erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) (some fatal) have occurred. Discontinue sunitinib malate for these events. ( 5.9 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS) : RPLS (some fatal) has been reported. Monitor for signs and symptoms of RPLS. Withhold sunitinib malate until resolution. ( 5.10 ) Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. Initiate and/or adjust therapy for thyroid dysfunction as appropriate. ( 5.11 ) Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. ( 5.12 ) Osteonecrosis of the Jaw (ONJ) : Withhold sunitinib malate for at least 3 weeks prior to invasive dental procedure and for development of ONJ until complete resolution. ( 5.13 ) Impaired Wound Healing : Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. ( 5.14 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.15 , 8.1 , 8.3 ) 5.1 Hepatotoxicity Sunitinib malate can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt sunitinib malate for Grade 3 hepatotoxicity until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 x upper limit of normal (ULN) or with >5 x ULN and liver metastases has not been established. 5.2 Cardiovascular Events Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported. In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients. In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to \u226550% or baseline by the time of last measurement. No patients who received sunitinib malate were diagnosed with CHF. Patients who presented with cardiac events within 12 months prior to sunitinib malate administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib malate clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction. Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue sunitinib malate in patients who experience clinical manifestations of CHF. Interrupt sunitinib malate and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained. 5.3 QT Interval Prolongation and Torsade de Pointes Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients. Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate. Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration ( 2.5 ), Drug Interactions ( 7.2 )] . 5.4 Hypertension In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%. Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold sunitinib malate until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients with who develop Grade 4 hypertension. 5.5 Hemorrhagic Events and Viscus Perforation Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3-5 event. Tumor-related hemorrhage was observed in patients treated with sunitinib malate. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with sunitinib malate for metastatic RCC, GIST, and metastatic lung cancer. Sunitinib malate is not approved for use in patients with lung cancer. Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with sunitinib malate. Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt sunitinib malate for Grade 3 or 4 hemorrhagic events until resolution to Grade \u22641 or baseline, then resume sunitinib malate at a reduced dose. Discontinue sunitinib malate in patients without resolution of Grade 3 or 4 hemorrhagic events. 5.6 Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate. 5.7 Thrombotic Microangiopathy Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of sunitinib malate as monotherapy and administered in combination with bevacizumab. Sunitinib malate is not approved for use in combination with bevacizumab. Discontinue sunitinib malate in patients developing TMA. Reversal of the effects of TMA has been observed after sunitinib malate was discontinued. 5.8 Proteinuria Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes. Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt sunitinib malate and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue sunitinib malate for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued sunitinib malate treatment in patients with moderate to severe proteinuria has not been evaluated. 5.9 Dermatologic Toxicities Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue sunitinib malate for these severe cutaneous adverse reactions. Necrotizing fasciitis, including fatal cases, has been reported in patients treated with sunitinib malate, including of the perineum and secondary to fistula formation. Discontinue sunitinib malate in patients who develop necrotizing fasciitis. 5.10 Reversible Posterior Leukoencephalopathy Syndrome Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue sunitinib malate in patients developing RPLS. 5.11 Thyroid Dysfunction Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of sunitinib malate. Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with sunitinib malate. Initiate and/or adjust therapies for thyroid dysfunction as appropriate. 5.12 Hypoglycemia Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n=83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes. Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia. 5.13 Osteonecrosis of the Jaw Osteonecrosis of the Jaw (ONJ) occurred in patients treated with sunitinib malate. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of sunitinib malate and periodically during sunitinib malate therapy. Advise patients regarding good oral hygiene practices. Withhold sunitinib malate treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold sunitinib malate for development of ONJ until complete resolution. The safety of resumption of sunitinib malate after resolution of osteonecrosis of the jaw has not been established. 5.14 Impaired Wound Healing Impaired wound healing has been reported in patients who received sunitinib malate [see Adverse Reactions ( 6.2 )] . Withhold sunitinib malate for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of sunitinib malate after resolution of wound healing complications has not been established. 5.15 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for 4 weeks following the final dose [see Use in Specific Populations ( 8.1 , 8.3 )] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Cardiovascular Events [see Warnings and Precautions ( 5.2 )] QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions ( 5.3 )] Hypertension [see Warnings and Precautions ( 5.4 )] Hemorrhagic Events [see Warnings and Precautions ( 5.5 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.6 )] Thrombotic Microangiopathy [see Warnings and Precautions ( 5.7 )] Proteinuria [see Warnings and Precautions ( 5.8 )] Dermatologic Toxicities [see Warnings and Precautions ( 5.9 )] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions ( 5.10 )] Thyroid Dysfunction [see Warnings and Precautions ( 5.11 )] Hypoglycemia [see Warnings and Precautions ( 5.12 )] Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.13 )] Impaired Wound Healing [see Warnings and Precautions ( 5.14 )] The most common adverse reactions (\u226525%) are fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in the Warnings and Precautions reflect exposure to sunitinib malate in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (\u226525%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia. Gastrointestinal Stromal Tumor The safety of sunitinib malate was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received sunitinib malate 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). Median duration of blinded study treatment was 2 cycles for patients on sunitinib malate (mean: 3.0; range: 1 to 9) and 1 cycle (mean; 1.8; range: 1 to 6) for patients on placebo at the time of the interim analysis. Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the sunitinib malate arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received sunitinib malate. Table 3 summarizes the adverse reactions for Study 1. Table 3. Adverse Reactions Reported in \u226510% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1 Adverse Reaction GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 94 56 97 51 Gastrointestinal Diarrhea 40 4 27 0 Mucositis/stomatitis 29 1 18 2 Constipation 20 0 14 2 Metabolism/Nutrition Anorexia a 33 1 29 5 Asthenia 22 5 11 3 Dermatology Skin discoloration 30 0 23 0 Rash 14 1 9 0 Hand-foot syndrome 14 4 10 3 Neurology Altered taste 21 0 12 0 Cardiac Hypertension 15 4 11 0 Musculoskeletal Myalgia/limb pain 14 1 9 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. a Includes decreased appetite. Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received sunitinib malate. Table 4 summarizes the laboratory abnormalities in Study 1. Table 4. Laboratory Abnormalities Reported in \u226510% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1 Laboratory Abnormality GIST Sunitinib Malate (N=202) Placebo (N=102) All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Any Laboratory Abnormality 34 22 Hematology Neutrophils decreased 53 10 4 0 Lymphocytes decreased 38 0 16 0 Platelets decreased 38 5 4 0 Hemoglobin decreased 26 3 22 2 Gastrointestinal AST/ALT increased 39 2 23 1 Lipase increased 25 10 17 7 Alkaline phosphatase increased 24 4 21 4 Amylase increased 17 5 12 3 Total bilirubin increased 16 1 8 0 Indirect bilirubin increased 10 0 4 0 Renal/Metabolic Creatinine increased 12 1 7 0 Potassium decreased 12 1 4 0 Sodium increased 10 0 4 1 Cardiac Decreased LVEF 11 1 3 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. a Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%). b Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%). After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label sunitinib malate [see Clinical Studies ( 14.1 )] . For 241 patients randomized to the sunitinib malate arm, including 139 who received sunitinib malate in both the double-blind and open-label phases, the median duration of sunitinib malate treatment was 6 cycles (mean: 8.5; range: 1 to 44). For the 255 patients who ultimately received open-label sunitinib malate treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1 to 37) from the time of the unblinding. Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received sunitinib malate. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received sunitinib malate. The most common Grade 3 or 4 adverse reactions in patients who received sunitinib malate in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%). Advanced Renal Cell Carcinoma The safety of sunitinib malate was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for sunitinib malate treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment. Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the sunitinib malate arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received sunitinib malate. Table 5 summarizes the adverse reactions for Study 3. Table 5. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3 Adverse Reaction Treatment-Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades % Grade 3-4 a % All Grades % Grade 3-4 b % Any Adverse Reaction 99 77 99 55 Gastrointestinal Diarrhea 66 10 21 <1 Nausea 58 6 41 2 Mucositis/stomatitis 47 3 5 <1 Vomiting 39 5 17 1 Dyspepsia 34 2 4 0 Abdominal pain c 30 5 12 1 Constipation 23 1 14 <1 Dry mouth 13 0 7 <1 Oral pain 14 <1 1 0 Flatulence 14 0 2 0 GERD/reflux esophagitis 12 <1 1 0 Glossodynia 11 0 1 0 Hemorrhoids 10 0 2 0 Constitutional Fatigue 62 15 56 15 Asthenia 26 11 22 6 Fever 22 1 37 <1 Weight decreased 16 <1 17 1 Chills 14 1 31 0 Chest Pain 13 2 7 1 Influenza like illness 5 0 15 <1 Metabolism/Nutrition Anorexia d 48 3 42 2 Neurology Altered taste e 47 <1 15 0 Headache 23 1 19 0 Dizziness 11 <1 14 1 Hemorrhage/Bleeding Bleeding, all sites 37 4 f 10 1 Cardiac Hypertension 34 13 4 <1 Edema peripheral 24 2 5 1 Ejection fraction decreased 16 3 5 2 Dermatology Rash 29 2 11 <1 Hand-foot syndrome 29 8 1 0 Skin discoloration/yellow skin 25 <1 0 0 Dry skin 23 <1 7 0 Hair color changes 20 0 <1 0 Alopecia 14 0 9 0 Erythema 12 <1 1 0 Pruritus 12 <1 7 <1 Musculoskeletal Pain in extremity/limb discomfort 40 5 30 2 Arthralgia 30 3 19 1 Back pain 28 5 14 2 Respiratory Cough 27 1 14 <1 Dyspnea 26 6 20 4 Nasopharyngitis 14 0 2 0 Oropharyngeal pain 14 <1 2 0 Upper respiratory tract infection 11 <1 2 0 Endocrine Hypothyroidism 16 2 1 0 Psychiatric Insomnia 15 <1 10 0 Depression g 11 0 14 1 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (<1%), dyspnea (<1%), asthenia (<1%), fatigue (<1%), limb pain (<1%), and rash (<1%). b Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (<1%), and depression (<1%). c Includes flank pain. d Includes decreased appetite. e Includes ageusia, hypogeusia, and dysgeusia. f Includes 1 patient with Grade 5 gastric hemorrhage. g Includes depressed mood. Table 6 summarizes the laboratory abnormalities in Study 3. Table 6. Laboratory Abnormalities Reported in \u226510% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3 Laboratory Abnormality Treatment-Na\u00efve RCC Sunitinib Malate (N=375) Interferon Alfa (N=360) All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Hematology Hemoglobin decreased 79 8 69 5 Neutrophils decreased 77 17 49 9 Platelets decreased 68 9 24 1 Lymphocytes decreased 68 18 68 26 Renal/Metabolic Creatinine increased 70 <1 51 <1 Creatine kinase increased 49 2 11 1 Uric acid increased 46 14 33 8 Calcium decreased 42 1 40 1 Phosphorus decreased 31 6 24 6 Albumin decreased 28 1 20 0 Glucose increased 23 6 15 6 Sodium decreased 20 8 15 4 Glucose decreased 17 0 12 <1 Potassium increased 16 3 17 4 Calcium increased 13 <1 10 1 Potassium decreased 13 1 2 <1 Sodium increased 13 0 10 0 Gastrointestinal AST increased 56 2 38 2 Lipase increased 56 18 46 8 ALT increased 51 3 40 2 Alkaline phosphatase increased 46 2 37 2 Amylase increased 35 6 32 3 Total bilirubin increased 20 1 2 0 Indirect bilirubin increased 13 1 1 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. a Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (<1%), creatine kinase (<1%), creatinine (<1%), glucose increased (<1%), calcium decreased (<1%), phosphorous (<1%), potassium increased (<1%), and sodium decreased (<1%). b Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (<1%), calcium increased (<1%), glucose decreased (<1%), potassium increased (<1%), and hemoglobin (<1%). Long-Term Safety in RCC The long-term safety of sunitinib malate in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with sunitinib malate did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4. Adjuvant Treatment of RCC The safety of sunitinib malate was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received sunitinib malate 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for sunitinib malate and 12.4 months (range: 0.03 to 13.7) for placebo. Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the sunitinib malate arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received sunitinib malate. Table 7 summarizes the adverse reactions in S-TRAC. Table 7. Adverse Reactions Reported in \u226510% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC Adverse Reaction Adjuvant Treatment of RCC Sunitinib Malate (N=306) Placebo (N=304) All Grades % Grade 3-4 % All Grades % Grade 3-4 % Any Adverse Reaction 99 60 88 15 Gastrointestinal Mucositis/Stomatitis a 61 6 15 0 Diarrhea 57 4 22 <1 Nausea 34 2 15 0 Dyspepsia 27 1 7 0 Abdominal pain b 25 2 9 <1 Vomiting 19 2 7 0 Constipation 12 0 11 0 Constitutional Fatigue/Asthenia 57 8 34 2 Localized edema c 18 <1 <1 0 Pyrexia 12 <1 6 0 Dermatology Hand-foot syndrome 50 16 10 <1 Rash d 24 2 12 0 Hair color changes 22 0 2 0 Skin discoloration/Yellow skin 18 0 1 0 Dry skin 14 0 6 0 Cardiac Hypertension e 39 8 14 1 Edema/Peripheral edema 10 <1 7 0 Neurology Altered taste f 38 <1 6 0 Headache 19 <1 12 0 Endocrine Hypothyroidism/TSH increased 24 <1 4 0 Hemorrhage/Bleeding Bleeding events, all sites g 24 <1 5 <1 Metabolism/Nutrition Anorexia/Decreased appetite 19 <1 5 0 Musculoskeletal Pain in extremity 15 <1 7 0 Arthralgia 11 <1 10 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. a Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain. b Includes abdominal pain, abdominal pain lower, and abdominal pain upper. c Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema. d Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic. e Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis. f Includes ageusia, hypogeusia, and dysgeusia. g Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria. Grade 4 adverse reactions in patients on sunitinib malate included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (<1%), stomatitis (<1%), and pyrexia (<1%). Grade 3-4 laboratory abnormalities that occurred in \u22652% of patients receiving sunitinib malate include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%). Advanced Pancreatic Neuroendocrine Tumors The safety of sunitinib malate was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received sunitinib malate 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13 to 532 days) for patients on sunitinib malate and 113 days (range: 1 to 614 days) for patients on placebo. Nineteen patients (23%) on sunitinib malate and 4 patients (5%) on placebo were on study for >1 year. Permanent discontinuation due to an adverse reaction occurred in 22% in the sunitinib malate arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received sunitinib malate. Table 8 summarizes the adverse reactions in Study 6. Table 8. Adverse Reactions Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6 Adverse Reaction pNET Sunitinib Malate (N=83) Placebo (N=82) All Grades % Grade 3-4 a % All Grades % Grade 3-4 % Any Adverse Reaction 99 54 95 50 Gastrointestinal Diarrhea 59 5 39 2 Stomatitis/oral syndromes b 48 6 18 0 Nausea 45 1 29 1 Abdominal pain c 39 5 34 10 Vomiting 34 0 31 2 Dyspepsia 15 0 6 0 Constitutional Asthenia 34 5 27 4 Fatigue 33 5 27 9 Weight decreased 16 1 11 0 Dermatology Hair color changes 29 1 1 0 Hand-foot syndrome 23 6 2 0 Rash 18 0 5 0 Dry skin 15 0 11 0 Cardiac Hypertension 27 10 5 1 Hemorrhage/Bleeding Bleeding events d 22 0 10 4 Epistaxis 21 1 5 0 Neurology Dysgeusia 21 0 5 0 Headache 18 0 13 1 Psychiatric Insomnia 18 0 12 0 Musculoskeletal Arthralgia 15 0 6 0 * Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%). b Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth. c Includes abdominal discomfort, abdominal pain, and abdominal pain upper. d Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia. Table 9 summarizes the laboratory abnormalities in Study 6. Table 9. Laboratory Abnormalities Reported in \u226510% of Patients With pNET Who Received Sunitinib Malate in Study 6 Laboratory Abnormality pNET Sunitinib Malate Placebo All Grades* % Grade 3-4* ,a % All Grades* % Grade 3-4* ,b % Gastrointestinal AST increased 72 5 70 3 Alkaline phosphatase increased 63 10 70 11 ALT increased 61 4 55 3 Total bilirubin increased 37 1 28 4 Amylase increased 20 4 10 1 Lipase increased 17 5 11 4 Hematology Neutrophils decreased 71 16 16 0 Hemoglobin decreased 65 0 55 1 Platelets decreased 60 5 15 0 Lymphocytes decreased 56 7 35 4 Renal/Metabolic Glucose increased 71 12 78 18 Albumin decreased 41 1 37 1 Phosphorus decreased 36 7 22 5 Calcium decreased 34 0 19 0 Sodium decreased 29 2 34 3 Creatinine increased 27 5 28 5 Glucose decreased 22 2 15 4 Potassium decreased 21 4 14 0 Magnesium decreased 19 0 10 0 Potassium increased 18 1 11 1 * The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. a Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%). b Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%). Venous Thromboembolic Events In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3-4 in 2.2% of patients. Pancreatic Function Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-na\u00efve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on sunitinib malate. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of sunitinib malate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia*. Gastrointestinal disorders: esophagitis. Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis. Immune system disorders: hypersensitivity reactions, including angioedema. Infections and infestations: serious infection (with or without neutropenia)*. The infections most commonly observed with sunitinib malate include respiratory, urinary tract, skin infections, and sepsis/septic shock. Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression*; myopathy and/or rhabdomyolysis with or without acute renal failure*. Renal and urinary disorders: renal impairment and/or failure*. Respiratory disorders: pulmonary embolism*, pleural effusion*. Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges. Vascular disorders: arterial (including aortic) aneurysms, dissections*, and rupture*; arterial thromboembolic events*. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction. General disorders and administration site conditions: impaired wound healing. *including some fatalities"
    ],
    "adverse_reactions_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 3. Adverse Reactions Reported in &#x2265;10% of GIST Patients Who Received Sunitinib Malate in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo* in Study 1</caption><col width=\"171.35pt\"/><col width=\"171.35pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=202)</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo (N=102)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4 %</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades %</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4 %</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>94</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>97</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>51</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Anorexia<sup>a</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Skin discoloration</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Altered taste</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Myalgia/limb pain</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Includes decreased appetite.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 4. Laboratory Abnormalities Reported in &#x2265;10% of GIST Patients Who Received Sunitinib Malate or Placebo in the Double-Blind Treatment Phase* in Study 1</caption><col width=\"187.8pt\"/><col width=\"187.8pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">GIST</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=202)</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo (N=102)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4*<sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4*<sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Any <content styleCode=\"bold\">Laboratory Abnormality</content></content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"/><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"/><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>22</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> AST/ALT increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Decreased LVEF</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Grade 4 laboratory abnormalities in patients on sunitinib malate included alkaline phosphatase (1%), lipase (2%), creatinine (1%), potassium decreased (1%), neutrophils (2%), hemoglobin (2%), and platelets (1%).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Grade 4 laboratory abnormalities in patients on placebo included amylase (1%), lipase (1%), and hemoglobin (2%).</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 5. Adverse Reactions Reported in &#x2265;10% of Patients With RCC Who Received Sunitinib Malate or Interferon Alfa* in Study 3</caption><col width=\"183.95pt\"/><col width=\"183.95pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=375)</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Interferon Alfa (N=360)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4<sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4<sup>b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>55</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Mucositis/stomatitis</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Abdominal pain<sup>c</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dry mouth</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Oral pain</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Flatulence</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> GERD/reflux esophagitis</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Glossodynia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hemorrhoids</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>62</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Fever</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Chills</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Chest Pain</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Influenza like illness</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Anorexia<sup>d</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Altered taste<sup>e</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Bleeding, all sites</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4<sup>f</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Edema peripheral</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Ejection fraction decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Skin discoloration/yellow skin</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Alopecia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Erythema</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Pruritus</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Pain in extremity/limb discomfort</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Back pain</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Respiratory</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Cough</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dyspnea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Oropharyngeal pain</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Upper respiratory tract infection</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hypothyroidism</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Depression<sup>g</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Grade 4 ARs in patients on sunitinib malate included back pain (1%), arthralgia (&lt;1%), dyspnea (&lt;1%), asthenia (&lt;1%), fatigue (&lt;1%), limb pain (&lt;1%), and rash (&lt;1%).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Grade 4 ARs in patients on interferon alfa included dyspnea (1%), fatigue (1%), abdominal pain (&lt;1%), and depression (&lt;1%).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup> Includes flank pain.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup> Includes decreased appetite.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>e</sup> Includes ageusia, hypogeusia, and dysgeusia.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>f</sup> Includes 1 patient with Grade 5 gastric hemorrhage.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>g</sup> Includes depressed mood.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 6. Laboratory Abnormalities Reported in &#x2265;10% of RCC Patients Who Received Sunitinib Malate or Interferon Alfa in Study 3</caption><col width=\"187.8pt\"/><col width=\"187.8pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Treatment-Na&#xEF;ve RCC</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=375)</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Interferon Alfa (N=360)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4*<sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4*<sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>68</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Creatine kinase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Uric acid increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Calcium increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Sodium increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Indirect bilirubin increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Grade 4 laboratory abnormalities in patients on sunitinib malate included uric acid (14%), lipase (3%), neutrophils (2%), lymphocytes (2%), hemoglobin (2%), platelets (1%), amylase (1%), ALT (&lt;1%), creatine kinase (&lt;1%), creatinine (&lt;1%), glucose increased (&lt;1%), calcium decreased (&lt;1%), phosphorous (&lt;1%), potassium increased (&lt;1%), and sodium decreased (&lt;1%).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Grade 4 laboratory abnormalities in patients on interferon alfa included uric acid (8%), lymphocytes (2%), lipase (1%), neutrophils (1%), amylase (&lt;1%), calcium increased (&lt;1%), glucose decreased (&lt;1%), potassium increased (&lt;1%), and hemoglobin (&lt;1%).</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 7. Adverse Reactions Reported in &#x2265;10% of Patients With RCC Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in S-TRAC</caption><col width=\"187.45pt\"/><col width=\"187.45pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adjuvant Treatment of RCC</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=306)</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo (N=304)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>15</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Mucositis/Stomatitis<sup>a</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Abdominal pain<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Fatigue/Asthenia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Localized edema<sup>c</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Pyrexia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Rash<sup>d</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Skin discoloration/Yellow skin</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hypertension<sup>e</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Edema/Peripheral edema</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Altered taste<sup>f</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph> 19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Endocrine</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hypothyroidism/TSH increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Bleeding events, all sites<sup>g</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Metabolism/Nutrition</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Anorexia/Decreased appetite</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Pain in extremity</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Includes mucosal inflammation, stomatitis aphthous ulcer, mouth ulceration, tongue ulceration, oropharyngeal pain, and oral pain.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Includes abdominal pain, abdominal pain lower, and abdominal pain upper.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup> Includes edema localized, face edema, eyelid edema, periorbital edema, swelling face, and eye edema.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup> Includes dermatitis, dermatitis psoriasiform, exfoliative rash, genital rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>e</sup> Includes hypertension, blood pressure increased, blood pressure systolic increased, blood pressure diastolic increased, and hypertensive crisis.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>f</sup> Includes ageusia, hypogeusia, and dysgeusia.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>g</sup> Includes epistaxis, gingival bleeding, rectal hemorrhage, hemoptysis, anal hemorrhage, upper gastrointestinal hemorrhage, and hematuria.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 8. Adverse Reactions Reported in &#x2265;10% of Patients With pNET Who Received Sunitinib Malate and More Commonly Than in Patients Given Placebo* in Study 6</caption><col width=\"171.35pt\"/><col width=\"171.35pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate (N=83)</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo (N=82)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4<sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Any Adverse Reaction</content></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>95</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>50</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Stomatitis/oral syndromes<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Abdominal pain<sup>c</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Constitutional</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>9</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Weight decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Dermatology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hair color changes</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hand-foot syndrome</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Rash</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dry skin</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cardiac</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hypertension</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hemorrhage/Bleeding</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Bleeding events<sup>d</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Epistaxis</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Neurology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. </paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Grade 4 adverse reactions in patients on sunitinib malate included fatigue (1%).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Includes aphthous stomatitis, gingival pain, gingivitis, glossitis, glossodynia, mouth ulceration, oral discomfort, oral pain, tongue ulceration, mucosal dryness, mucosal inflammation, and dry mouth.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup> Includes abdominal discomfort, abdominal pain, and abdominal pain upper.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>d</sup> Includes hematemesis, hematochezia, hematoma, hemoptysis, hemorrhage, melena, and metrorrhagia.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 9. Laboratory Abnormalities Reported in &#x2265;10% of Patients With pNET Who Received Sunitinib Malate in Study 6</caption><col width=\"146.15pt\"/><col width=\"146.15pt\"/><col/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" rowspan=\"3\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Laboratory <content styleCode=\"bold\">Abnormality</content></content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"4\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">pNET</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td></tr><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4*<sup>,a</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">All Grades*</content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Grade 3-4*<sup>,b</sup></content></paragraph><paragraph><content styleCode=\"bold\">%</content></paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> AST increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>72</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Alkaline phosphatase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> ALT increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Total bilirubin increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Amylase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Lipase increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Neutrophils decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Hemoglobin decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Platelets decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Lymphocytes decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Renal/Metabolic</content></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Glucose increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Albumin decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Phosphorus decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Calcium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Sodium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Creatinine increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Glucose decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Potassium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Magnesium decreased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph> Potassium increased</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* The denominator used to calculate the rate varied from 52 to 82 for sunitinib malate and 39 to 80 for Placebo based on the number of patients with a baseline value and at least one post-treatment value. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Grade 4 laboratory abnormalities in patients on sunitinib malate included creatinine (4%), lipase (4%), glucose decreased (2%), glucose increased (2%), neutrophils (2%), ALT (1%), AST (1%), platelets (1%), potassium increased (1%), and total bilirubin (1%).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Grade 4 laboratory abnormalities in patients on placebo included creatinine (3%), alkaline phosphatase (1%), glucose increased (1%), and lipase (1%).</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors : Consider dose reduction of sunitinib malate when administered with strong CYP3A4 inhibitors. ( 7.1 ) CYP3A4 Inducers : Consider dose increase of sunitinib malate when administered with strong CYP3A4 inducers. ( 7.1 ) 7.1 Effect of Other Drugs on Sunitinib Malate Strong CYP3A4 Inhibitors Coadministration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] . Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for sunitinib malate when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.5 )] . Strong CYP3A4 Inducers Coadministration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] . Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for sunitinib malate when it must be co-administered with CYP3A4 inducers [see Dosage and Administration ( 2.5 )] . 7.2 Drugs that Prolong QT Interval Sunitinib malate is associated with QTc interval prolongation [see Warnings and Precautions ( 5.3 ), Clinical Pharmacology ( 12.2 )] . Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day. 8.2 Lactation There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data) . Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with sunitinib malate and for at least 4 weeks after the last dose. Data Animal Data In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma. 8.3 Females and Males of Reproductive Potential Sunitinib malate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Verify pregnancy status of females of reproductive potential prior to initiating treatment with sunitinib malate. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with sunitinib malate and for at least 4 weeks after the last dose. Males Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with sunitinib malate and for 7 weeks after the last dose. Infertility Based on findings in animals, sunitinib malate may impair male and female fertility [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day. 8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology ( 12.3 )] . Sunitinib malate was not studied in patients with severe (Child-Pugh Class C) hepatic impairment. 8.7 Renal Impairment No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology ( 12.3 )] . No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology ( 12.3 )] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data) . Advise females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses \u22643 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at \u22651 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg). Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses \u22651 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses \u22641 mg/kg/day."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of sunitinib malate in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials. Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults. The effect on open tibial growth plates in pediatric patients who received sunitinib malate has not been adequately studied. See Juvenile Animal Toxicity Data below. Juvenile Animal Toxicity Data Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for \u22653 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses \u22655 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was \u22642 mg/kg/day."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received sunitinib malate, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%). In the GIST study, 73 (30%) of the patients who received sunitinib malate were 65 years and older. In the mRCC study, 152 (41%) of patients who received sunitinib malate were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. In the pNET study, 22 (27%) of the patients who received sunitinib malate were 65 years and older. Clinical studies of sunitinib malate did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Treatment of overdose with sunitinib malate should consist of general supportive measures. There is no specific antidote for overdosage with sunitinib malate. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of sunitinib malate, or without adverse reactions. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3,000 mg/m 2 ) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations."
    ],
    "description": [
      "11 DESCRIPTION Sunitinib is a kinase inhibitor present in sunitinib malate capsules as the malate salt. Sunitinib malate is described chemically as (2 S )-2-hydroxybutanedoic acid with N -[2-(diethylamino)ethyl]-5-[( Z )-(5-fluoro-1,2-dihydro-2-oxo- 3H -indol-3-ylidine)methyl]-2,4-dimethyl- 1H -pyrrole-3-carboxamide (1:1). The molecular formula is C 22 H 27 FN 4 O 2 \u25cf C 4 H 6 O 5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is: Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 0.4 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. The 12.5 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, and titanium dioxide. The 25 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The 37.5 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide. The 50 mg capsule shell contains FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The black printing ink which is common for all strengths contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, shellac, and may also contain propylene glycol. 1"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo . 12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions ( 5.3 )] . 12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Coadministration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Coadministration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR\u03b2, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFR\u03b2- and VEGFR2-dependent tumor angiogenesis in vivo ."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Exposure-Response Relationship Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures. Cardiac Electrophysiology Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions ( 5.3 )] ."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors. Sunitinib AUC and C max increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL. Absorption Following oral administration of sunitinib, the time to maximum plasma concentration (T max ) ranged from 6 to 12 hours. Effect of Food The administration of a single dose of sunitinib malate 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on sunitinib malate or active metabolites exposure. Distribution The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL. Elimination Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%. Metabolism Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity. Excretion After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine. Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively. Specific Populations No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Patients with Renal Impairment No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function. Drug Interaction Studies Clinical Studies Effect of strong CYP3A4 inhibitors on sunitinib : Coadministration of a single sunitinib malate dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite C max and AUC 0-inf by 49% and 51%, respectively, in healthy subjects. Effect of strong CYP3A4 inducers on sunitinib : Coadministration of a single sunitinib malate dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite C max and AUC 0-inf by 23% and 46%, respectively in healthy subjects. In Vitro Studies In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of \u226525 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland. Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test. In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses \u22641.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at \u22652 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite). In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses \u226410 mg/kg/day (approximately \u226526 times the combined AUC in patients administered the RDD of 50 mg)."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Gastrointestinal Stromal Tumor Study 1 Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of sunitinib malate in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving sunitinib malate plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg sunitinib malate or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label sunitinib malate and patients randomized to sunitinib malate were permitted to continue treatment per investigator judgment. At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the sunitinib malate arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the sunitinib malate and placebo groups with regard to age (69% versus 72% <65 years for sunitinib malate versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced. The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for sunitinib malate over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1. Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase) Efficacy Parameter Sunitinib Malate (N=207) Placebo (N=105) p-value (log-rank test) HR (95% CI) Time-to-tumor progression a 27.3 6.4 <0.0001* 0.33 [median, weeks (95% CI)] (16.0, 32.1) (4.4, 10.0) (0.23, 0.47) Progression-free survival b 24.1 6.0 <0.0001 0.33 [median, weeks (95% CI)] (11.1, 28.3) (4.4, 9.9) (0.24, 0.47) Objective response rate (PR) 6.8 0 0.006 c [%, (95% CI)] (3.7, 11.1) * A comparison is considered statistically significant if the p-value is <0.00417 (O\u2019Brien Fleming stopping boundary). Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. a Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation. b Time from randomization to progression or death due to any cause. c Pearson chi-square test. Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression. The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the sunitinib malate arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis, the study was unblinded, and patients on the placebo arm were offered open-label sunitinib malate treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive sunitinib malate in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the sunitinib malate arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)]. Study 2 Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of sunitinib malate on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%). 1 14.2 Renal Cell Carcinoma Treatment-Na\u00efve Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent sunitinib malate with interferon alfa was conducted in patients with treatment-na\u00efve RCC. The objective was to compare PFS in patients receiving sunitinib malate versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study. The ITT population included 750 patients, 375 randomized to sunitinib malate and 375 randomized to interferon alfa. Demographics were comparable between the sunitinib malate and interferon alfa groups with regard to age (59% versus 67% <65 years for sunitinib malate versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively). There was a statistically significant advantage for sunitinib malate over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus \u22641.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored sunitinib malate over interferon alfa. The ORR was higher in the sunitinib malate arm (see Table 11). Table 11. Treatment-Na\u00efve RCC Efficacy Results (Interim Analysis) from Study 3 Efficacy Parameter Sunitinib Malate (N=375) Interferon Alfa (N=375) p-value (log-rank test) HR (95% CI) Progression-free survival a 47.3 22.0 <0.000001 b 0.415 [median, weeks (95% CI)] (42.6, 50.7) (16.4, 24.0) (0.320, 0.539) Objective response rate a 27.5 5.3 <0.001 c NA [%, (95% CI)] (23.0, 32.3) (3.3, 8.1) Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory; 90 patients\u2019 scans had not been read at time of analysis. b A comparison is considered statistically significant if the p-value is <0.0042 (O\u2019Brien Fleming stopping boundary). c Pearson chi-square test. Figure 2. Kaplan-Meier Curve of PFS in Treatment-Na\u00efve RCC Study 3 (Intent-to-Treat Population) Abbreviations: CI=confidence interval; IFN-\u03b1=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma. At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the sunitinib malate arm and 94.9 weeks for the interferon alfa arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with sunitinib malate as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with sunitinib malate. Cytokine-Refractory The use of single-agent sunitinib malate in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated. One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg sunitinib malate on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86% to 94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit. The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies. The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff. Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5 Efficacy Parameter Study 4 (N=106) Study 5 (N=63) Objective response rate [%, (95% CI)] 34.0 a (25.0, 43.8) 36.5 b (24.7, 49.6) Duration of response [median, weeks (95% CI)] NR* (42.0, *) 54 b (34.3, 70.1) *Data not mature enough to determine upper confidence limit. Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. a Assessed by blinded core radiology laboratory. b Assessed by investigators. Adjuvant Treatment In the adjuvant treatment setting, sunitinib malate was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as \u2265T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg sunitinib malate once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Demographics were generally comparable between the sunitinib malate and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% sunitinib malate and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on sunitinib malate had a performance status of 2. The major efficacy outcome measure was disease-free survival (DFS) in patients receiving sunitinib malate versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with sunitinib malate compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths. Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC Sunitinib Malate N=309 Placebo N=306 p-value a HR a (95% CI) Median DFS [years (95% CI)] 6.8 (5.8, NR) 5.6 (3.8, 6.6) 0.03 0.76 (0.59, 0.98) DFS Events 113 (36.6%) 144 (47.1%) 5 Year DFS Rate 59.3% 51.3% a P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. Table 14. Disease-free Survival by Baseline Disease Characteristics Number of Events/Total n/N Median DFS [years (95% CI)] HR a (95% CI) Sunitinib Malate Placebo Sunitinib Malate Placebo T3 Intermediate b 35/115 46/112 NR (5.2, NR) 6.4 (4.7, NR) 0.82 (0.53, 1.28) T3 High c 63/165 79/166 6.8 (5.0, NR) 5.3 (2.9, NR) 0.77 (0.55, 1.07) T4/Node Positive d 15/29 19/28 3.5 (1.2, NR) 1.7 (0.4, 3.0) 0.62 (0.31, 1.23) Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached a HR based on a Cox proportional hazards model b T3 Intermediate: T3, N0 or NX, M0, any Fuhrman\u2019s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman\u2019s grade 1, ECOG PS \u22651 c T3 High: T3, N0 or NX, M0, Fuhrman\u2019s grade \u22652, ECOG PS \u22651 d T4/Node Positive: T4, N0 or NX, M0, any Fuhrman\u2019s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman\u2019s grade, any ECOG PS Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population) Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients. 1 1 14.3 Pancreatic Neuroendocrine Tumors Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent sunitinib malate conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg sunitinib malate (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving sunitinib malate versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study. Demographics were comparable between the sunitinib malate and placebo groups. Additionally, 49% of sunitinib malate patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of sunitinib malate patients received prior systemic therapy compared with 72% of placebo patients and 35% of sunitinib malate patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to sunitinib malate in a separate extension study. As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for sunitinib malate over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring sunitinib malate was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the sunitinib malate arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring sunitinib malate over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4. Table 15. pNET Efficacy Results from Study 6 Efficacy Parameter Sunitinib Malate (N=86) Placebo (N=85) p-value HR (95% CI) Progression-free survival [median, months (95% CI)] 10.2 (7.4, 16.9) 5.4 (3.4, 6.0) 0.000146 a 0.427 (0.271, 0.673) Objective response rate [%, (95% CI)] 9.3 (3.2, 15.4) 0 0.0066 b NA Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. a 2-sided unstratified log-rank test. b Fisher\u2019s Exact test. Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6 Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors. 1"
    ],
    "clinical_studies_table": [
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 10. GIST Efficacy Results From Study 1 (Double-Blind Treatment Phase)</caption><col width=\"210.95pt\"/><col width=\"210.95pt\"/><col width=\"210.95pt\"/><col width=\"210.95pt\"/><col width=\"210.95pt\"/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N=207)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N=105)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>Time-to-tumor progression<sup>a</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>27.3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>6.4</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;0.0001*</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0.33</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(16.0, 32.1)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(4.4, 10.0)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"><paragraph>(0.23, 0.47)</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph>Progression-free survival<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>24.1</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>6.0</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>&lt;0.0001</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>0.33</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(11.1, 28.3)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(4.4, 9.9)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"><paragraph>(0.24, 0.47)</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph>Objective response rate (PR)</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>6.8</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>0.006<sup>c</sup></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"/></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(3.7, 11.1)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>* A comparison is considered statistically significant if the p-value is &lt;0.00417 (O&#x2019;Brien Fleming stopping boundary). </paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Time from randomization to progression; deaths prior to documented progression were censored at time of last radiographic evaluation.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Time from randomization to progression or death due to any cause.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup> Pearson chi-square test.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 11. Treatment-Na&#xEF;ve RCC Efficacy Results (Interim Analysis) from Study 3</caption><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N=375)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Interferon Alfa</content></paragraph><paragraph><content styleCode=\"bold\">(N=375)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph><paragraph><content styleCode=\"bold\">(log-rank test)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>Progression-free survival<sup>a</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>47.3</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>22.0</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>&lt;0.000001<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>0.415</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(42.6, 50.7)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(16.4, 24.0)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"><paragraph>(0.320, 0.539)</paragraph></td></tr><tr><td styleCode=\" Toprule Lrule Rrule\"><paragraph>Objective response rate<sup>a</sup></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>27.5</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>5.3</paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>&lt;0.001<sup>c</sup></paragraph></td><td align=\"center\" styleCode=\" Toprule Rrule\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\" Lrule Rrule\"><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(23.0, 32.3)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"><paragraph>(3.3, 8.1)</paragraph></td><td align=\"center\" styleCode=\" Rrule\"/><td align=\"center\" styleCode=\" Rrule\"/></tr><tr><td colspan=\"5\" styleCode=\" Toprule\"><paragraph>Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> Assessed by blinded core radiology laboratory; 90 patients&#x2019; scans had not been read at time of analysis.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> A comparison is considered statistically significant if the p-value is &lt;0.0042 (O&#x2019;Brien Fleming stopping boundary).</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>c</sup> Pearson chi-square test.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 12. Cytokine-Refractory RCC Efficacy Results from Study 4 and Study 5</caption><col width=\"192pt\"/><col width=\"192pt\"/><col width=\"192pt\"/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Study 4</content></paragraph><paragraph><content styleCode=\"bold\">(N=106)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Study 5</content></paragraph><paragraph><content styleCode=\"bold\">(N=63)</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Objective response rate </paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>34.0<sup>a</sup></paragraph><paragraph>(25.0, 43.8)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>36.5<sup>b</sup></paragraph><paragraph>(24.7, 49.6)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Duration of response </paragraph><paragraph>[median, weeks (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NR*</paragraph><paragraph>(42.0, *)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>54<sup>b</sup></paragraph><paragraph>(34.3, 70.1)</paragraph></td></tr><tr><td colspan=\"3\"><paragraph>*Data not mature enough to determine upper confidence limit.</paragraph></td></tr><tr><td colspan=\"3\"><paragraph>Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma.</paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>a</sup> Assessed by blinded core radiology laboratory.</paragraph></td></tr><tr><td colspan=\"3\"><paragraph><sup>b</sup> Assessed by investigators.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 13. Disease-free Survival Results as Assessed by BICR in Adjuvant RCC (Intent to Treat Population) from S-TRAC</caption><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><col width=\"198.95pt\"/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"/><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">N=309</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">N=306</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">p-value<sup>a</sup></content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">HR<sup>a</sup> (95% CI)</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Median DFS [years (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>6.8 (5.8, NR)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>5.6 (3.8, 6.6)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.03</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.76 (0.59, 0.98)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>DFS Events</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>113 (36.6%)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>144 (47.1%)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"/></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>5 Year DFS Rate</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>59.3%</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>51.3%</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"/></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> P-value based on log-rank test stratified by University of California Los Angeles Integrated Staging System (UISS) prognostic group; HR based on a Cox proportional hazard model stratified by UISS prognostic group</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma.</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 14. Disease-free Survival by Baseline Disease Characteristics</caption><col width=\"164.85pt\"/><col width=\"164.85pt\"/><col width=\"164.85pt\"/><col width=\"164.85pt\"/><col/><col/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"/><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Number of Events/Total</content></paragraph><paragraph><content styleCode=\"bold\">n/N</content></paragraph></td><td align=\"center\" valign=\"bottom\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Median DFS </content></paragraph><paragraph><content styleCode=\"bold\">[years (95% CI)]</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">HR<sup>a</sup></content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"/><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Sunitinib Malate</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Placebo</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Sunitinib Malate</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Placebo</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"/></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>T3 Intermediate<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>35/115</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>46/112</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NR </paragraph><paragraph>(5.2, NR)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>6.4</paragraph><paragraph>(4.7, NR)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.82</paragraph><paragraph>(0.53, 1.28)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>T3 High<sup>c</sup></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>63/165</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>79/166</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>6.8</paragraph><paragraph>(5.0, NR)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>5.3</paragraph><paragraph>(2.9, NR)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.77</paragraph><paragraph>(0.55, 1.07)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>T4/Node Positive<sup>d</sup></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>15/29</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>19/28</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>3.5</paragraph><paragraph>(1.2, NR)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>1.7</paragraph><paragraph>(0.4, 3.0)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.62</paragraph><paragraph>(0.31, 1.23)</paragraph></td></tr><tr><td colspan=\"6\"><paragraph>Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached</paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>a</sup> HR based on a Cox proportional hazards model</paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>b</sup> T3 Intermediate: T3, N0 or NX, M0, any Fuhrman&#x2019;s grade, ECOG PS 0 OR T3, N0 or NX, M0, Fuhrman&#x2019;s grade 1, ECOG PS &#x2265;1</paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>c</sup> T3 High: T3, N0 or NX, M0, Fuhrman&#x2019;s grade &#x2265;2, ECOG PS &#x2265;1</paragraph></td></tr><tr><td colspan=\"6\"><paragraph><sup>d</sup> T4/Node Positive: T4, N0 or NX, M0, any Fuhrman&#x2019;s grade, any ECOG PS OR Any T, N1-2, M0, any Fuhrman&#x2019;s grade, any ECOG PS</paragraph></td></tr></tbody></table>",
      "<table width=\"800px\" cellspacing=\"0\" cellpadding=\"5\"><caption>Table 15. pNET Efficacy Results from Study 6</caption><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><col width=\"194pt\"/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Sunitinib Malate</content></paragraph><paragraph><content styleCode=\"bold\">(N=86)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(N=85)</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td><td align=\"center\" valign=\"bottom\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">HR</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Progression-free survival </paragraph><paragraph>[median, months (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>10.2</paragraph><paragraph>(7.4, 16.9)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>5.4</paragraph><paragraph>(3.4, 6.0)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.000146<sup>a</sup></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.427</paragraph><paragraph>(0.271, 0.673)</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Objective response rate </paragraph><paragraph>[%, (95% CI)]</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>9.3</paragraph><paragraph>(3.2, 15.4)</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>0.0066<sup>b</sup></paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>NA</paragraph></td></tr><tr><td colspan=\"5\"><paragraph>Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>a</sup> 2-sided unstratified log-rank test.</paragraph></td></tr><tr><td colspan=\"5\"><paragraph><sup>b</sup> Fisher&#x2019;s Exact test.</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 12.5 mg capsules Hard gelatin capsule with maroon opaque cap and body, imprinted with TEVA over 8199 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 0093-8199-28 25 mg capsules Hard gelatin capsule with light brown opaque cap and maroon opaque body, imprinted with TEVA over 8224 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 0093-8224-28 37.5 mg capsules Hard gelatin capsule with yellow opaque cap and body, imprinted with TEVA over 8229 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 0093-8229-28 50 mg capsules Hard gelatin capsule with light brown opaque cap and body, imprinted with TEVA over 8231 on both cap and body in black ink. Available as follows: Bottles of 28 capsules: NDC 0093-8231-28 Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Hepatotoxicity Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity [see Warnings and Precautions ( 5.1 )] . Cardiovascular Events Advise patients to contact their healthcare provider if they develop symptoms of heart failure [see Warnings and Precautions ( 5.2 )] . QT Prolongation and Torsade de Pointes Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately in the event of syncope, pre-syncopal symptoms, and cardiac palpitations [see Warnings and Precautions ( 5.3 )] . Hypertension Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions ( 5.4 )] . Hemorrhagic Events Advise patients that sunitinib malate capsules can cause severe bleeding. Advise patients to immediately contact their healthcare provider for bleeding or symptoms of bleeding [see Warnings and Precautions ( 5.5 )] . Gastrointestinal Disorders Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during sunitinib malate capsules treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking sunitinib malate capsules [see Warnings and Precautions ( 5.5 ), Adverse Reactions ( 6.1 )] . Dermatologic Effects and Toxicities Advise patients that depigmentation of the hair or skin may occur during treatment with sunitinib malate capsules due to the drug color (yellow). Other possible dermatologic effects may include dryness, thickness or cracking of skin, blister or rash on the palms of the hands and soles of the feet. Severe dermatologic toxicities including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, erythema multiforme, and necrotizing fasciitis have been reported. Advise patients to immediately inform their healthcare provider if severe dermatologic reactions occur [see Warnings and Precautions ( 5.9 ), Adverse Reactions ( 6.1 )] . Reversible Posterior Leukoencephalopathy Syndrome Inform patients of the signs and symptoms of reversible posterior leukoencephalopathy syndrome. Advise patients to contact their healthcare provider if they develop symptoms of reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions ( 5.10 )] . Thyroid Dysfunction Advise patients that sunitinib malate capsules can cause thyroid dysfunction. Advise patient to contact their healthcare provider if symptoms of abnormal thyroid function occur [see Warnings and Precautions ( 5.11 )] . Hypoglycemia Advise patients that sunitinib malate capsules can cause severe hypoglycemia and may be more severe in patients with diabetes taking antidiabetic medications. Inform patients of the signs, symptoms, and risks associated with hypoglycemia. Advise patients to immediately inform their healthcare provider if severe signs or symptoms of hypoglycemia occur [see Warnings and Precautions ( 5.12 )] . Osteonecrosis of the Jaw Advise patients regarding good oral hygiene practices and to inform their healthcare provider of any planned dental procedures. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions ( 5.13 )] . Impaired Wound Healing Advise patients that sunitinib malate capsules impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedures [see Warnings and Precautions ( 5.14 )] . Concomitant Medications Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications and dietary supplements [see Drug Interactions ( 7 )] . Embryo-Fetal Toxicity Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.15 ), Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment and for 4 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations ( 8.3 )] . Advise males with female partners of reproductive potential to use effective contraception during treatment and for 7 weeks after receiving the last dose of sunitinib malate capsules [see Use in Specific Populations ( 8.3 )] . Lactation Advise women not to breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks after the last dose [see Use in Specific Populations ( 8.2 )] . Infertility Advise patients that sunitinib malate capsules may impair male and female fertility [see Use in Specific Populations ( 8.3 ), Nonclinical Toxicology ( 13.1 )] . Missed Dose Advise patients that miss a dose of sunitinib malate capsules by less than 12 hours to take the missed dose right away. Advise patients that miss a dose of sunitinib malate capsules by more than 12 hours to take the next scheduled dose at its regular time. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. A 1/2025"
    ],
    "spl_medguide": [
      "MEDICATION GUIDE Sunitinib Malate (soo ni' ti nib mal' ate) Capsules What is the most important information I should know about sunitinib malate capsules? Sunitinib malate capsules can cause serious side effects including: Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d for more information about side effects. What are sunitinib malate capsules? Sunitinib malate capsules are a prescription medicine used to treat: a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or you cannot take imatinib mesylate. advanced kidney cancer (advanced renal cell carcinoma or RCC). adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery. a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery. It is not known if sunitinib malate capsules are safe and effective in children. Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you: have any heart problems have high blood pressure have thyroid problems have a history of low blood sugar or diabetes have kidney function problems (other than cancer) have liver problems have any bleeding problem plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See \u201cWhat are the possible side effects of sunitinib malate capsules?\u201d have seizures have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth are pregnant or plan to become pregnant. Sunitinib malate can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules. You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose. Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take sunitinib malate capsules? Take sunitinib malate capsules exactly the way your healthcare provider tells you. Take sunitinib malate capsules 1 time each day with or without food. If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to. If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop. Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body. Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects. If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose. Call your healthcare provider right away, if you take too many sunitinib malate capsules. What are possible side effects of sunitinib malate capsules? Sunitinib malate capsules may cause serious side effects, including: See \u201cWhat is the most important information I should know about sunitinib malate capsules?\u201d Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules you feel faint or lightheaded, or you pass out dizziness feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider\u2019s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure: severe headache lightheadedness dizziness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Bleeding problems. Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including: painful, swollen stomach (abdomen) vomiting blood coughing up blood black, sticky stools bloody urine headache change in your mental status Serious stomach and intestinal problems, that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules. Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS. Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]). RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS). TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body\u2019s organs such as the brain and kidneys, and can sometimes lead to death. Protein in your urine. Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. Serious skin and mouth reactions. Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: severe rash with blisters or peeling of the skin. painful sores or ulcers on the skin, lips or inside the mouth. tissue damage (necrotizing fasciitis). If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away. Thyroid problems. Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules: tiredness that gets worse and does not go away loss of appetite problems with heat feeling nervous or agitated, tremors sweating nausea or vomiting diarrhea fast heat rate weight gain or weight loss feeling depressed irregular menstrual periods or no menstrual periods headache hair loss Low blood sugar (hypoglycemia). Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules: headache drowsiness weakness dizziness confusion irritability hunger fast heart beat sweating feeling jittery Jawbone problems (osteonecrosis). Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures. Wound healing problems. Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects. Common side effects of sunitinib malate capsules include: tiredness weakness diarrhea pain, swelling or sores inside of your mouth nausea loss of appetite indigestion vomiting stomach-area (abdominal) pain blisters or rash on the palms of your hands and soles of your feet high blood pressure taste changes low platelet counts The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of sunitinib malate capsules. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store sunitinib malate capsules? Store sunitinib malate capsules at room temperature, between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Keep sunitinib malate capsules and all medicines out of the reach of children. General information about the safe and effective use of sunitinib malate capsules. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which they were not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them. You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. What are the ingredients in sunitinib malate capsules? Active ingredient: sunitinib malate Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. The 12.5 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, and titanium dioxide. The 25 mg capsule shell contains D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The 37.5 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide. The 50 mg capsule shell contains FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6, gelatin, and titanium dioxide. The black printing ink which is common for all strengths contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, shellac, and may also contain propylene glycol. Manufactured For: Teva Pharmaceuticals , Parsippany, NJ 07054 For more information, call Teva at 1-888-838-2872. This Medication Guide has been approved by the U.S. Food and Drug Administration. Rev. A 1/2025"
    ],
    "spl_medguide_table": [
      "<table width=\"1000px\" cellspacing=\"0\" cellpadding=\"5\"><col width=\"1000px\"/><col/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">MEDICATION GUIDE</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib Malate (soo ni&apos; ti nib mal&apos; ate) Capsules</content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules can cause serious side effects including:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Severe liver problems, that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with sunitinib malate capsules:</content><list listType=\"unordered\" styleCode=\"Circle\"><item>itching</item><item>yellow eyes or skin</item><item>dark urine</item><item>pain or discomfort in the right upper stomach area</item></list></item></list><paragraph>Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with sunitinib malate capsules. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop liver problems.</paragraph> See &#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D; for more information about side effects.</td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">What are sunitinib malate capsules?</content></paragraph><paragraph>Sunitinib malate capsules are a prescription medicine used to treat:</paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when: <list listType=\"unordered\" styleCode=\"Circle\"><item>you have taken the medicine imatinib mesylate and it did not stop the cancer from growing, or</item><item>you cannot take imatinib mesylate.</item></list></item><item>advanced kidney cancer (advanced renal cell carcinoma or RCC).</item><item>adults with kidney cancer that has not spread (localized), and who are at high risk of RCC coming back again after having kidney surgery.</item><item>a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that has progressed and cannot be treated with surgery.</item></list> It is not known if sunitinib malate capsules are safe and effective in children. </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Before taking sunitinib malate capsules tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>have any heart problems</item><item>have high blood pressure</item><item>have thyroid problems</item><item>have a history of low blood sugar or diabetes</item><item>have kidney function problems (other than cancer)</item><item>have liver problems</item><item>have any bleeding problem</item><item>plan to have surgery or have had a recent surgery. You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery. See <content styleCode=\"bold\">&#x201C;What are the possible side effects of sunitinib malate capsules?&#x201D;</content></item><item>have seizures</item><item>have or have had pain in the mouth, teeth or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth</item><item>are pregnant or plan to become pregnant. Sunitinib malate can harm your unborn baby. <paragraph><content styleCode=\"bold\">Females</content> who are able to become pregnant:</paragraph><list listType=\"unordered\" styleCode=\"Circle\"><item>Your healthcare provider should do a pregnancy test before you start treatment with sunitinib malate capsules.</item><item>You should use effective birth control (contraception) during treatment and for at least 4 weeks after your last dose of sunitinib malate capsules.</item><item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with sunitinib malate capsules.</item></list></item></list><paragraph><content styleCode=\"bold\">Males</content> with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 weeks after your last dose of sunitinib malate capsules. Sunitinib malate capsules may cause fertility problems in males and females. Tell your healthcare provider if this is a concern for you.</paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with sunitinib malate capsules and for at least 4 weeks (1 month) after the last dose.</item></list> Tell all of your healthcare providers and dentists that you are taking sunitinib malate capsules. They should talk to the healthcare provider who prescribed sunitinib malate capsules for you, before you have <content styleCode=\"bold\">any</content> surgery, or medical or dental procedure.</td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using sunitinib malate capsules with certain other medicines can cause serious side effects.</paragraph><paragraph>You may have an increased risk of severe jawbone problems (osteonecrosis) if you take sunitinib malate capsules and a bisphosphonate medicine. <content styleCode=\"bold\">Especially tell</content> your healthcare provider if you are taking or have taken an osteoporosis medicine.</paragraph> Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">How should I take sunitinib malate capsules?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Take sunitinib malate capsules exactly the way your healthcare provider tells you.</item><item>Take sunitinib malate capsules 1 time each day with or without food.</item><item>If you take sunitinib malate capsules for GIST or RCC, you will usually take your medicine for 4 weeks   (28 days) and then stop for 2 weeks (14 days). This is 1 cycle of treatment. You will repeat this cycle for as long as your healthcare provider tells you to.</item><item>If you take sunitinib malate capsules for pNET, take it 1 time each day until your healthcare provider tells you to stop.</item><item>Do not drink grapefruit juice or eat grapefruit during your treatment with sunitinib malate capsules. They may cause you to have too much sunitinib malate in your body.</item><item>Your healthcare provider may do blood tests before each cycle of treatment to check you for side effects.</item><item>If you miss a dose of sunitinib malate capsules by less than 12 hours, take the missed dose right away. If you miss a dose of sunitinib malate capsules by more than 12 hours, just take your next dose at your regular time. Do not make up the missed dose. Tell your healthcare provider about any missed dose.</item><item>Call your healthcare provider right away, if you take too many sunitinib malate capsules.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Lrule Rrule\"><paragraph><content styleCode=\"bold\">What are possible side effects of sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Sunitinib malate capsules may cause serious side effects, including:</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>See <content styleCode=\"bold\">&#x201C;What is the most important information I should know about sunitinib malate capsules?&#x201D;</content></item><item><content styleCode=\"bold\">Heart problems.</content> Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. </item><item><content styleCode=\"bold\">Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heart beats that can be life threatening.</content> Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with sunitinib malate capsules. Tell your healthcare provider right away if you feel dizzy, faint, or have abnormal heartbeats during your treatment with sunitinib malate capsules</item></list></td></tr><tr><td styleCode=\" Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>you feel faint or lightheaded, or you pass out</item><item>dizziness</item></list></td><td styleCode=\" Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item> feel your heart beat is irregular or fast</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\">High blood pressure.</content> High blood pressure is common with sunitinib malate capsules and may sometimes be severe. Follow your healthcare provider&#x2019;s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high, or if you have any of the following signs or symptoms of high blood pressure:</item></list></td></tr><tr><td styleCode=\" Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>severe headache</item><item>lightheadedness</item></list></td><td styleCode=\" Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>dizziness</item><item>change in vision</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Lrule Rrule\"><paragraph>Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. </paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\">Bleeding problems.</content> Bleeding is common with sunitinib malate capsules, but sunitinib malate capsules can also cause severe bleeding problems that can lead to death. Your healthcare provider will monitor you for bleeding and may do blood tests if needed. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with sunitinib malate capsules, including:</item></list></td></tr><tr><td styleCode=\" Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>painful, swollen stomach (abdomen)</item><item>vomiting blood</item><item>coughing up blood</item><item>black, sticky stools</item></list></td><td styleCode=\" Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>bloody urine</item><item>headache </item><item>change in your mental status</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Serious stomach and intestinal problems, that can sometimes lead to death.</content> Some people have had tears in their stomach or intestine (perforation), or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with sunitinib malate capsules.</item><item><content styleCode=\"bold\">Tumor lysis syndrome (TLS).</content> TLS is caused by the fast breakdown of cancer cells and may lead to death. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.</item><item><content styleCode=\"bold\">Abnormal changes in the brain (Reversible Posterior Leukoencephalopathy Syndrome [RPLS]).</content> RPLS can cause a collection of symptoms including headache, confusion, and vision loss. Some people who have taken sunitinib malate capsules have developed RPLS that can lead to death. </item><item><content styleCode=\"bold\">Thrombotic microangiopathy (TMA) including thrombotic thrombocytopenia purpura (TTP) and hemolytic uremic syndrome (HUS).</content> TMA is a condition that involves injury to the smallest blood vessels, and blood clots that can happen while taking sunitinib malate capsules. TMA is accompanied by a decrease in red cells and cells that are involved with clotting. TMA may harm your body&#x2019;s organs such as the brain and kidneys, and can sometimes lead to death.</item><item><content styleCode=\"bold\">Protein in your urine.</content> Some people who have taken sunitinib malate capsules have developed protein in their urine, and in some cases, kidney problems that can lead to death. Your healthcare provider will check you for this problem. </item><item><content styleCode=\"bold\">Serious skin and mouth reactions.</content> Treatment with sunitinib malate capsules has caused severe skin reactions that can lead to death, including: <list listType=\"unordered\" styleCode=\"Circle\"><item>severe rash with blisters or peeling of the skin.</item><item>painful sores or ulcers on the skin, lips or inside the mouth.</item><item>tissue damage (necrotizing fasciitis).</item></list></item></list><paragraph>If you have any signs or symptoms of severe skin reactions, stop taking sunitinib malate capsules and call your healthcare provider or get medical help right away.</paragraph><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\">Thyroid problems. </content>Your healthcare provider may do tests to check your thyroid function during sunitinib malate capsules treatment. Tell your healthcare provider if you have any of the following signs and symptoms during your treatment with sunitinib malate capsules:</item></list></td></tr><tr><td styleCode=\" Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>tiredness that gets worse and does not go away</item><item>loss of appetite</item><item>problems with heat</item><item>feeling nervous or agitated, tremors</item><item>sweating</item><item>nausea or vomiting</item><item>diarrhea</item></list></td><td styleCode=\" Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>fast heat rate</item><item>weight gain or weight loss</item><item>feeling depressed</item><item>irregular menstrual periods or no menstrual periods</item><item>headache</item><item> hair loss</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disk\"><item><content styleCode=\"bold\"><content styleCode=\"bold\">Low blood sugar (hypoglycemia). </content></content>Low blood sugar can happen with sunitinib malate capsules, and may cause you to become unconscious, or you may need to be hospitalized. Low blood sugar with sunitinib malate capsules may be worse in people who have diabetes and take antidiabetic medicines. Your healthcare provider should check your blood sugar levels regularly during treatment with sunitinib malate capsules and may need to adjust the dose of your antidiabetic medicines. Call your healthcare provider right away if you have any of the following signs or symptoms of low blood sugar during your treatment with sunitinib malate capsules:</item></list></td></tr><tr><td styleCode=\" Lrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>headache</item><item>drowsiness</item><item>weakness</item><item>dizziness</item><item>confusion</item></list></td><td styleCode=\" Rrule\"><list listType=\"unordered\" styleCode=\"Circle\"><item>irritability</item><item>hunger</item><item>fast heart beat</item><item>sweating</item><item> feeling jittery</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Lrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Jawbone problems (osteonecrosis). </content>Severe jawbone problems have happened in some people who take sunitinib malate capsules. Certain risk factors such as taking a bisphosphonate medicine or having dental disease may increase your risk of getting osteonecrosis. Your healthcare provider may tell you to see your dentist before you start taking sunitinib malate capsules. Your healthcare provider may tell you to avoid dental procedures, if possible, during your treatment with sunitinib malate capsules, especially if you are receiving a bisphosphonate medicine into a vein (intravenous). Tell your healthcare provider if you plan to have any dental procedures before or during treatment with sunitinib malate capsules. <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned dental procedures.</item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after dental procedures.</item></list></item><item><content styleCode=\"bold\">Wound healing problems.</content> Wound healing problems have happened in some people who take sunitinib malate capsules. Tell your healthcare provider if you plan to have any surgery before or during treatment with sunitinib malate capsules. <list listType=\"unordered\" styleCode=\"Circle\"><item>You should stop taking sunitinib malate capsules at least 3 weeks before planned surgery.</item><item>Your healthcare provider should tell you when you may start taking sunitinib malate capsules again after surgery.</item></list></item></list><paragraph><content styleCode=\"bold\">Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with sunitinib malate capsules if you develop serious side effects.</content></paragraph><content styleCode=\"bold\">Common side effects of sunitinib malate capsules include:</content></td></tr><tr><td styleCode=\" Lrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>tiredness</item><item>weakness</item><item>diarrhea</item><item>pain, swelling or sores inside of your mouth</item><item>nausea</item><item>loss of appetite</item><item>indigestion</item></list></td><td styleCode=\" Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>vomiting</item><item>stomach-area (abdominal) pain</item><item>blisters or rash on the palms of your hands and soles of your feet</item><item>high blood pressure</item><item>taste changes</item><item> low platelet counts</item></list></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Lrule Rrule\"><paragraph>The medicine in sunitinib malate capsules is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. Sunitinib malate capsules may also cause other skin problems including: dryness, thickness or cracking of the skin.</paragraph><paragraph>These are not all of the possible side effects of sunitinib malate capsules. </paragraph> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Lrule Rrule\"><paragraph><content styleCode=\"bold\">How do I store sunitinib malate capsules?</content></paragraph><list listType=\"unordered\" styleCode=\"Disc\"><item>Store sunitinib malate capsules at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item></list><paragraph><content styleCode=\"bold\"><content styleCode=\"bold\">Keep sunitinib malate capsules and all medicines out of the reach of children.</content></content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of sunitinib malate capsules.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sunitinib malate capsules for a condition for which they were not prescribed. Do not give sunitinib malate capsules to other people, even if they have the same symptoms that you have. They may harm them.</paragraph> You can ask your healthcare provider or pharmacist for information about sunitinib malate capsules that is written for health professionals. </td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">What are the ingredients in sunitinib malate capsules?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> sunitinib malate</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content> croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30. </paragraph><paragraph>The 12.5 mg capsule shell contains D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, and titanium dioxide.</paragraph><paragraph>The 25 mg capsule shell contains D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, gelatin, and titanium dioxide. </paragraph><paragraph>The 37.5 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide.</paragraph><paragraph>The 50 mg capsule shell contains FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, gelatin, and titanium dioxide.</paragraph><paragraph>The black printing ink which is common for all strengths contains black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, shellac, and may also contain propylene glycol.</paragraph><paragraph>Manufactured For: <content styleCode=\"bold\">Teva Pharmaceuticals</content>, Parsippany, NJ 07054  For more information, call Teva at 1-888-838-2872.</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL PRINCIPAL DISPLAY PANEL NDC 0093-8199-28 Sunitinib Malate Capsules 12.5 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules img-1",
      "PACKAGE LABEL PRINCIPAL DISPLAY PANEL NDC 0093-8224-28 Sunitinib Malate Capsules 25 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules img-2",
      "PACKAGE LABEL PRINCIPAL DISPLAY PANEL NDC 0093-8229-28 Sunitinib Malate Capsules 37.5 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules img-3",
      "PACKAGE LABEL PRINCIPAL DISPLAY PANEL NDC 0093-8231-28 Sunitinib Malate Capsules 50 mg* PHARMACIST: Dispense the accompanying Medication Guide to each patient. Rx only 28 Capsules img-3"
    ],
    "set_id": "a9479e5f-914f-46ca-95c1-327c66457e47",
    "id": "20ff6da6-32c4-421d-b7b0-604a502bfcb5",
    "effective_time": "20250131",
    "version": "4",
    "openfda": {
      "application_number": [
        "ANDA213803"
      ],
      "brand_name": [
        "Sunitinib Malate"
      ],
      "generic_name": [
        "SUNITINIB MALATE"
      ],
      "manufacturer_name": [
        "Teva Pharmaceuticals USA, Inc."
      ],
      "product_ndc": [
        "0093-8199",
        "0093-8224",
        "0093-8229",
        "0093-8231"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "SUNITINIB MALATE"
      ],
      "rxcui": [
        "616279",
        "616285",
        "616289",
        "1541890"
      ],
      "spl_id": [
        "20ff6da6-32c4-421d-b7b0-604a502bfcb5"
      ],
      "spl_set_id": [
        "a9479e5f-914f-46ca-95c1-327c66457e47"
      ],
      "package_ndc": [
        "0093-8199-28",
        "0093-8224-28",
        "0093-8229-28",
        "0093-8231-28"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "LVX8N1UT73"
      ]
    }
  }
]